NZ749999B2 - Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity - Google Patents

Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity Download PDF

Info

Publication number
NZ749999B2
NZ749999B2 NZ749999A NZ74999914A NZ749999B2 NZ 749999 B2 NZ749999 B2 NZ 749999B2 NZ 749999 A NZ749999 A NZ 749999A NZ 74999914 A NZ74999914 A NZ 74999914A NZ 749999 B2 NZ749999 B2 NZ 749999B2
Authority
NZ
New Zealand
Prior art keywords
mmol
amine
hexyloxy
mixture
compound
Prior art date
Application number
NZ749999A
Other versions
NZ749999A (en
Inventor
Nureddin Aman
Rui Li
Ming Lu
Julian Reading
David M Simpson
Borstel Reid W Von
Stephen Wolpe
Dennis Bryan Zerby
Original Assignee
Wellstat Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corporation filed Critical Wellstat Therapeutics Corporation
Priority claimed from NZ709885A external-priority patent/NZ709885A/en
Publication of NZ749999A publication Critical patent/NZ749999A/en
Publication of NZ749999B2 publication Critical patent/NZ749999B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Quinazoline compounds of formula IB1 are described, along with their use as lysosomotropic agents against inflammation, fungi, unicellular parasitic microorganisms and cancer. The described compounds are useful for the treatment of diseases characterized by pathogenic cells featuring lysosomes or other acidic vacuoles with disease-related alterations predisposing them to accumulation of compounds of the invention, which then selectively inactivate or eliminate such pathogenic cells. her acidic vacuoles with disease-related alterations predisposing them to accumulation of compounds of the invention, which then selectively inactivate or eliminate such pathogenic cells.

Description

AMINE NDS HAVING ANTI—INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY BACKGROUND OF THE INVENTION Most nucleated otic cells, whether unicellular organisms or tuents of multicellular organism including humans, contain acidified vacuoles that are critical for cellular maintenance and function. In mammalian cells, these vacuoles comprise lysosomes and other mal vesicular organelles. The pH of the interior of lysosomes is typically about 4.5 to 5, maintained by vacuolar ATP—dependent proton pumps and also by Donnan equilibrium effects. mes contribute to cytosolic pH buffering, ting the cell from acidic environments, and are also primary sites for degrading and recycling the constituents of aging or damaged organelles such as mitochondria, a process known as autophagy. There are several important pathological conditions where lysosomal characteristics are altered and contribute to disease enesis, presenting a potential target for pharmacological therapy.
A growing body of ce indicates that a common phenotypic change in invasive cancer cells is a redirection of lysosomes to participate in destruction of surrounding cells via exocytosis of acidic contents, including enzymes. Proteolytic enzymes normally found in lysosomes but secreted by cancer cells, such as cathepsins, can degrade extracellular matrix proteins, facilitating tumor invasion and metastasis. Furthermore, lysosomes and other acidic vacuolar lles are often enlarged in cancer cells, which aids pH buffering; many solid tumors generate an acidic extracellular environment, favoring on, which requires that cancer cells adapt to both produce and tolerate a low extracellular pH. Cancer cells selected in vitro for invasive potential have larger, more acidic lysosomes than do less aggressive cells. Cancer cells exposed to ionizing radiation undergo a tive response involving enlargement and acidification of lysosomes. A related tive response through cancer cells acquire survival advantages is activation of autophagy, which involves fusion of autophagosomes containing damamged organelles or other cell debris, with lysosomes; disruption of autophagy can impair 2014/013992 cancer cell viability. Some cancer cells also sequester chemotherapy agents in lysosomes, as a mechanism of drug resistance. Chloroquine, an antimalarial drug that accumulates in mammalian lysosomes, iates, or restores sensitivity to, anticancer ty of several classes of chemotherapy agents and targeted small molecule and antibody cancer treatments.
Lysosomotropic ?uorescent dyes such as acridine orange can be used to visually differentiate tumors in situ from surrounding tissues, indicating a potential sharp distinction for specific lysosome—targeting cytotoxic agents to selectively kill cancer cells.
Lysosomal alterations are also important features of common in?ammatory diseases, especially those involving activated macrophages, where exocytosis of lysosomal s, cytokines, and some in?ammatory ors such as HMBGI that are processed and released via lysosomes can participate in tissue damage and both local and ic in?ammation. orticoid signaling is also linked to lysosomes, such that compromising lysosomal function can enhance anti-in?ammatory pathways mediating glucocorticoid effects.
Most fungi have acidic vacuoles r to lysosomes. These acidic vacuoles are al for ion and pH homeostasis, storage of amino acids, autophagy and for processing some proteins.
Vacuoles are acidified via a proton pump, the ar H+-ATPase, or ase”, and it is known that fungi with inactivating mutations of subunits of V-ATPase that result in impaired e acidification also lose virulence and grow poorly. Ergosterol, a fungal—specific steroid analogous to cholesterol in mammalian cells as a major membrane component, is critical for conformation and activity of the V—ATPase, and V—ATPase dysfunction appears to be a major mechanism of antifungal activity of ergosterol synthesis inhibitors, which includes l classes of existing ngal agents. Antifungal agents that act via binding to specific proteins, e. g. enzyme inhibitors, are inherently vulnerable to development of drug ance via single mutations in genes encoding target proteins. Agents that target fungi via adequately specific targeting and disruption of fungal acidic vacuoles by cation trapping may be less susceptible to development of resistance through point mutations than are drugs acting by binding to speci?c protein targets, due to impaired viability and virulence when vacuolar acidification, is impaired.
Clinically ant larial drugs are known that accumulate in acidic es and lysosomes and their biological activity is largely mediated through their concentration in acidic vacuoles, not only in malaria but in atory diseases, some cancers and non—malarial infections by fungi and unicellular and oal parasites. Quinoline analog antimalarial drugs target malaria plasmodia via cation trapping in acidic digestive vacuoles, where they can accumulate to concentrations several orders of magnitude higher than in extracellular spaces. A large molar fraction of chloroquine, me?oquine, quinacrine and several of their congeners are ged at the usual extracellular pH of about 7.4 and the cytoplasmic pH of 7.1, and can thereby pass through cellular and organelle membranes. In an acidic environment such as the interior of a lysosome or fungal acidic vacuole, these antimalarials are predominantly cationic and are thereby restricted from free passage through the vacuolar membrane. Antimalarials such as chloroquine impair processing of heme from hemoglobin ingested by malaria plasmodia after accumulating in the feeding vacuoles, ting for much of their specific toxicity to dia. However, chloroquine and similar quinoline-analog antimalarials can accumulate in mammalian lysosomes and fungal acidic vacuoles and impair vacuolar function to a degree sufficient to provide some clinical benefit, if only by partically deacidifying the vacuoles.
Chloroquine is used for treatment of in chronic autoimmune and in?ammatory diseases such as ic lupus erythematosis or rheumatoid arthritis, with moderate efficacy. A degree of antifungal activity has been reported for larials such as chloroquine or quinacrine, both as single agents or in combination with other s of antifungal agents, such as ?uconazole, notably in animal models of systemic cryptococcosis. However, their activity is suboptimal, yielding incomplete fungal growth inhibition. Recent work has also demonstrated moderate growth inhibitory activity of chloroquine, me?oquine and other weakly cationic drugs such as siramesine in animal models of . Existing lysosomotropic agents such as antimalarial quinolone compounds can thus display some eutically relevant activity in es in which acidic vacuoles contribute to pathogenesis. However, the activity and potency of antimalarials in such diseases are limited, as the target cells can te accumulation of relatively high concentrations of the antimalarials; the specific lethal effect of ine compounds in malaria is largely attributed to disruption of heme processing within plasmodial feeding vacuoles, a ism of cytotoxicity not applicable in the areas of in?ammatory disease, cancer or fungal infections. Despite the body of evidence indicating strong ial for targeting lysosomes for treating cancers, existing agents have not shown adequate activity or therapeutic index for effectively treating cancer in humans.
“Lyosomotropic detergents”, comprising weakly cationic heterocyclic moieties bearing a single alkyl chain with approximately 10 to 14 carbon atoms, were reported be potently cytotoxic to mammalian cells and to display broad spectrum antifungal activity in vitro. This class of agents accumulate in lysosomes and acidic vacuoles via the same type of cation trapping process through which antimalarials are trated, and when they reach a al micellar tration in the vacuole, they behave as detergents, damaging vacuolar membranes. They display a characteristic sigmoid dose—response curve, as a uence of their formation of micellar micro ures. However, there is no information about ty or safety of this class of agents in Vivo in animal models of relevant diseases.
Y OF THE INVENTION This invention es a compound represented by Formula I or a pharmaceutically acceptable 2O salt thereof G-NH-A-Q-X-Y-Z I wherein G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms. G can be unsubstituted, or it can substituted at a ring carbon by amino, dimethylamino, hydroxy, halo, methyl, per?uoromethyl, or alkyl having from 1 to 16 carbon atoms which alkyl is either unsubstituted or substituted by hydroxy or alkoxy having 1 to 12 carbon atoms or acetoxy. Or it can be substituted at a ring en by alkyl having from 1 to 16 carbon atoms which alkyl is either unsubstituted or substituted by hydroxy or alkoxy having from 1 to 8 carbon atoms. N is nitrogen, H is hydrogen, and NH is absent or present. A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent; Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be 0 or NH. X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom. Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two en atoms. Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either unsubstituted or tuted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(O)R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl having from 1 to 6 carbon atoms, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.
In a particular aspect, the present invention provides a compound represented by Formula IB1 or a ceutically acceptable salt thereof wherein n is 1; Q is absent; R1 is en or halo; and R7 is phenyl substituted by alkoxy having from 6 to 10 carbon atoms or phenoxy.
This invention also provides a use or method for treating or preventing a condition in a mammalian subject; the condition being selected from the group consisting of an inflammatory disease, a fungal ion, a unicellular parasitic infection, and a neoplastic disease; comprising administering to the t an effective amount of the compound or salt of the invention. It also provides compositions comprising these compounds or salt. And it provides a method of inhibiting a fungus ex vivo, comprising contacting a surface or the fungus with the compound or salt.
[FOLLOWED BY PAGE 5a] DETAILED DESCRIPTION OF THE INVENTION Without wishing to be bound by theory, this ion provides compounds and their use for treating diseases characterized by pathogenic cells featuring lysosomes or other acidic vacuoles with disease-related alterations predisposing them to accumulation of nds of the invention, which then selectively inactivate or eliminate such pathogenic cells. Compounds of the ion, many of which are aminoquinoline and aminoquinazoline derivatives, feature significant improvements in potency and activity over known aminoquinoline drugs such as chloroquine, as a consequence of structural moieties that potently disrupt lysosomal or ar membrane integrity when the compounds accumulate in acidic vacuoles in cells. Diseases that are at least moderately sive to antimalarial quinoline derivatives and analogs are in l more effectively d with compounds of the invention. Such diseases broadly comprise inflammatory diseases, neoplastic diseases, including both hematologic cancers and solid tumors, [FOLLOWED BY PAGE 6] WO 20995 and infections by eukaryotic pathogens, including fungi and l classes of protozoal or other unicellular parasites.
DEFINITIONS As used herein the term “alkyl” means a linear or branched—chain or cyclic alkyl group. An alkyl group identified as having a certain number of carbon atoms means any alkyl group having the specified number of carbons. For example, an alkyl having three carbon atoms can be propyl or isopropyl; and alkyl having four carbon atoms can be n—butyl, l—methylpropyl, 2—methylpropyl or t-butyl.
As used herein the term “halo” refers to one or more of fluoro, chloro, bromo, and iodo.
As used herein the term “per?uoro” as in per?uoromethyl, means that the group in question has ?uorine atoms in place of all of the hydrogen atoms.
Certain chemical compounds are referred to herein by their chemical name or by the two-letter code shown below. The following are compounds of this invention.
CH Hexyloxy)octy1]quinolin—4—amine CI utoxyoctyl)quinolin—4—amine CJ N—(8-Methoxyoctyl)quinolin—4—amine CK N—[6-(Hexyloxy)hexyl]quinolin—4—amine CL N—(6—Butoxyhexyl)quinolin—4—amine AL N—[lO—(Hexyloxy)decyl] quinolin—4—amine AM N—(lO—Butoxydecyl)quinolin—4—amine CM N—(5—Methoxypentyl)quinolin—4—amine WO 20995 AV N—[8—(Hexyloxy)octyl] —2—methy1quinolin—4—amine AW 7—Ch10ro—N— [8—(hexy10xy)0ctyl]quinolin—4—amine AX 8—Ch10r0—N—[8—(hexyloxy)octyl]quinolin—4—amine AY N—[8—(Hexyloxy)octyl] —7—(tri?uoromethyl)quinolin—4—amine CN N—[8—(Hexyloxy)octyl] —8—(tri?uoromethyl)quinolin—4—amine BB N— { 5—[3—(Hexyloxy)propoxy]penty1}quin01in—4—amine BC N— { 3—[5—(Hexy10xy)penty10xy]propy1}quinolin—4—amine AJ 3—Eth0xypropoxy)octyl]quinolin—4—amine BD N—[8—(2—Pr0p0xyethoxy)octyl]quinolin—4—amine CO N—[8—(Benzyloxy)octyl]quinolin-4—amine AR N-(6-Phenoxyhexyl)quinolinamine AN N-(8-Phenoxyocty1)quinolinamine CP N— { 2-[2-(Hexy10xy)phenoxy] ethyl } quinolinamine CQ N— { 3-[2-(Hexyloxy)phenoxy]propyl } quinolinamine CR N— { 4- [2- (Hexyloxy)phenoxy]butyl } quinolin—4-amine CS 2-Ethoxyphenoxy)propy1]quinolin—4—amine CT N—[3-(2-Methoxyphenoxy)propy1]quinolin—4—amine CU N— { 3-[2— (Benyloxy)phenoxy]propy1}quinolinamine BH N—[8-(3—Methoxyphenoxy)octyl]quinolin—4—amine CV N— { 4—[3—(Hexyloxy)phenoxy]buty1}quin01in—4—amine AZ N—{ 3—[3—(Hexyloxy)phenoxy]propy1}quin01in—4—arnine CW N— { 2—[3—(Hexy10xy)phenoxy]ethy1}quin01in-4—amine AD N—[8—(4—Meth0xyphenoxy)octyl]quinolin—4—amine CX N—[6—(4—Methoxyphenoxy)hexyl]quinolin—4—amine BA N— { 2—[4— (Hexyloxy)phen0xy]ethy1}quinolin—4—amine CY N—{ 3—[4—(Hexyloxy)phenoxy]pr0py1}quinolin—4—amine CZ N— { 4—[4— oxy)phenoxy]buty1}quinolin—4—amine BE N—[8—(m—T01y10xy)0cty1]quinolin—4—amine BF N—[8—(p—T01yloxy)octyl]quinolin—4—amine BG N—[8—(0—T01y10xy)octyl]quinolin—4—amine DA N—[8—(4—tert—Butylphenoxy)octyl]quinolin—4—amine BJ N—[8—(4—F1u0r0phenoxy)octyl]quin01in—4—amine BI N—[8—(3—F1u0r0phenoxy)octyl]quin01in—4—amine DB N—[8—(2—F1u0r0phenoxy)octyl]quin01in—4—amine DC N—(Bipheny1—4—y1)quinolin—4—amine A0 N-(4-Hexylpheny1)quinolinamine AP Hexyl 4-(quinolinylamino)benzoate DD N-(4-Phenoxypheny1)quinolinamine DE N—(3-Phenoxypheny1)quinolin—4—amine DF N—(2-Phenoxypheny1)quinolin—4—amine DG N—[4-(Quinolin—4—ylamino)pheny1]hexanamide DH N—[3-(Quinolin—4—ylamino)pheny1]hexanamide AQ N—Hexy1—4—(quinolin—4—y1amino)benzamide BV N—Hexy1—3—(quinolin—4—y1amino)benzamide DI N—(4—Methoxypheny1)quinolin—4—amine DJ N—[4—(Benzyloxy)phenyl]quinolin—4—amine DK utoxypheny1)quinolin—4—amine DL N—[4—(Hexy10xy)phenyl]quinolin—4—amine DM N—[3—(Benzy10xy)phenyl]quinolin—4—amine DN N—[3—(Hexy10xy)phenyl]quinolin—4—amine DO N—[2—(Benzy10xy)phenyl]quinolin—4—amine DP N—[2—(Hexyloxy)phenyl]quinolin—4—amine BL 1u0r0—4—(hexyloxy)phenyl]quinolin—4—amine DQ N—Benzquuinolin—4—amine DR N—Phenethquuinolin—4—amine AA N—[4—(Hexy10xy)benzyl]quinolin—4-amine AC N—[3—(Hexy10xy)benzyl]quinolin—4-amine DS N—[2—(Hexy10xy)benzyl] quinolin—4—amine BK N—[3—F1u0r0—4—(hexyloxy)benzy1]quinolin—4—amine DT N-[4-(Decy10xy)benzy1]quinolinamine DU N-[3-(Decy10xy)benzy1]quinolinamine AF N-(3-Phenoxybenzyl)quinolinamine BU N—[3-(Benzyloxy)bcnzyl]quinolin—4—amine DV N—(3-Phenethoxybenzyl)quinolin—4—amine DW N—[4-(Quinolin—4—ylamino)buty1]benzamide DX N—[6-(Quinolin—4—ylamino)hexy1]benzamide DY N—[8-(Quinolin—4—ylamin0)octy1]benzamide DZ 3—Methoxy—N—[8—(quinolin—4—y1amino)0ctyl]benzamide EA 4—Methoxy—N—[8—(quinolin—4—y1amino)octyl]benzamide EB 2—(Hexy10xy)—N—[2—(quinolin—4—ylamin0)ethy1]benzamide EC yloxy)—N—[3—(quinolin—4—y1amin0)pr0py1]benzamide ED 2—(Hexyloxy)—N—[4—(quinolin—4—ylamin0)buty1]benzamide EE N—[8—(Quinolin—4—ylamino)octyl]picolinamide EF N—[8—(Quinolin—4—ylamino)octyl]nicotinamide EG N—[8—(Quinolin—4—ylamino)octyl]isonicotinamide BZ N—(Pyridin—4—ylmethyl)quinolin—4—amine BY N—(Pyridin—3—ylmethyl)quinolin—4—amine EH N—(Pyridin—Z—ylmethyl)quinolin—4—amine EI N—Hexquuinolin—4—amine AG y1)quin01in—4—amine EJ N—(Dodecyl)quinolin—4—amine AI N1,NS—Di(quinolin—4—y1)octane—1,8—diamine EK N—[8—(Hexy10xy)0cty1]quinolin—6—amine EL N-[8-(Hexy10xy)octy1]quinolinamine EM N-[8-(Hexy10xy)octy1]quinolinamine EN N-[8-(Hexyloxy)octy1] (tri?uoromethyl)quinolinamine EO 7—Ch10r0-N—decquuinolin—4—amine EP 7—Ch10ro-N—dodecquuinolin—4—amine AH N—(Decyl)quinazolin—4—amine EQ N—Dodecquuinazolin—4—amine ER 1—7—?uoroquinazolin—4—amine ES N—Dodecy1—7—?uor0quinazolin—4—amine ET 7—Chlor0—N—decy1quinazolin—4—amine EU 7—Chlor0—N—d0decy1quinazolin—4—amine EV N—(6—But0xyhexy1)quinazOlin—4—amine EW N—[8—(Hexyloxy)octyl]quinazolin—4—amine AE N—[8—(4—Meth0xyphenoxy)octyl]quinazolin—4—amine EX N— { 2— [2— (Hexyloxy)phen0xy] ethyl } quinazolin—4—amine EY N—{ 3—[2—(Hexyloxy)phenoxy]pr0py1}quinazolin—4—amine EZ N—{ 4—[2—(Hexyloxy)phen0xy]buty1}quinazolin—4—amine FA N—[8—(Quinazolin—4—ylamin0)octyl]nicotinamide AK N—[3—(Hexy10xy)benzyl] quinazolin—4—amine CG N—[3—(Decy10xy)benzyl]quinazolin-4—amine BM N—(3—Phenoxybenzyl)quinazolin—4—amine BN Decy10xy)benzyl]quinazolin-4—amine AB N—[4—(Hexy10xy)benzyl] quinazolin-4—amine FB 1-[2-(Ethoxymethy1)-1H—imidazo[4,5-c]quinoliny1]methy1propanol FC 1-(4-Aminoisobuty1—1H—imidazo[4,5-c]quinoliny1)penty1 acetate FD 1-Isobutylpentadecy1— lH-imidazo[4,5-c]quinolin01 BP l-Octyl-1H-imidazo[4,5-c]quinoline FE decyl— dazo[4,5—c]quin01ine FF l—Hexadecyl— 1H—imidazo[4,5—c]quin01in—4—amine PG 1—[2-(D0decy10xy)ethy1]—1H—imidazo[4,5—c]quinoline PH 1—[2-(Dodecy10xy)ethy1]—N,N—dimethy1—lH—imidazo[4,5—c]quinolin—4—amine F1 1—[6-(Octyloxy)hexy1]—1H—imidazo[4,5—c]quinoline CD 1—(8—Ethoxy0cty1)—1H—imidazo[4,5—c]quinoline CE 1—(8—Meth0xy0cty1)—1H—imidazo[4,5—c]quinoline BQ 1—(8—Butoxyocty1)—1H—imidazo[4,5—c]quinoline FJ 1—[9—(Hexy10xy)nonyl] — 1H—imidazo[4,5—c]quinoline FK 1—(10—Butoxydecy1)—1H—imidazo[4,5—c]quinoline BO 4—Amin0—1—[8—(hexyloxy)0cty1]pyridinium salts FL ethoxyoctylamino)— 1 —methy1pyridinium iodide AS 1—[8—(Hexy10xy)octyl] — 1H—imidazo[4,5—c]pyridine FM l—Hexadecyl— dazo[4,5—c]pyridine AT 1—( 1 0—But0xydecy1)— 1H—imidazo[4,5—c]pyridine FN N—(8—Meth0xyocty1)pyridin—4—amine F0 N—[8—(Hexyloxy)0cty1]pyridin—3—amine FP N—[8—(Hexyloxy)0cty1]pyridin—2—amine AU N—[8—(Hexyloxy)0cty1]pyrimidin—4—amine FQ N—[8—Hexyloxy)octy1)pyrimidin—2—amine FR 1—[8—(Hexy10xy)octy1]—4—pheny1—1H—imidazole FS N-[8-(Hexy10xy)octy1]isoquinolinamine FT N-[8-(Hexy10xy)octy1]isoquinolin-S-amine FU N-[8-(Hexyloxy)octy1]quinoxalin-Z-amine CC 1—[8—(Hexy10xy)octy1]—lH—benzimidazole FV N—[8-(Hexyloxy)octy1]pyrazin—2—amine 1—[8—(Hexyloxy)octyl]—1H—indole FX 3—[8-(Hexyloxy)0ctyl] —3H—imidazo[4,5—b]pyridine FY cyl—1H—imidazo[4,5—c]quinoline FZ 1—[3-(Decy10xy)propyl]—1H—imidazo[4,5—c]quinoline GA 1—[4—(Decy10xy)butyl]—1H—imidazo[4,5—c]quinoline GB 1—[8—(Hexyloxy)octyl]—1H—imidazo[4,5—c]quinoline GC 1—{5—[3—(Hexyloxy)pr0poxy]penty1}—1H—imidazo[4,5—c]quinoline GD 1—{3—[3—(Hexyloxy)phenoxy]pr0py1}—1H—imidazo[4,5—c]quinoline The following compounds were less active in the biological activity example(s) in which they were .
BR N—(2—Methoxyethyl)quinolin—4—amine BS N—[2—(Morpholin—4—yl)ethyl]quinolin—4—amine BT N—[3—(Quinolin—4—ylamino)propyl]benzamide BW N—(2—Diethylaminoethyl)—4—(quinolin-4—y1amino)benzamide BX N—(4—Dimethylaminobenzyl)quinolin—4—amine CA N—(Pyridin—4—ylmethyl)—8—(hexyloxy)octanamide CB N—(Quinolin—6—yl)—8—(hexyloxy)octanamide CF l—{ 3— [(5—(Hexyloxy)pentoxy]propyl} lH—imidazo[4,5—c]quinoline As used herein the transitional term “comprising” is nded. A claim utilizing this term can contain elements in addition to those recited in such claim.
As used in the claims the word “or” means “and/or” unless such reading does not make sense in context. So for example, when it is stated in connection with Formula I that variable G can be tuted at a ring carbon “or” at a ring nitrogen, it may be substituted at a ring carbon, at a ring nitrogen, or at both a ring carbon and a ring nitrogen.
The following iations are used in the chemical synthesis examples and elsewhere in this description: DCM dichloromethane DIEA N,N—diisopropylethylamine DMA N,N—dimethylacetamide DMAP4—(N,N—dimethylamino)pyridine DME 1,2-dimethoxyethane DMF N,N—dimethylformamide DMSOdimethyl sulfoxide EA ethyl e Et20 diethyl ether EtOH ethanol FC ?ash chromatography Hex hexanes IPA 2—propanol LAH lithium ydridoaluminate MeOH methanol mp g point NMP N—methylpyrrolidinone NMR nuclear magnetic resonance spectrometry SPE solid phase extraction TEA triethylamine THF tetrahydrofuran TLC thin layer chromatography COMPOUNDS In an embodiment of the compound or salt of Formula I, G is selected from the group consisting of substituted or unsubstituted quinolyl, substituted or tituted quinazolyl, unsubstituted isoquinolyl, unsubstituted quinoxalyl, unsubstituted benzimidazolyl, unsubstituted pyridyl, unsubstituted nyl, unsubstituted indolyl, substituted or unsubstituted imidazoquinolyl, substituted pyridinium, unsubstituted imidazopyridine, unsubstituted pyrimidyl, and tuted imidazolyl. In another embodiment of the compound or salt of Formula I Y—Z is selected from the group consisting of alkoxyphenylalkyl, phenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, yphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl, N—alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl, (halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl, isonicotinamidoalkyl, N—(quinolylamino)alkyl, N—(quinazolylamino)alkyl, phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl, pyridylalkyl and hydroxyalkyl.
Some of the compounds of this inveniton in which G is unsubstituted or substituted quinolyl can be represented by Formula IA HN—A-Q-X-Y-Z | / IA wherein A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent. Q is absent or present and is O, NHC(O), or NH, ed that if A is absent Q must be absent, and if both X and Y are absent Q cannot be 0 or NH.
X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom. Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms. Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either tituted or substituted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(O)R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl having from 1 to 6 carbon atoms, ed that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms. One of R1 and R2 is hydrogen and the other is selected from the group ting of hydrogen, halo, methyl, and per?uoromethyl. In an embodiment of this invention both R1 and R2 are hydrogen. In an embodiment of Formula IA, A—Q—X—Y—Z is selected from the group ting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl, alkyl, alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl, lcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl, otinamidoalkyl, phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl, pyridylalkyl and N—(quinolylamino)alkyl.
A more ic embodiment of compounds in which G quinolyl can be represented by Formula /(CH2)n(O)p(CH2)qR3 \ \ 1A1 wherein n is 0, 1,2, 3,4, 5, 6,7, 8, 9, 10, 11, or 12, provided that ifp is 1 then n must not be 0 or 1. p is 0 or 1; and q is 0 or 1. One of R1 and R2 is hydrogen and the other is selected from the group consisting of hydrogen, halo, methyl, and per?uoromethyl. R3 can be alkyl having from 1 to 10 carbon atoms either unsubstituted or substituted by: a) a phenyl or monocyclic or bicyclic aromatic ring having one or two nitrogen atoms or phenoxy either unsubstituted or substituted by phenoxy or alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbon atoms, provided that if R3 is alkyl substituted by alkoxy then alkyl must have more than 1 carbon atom. atively R3 can be phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl or phenoxy, b) alkoxy having from 1 to 10 carbon atoms tituted or substituted by phenyl or phenoxy, provided that when substituted by phenoxy the alkoxy must have more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR6, C(O)NHR6, or NHC(O)R6, wherein R6 is alkyl having from 1 to 6 carbon atoms.
In an embodiment of the compounds of Formula 1A1, R1 is hydrogen and R2 is en. In a more specific embodiment n is 2, 3, 4, 5, 6, 7, 8, 9, or 10; p is l; and R3 is alkyl having from 1 to 6 carbon atoms. es of such compounds include N—[8—(Hexyloxy)octyl]quinolin—4— amine, N—(8—Butoxyoctyl)quinolin—4—amine, ethoxyoctyl)quinolin—4—amine, N—[6— (Hexyloxy)hexyl]quinolin—4—amine, N—(6—Butoxyhexyl)quinolin—4—amine, N—[lO— (Hexyloxy)decyl]quinolin—4—amine, N—(l0—Butoxydecyl)quinolin—4—amine, N—(S— Methoxypentyl)quinolin—4—amine.
In another embodiment of the compounds of Formula IAl, n is 2, 3, 4, 5, 6, 7, 8, 9, or 10; p is 1; one of R1 and R2 is hydrogen and the other is selected from the group consisting of halo, methyl, and per?uoromethyl; and R3 is alkyl haVing from 1 to 6 carbon atoms. es of such compounds include N—[8—(Hexyloxy)octyl]—2-methquuinolin—4—amine, 7—Chloro—N—[8- (hexyloxy)octyl]quinolin—4—amine, 8—Chloro—N—[8—(hexyloxy)octyl]quinolin—4—amine, N—[8— (Hexyloxy)octyl]—7—(tri?uoromethyl)quinolin—4—amine, N—[8—(Hexyloxy)octyl]—8— (tri?uoromethyl)quinolin—4—amine.
In another embodiment of the compounds of Formula 1A1 in which R1 is hydrogen and R2 is hydrogen: n is 2, 3, 4, 5, 6, 7, 8, 9, or 10; p is 1; R3is alkyl having from 2 to 5 carbon atoms substituted by alkoxy having from 1 to 6 carbon atoms. Examples of such compounds include N-{ 5-[3-(Hexyloxy)propoxy]pentyl}quinolinamine, N- { 3-[5-(Hexyloxy)pentyloxy]propyl} quinolinamine, N-[8-(3-Ethoxypropoxy)octyl]quinolinamine, N—[8—(2- Propoxyethoxy)octyl]quinolin—4—amine.
A subset of nds of Formula 1A1 can be represented by Formula IAla /(CH2)n(O)p(CH2)q HN \ A IAla \ \ /\R4 wherein n is 0, l, 2, 3, 4, 5, 6, 7, or 8; p is 0 or 1; q is 0 or 1, provided that ifp is 1 then n must not be 0 or 1. One of R1 and R2 is hydrogen and the other is selected from the group consisting of hydrogen, halo, methyl, and per?uoromethyl. R4 is hydrogen or halo. R5 is selected from the group consisting of hydrogen; halo; unbranched or ed alkyl having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl or phenoxy; alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy, provided that when substituted by phenoxy the alkoxy must have more than one carbon atom; ; phenyl; phenoxy; C(O)OR6; C(O)NHR6; or NHC(O)R6, wherein R6 is alkyl having from 1 to 6 carbon atoms. In ment of Formula IAla R1 is hydrogen and R2 is hydrogen. In a more specific embodiment p is l and R4 is hydrogen. In a still more specific embodiment R5 is en. Examples of such compounds include N—[8—(Benzyloxy)octyl]quinolin—4—amine, henoxyhexyl)quinolin—4—amine, N-(8—Phenoxyoctyl)quinolin—4—amine.
In another embodiment of Formula IAla, both R1 and R2 are en, q is 0, and R5 is alkoxy having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl. In a more specific embodiment R5 is in the ortho position. Examples of such compounds include N-{ 2-[2-(Hexyloxy)phenoxy]ethyl}quinolinamine, N- { 3-[2-(Hexyloxy)phenoxy]propyl} quinolinamine, N-{4-[2-(Hexyloxy)phenoxy]butyl }quinolinamine, N—[3-(2- Ethoxyphenoxy)propyl]quinolinamine, 2-Methoxyphenoxy)propyl] quinolinamine, N—{ 3—[2—(Benyloxy)phenoxy]propy1}quinolin—4—amine. Alternatively R5 is in the meta position.
Examples of such compounds include N—[8—(3—Methoxyphenoxy)octyl]quinolin—4—amine, N—{4- [3—(Hexyloxy)phenoxy]butyl}quinolin—4—amine, N—{ 3-[3-(Hexyloxy)phenoxy]propyl}quinolin amine, N—{2-[3—(Hexyloxy)phenoxy]ethyl} quinolinamine. Alternatively R5 is in the para position. Examples of such compounds include N—[8-(4—Methoxyphenoxy)octyl]quinolin—4— amine, N—[6-(4—Methoxyphenoxy)hexyl]quinolin—4—amine, N— { 2—[4—(Hexyloxy)phenoxy]ethyl} quinolin—4—amine, 4—(Hexyloxy)phenoxy] }quinolin—4—amine, N—{4—[4— (Hexyloxy)phenoxy]butyl}quinolin—4—amine.
In another embodiment of Formula IAla, R1 is en and R2 is hydrogen, p is 1, R4 is hydrogen, and R5 is unbranched or branched alkyl having from 1 to 6 carbon atoms. Examples of such compounds e N—[8—(m—Tolyloxy)octyl]quinolin—4—amine, N—[8—(p—Tolyloxy)octyl] quinolin—4—amine, N—[8—(0—Tolyloxy)octyl]quinolin—4—amine, N—[8—(4—tert—Butylphenoxy)octyl] quinolin—4—amine. atively R5 is ?uoro. Examples of such compounds include N—[8—(4—Fluorophenoxy)octyl]quinolin—4—amine, N—[8—(3—Fluorophenoxy)octyl]quinolin—4—amine, N—[8—(2—Fluorophenoxy)octyl]quinolin—4—amine.
In r embodiment of Formula IAla, R1 is hydrogen and R2 is hydrogen, and p is 0. In a more specific embodiment q is 0. In a still more specific embodiment n is 0. Examples of such compound include N—(Biphenyl—4—yl)quinolin—4—amine, N—(4—Hexylphenyl)quinolin—4—amine, Hexyl 4—(quinolin—4—ylamino)benzoate, henoxyphenyl)quinolin—4—amine, N—(3—Phenoxyphenyl)quinolin—4—amine, N-(2—Phenoxyphenyl)quinolin—4—amine, N—[4—(Quinolin—4—ylamino)phenyl]hexanamide, N—[3—(Quinolin—4—ylamino)phenyl]hexanamide, N—Hexyl—4—(quinolin—4—ylamino)benzamide, N—Hexyl—3—(quinolin—4—ylamino)benzamide.
Alternatively R5 is alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl. Examples of such compounds include N-(4-Methoxyphenyl)quinolinamine, N-[4-(Benzyloxy)phenyl]quinolinamine, N-(4-Butoxyphenyl)quinolinamine, N-[4-(Hexyloxy)phenyl]quinolinamine, N-[3-(Benzyloxy)phenyl]quinolinamine, N-[3-(Hexyloxy)phenyl]quinolinamine, N-[2-(Benzyloxy)phenyl]quinolinamine, N—[2—(Hexyloxy)phenyl]quinolin—4—amine, N—[2—Fluoro(hexyloxy)phenyl]quinolin—4—amine. In another embodiment of a IAla, R1 is hydrogen and R2 is hydrogen, p is 0, q is 0, and n is 1 or 2. Examples of such compounds include N—Benzquuinolin—4—amine, and N—Phenethquuinolin—4—amine.
In another embodiment of a IAla, R1 is hydrogen and R2 is hydrogen, p is 0, and q is 1. In a more specific embodiment R5 is alkoxy having from 1 to 10 carbon atoms. Examples of such compounds include N—[4—(Hexyloxy)benzyl]quinolin-4—amine, N—[3—(Hexyloxy)benzyl]quinolin— 4—amine, N—[2—(Hexyloxy)benzyl]quinolin—4—amine, N—[3—Fluoro—4—(hexyloxy)benzyl]quinolin—4— amine, N—[4—(Decyloxy)benzyl]quinolin—4—amine, N—[3—(Decyloxy)benzyl]quinolin—4—amine. atively R5 is y, or alkoxy having from 1 to 10 carbon atoms substituted by phenyl.
Examples of such compounds include N—(3—Phenoxybenzyl)quinolin—4—amine, N— [3—(Benzyloxy)benzyl]quinolin—4—amine, N—(3—Phenethoxybenzyl)quinolin—4—amine.
Another more specific embodiment of compounds in which G quinolyl can be represented by Formula 1A2 /(CH2)nN HAR13 \ 1A2 wherein n is 2, 3, 4, 5, 6, 7, or 8. R13 is phenyl unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms; or 2-, 3-, or 4-pyridyl. In one embodiment R13 is unsubstituted phenyl.
Examples of such compounds include N—[4—(Quinolinylamino)butyl]benzamide, N—[6—(Quinolinylamino)hexyl]benzamide, Quinolin—4—ylamino)octyl]benzamide. In another embodiment R13 is phenyl substituted by alkoxy having from 1 to 6 carbon atoms.
Examples of such compounds include 3—Methoxy—N—[8-(quinolin—4—ylamino)octyl]benzamide, 4—Methoxy-N—[8—(quinolin—4—ylamino)octyl]benzamide, 2—(Hexyloxy)—N—[2—(quinolin—4— ylamino)ethyl]benzamide, 2—(Hexyloxy)—N—[3—(quinolin—4—ylamino)propyl]benzamide, 2—(Hexyloxy)—N—[4—(quinolin—4—ylamino)butyl]benzamide. Alternatively R13 is 2—pyridyl, 3— l, or 4—pyridyl. Examples of such compounds include N—[8—(Quinolin—4— o)octyl]picolinamide, N—[8—(Quinolin—4—ylamino)octyl]nicotinamide, N—[8—(Quinolin—4—ylamino)octyl]isonicotinamide.
Other examples of nds of a IA include N—(Pyridin—4—ylmethyl)quinolin—4—amine, N—(Pyridin—3—ylmethyl)quinolin—4—amine, N—(Pyridin—2—ylmethyl)quinolin—4—amine, N—Hexquuinolin—4—amine, N—(Decyl)quinolin—4—amine, N—(Dodecyl)quinolin—4—amine, N1,NS—Di(quinolin—4—yl)octane—1,8—diamine. Other examples of compounds of Formula I in which G is yl include N—[8—(Hexyloxy)octyl]quinolin—6—amine, N—[8—(Hexyloxy)octyl] quinolin—3—amine, N—[8—(Hexyloxy)octyl]quinolin—8—amine, N—[8—(Hexyloxy)octyl]—2— (tri?uoromethyl)quinolin—4—amine, 7—Chloro—N—decquuinolin—4—amine, 7—Chloro—N— dodecquuinolin—4—amine.
Some of the compounds of this inveniton in which G is unsubstituted or substituted quinazolyl can be represented by a IB HN—A-Q-X-Y-Z R,_| l 2 IB wherein A is absent or t and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent. Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be 0 or NH.
X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or y X must have more than 1 carbon atom. Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms. Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, phenyl, y, or R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl having from 1 to 6 carbon atoms, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms. R1 is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl.
In an embodiment of Formula IB, R1 is hydrogen. In another embodiment, Y—Z is selected from the group ting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, henyl, alkoxycarbonylphenyl, N—alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl, isonicotinamidoalkyl, phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl, lalkyl, N—(quinazolylamino)alkyl, and N—(quinolylamino)alkyl.
A subset of compounds of Formula IB can be represented by Formula IBl 2)nQR7 / \N R1_ | J \ / wherein n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; Q is absent or present and is O or NHC(O), provided that if Q is present n cannot be 0 or 1; and provided that if Q is absent, then (CH2)nR7 must have more than 5 carbon atoms. R1 is hydrogen or halo. R7 is selected from the group consisting of: hydrogen; alkyl having from 1 to 6 carbon atoms; and phenyl or monocyclic aromatic ring having one nitrogen atom, unsubstituted or substituted by alkyl having from 1 to 6 carbon atoms or alkoxy haVing from 1 to 10 carbon atoms or phenyl or phenoxy. In an embodiment Q is absent. Examples of such compounds include N—(Decyl)quinazolin—4—amine, N—Dodecquuinazolin—4—amine, l—7—?uoroquinazolin—4—amine, N—Dodecyl—7— ?uoroquinazolin—4—amine, 7—Chloro—N—decquuinazolin—4—amine, 7—Chloro—N—dodecquuinazolin— e. In r embodiment Q is O or NHC(O). Examples of such compounds include N—(6— Butoxyhexyl)quinazolin—4—amine, N—[8—(Hexyloxy)octyl]quinazolin—4—amine, N—[8—(4—Methoxyphenoxy)octyl]quinazolin—4—amine, N—{2—[2—(Hexyloxy)phenoxy]ethyl} olin—4—amine, N— { 3— [2—(Hexyloxy)phenoxy]propyl zolin—4—amine, N— { 4—[2—(Hexyloxy)phenoxy]butyl }quinazolin—4—amine, N— [8—(Quinazolin—4— ylamino)octyl]nicotinamide. In an embodiment of Formula IB 1, n is 1, Q is , and R7 is phenyl substituted by alkoxy having from 1 to 10 carbon atoms or phenoxy. Examples of such compounds include N—[3—(Hexyloxy)benzyl]quinazolin—4—amine, N— [3—(Decyloxy)benzyl]quinazolin—4—amine, N—(3—Phenoxybenzyl)quinazolin—4—amine, N— [4—(Decyloxy)benzyl]quinazolin—4—amine, Hexyloxy)benzyl]quinazolin—4—amine.
Some of the compounds of this invention in which G is unsubstituted or substituted imidazoquinolyl can be represented by Formula IC |\ \ 1C N R1 Wherein R1 is hydrogen, OH, NHz, or N(CH3)2; R2 is ed from the group consisting of hydrogen, halo, methyl, and per?uoromethyl; R8 is hydrogen, or alkyl having from 1 to 15 carbon atoms tituted or substituted by alkoxy having 1 or 2 carbon atoms or acetoxy; and R9 is a branched or unbranched alkyl having from 1 to 16 carbon atoms, unsubstituted or substituted by hydroxy, or alkoxy having from 1 to 12 carbon atoms, provided that if substituted by hydroxy or alkoxy R9 must have more than 1 carbon atom. In an embodiment R2 is hydrogen.
Examples of such compounds include l—[2—(Ethoxymethyl)—lH—imidazo[4,5—c]quinolin—l—yl]-2— methylpropan—2—ol, l—(4—Amino—l—isobutyl—1H—imidazo[4,5—c]quinolin—2—yl)pentyl acetate, 1—Isobutyl—2—pentadecyl— lH—imidazo[4,5—c]quinolin—4—ol, l—Octyl— lH—imidazo[4,5—c]quinoline, 1—Hexadecyl— lH—imidazo[4,5—c]quinoline, 1—Hexadecyl— lH—imidazo[4,5—c]quinolin—4—amine, l—Dodecyl— dazo[4,5—c]quinoline, l—{ 5—[3—(Hexyloxy)propoxy]pentyl } — lH—imidazo[4,5— c]quinoline, 3—(Hexyloxy)phenoxy]propyl}—lH—imidazo[4,5—c]quinoline. In another embodiment of Formula IC, R2 is hydrogen, and R9 is an unbranched alkyl having from 2 to 10 carbon atoms, substituted by alkoxy having from 1 to 12 carbon atoms. Examples of such compounds include l—[2—(Dodecyloxy)ethyl]—lI-I—imidazo[4,5—c]quinoline, Dodecyloxy)ethyl]—N,N—dimethyl—lH—imidazo[4,5—c]quinolin—4—amine, l—[6— (Octyloxy)hexyl] — lH—imidazo[4,5—c]quinoline, l—(8—Ethoxyoctyl)— lH—imidazo[4,5—c]quinoline, l-(8—Methoxyoctyl)— lH—imidazo[4,5—c]quinoline, l—(8—Butoxyoctyl)— lH—imidazo[4,5— c]quinoline, l—[9—(Hexyloxy)nonyl] — lH—imidazo[4,5—c]quinoline, l—( l 0—Butoxydecyl)— 1H— imidazo[4,5—c]quinoline, l—[3—(Decyloxy)propyl]—1H—imidazo[4,5—c]quinoline, l—[4— (Decyloxy)butyl] — lH—imidazo[4,5—c]quinoline, 1—[8—(Hexyloxy)octyl] — lH—imidazo[4,5— c]quinoline.
Some of the compounds of this invention in which G is substituted pyridinium can be represented by Formula ID wherein R10 is alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, provided that if tuted by alkoxy R10 must have more than 1 carbon atom. Rllis hydrogen; or alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 3 carbon atoms, provided that if substituted by alkoxy R11 must have more than 1 carbon atom. X" is a rion. Examples of such compounds include a 4—Amino-l—[8—(hexyloxy)octyl]pyridinium salt, and 4—(8—Methoxyoctylamino)— l— pyridinium iodide.
WO 20995 In an embodiment of this invention G is lH—imidazo[4,5—c]pyridine. Some of those compounds can be represented by Formula IE /\\? IE wherein R12 is alkyl having from 2 to 16 carbon atoms, unsubstituted or substituted by alkoxy having from 4 to 6 carbon atoms. Examples of such compounds include l—[8—(Hexyloxy)octyl]— lH—imidazo[4,5—c]pyn'dine, l—Hexadecyl—lH—imidazo[4,5—c]pyn'dine, l—(lO—Butoxydecyl)—1H— imidazo[4,5—c]pyridine.
Examples of this invention in which G is pyridyl include N-(8-Methoxyoctyl)pyridineamine, N—[8-(Hexyloxy)octyl]pyridinamine, and N-[8-(Hexyloxy)octyl]pyridin-2—amine.
Examples of this invention in which G is pyrimidyl include N-[8-(Hexyloxy)octyl]pyrimidin amine, and N—[8-Hexyloxy)octyl)pyrimidin—2—amine. In an embodiment of this invention G is 5- aryl dazolyl. Examples of such compounds include 1—[8—(Hexyloxy)octy1]—4—phenyl—1H- imidazole. Examples of compounds of this invention in which G is isoquinolyl include N—[8— (Hexyloxy)octyl]isoquinolin—l—amine, N—[8—(Hexyloxy)octyl]isoquinolin—S—amine. Examples of compounds in which G is alyl include Hexyloxy)octyl]quinoxalin—Z—amine.
Examples of compounds in which G is benzimidazolyl include l—[8—(Hexyloxy)octyl]—1H— benzimidazole. es of compounds in which G is pyrazinyl include N—[8— (Hexyloxy)octyl]pyrazin—2—amine. Examples of compounds in which G is indolyl include l—[8— (Hexyloxy)octyl]—lH—indole. In an embodiment of this invention G is 3H—imidazo[4,5— b]pyridine. es of such compounds include Hexyloxy)octyl]—3H—imidazo[4,5— b]pyridine.
In certain embodiments of this invention, one or more of the following compounds are excluded: imiquimod; 4—(n—decylamino)quinoline [5891 ]; 4—decylaminoquinazoline [22754— 1 2—7].
In an embodiment of the compound of this invention, the compound is in substantially (at least 98%) pure form. This invention provides prodrugs of the compounds and salts bed above, and their uses as described . Whenever a phenyl ring is substituted, the substitution may be at the ortho—, meta—, or osition.
REACTION SCHEMES The compounds of the present invention can be made in accordance with the following reaction schemes.
The compound of formula I wherein G is a monocyclic or bicyclic aromatic ring having one or two ring nitrogen atoms, either unsubstituted or substituted at a ring carbon by halo, methyl, or per?uoromethyl; N is nitrogen, H is en; 2O A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent; Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be 0 or NH; X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom; Y is absent or present and is phenyl tituted or substituted by halo, or is a monocyclic or bicyclic ic ring having one nitrogen atom; Z is absent or present and is: a) hydrogen, b) alkyl having from 1 to 12 carbon atoms either unsubstituted or tuted by one phenyl or phenoxy group, c) alkoxy having from 1 to 10 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, d) phenyl, e) phenoxy, or f) NHC(O)R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl with l to 6 carbon atoms except if both X and Y are absent, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms, can be prepared from the on of the compound of formula 1 with the compound of formula 2 where LG is a leaving group such as a halogen, a sulfonyloxy, a siloxy, or a borate via the reaction scheme in Scheme 1. If LG is located in a position on the aromatic ring that is activated by a nitrogen atom, the reaction of step (a) can proceed thermally without the use of a catalyst, and LG is halo is red, and LG is chloro is most red. G is preferably selected from the group of compounds consisting of unsubstituted or substituted 4—quinolyl, 4—quinazolyl, 2—quinolyl, azolyl, l—isoquinolyl, uinolyl, 2— alyl, l—phthalazyl, 2—pyridyl, 4—pyridyl, 2—pyrimidyl, 4—pyrimidyl, and 2—pyrazinyl. The compound of formula 1 and the compound of formula 2 and a suitable base such as triethylamine, tripropylamine, N—methylmorpholine, or diisopropylethylamine are heated in a suitable solvent such as l—pentanol, l—butanol, 2—propanol, dimethylformamide, N— methylpyrrolidinone, or a mixture of suitable solvents. If LG is not located in a position on the aromatic ring that is activated by a en atom, the reaction can proceed with the use of a catalyst such as a transition metal complex catalyst such as a palladium complex or a nickel complex.
Scheme 1.
HZN—A—Q—X—Y—Z G—NH—A—Q—x—Y—z 1 G—LG The compound of formula 7 where T is CH and R2 is present or T is N and R2 is absent and where either: a) n is 2—12 and p is l; or b) n is 0 or 1 and p is 0; and where q is 0 or 1, and one of R1 and R2 is hydrogen and the other is ed from the group consisting of hydrogen, halo, methyl, and per?uoromethyl, and R3 is alkyl having from 1 to 10 carbon atoms either unsubstituted or tuted by: a) a monocyclic or bicyclic aromatic ring having one or two en atoms or phenyl either unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbons, provided that if R3 is alkyl substituted by alkoxy 2014/013992 then alkyl cannot have 1 carbon atom; phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or y ed that when substituted by phenoxy the alkoxy must have more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR6, C(O)NHR6, or NHC(O)R6 wherein R6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the nd of a 3 or starting from the compound of formula 6 via the reaction scheme in Scheme 2.
Some compounds of the formula 3 and some compounds of the formula 6 are commercially available. The compound of formula 3 is reacted with the compound of formula 4 to give the compound of formula 5 via reaction of step (a): the compound of formula 3 is treated with a suitable base and then is reacted with the compound of formula 4. The selectivity of the reaction for substitution of only one of the bromides of the compound of formula 4 can be increased by using a stoichiometric excess of the compound of formula 3. If n is 1, any base that is commonly used to convert an alcohol to an alkoxide is suitable, such as sodium hydride or a hindered alkali metal de such as sodium isopropoxide. If n is 1, the base must be completely reacted with the compound of formula 3 before the addition of the compound of formula 4 is performed. If n is 0, any base that is ly used to convert a phenol to a phenoxide is suitable, such as potassium carbonate or sodium carbonate. If n is 0, the compound of formula 4 may be present when the base is reacted with the compound of formula 3.
The compound of formula 5 is converted to the compound of formula 6 via reactions of step (b), the Gabriel synthesis of primary . The compound of formula 5 is d with potassium phthalimide under conventionally used conditions to give the phthalimide intermediate, which is converted to the compound of formula 6 under conventionally used conditions such as hydrazine monohydrate in ethanol at re?ux. Any method for the cleavage of phthalimides may be used.
The compound of formula 6 is converted to the compound of formula 7 via step (c): the compound of a 6 reacts with the compound of a 7 in the presence of a tertiary amine base such as triethylamine, diisopropylethylamine, or tripropylamine at elevated temperature in a suitable solvent, such as anol heated at re?ux if T is N or 1—pentanol heated at re?ux or dimethylformamide or N—methylpyrrolidinone at 130— 150 0C if T is CH.
Scheme 2.
HO—(CH2)q—R3 Br—(CH2)n—(O)p—(CH2)q—R3 Br—(CH2)n—Br 3 5 HN-(CH2)n—(O)p—(CH2)q-R3 (C) R1_/ / ILRZ HzN-<CH2>,-<0>,,—(CH2)q-R3 \ \N) Cl 6 7 1_ L R R \ J \ The compound of formula 3 where q is 0 or 1 and R3 is alkyl having from 1 to 10 carbon atoms substituted by alkoxy having from 1 to 12 carbon atoms, ed that if R3 is alkyl substituted by alkoxy then alkyl cannot have one carbon, can be prepared via the reaction scheme in Scheme 3. In step (a), the compound of formula 9 where n is 2—11 is treated with any base that is commonly used to convert an alcohol to an de, such as sodium hydride or a hindered alkali metal alkoxide such as sodium isopropoxide. Then, the compound of formula 10 where R6 is alkyl having from 1 to 12 carbon atoms is added. The selectivity of the reaction for alkylation of only one of the hydroxyls of the compound of formula 9 can be increased by using a stoichiometric excess of the compound of formula 9.
Scheme 3.
HO—(CH2)n—OH 2)q—R3 Br—R6 9 3 The compound of formula 3 where q is 0 or 1 and R3 is phenyl tuted by halo, alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy, can be prepared from the compound of formula 11 where q is O or 1 and R4 is hydrogen or halo Via the reaction scheme in Scheme 4. The compound of formula 11 is treated with a le base such as potassium carbonate or sodium carbonate and reacted with the compound of formula 10, where R6 is alkyl having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy. When using carbonate bases with the compound of formula 11 wherein q is 1, the aromatic yl will react selectively with the compound of formula 10, despite the presence of the aliphatic yl. If n is 0, the use of a stoichiometric excess of the compound of formula 11 will minimize the quantity of the dialkylated side product.
Scheme 4.
HO‘(CH2)q \ (a) ’\J,—OH HO—(CHg) -R3q Br—R6 R4 3 11 The compound of formula 6 where n is 0, p is 0, q is 0, and R3 is phenyl unsubstituted or substituted by halo, 6 wherein R6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the compound of formula 12 where R4 is hydrogen or halo and the compound of formula 13 where R6 is alkyl having from 1 to 6 carbon atoms via the reaction scheme in Scheme 5. The compound of formula 12 may be commercially available or can be prepared from the carboxylic acid using conventional methods. The compound of formula 14 where R4 is hydrogen or halo and R5 is 6 wherein R6 is alkyl having from 1 to 6 carbon atoms is ed from the reaction of the compound of a 12 with the compound of formula 13 in the presence of a base such as pyridine or triethylamine via step (a). Any of the conventional methods for the preparation of carboxylic esters from carboxylic acids or their derivatives and alcohols may be used to prepare the compound of formula 14. If the compound of a 13 is replaced by the amine , the reaction scheme will e the compound of formula 6 where R3 is substituted by R6. The compound of formula 14 is reduced to form the compound of formula 6 by catalytic reduction using hydrogen and a palladium on charcoal catalyst via step (b). Any of the conventional methods for selective reduction of nitro groups to amino groups in the presence of carboxylic ester groups can be used in step (b).
Scheme 5.
D (a) C(O)C1 '\—R5 x) x) 02N \ HO—R6 02N R4 R4 12 14 J (b) HzN-(CH2>n-(O>p—(CH2)q-R3 The compound of formula 6 where n is O, p is 0, q is 0, and R3 is phenyl unsubstituted or substituted by halo, NHC(O)R6 wherein R6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the compound of formula 15 where R4 is hydrogen or halo and the compound of formula 16 where R6 is alkyl having from 1 to 6 carbon atoms via the reaction scheme in Scheme 5. The compound of a 15 and the compound of formula 16 can react to produce the compound of formula 14 where R4 is hydrogen or halo and R5 is NHC(O)R6 n R6 is alkyl having from 1 to 6 carbon atoms via the reaction of step (a) under any conventional conditions for preparing carboxamides from the reaction of amines with carboxylic acid chlorides. The compound of formula 14 is reduced to form the compound of formula 6 by 2014/013992 catalytic reduction using hydrogen and a palladium on charcoal st via step (b). Any of the conventional methods for reduction of nitro groups to amino groups can be used in step (b).
Scheme 6. n,a—NHz\ n,TRs 02N CIC(0>—R6 OZN \ R4 R4 14 j (b) H2N—(CH2)n—(O)p—(CH2)q_R3 The compound of formula 6 where n is 0, p is 0, q is 0, and R3 is phenyl unsubstituted or substituted by halo, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or y group, can be prepared starting from the compound of formula 17 where R4 is hydrogen or halo and the compound of formula 10 where R6 is alkyl having from 1 to 12 carbon atoms either tituted or substituted by phenyl or phenoxy via the reaction scheme in Scheme 7. A mixture of compound of formula 17 and compound of formula 10 is reacted in the presence of a suitable base such as ium carbonate or sodium carbonate and a suitable solvent such as dimethylformamide to give compound of formula 14 where R4 is hydrogen or halo and R5 is alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group. The compound of formula 14 is reduced to form the compound of formula 6 by catalytic reduction using hydrogen and a palladium on charcoal catalyst via step (b). Any of the conventional s for reduction of nitro groups to amino groups can be used in step (b).
Scheme 7. n,70H\ n,TRs 02N Br—R6 OZN \ R4 R4 17 14 j (b) H2N"(CHM—(0)1)—(CH2)q‘R3 The compound of formula 6 where n is 0, p is 0, q is l and R3 is either phenyl or a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms, that is unsubstituted or substituted by halo and by: a) alkyl having from 1 to 12 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, c) phenyl, d) phenoxy, or e) NHC(O)R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the compound of formula 3 where q is 1 and R3 is either phenyl or a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms, that is unsubstituted or substituted by halo and by: a) alkyl having from 1 to 12 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms either tituted or substituted by one phenyl or phenoxy group, c) phenyl, d) phenoxy, or e) NHC(O)R6 or C(O)NHR6 or C(O)OR6 where R6 is alkyl having from 1 to 6 carbon atoms via the reaction scheme in Scheme 8. The compound of formula 3 is converted to the compound of formula 18 Via the reaction of step (a) by treatment with thionyl de.
Any of the reagents and reactions that are used conventionally to convert an alcohol and ularly a benzylic alcohol to a halide and ularly a ic halide can be used in step (a). Alternatively, the compound of formula 3 is converted to the compound of formula 19 via the reaction of step (b) by treatment with methanesulfonyl chloride and triethylamine. In step (b), any sulfonylation reagent that is conventionally used to convert a hydroxyl to a leaving group can be tuted for esulfonyl chloride, and any suitable base can be used in place of triethylamine. The compound of a 18 or the compound of formula 19 is converted to the compound of formula 6 via reactions of step (c), the Gabriel synthesis of primary amines. The compound of formula 18 or the compound of a 19 is reacted with potassium phthalimide under conventionally used ions to give the phthalimide ediate, which is converted to the compound of formula 6 under conventionally used conditions such as hydrazine monohydrate in ethanol at re?ux. Any method for the cleavage of phthalimides may be used.
Scheme 8.
Cl—(CH2)q—R3 HO—(CH2)q—R3 HZN—(CH2)n—(O)p—(CH2)q—R3 (b) (C) 6 \ / O'(CH2)q-R3 The nd of formula 24 where T is CH and R2 is present or T is N and R2 is absent and wherein n is 2, 3, 4, 5, 6, 7, or 8; R1 and R2 are hydrogen; and R13 is , 2—, 3—, or 4—pyridyl unsubstituted or substituted by: a) alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, b) alkoxy having from 1 to 12 carbon atoms either tituted or substituted by one phenyl or phenoxy group, c) phenyl, or d) phenoxy can be prepared starting from the compound of formula 20 where R6 is alkyl of l to 6 carbon atoms or, if commercially available, starting from the compound of formula 21 where R6 is alkyl of l to 6 carbon atoms and R13 is phenyl, 2—, 3—, or 4—pyridyl unsubstituted or substituted by: a) alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, b) alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, c) phenyl, or d) phenoxy via the reaction scheme in Scheme 9. The nd of formula 20 is reacted with the compound of formula 10 where R6 is alkyl having from 1 to 6 carbon atoms in the presence of a suitable base such as potassium carbonate via the reaction of step (a). The benzoic acid derivative of the compound of formula 20 can be used as the starting material, as well, if two equivalents of the compound of formula 10 and two equivalents of a suitable base are used. The compound of formula 21 can be reacted with the compound of a 22 where n is 2—8 to produce the nd of formula 23 via the reaction of step (b). Step (b) can be d out in the absence of solvent at a temperature of 100—130 0C.
The selectivity of acylation of only one of the amino groups of the compound of formula 22 can be increased by using a stoichiometric excess of the compound of formula 22. The compound of a 23 can be reacted with the compound of formula 8 to give the compound of formula 24 via the on of step (c). A e of the compound of a 23 and the compound of formula 7 where T is CH and R1 and R2 are hydrogen is heated inl—pentanol at re?ux or dimethylformamide or N—methylpyrrolidinone or a e thereof at 130—160 0C in the presence of a suitable base such as triethylamine, tripropylamine, N—methylmorpholine, or diisopropylethylamine to give the compound of formula 24 where T is CH. A mixture of the compound of formula 23 and the compound of formula 7 where T is N and R1 and R2 are hydrogen is heated in 2-propanol at re?ux in the presence of a suitable base such as triethylamine or diisopropylethylamine to give the compound of formula 24 where T is N. As an alternative preparation of the compound of formula 24, compound of formula 8 where T is CH and R2 is present or T is N and R2 is absent can be d with the compound of formula 22 to give the compound of formula 25 where T is CH and R2 is present or T is N and R2 is absent via the reaction of step (d). Step (d) is performed using the same t, ature, and base as described for step (c). The compound of formula 21 can be converted to the compound of formula 26 via the reactions of step (e). Any conventional method for the conversion of a carboxylic ester to a carboxylic acid chloride can be used for step (e); e. g., basic saponification and then reaction with thionyl chloride, oxalyl chloride, phosphoryl chloride, or phosphorus(V) chloride. The compound of formula 25 where T is CH or N and where R1 and R2 are hydrogen and the compound of formula 26 can be reacted to give the compound of formula 24 where T is CH or N via the reaction of step (f) using any of the conventional methods for the formation of carboxamides from ylic acid chlorides and amines.
Scheme 9.
O 0 R6O \ R6OJLR13 | —OH Br—R6 21 10 HZN—(CH2)n-NH2 (c) JOL HZN-(CH2)n—E R13 / / 23 \ \ }_R2 (d) / / T R—\1 2 \ J—R HzN—(CH2)n—NH2 N The compound of formula I wherein G is imidazoquinolyl unsubstituted or substituted at a ring carbon by halo, methyl, or perfluoromethyl; NH is absent; R1 is hydrogen, OH, NH;, or N(CH3)2; and either: a) AQXYZ is represented by R8, and R9 is a branched or ched alkyl having from 1 to 16 carbon atoms, unsubstituted or substituted by hydroxy or alkoxy having from 1 to 12 carbon atoms, provided that if substituted by hydroxy or alkoxy R9 cannot have 1 carbon atom, or b) AQXYZ is represented by R9, and R8 is hydrogen or alkyl having from 1 to carbon atoms unsubstituted or substituted by alkoxy having 1 or 2 carbon atoms or acetoxy can be prepared starting from the compound of formula 27 where R1 is hydrogen or hydroxy and R2 is hydrogen, halo, methyl, or per?uoromethyl via the reaction scheme in Scheme 10. In step (a), compound of the formula 27 where R1 is hydrogen or hydroxy is nitrated to produce the nd of the formula 28 using nitric acid in hot acetic acid or propionic acid. In step (b), the compound of formula 28 is treated with a chlorinating agent such as phosphoryl chloride, alone or in combination with phosphorus(V) chloride, or with phenylphosphonic dichloride to produce the compound of a 29, where R1 is chloro if the compound of formula 28 had hydroxy as R1. In step (c), the compound of a 29 is reacted with the compound of formula 30 in the ce of a tertiary amine base such as triethylamine in an inert solvent such as dichoromethane, aided by gentle warming to produce the compound of formula 31. It is well- established in the ture that the 4-chloro of the compound of formula 29 where R1 is chloro is the more reactive with amines. Any of the amines described in the invention can be used in step (c). It was discovered that if compound of formula 29 where R1 is chloro is d with the compound of formula 30 in a mixture of dimethylformamide and dichloromethane initially, and then the dichloromethane is replaced with toluene and the mixture is heated at re?ux, the compound of formula 31 where R1 is N(CH3)2 is produced. In step (d), the nitro group of the nd of a 31 is reduced by any of a number of methods. If R1 is hydrogen or chloro, enation using 5% or 10% Pd—C or reduction using zinc dust and hydrochloric acid will produce the compound of formula 32 where R1 is hydrogen. If R1 is chloro, hydrogenation using % Pt—C will produce the compound of formula 32 where R1 is chloro. If R1 is dimethylamino, all these s leave R1 unchanged. In step (e), the ortho—diamine of the compound of formula 32 is heated with the ylic acid compound of formula 33 or the compound of formula 34, the ortho ester of the nd of 33, to produce the compound of formula 35. Any ortho ester analog of the compound of formula 33 may be used. In step (f), if the compound of formula 35 where R1 is chloro is treated with hydrolytic conditions, the compound of formula 36 Where R1 is hydroxy is produced. In step (f), if the compound of formula 35 Where R1 is chloro is d with ammonia or a primary amine, the Rl—amino tive of the compound of formula 36 is produced. In step (f), if the compound of formula 35 Where R1 is chloro is treated with zinc dust and hydrochloric acid, the compound of formula 36 Where R1 is hydrogen is produced. The compound of formula 35 Where R1 and R2 and R8 are hydrogen and R9 is stable to organolithium bases can be reacted with an organolithium base and then alkylated by an halide or aldehyde to give the compound of formula 36 where R8 contains the derivative of the tion reagent.
REMAINDER OF PAGE INTENTIONALLY BLANK Scheme 10.
R2 C61 N R1 NH NH / NH2 (d) R—2 /| N R1 (C) or Rs—C(OCH3)3 R\9 R8 N’\< / / (f) R—\2 I N R1 WO 20995 If the compound of a 33, or the compound of formula 34, or the compound of formula 37 wherein n is 0—12, provided that ifp is 1 then n must not be 0 or 1; p is 0 or 1; q is 0 or 1; R3 is selected from the group consisting of: alkyl having from 1 to 10 carbon atoms either unsubstituted or substituted by: a) a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms either unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbon atoms, provided that if R3 is alkyl substituted by alkoxy then alkyl must have more than 1 carbon atom; and phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms tituted or substituted by phenyl or phenoxy, provided that when substituted by phenoxy the alkoxy must have more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR6, C(O)NHR6, or NHC(O)R6, wherein R6 is alkyl having from 1 to 6 carbon atoms is not available commercially or as a tic intermediate, the compound of formula 5 can be converted to the compound of formula 37 and hence to the compound of formula 33, or the compound of formula 5 can be converted to the compound of formula 34 via the Pinner reaction by the scheme shown in Scheme 11. In step (a), the compound of formula 5 is d with the alkali metal salt of acetic acid, such as potassium acetate or sodium acetate or lithium acetate, in a suitable solvent such as dimethylformamide. Then, the acetate ester is hydrolyzed at tely basic pH to produce the nd of formula 37. The nd of formula 37, a primary l, can be oxidized to the ylic acid compound of the formula 33 via the reaction of step (b) using any of the numerous suitable methods for the oxidation of alcohols to acids, such as the Jones oxidation. Alternatively, the compound of formula 5 is reacted with an alkali metal cyanide such as sodium cyanide or potassium cyanide in a suitable solvent such as dimethylformamide to produce the nd of formula 38 via the reaction of step (c). In step (d), the compound of formula 38 is treated with an alcohol such as methanol and an acid catalyst such as hydrochloric acid to form the compound of formula 34.
Scheme 11.
Br—(CH2)n—(O)p—(CH2)q—R3 —> HO—(CH2)n—(O)p—(CH2)q—R3 37 j (c) (b) NC—(CH2)n—(O)p—(CH2)q—R3 H0(0)C—R8 J (d) 3C—R8 The nd of formula ID wherein R10 is alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, provided that if substituted by alkoxy R10 must have more than 1 carbon atom; R11 is hydrogen, or alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 3 carbon atoms, provided that if substituted by alkoxy R11 must have more than 1 carbon atom; and X‘ is a counterion can be prepared by the scheme shown in Scheme 12. If the compound of formula 41 is not commercially available, compound 39, 4—chloropyridine hloride, can be used to prepare it via the on of step (a). Compound 39 is heated at 0 0C in a hindered alcohol such as 2—propanol in the presence of a tertiary amine base such as triethylamine with the compound of formula 40 to give the compound of formula 41. Via the reaction of step (b), the compound of formula 41 is reacted with an alkyl sulfonate such as the compound of formula 42 in a suitable solvent such as acetone to give the compound of formula ID, Where X" is a counterion such as methanesulfonate, iodide, bromide, or de. Any alkyl iodide or alkyl bromide or alkyl sulfonate derivative of R10 can be used in the reaction of step (b).
Scheme 12.
R11 R1\1 Cl \NH NH / (a) b < > I d N \ a\ + X_ N HCl 1111—an RIO—0302CH3 If 40 41 42 The compound of formula 48, Where R12 is alkyl having from 2 to 16 carbon atoms, unsubstituted or substituted by alkoxy having from 4 to 6 s, can be prepared starting from compound 43, 4—hydroxy—3—nitropyridine, by the scheme shown in Scheme 13. Compound 43 is reacted with a suitable halogenating agent such as phenylphosphonic ride to give compound 44, 4-chloronitropyridine via the reaction of step (a). Compound 44 is reacted with the compound of formula 45 in the presence of a suitable base such as triethylamine in a suitable t such as pyridine to e the compound of formula 46 via the reaction of step (b). Any of the amines described in the invention can be used in step (b). The nitro group of the compound of formula 46 is reduced to the amino group of the compound of formula 47 by catalytic hydrogenation via the reaction of step (c). The compound of formula 47 is heated in yl orthoformate to e the compound of formula 48 via the reaction of step (d). Using the same steps (b), (c), and (d), but starting from commercially available compound 49, 2—chloro- 3—nitropyridine, the compound of formula 52 is prepared.
REMAlNDER OF PAGE INTENTIONALLY BLANK 2014/013992 Scheme 13.
(FNOZ (b) N Rlz—NHZ 43 44 45 R12—NH2 Any compound of formula 53 where G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring en atoms where a ring nitrogen atom is bonded to hydrogen can react with the compound of formula 55 where Br—AQXYZ is a y alkyl bromide to produce the compound of the formula 54, where AQXYZ is given by claim 1 for the compound of formula I, by the scheme shown in Scheme 14. The compound of the formula 53 is treated with a strong base such as sodium tert—butoxide in a suitable solvent such as dimethylformamide, and the ing amide anion is treated with the compound of formula 55 to e the compound of formula 54 via the reaction of step (a). If the amide anion is in resonance with a neighboring en, the alkylation by the nd of formula 55 occurs at the less hindered nitrogen ively. The primary alkyl iodide, chloride, alkanesulfonate, or arylsulfonate of AQXYZ can be used in place of the compound of formula 55 for the reaction of step (a).
Scheme 14. 1'4 (a) 1?me G G Br—AQXYZ 53 55 54 Any compound of formula 58 where G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms as defined in Claim 1, where a ring carbon atom is bonded to an NHZ group, can undergo an alkylation procedure to produce a compound with the formula 59, where A, Q, X, Y, and Z are as defined in Claim 1, starting from the compound of formula 56, where (AQXYZ) is a l that is terminated by a primary alcohol group, by the scheme shown in Scheme 15. Many nds of the formula 58 are available commercially.
The compound of the formula 56, where the radical (AQXYZ) is terminated by a primary alcohol function and where (AQXYZ) does not contain another alcohol group or an amino group, can undergo oxidation by any of a variety of conventional methods such as the Swern oxidation or oxidation by tetrapropylammonium perruthenate/N—methylmorpholine N—oxide to produce the nd of formula 57 via the reaction of step (a). The compound of formula 58 2014/013992 can undergo reductive alkylation by the compound of formula 57 via the reaction of step (b) using any conventional method for amine reductive alkylation such as by sodium cyanoborohydride in tetrahydrofuran. Alternatively, the compound of formula 58 can undergo acylation by the carboxylic acid radical of (AQXYZ) via the reaction of step (d) using any conventional method for amide formation such as a carbodiimide sation or a mixed anhydride acylation using isopropyl chloroformate. Also, step (d) can be carried out using the acid chloride derivative of the compound of formula 60, Which can be ed using any conventional reagent for the preparation of acid chlorides such as thionyl chloride or oxalyl chloride. The nd of formula 60 can be produced from the compound of formula 56 via the reaction of step (c) using any suitable tional t for the oxidation of alcohols such as the Jones reagent. The amide group of the compound of formula 61, Where (AQXYZ) does not contain an ester or another amide group, can be reduced to the amino group of the compound of formula 59 via the reaction of step (e) using a suitable reducing agent such as lithium aluminum hydride.
DER OF PAGE INTENTIONALLY BLANK Scheme 15.
HOCHz—(AQXYZ) —> HOOC—(AQXYZ) 56 60 (3) G (d) CHO—(AQXYZ) o >—(AQXYZ) 57 HI‘II ITIHz 61 (b) G <6) uHAQXYz Any compound of formula 58 where G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms as defined in Claim 1, where a ring carbon atom is bonded to an NHZ group, can undergo an alkylation procedure to produce a compound with the formula 59, where A, Q, X, Y, and Z are as defined in Claim 1, starting from the compound of formula 56, where (AQXYZ) is a radical that is terminated by a primary alcohol group, by the scheme shown in Scheme 16. Many nds of the a 58 are available commercially.
The compound of the formula 56, where the radical (AQXYZ) is terminated by a primary alcohol on and where ) does not contain another alcohol or amino group, can o a sulfonylation reaction using methanesulfonyl chloride and an amine base such as pyridine or triethylamine to produce the compound of formula 62 Via the reaction of step (a). The compound of formula 58 can undergo substitutive alkylation by the compound of formula 62 to produce the compound of formula 59 via the reaction of step (b) using any conventional method for amine alkylation, such as heating the mixture in tetrahydrofuran or dimethylformamide in the absence or ce of a base such as ylamine, diisopropylamine, or N—methylmorpholine. s of the compound of formula 62 where the methanesulfonate group is ed by a conventional good leaving group such as iodide, bromide, chloride, or a different sulfonate group can be used in step (b).
Scheme 16.
HOCHz—(AQXYZ) —’ CH3SOZOCH2—(AQXYZ) 56 62 G (b) $HAQXYZ USES AND METHODS OF TREATMENT This invention provides certain compounds, described below, for treating diseases characterized by pathogenic cells ing lysosomes or other acidic vacuoles with disease—related alterations predisposing them to accumulation of compounds of the ion, which then selectively vate or eliminate such pathogenic cells. Compounds of the invention, many of which are aminoquinoline and aminoquinazoline derivatives, feature significant improvements in potency 2014/013992 and activity over known aminoquinoline drugs such as chloroquine, as a consequence of structural moieties that ly disrupt lysosomal or vacuolar membrane integrity when the compounds late in acidic vacuoles in cells. Diseases that are at least moderately sive to antimalarial quinoline derivatives and analogs are in general more effectively treated with compounds of the invention. Such diseases broadly comprise atory diseases, neoplastic diseases, including both hematologic cancers and solid tumors, and infections by eukaryotic ens, including fungi and several classes of protozoal or other unicellular parasites.
ANTI—INFLAMMATORY USE An important action of nds of the invention is anti—in?ammatory activity, providing utility for treating or preventing diseases or symptoms related to excessive tissue in?ammation.
This invention also provides compositions containing a compound of this invention as well as the use of a compound of this invention for the manufacture of a medicament for treatment or prevention of in?ammatory diseases. Compounds of the invention y selectivity for suppressing or inactivating macrophages that have been stimulated into a pro-in?ammatory state, with less of an effect on non-stimulated macrophages. ted pro-in?ammatory hages contribute to pathogenesis of a large variety of in?ammatory and autoimmune diseases.
Macrophages are both antigen presenting cells and effectors for tissue damage directed by active T cells, and participate in tissue damage and dysfunction in diseases including but not limited to rheumatoid arthritis, systemic lupus erythematosis, psoriasis, in?ammatory bowel disease, and atopic dermatitis. In?ammatory macrophages participate in many systemic diseases, including autoimmune diseases, cardiovascular and metabolic diseases, and neurodegenerative conditions. Activated macrophages play a primary role in tissue damage in instability of atherosclerotic plaques, with consequent risk of rupture and thrombotic vessel ion. Activated macrophages in adipose tissue contribute to metabolic abnormalities including n ance, type 2 diabetes and other consequences of obesity. Osteoclasts are macrophage—like cells that mediate bone degeneration in osteoporosis and in participate in bone destruction and “bone pain” in cancers arising in or metastasized to bones. Compositions of the invention are useful for treating these and other disorders in which activated macrophages contribute to in?ammatory disease pathogenesis.
Several s of topical agents are used for treatment of in?ammatory diseases of the skin, such as atopic dermatitis, eczema or psoriasis. Corticosteroids are widely used, but have the potential for both local and systemic toxicities, particularly with prolonged use. They can cause local skin atrophy or thinning, which may lead to disruption of the skin, as well as telangiectasia.
Furthermore, topical corticosteroids can be absorbed systemically in amounts sufficient to cause systemic side effects. A second class of agents for ent of atopic dermatitis is T cell immunosuppressants, such as the calcineurin inhibitors tacrolimus and pimecrolimus. Their local and systemic immunosuppressive effects have led to concerns about depressing immunosurveillance of cancers, including melanomas and lymphomas.
Vitamin D analogs, y calcipotriene, are known for topical treatment of sis.
Calciptoriene acts by ting excessive proliferation of keratinocytes. Application to normal skin is contra-indicated due to a bleaching effect and there is also a possibility of e events from systemic absorption. Dermal irritation or g is known as a side effect of otriene.
Compounds of the invention are ularly active against macrophage precursors that have been activated by exposure to n D3. It is possible that psoriasis ent with calcipotriene, while providing some improvements by inhibiting keratinocyte proliferation, may also direct local macrophages toward a pro—in?ammatory state, buting to known side effects such as irritation, and limiting the net therapeutic effect. The y of compounds of the invention to inactivate pro—in?ammatory vitamin D3-primed macrophage sors as shown in several Examples below indicates that combination topical treatment with compounds of the invention and vitamin D analogs may provide unexpected benefits in psoriasis and psoriatic dermatitis, both in treating the in?ammatory epidermal hyperproliferation and in reducing irritation or itching as side effects of vitamin D analogs.
Compounds of the invention are useful for treating ocular in?ammation, including keratitis, whether caused by infection l, bacterial, amoebic) or by non—infectious triggers such as corneal injury or contact lenses. Compounds of the invention are especially suitable for fungal keratitis, counteracting both infectious fungi and concurrent in?ammatory damage. Compounds of the invention t l enesis and other in?ammatory changes in response to mechanical or chemical injury.
Compounds of the invention are useful for treating a variety of in?ammatory or hyperproliferative skin conditions or lesions, including but not limited to eczema, atopic dermatitis, psoriasis, and impetigo. Impetigo is a superficial bacterial skin infection with atory damage to the mia; compounds of the invention both suppress in?ammation and have direct inhibitory or bactericidal effects on gram positive bacteria, including but not d to Staphylococcus aureus and Staphylococcus pyogenes, the primary organisms responsible for go. nds of the invention also inhibit oplastic and neoplastic skin alterations, which often exhibit characteristics of both in?ammation and neoplasia, including but not limited to actinic keratosis, seborrheic keratoses and warts.
Examples E and F demonstrate efficacy of compounds of the invention for treating skin in?ammation and psoriatic dermatitis in established mouse models of human skin disorders.
Macrophages and related cells types contribute to pathogenesis of autoimmune diseases involving the adaptive immune system both as antigen presenting cells and as effectors damaging tissues after inappropriate stimulation by T cells, which secrete interferon gamma and other in?ammatory mediators that recruit and activate macrophages. Compounds of the invention disrupt antigen presentation by hages and dendritic cells, and also inactivate pro—in?ammatory effector macrophages that damage tissues. A general ce is that compounds of the invention are useful for treating c or episodic autoimmune diseases where chloroquine, hydroxychloroquine or other antimalarial ine analogs display activity in humans or relevant animal models, and are generally more potent and active than the larials in in?ammatory and non—malaria infectious diseases. Such diseases include but are not limited to rheumatoid arthritis, systemic and discoid lupus erythematosis, psoriatic arthritis, vasculitis, ns syndrome, scleroderma, autoimmune hepatitis, and multiple sclerosis.
Macrophage activation syndrome (MAS) is an acute cation of several autoimmune diseases, especially in ood—onset conditions such as idiopathic juvenile arthritis where it affects more than 10% of patients, and also in in?ammatory bowel diseases. In MAS, macrophages are over—activated, causing damage to the hematopoietic system and systemic in?ammation; MAS is sometimes lethal. Compounds of the invention are useful for treatment of MAS, and are optionally delivered orally or by intravenous injection or infusion.
Example G shows beneficial activity of compounds of the invention when administered orally to mice in a model of le sis, an autoimmune disease.
For treatment of chronic mune disorders, compounds of the invention are administered systemically, preferably orally. For treatment of acute in?ammatory conditions, or ?ares of autoimmune diseases, intravenous treatment with compounds of the invention is an optional suitable delivery route.
For oral or intravenous treatment of autoimmune or in?ammatory diseases, compounds of the invention are typically administered in doses ranging from 1 to 1000 rams per day, advantageously 100 to 600 milligrams per day, in single doses or divided into two or three doses per day.
ANTIFUNGAL AND ANTIPARASITIC USES The compounds of this invention are useful in inhibiting fungal growth, both in viva and ex viva.
Accordingly this invention also provides methods and uses for ting the growth of a fungus in a mammalian subject, for example a human. These methods can be used to treat and to prevent fungal infection. Ex viva, it is useful to treat surfaces with a nd of this invention to t or prevent fungal growth, or in agriculture or ulture to prevent or treat fungi that affect valuable plants. This invention also provides compositions containing a compound of this ion as well as the use of a compound of this invention for the manufacture of a ment for inhibiting the growth of a fungus.
This invention is based, in part, on the finding that the compounds of this ion are effective in inhibiting the growth of a variety of fungal species, as shown in the biological activity examples below. Without wishing to be bound by theory, it is believed that compounds of this disclosure exploit the ability of the fungal acidic vacuole. They are believed to 2014/013992 accumulate in acidic es via cation ng, and furthermore exert antifungal activity by disrupting the structure and function of the acidic vacuoles.
In accordance with this invention, the growth of fungi generally is inhibited. Examples of fungi that can be inhibited include but are not limited to Candida, Saccharomyces, Trichophyton, Cryptococcns, Aspergillus, and Rhizopns. In more specific embodiments of this invention the fungus is Candida albicans; a glabrata; Saccharomyces cerevisiae ; Trichophyton rnbmm; Cryptococcus mans, for example Cryptococcns neoformans pes D and A; and Aspergillns fumigatus.
This invention also provides methods of treating and preventing parasitic infections. Due to the capability of compounds of the invention to enter and accumulate within acidic vacuoles in cells, they are useful for treating infections due to parasitic rnicroorganisins that reside within acidic vacuoles in macrophages and other cell types. 'l‘tiberculosis (mycobacteria‘), listeria or staphylococcus (gram positive bacteria), coccus (fungus), and leishrnania and trypanosornes (amoehae), Coxielia bzmzezii (gram negative ia), and Plasmodium (some of which cause malaria) are nonlirniting examples of important such infectious organisms, in. which nce within macrophages can protect the organisms from cellular or humoral immunity, or reduce the efficacy of drug treatments.
Compounds of the invention, which bear lipophilic moieties and are generally partially neutral at physiological pH (7.3), can pass freely into acidic vacuoles harboring parasites, and are concentrated and tapped there due to ionization in the acidic environment (pH 4—6.5). These compounds disrupt the structure and function of acidic vacuoles as hospitable sites for parasites and also have direct antiparasitic activity, due to acidic vacuoles within many parasitic organisms. tes whose viability or virulence is dependent on ity and function of an acidic vacuole are also vulnerable to compounds of the invention, r to the basis "or their antifungal activity. The acidic vacuole of malaria plasn‘iodia provides an environment for concentration of compounds of the invention. Similarly, trypanosomes have a large acidic vacuole which is necessary for utilization of environmental nutrients. nds of the invention are useful for treatment or prevention of malaria and trypanosonie in ‘ections. More hroadly, protozoal parasites in general use acidified digestive vacuoles for acquisition and digestion of food, and are therefore susceptible to antiparasitic actions of compounds of the invention.
The larial drug chloroquine is reported to have antiparasitic ty against a variety of organisms harbored in acidic vacuoles in host cells, or which have acidic vacuoles lves, including hut not limited to tuberculosis mycobacteria, cryptosporidium, leishmania and cryptococcus. in general, chloroquine acts hy accumulating in acidic vacuoles via cation trapping. Activity of chloroquine is thus an indicator of likely ty of compounds of the inventions {many of which comprise an aminoquinoline or other cycle similar to that of chloroquine for the purpose of targeting acidic vacuoles), with the difference that compounds of the invention are substantially more potent and active than is chloroquine, as demonstrated in Cryptomccas neaformans in Example K, where chlm‘oquine produced less than 50% growth tion at a concentration of 100 micromolar, s many nds of the invention produced lOt % growth tion at much lower concentrations. Chloroquine, despite published s showing that it can improve survival in animal models of cryptococcosis, displays a ceiling of about 40% inhibition of C. neoformans growth in vitro, whereas compounds of the invention are substantially more potent than chloroquine and can cause .lll?‘ih inhibition of coccus growth, due to superior disruption of the membranes of acidic vacuoles in which the respective drugs are accumulated.
For treatment of fungal or parasitic infections, compounds of the invention are administered in vehicles and by routes of administration appropriate for the nature and location of the infection.
For dermal or nail in ‘ections, compound of the invention are applied in a topical ation which is optionally a lotion, ointment, solution, suspension, or spray. For ocular fungal infections, compounds of the invention are ated in eyedrops. For ic infections, compounds of the invention are administered orally in tablets, es, dragees, solutions or suspensions, or administered systemically by injection in , lipid ons, liposomes or other standard parenteral vehicles. Lung infections, especially involving organisms residing in alveolar macrophages, are optionally treated via inhalational delivery of compounds of the invention and suitable excipients known to be acceptable for inhalational drng delivery. For intravenous or oral administration to treat systemic in ‘ections, compounds of the invention are stered in doses ranging from If.) to 2000 milligrams per day, advantageously 200 to 100% milligrams per day.
Other classes of antifungal agents in clinical use include inhibitors of ergosterol synthesis (“azole” antifungals including but not limited to zole, ketoconazole, voriconazole, and allylamines including but not limited to afine), polyene antifungals which act by binding to fungal membrane constituents, especially erol (including but not limited to amphotericin B or nystatin), echinocandin inhibtors of gluoan synthesis (including but not limited to ungin), and other agents known as active antifungals in medical practice. Compounds of the invention act via a distinct mechanism of action versus existing clinically important antifungals and are optionally coadministered with one or more other antifungal agent to improve l antifungal treatment. Compounds of the invention are coadministered as separate pharmaceutical formulations, or are optionally formulated into a single combined-drug product. A combination of compounds of the inventions with azole antifungals is particularly advantageous as a completely oral regimen for use against cyptoccoccosis, which otherwise generally requires amphotericin B injections or infusions for intial induction. Compounds of the ion are also optionally coadministered with amphotericin B. One formulation of amphotericin B involves its incorporation into lipids comprising the membranes of liposomes. e many of the compounds of the ion bear lipophilic moieties that insert into lipid membranes, they are advantageously orated into liposomes, either as single agents or in combination with amphotericin B or other known polyene antifungal agents.
ANTICANCER USES This invention provides compounds that are useful for ic treatment of cancer, based on consistent lysosomal changes characterizing ve cancers. Lysosomal changes in cancer, including their enlargement and acidification, facilitates survival of cancer cells in acidic extracellular environments and also se the ability of cancer cells to invade surrounding tissues, through exocytosis of lysosomal contents, including ses and polysaccharidases which can degrade extracellular matrix components. However, these typed changes in lysosomal properties can render cancer cells vulnerable to lysosome—disrupting agents with appropriate physicochemical properties for selectively accumulating in and damaging lysosomes in cancer cells versus normal tissues. nds of the invention accumulate in lysosomes in cancer cells and disrupt their integrity, thereby displaying potent selective cytotoxic activity against cancer cells in vivo and in vitro.
Because one major ism for cancer cell resistance to a variety of chemotherapy agents is to sequester them in lysosomes and other acidic vesicular compartments, compounds of the invention are able to restore or enhance sensitivity of cancer cells to a variety of classes of anticancer agents, ing antimetabolites, tyrosine kinase inhibitors, anticancer antibodies against growth factor receptors, anthracyclines, platinum nds, alkylating agents, and antibodies. Compounds of the invention typically do not display toxicities overlapping dose limiting toxicities of most ncer agents, permitting combination of compounds of the invention with other classes of antineoplastic drugs with a net improvement in efficacy and therapeutic index.
Cancer cells exposed to sublethal doses of ionizing radiation undergo a protective response that increases their resistance to subsequent irradiation. A component of this protective response is formation of enlarged mes or other ied vacuolar organelles; inhibition of the vacuolar ATPase responsible for acidifying lysosomes with bafilomycin A prevents the protective se in sublethally irradiated cells and sensitizes cancer cells to ionizing radiation Lysosomal damage is a icant mediator of radiation-induced death in cancer cells. By disrupting the integrity of lysosomal membranes, compounds of the invention are useful for reducing resistance of cancer cells to therapeutic ionizing radiation and for potentiating anticancer effectiveness of ionizing ion y. nds of the invention are optionally administered prior to ionizing radiation therapy of cancer er with external irradiation or stration of antibody—targeted radioisotopes) as radiosensitizers, or they may be given after irradiation to attack surviving cancer cells undergoing protective responses to nonlethal ation involving production or enlargement of acidic vacuoles.
One mechanism imparting selective survival and proliferation advantages in some cancers is upregulation of autophagy, a process through which damaged organelles or other cell debris are engulfed by autophagosomes, which fuse with lysosomes to digest and recycle constituent les. By concentrating in and disrupting mes, compounds of the invention impair autophagy in cancer cells, y reducing their viability and resistance to other anticancer treatments.
For treatment of cancer, compounds of the invention are administered by oral or intravenous stration in doses of 10 to 2000 milligrams per day. Compounds of the invention are administered as single agents or in combination with other cancer treatments appropriate for a particular type of cancer, and generally in doses when such agents are used alone, as compounds of the invention will generally not have overlapping toxicities with other classes of anticancer agents that would necessitate substantial dose reduction.
PHARMACEUTICAL COMPOSITIONS This ion provides a ceutical composition comprising a biologically active agent as described herein and a pharmaceutically acceptable carrier. Further embodiments of the ceutical composition of this invention comprise any one of the embodiments of the biologically active agents bed above. In the interest of avoiding unnecessary redundancy, each such agent and group of agents is not being repeated, but they are incorporated into this description of pharmaceutical compositions as if they were ed.
Preferably the ition is adapted for oral administration, e.g. in the form of a tablet, coated tablet, dragee, hard or soft gelatin capsule, solution, emulsion or suspension. In general the oral composition will comprise from 10 to 1000 mg of the compound of this invention. It is convenient for the t to swallow one or two tablets, coated tablets, s, or gelatin capsules per day. However the composition can also be adapted for administration by any other conventional means of systemic administration including rectally, e. g. in the form of suppositories, parenterally, e. g. in the form of injection solutions, or nasally.
The biologically active compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of ceutical itions. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard n capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi—solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, r, usually required in the case of soft gelatin capsules, other than the soft gelatin itself. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, ol, ble oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi—liquid or liquid polyols and the like.
The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, g agents, emulsifiers, sweeteners, nts, ?avorants, salts for varying the osmotic pressure, buffers, coating agents or idants. They can also contain still other therapeutically le substances, particularly anti-in?ammatory or antifungal agents (depending on whether an in?ammatory disease or a fungal infection or cancer are being addressed in a patient) that act through mechanisms other than those underlying the effects of the compounds of the invention.
For treatment of cancer, preferred additional drugs that can advantageously be coadministered or coformulated with a compound of the invention comprise orally active anticancer agents.
Because compounds of the ion act through a unique mechanism not shared by other anticancer drugs, they are compatible with a large variety of concurrent therapies, including antimetabolites, anthracyclines, tyrosine kinase tors, platinum drugs, or alkylating agents.
Such agents, when orally active, are administered or coformulated to deliver quantities of drugs determined in previous clinical trials to be effective and adequately tolerated.
For systemic treatment of diseases, including some cancers, in?ammatory conditions and fungal or oal infections, compounds of the invention are optionally administered by enous injection or infusion. For intravenous administration, compounds of the invention are dissolved in suitable intravenous formulations as ons or in lipid emulsions, using standard ents known in the art as well—tolerated intravenous formulation ingredients and compositions.
Suitable volumes and concentrations are selected for delivery of 10 to 2000 miligrams of compounds of the invention per day, depending on the specific ements for a compound, and a disease condition as determined in clinical trials.
Compounds of the invention are optionally incorporated into liposomal formulations. The ilic moieties of compounds of the invention permit their direct incorporation into lipid layers of lipososomes. Liposomes are advantageous in some conditions for intravenous administration due to improved efficacy and milder infusion reactions versus osomal formulations. Liposomes are also le for inhalational delivery to treat fungal or parasitic infections of the lungs, or in?ammation of the lungs and airways. In some embodiments, compounds of the invention are incorporated into liposomal delivery formulations with other drugs, including but not limited to ngal agents such as liposomal amphotericin B, or anticancer agents such as liposomal doxorubicin.
For treatment of atory skin conditions or fungal infections of the skin or nails, or of nasal es, compounds of the invention are applied topically in a pharmaceutically acceptable ation. The l. composition can be in various forms, including, but not limited. to, a on, spray, gel, hydrogel, lotion, cream, ointment, paste, or an emulsion in the form of liquid suspension, lotion, or cream. ’l‘he composition can also be applied via a dermal patch, or bandage which can he applied on the ed. area as needed, to provide an extended exposure of the skin to the medication; in such tormulations, appropriate standard topical medicament excipients and vehicles are suitable for deliverin(IQ compounds of the invention.
Standard constituents for topical formulations are known in the art and are suitable as vehciles for compounds of the ion. {lintnient bases can comprise one or more of hydrocarbons (paraffin wax, soft. paraffin, crystalline wax, or ceresine), absorption hases (wool fat or beeswax}, macrogols (polyethylene glycol), or vegetable oils. Lotions and creams are water in oil or oil in water emulsions; the oil components can comprise long chain fatty acids, alcohols or esters, and al contain bioconipatihle nonionic surfactants. Compounds of the invention are incorporated into topical vehicles in concentrations g from 0.01% to 5%, preferably 0.02 to 1%. Compounds of the invention are applied to skin lesions once to three times per day for durations dependent on the rate of resolution of the condition.
For treatment of some lung ions, including fungal infections or parasites ng in ar macrophages, inhalational as of compounds of the invention are suitable.
Excipients and inhalational drug delivery devices are known in the art and are useful for delivering nds of the invention to treat lung infections, including cryptococcus and tuberculosis.
Compounds of the invention are advantageously coformulated with other antifungal or anti— atory agents for topical or systemic administration, particularly when both drugs are appropriately administered via the same route and le. Compounds of the invention are compatible with standard formulations and excipients used for other topical or systemic ngal or anti—inflammatory agents, including but not limited to ointments and tablets or capsules. Advantageous drug categories for combination in topical anti—in?ammatoty formulations include corticosteroids, calcineurin inhibitors and vitamin D ues, and other agents known to have independent therapeutic acitivity in in?ammatory skin conditions.
The invention will be better understood by reference to the following examples, which illustrate but do not limit the invention described herein.
EXAMPLES CHEMICAL SYNTHESIS EXAMPLES Example 1: N—[8—(Hexyloxy)octyl]quinolin—4—amine HN/\/\/\/\/O\/\/\/ CKE/ A mixture of 4—chloroquinoline (300 mg, 1.84 mmol), 8—(hexyloxy)octan—l—amine (558 mg, 2.44 mmol), and DMAP (260 mg, 2.13 mmol) was heated at 135 0C for 3 hr. The mixture was cooled and partitioned between DCM and 5% N32C03. The organic phase was dried over NazSO4 and concentrated. FC (10%, 12%, 14% MeOH/DCM step nt) gave 279 mg of product as a W0 2014/120995 solid. Rf 0.26 (10% MeOH/DCM); mp 5.5 °C (from EA/Hex); 1H NMR ) 8 8.51 (d, 1H, J=5.2 Hz), 7.94 (d, 1H, J:8.4 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.57 (m, 1H), 7.37 (m, 1H), 6.37 (d, 1H, J=5.5 Hz), 5.24 (br s, 1H, NH), 3.39—3.34 (m, 4H), 3.25 (m, 2H), 1.73—1.26 (m, 20H), 0.84 (m, 3H).
Example 2: N—(8—Butoxyoctyl)quinolin—4—amine 8—Butoxyoctan—1—ol 60% Sodium hydride in mineral oil (3.5 g, 87.5 mmol) was washed twice with 20 mL of hexanes. Anhydrous DMF (300 mL) was added, the mixture was cooled with an ice bath, and 1,8—octanediol (51.2 g, 351 mmol) was added. After 1.5 hr, obutane (6 g, 43.8 mmol) was added slowly. The mixture was warmed to room temperature. After 24 hr, the mixture was concentrated. The residue was taken up in B20 (500 mL) and washed with saturated NaHC03 and H20 (400 mL each). The aqueous phases were extracted with Et2O (3x400 mL). The combined organic phases were dried over , filtered, and concentrated to give 3.9 g colorless oil. Rf0.4 (30% EA/Hex); 1H NMR (CDC13) 5 3.6 (t, 2H), 3.4-3.3 (m, 4H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 10H), 0.9 (t, 3H). 8—Butoxyoctyl methanesulfonate A mixture of 8-butoxyoctan—1—ol (3.99 g, 20.2 mmol) and TEA (3.4 mL, 24.2 mmol) in 70 mL of DCM was cooled using an ice bath. Then, methanesulfonyl chloride (1.87 mL, 24.1 mmol) was added. After 2 hr, the mixture was washed with H2O, saturated NaHC03, H2O, 1M HCl, and H20 (50 mL each). The organic phase was dried over Na2SO4, filtered through a pad of silica gel, and concentrated to give 1.3 g of colorless oil. 1—Butoxy—8—iodooctane A mixture of 8—butoxyoctyl esulfonate (1.3 g, 6.6 mmol) and sodium iodide (1.0 g, 6.7 mmol) in 100 ml of e was heated at re?ux for 2 hr. The mixture was cooled, filtered, and concentrated. The residue was taken up in EA (400 mL) and washed with saturated NaHC03 and brine (100 mL each). The c phase was dried over NaZSO4, filtered, and concentrated to give 1.3 g of yellow .
N—(8—Butoxyoctyl)phthalimide l—Butoxy—8—iodooctane (6.2 g, 20.2 mmol) and potassium imide (3.73 g, 20.2 mmol) in 50 mL of DMF were mixed at 60—80 0C for 12 hr. The cooled mixture was concentrated, and the residue was partitioned between EA (3x300 mL) and 5% NaZSZOg, H20, and brine (100 mL each). The combined organic phases were dried over NaZSO4, filtered, and concentrated to give 5.2 g of solid. 1H NMR (CDC13) 5 7.8 and 7.7 (m, 4H, AA’BB’), 3.6 (t, 2H), 3.4-3.3 (m, 4H), 1.7-1.2 (m, 16H), 0.9 (t, 3H). 8-Butoxyoctan—1—amine Hydrazine monohydrate (0.92 mL, 19 mmol) was added to a mixture of N—(8—butoxyocty1)phthalimide (5.2 g, 15.9 mmol) and 80 mL of EtOH. The mixture was heated at re?ux for 2 hr. Then, the mixture was cooled with an ice bath and d vigourously while 200 mL of EtZO were added. The precipitate was filtered and washed with Et20, and the organic phases were concentrated to give 3.9 g of amber oil. 1H NMR (CDgOD) 3.5-3.4 (m, 4H), 2.9 (t, 2H), 1.7-1.3 (m, 16H), 0.9 (t, 3H).
N—(8-Butoxyoctyl)quinolinamine A mixture of 8-butoxyoctanamine (0.569 mg, 2.89 mmol), 4—chloroquinoline (710 mg, 4.33 mmol), TEA (5 mL, 36 mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 0C for 4 days. The mixture was cooled and partitioned between EA and 5% Na2C03 and brine, dried over Na2804, ed, and concentrated. Purification by EC (60% EA/Hex + 2% TEA) gave 244 mg of oil. 1H NMR (CDC13) 5 8.9 (m, 1H, NH), 8.7 (d, 1H), 8.2—8.1 (m, 2H), 7.6 (m, 1H), 7.4 (m, 1H), 6.4 (d, 1H), 3.5 (m, 2H), 3.4—3.3 (m, 4H), 1.8 (m, 2H), 3 (m, 14H), 0.9 (t, 3H).
Example 3: N—(8—Methoxyoctyl)quinolin—4—amine HN/\/\/\/\/O\ :\J\T/ 8—(Benzyloxy)octan—l—ol A 60% dispersion of sodium hydride in mineral oil (5.38 g, 134 mmol) was washed with hexanes to remove the oil. While cooling with an ice bath, a mixture of l,8—octanediol (24.49 g, 168 mmol) in 300 mL of DMF was added slowly. The mixture was allowed to warm to room temperature. After 1 hr, a mixture of benzyl chloride (7.70 mL, 66.7 mmol) in 30 mL of DME was added se. After 2 hr, additional benzyl chloride (1.00 mL, 8.7 mmol) was added, and the mixture was stirred overnight. Then, 2 mL of concentrated NH4OH was added. After 1 hr, the volatile components were evaporated. The residue was taken up in EtZO and thrice washed with 1M HCl and once with brine. The organic phase was dried over ous MgSO4 and ated onto silica gel. SPE, washing with 5% EA/Hex and then eluting with 20% EA/Hex gave 12.19 g of the product as a colorless oil. (Eluting with EA gave 12.19 g of recovered 1,8—octanediol after recrystallization from EA/Hex.) Rf 0.55 (20% EA/Hex). [(8-Methoxyoctyloxy)methyl]benzene A 60% dispersion of sodium hydride in mineral oil (2.1 g, 52 mmol) was washed with hexanes to remove the oil. While g with an ice bath, a mixture of 8-(benzyloxy)octanol (9.9 g, 42 mmol) in 25 mL of DMF was added . The e was allowed to warm to room temperature. After 1 hr, dimethyl e (4.0 mL, 42 mmol) was added, and the mixture was stirred overnight. The mixture was d with Eth, washed with 1 M HCl, twice with 0.1 M HCl, and brine, dried over MgSO4, and concentrated.
SPE, washing with 1% EA/Hex and then eluting with 10% EtzO/Hex gave 8.63 g of the product as an oil. Rf0.62 (20% EA/Hex); 1H NMR (CDC13) 5 7.36—7.24 (m, 5H), 4.49 (s, 2H), 3.45 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.7 Hz), 3.32 (s, 3H), 1.62-1.50 (m, 4H), 1.40—1.25 (m, 8H). 8—Methoxyoctan—1—ol A e of [(8—methoxyoctyloxy)methyl]benzene (8.60 g, 34.4 mmol) and 860 mg of 5% Pd—C in 80 mL of THF was stirred under an atmosphere of hydrogen for 40 hr. The mixture was placed under an atmosphere of argon and filtered through a pad of Celite, washing with additional THF. An aliquot was evaporated to dryness for spectroscopy. Rf 0.26 (30% EA/Hex); 1H NMR (CDCl3) 5 3.59 (t, 2H, J=6.7 Hz), 3.33 (t, 2H, J=6.4 Hz), 3.29 (s, 3H), 1.84 (s, 1H, OH), 1.60-1.45 (m, 4H), 1.40-1.25 (m, 8H).
WO 20995 8—Methoxyoctyl methanesulfonate A mixture of 8—methoxyoctan—l—ol (34.3 mmol) in 100 mL of THF was cooled by an ice bath. Methanesulfonyl chloride (4.50 mL, 57.5 mmol) and TEA (8.30 mL, 59.2 mmol) were added, and a white precipitate formed quickly. After 2 hr, the mixture was diluted with EA and washed with H20, saturated NaHCOg, brine, 1M HCl, and brine, and the organic phase was dried over MgSO4 and concentrated. SPE, washing with 10% EA/Hex and then eluting with 30% EA/Hex gave 7.34 g of oil containing 8—methoxyocty1 methanesulfonate and 8—methoxyoctan—1—ol in a 9:1 mole ratio, as determined by NMR. 8— Methoxyoctyl methanesulfonate had Rf 0.31 (30% EA/Hex); 1H NMR (CDC13) 5 4.19 (t, 2H, J=6.7 Hz), 3.34 (t, 2H, J=6.5 Hz), 3.30 (s, 3H), 2.98 (s, 3H), 1.72 (m, 2H), 1.52 (m, 2H), 1.40— 1.25 (m, 8H).
N—(8—Methoxyoctyl)phthalimide A 9:1 e of 8—methoxyocty1 methanesulfonate and 8— methoxyoctan—l—ol (4.10 g) was taken up in 80 mL of DMF and potassium phthalimide (4.4 g, 24 mmol) was added. The e was heated at 80-100 0C for 4 hr. Then, the mixture was , diluted with EA, and washed with H20, twice with 0.1M HCl, and brine. The organic phase was dried over MgSO4 and concentrated onto silica gel. SPE, eluting with 30% EA/Hex, gave 4.32 g of the product as a solid. Rf 0.50 (30% EA/Hex); 1H NMR (CDClg) 8 7.81 and 7.67 (m, 4H, AA’BB’), 3.64 (t, 2H, J=7.3 Hz), 3.32 (t, 2H, J=6.7 Hz), 3.29 (s, 3H), 1.62 (m, 2H), 1.50 (m, 2H), 1.40-1.20 (m, 8H). 8—Methoxyoctan—1—amine Hydrazine monohydrate (1.00 mL, 20.6 mmol) was added to a mixture of N—(8—methoxyoctyl)phthalimide (4.32 g, 14.9 mmol) in 100 mL of EtOH, and the mixture was heated at re?ux for 6 hr, during which a white precipitate formed. Then, the mixture was cooled, 4 mL of 6M HCl were added, most of the volatile components were evaporated, 100 mL of 0.1M HCl were added, and the mixture was allowed to stand for 30 min. The precipitate was filtered and washed twice with 50 mL of 0.1M HCl. The combined filtrate was washed thrice with 50 mL of EtzO. The pH of the filtrate was ed to greater than 10 by adding solid NaOH while cooling with an ice bath. The filtrate was extracted with DCM (150 mL, 2x100 mL). The organic phases were dried over ous NaZSO4 and concentrated to give 2.17 g of oil. 1H NMR(CDC13) 5 3.30 (t, 2H, J=6.6 Hz), 3.27 (s, 3H), 2.62 (m, 2H), 1.53—1.24 (m, 12H), 1.41 (s, 2H, N?z).
N—(8—Methoxyoctyl)quinolin—4—amine A mixture of 4—chloroquinoline (3.00 mmol), 8— methoxyoctan—l—amine (233 mg, 1.46 mmol), DIEA (0.52 mL, 3.00), and 4 mL of IPA was heated at 135 0C for 16 hr in a sealed tube. The mixture was treated with additional 8— methoxyoctan—l—amine (343 mg, 2.16 mmol) and heated for an additional 64 hr. Then, the mixture was treated with additional 8—methoxyoctan—l—amine (140 mg, 0.88 mmol) and heated for an additional 48 hr. The mixture was cooled and the volatile components were evaporated.
The residue was partitioned between EA and 5% N32CO3, and the organic phases were washed with brine, dried over anhydrous NaZSO4, and concentrated. The product was purified using PC, eluting with 10% and then 15% MeOH/DCM. The product—containing fractions were trated, and the residue was taken up in DCM, washed with 5% Na2C03, dried over ous NaZSO4 and ated to give 694 mg of the product as a solid. Rf 0.26 (10% MeOH/DCM); 1H NMR(CDC13) 8 8.41 (d, 1H, J=5.7 Hz), 7.93 (m, 1H), 7.52 (m, 1H), 7.30 (m, 1H), 6.33 (d, 1H, J=5.7 Hz), 6.09 (br s, 1H, NH), .23 (m, 7H), 1.65, (m, 2H), 1.48 (m, 2H), 1.33-1.25 (m, 8H).
Example 4: N-[6—(Hexyloxy)hexy1]quinolin—4—amine HNW/OM C(j/ 6—(Hexyloxy)hexan—1—amine was made starting from xanediol following the method for the preparation of 10—(hexyloxy)decan—1—amine. 6—(Hexyloxy)hexan—l—ol Rf0.16 (10% EA/Hex); 1H NMR (CDCl3) 5 3.59 (m, 2H), 3.36 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.8 Hz), 1.87 (s, 1H, OH), 1.56—1.47 (m, 6H), 1.36—1.25 (m, 10H), 0.85 (m, 3H). 6—(Hexyloxy)hexyl methanesulfonate Rf0.16 (20% EA/Hex); 1H NMR (CDC13) 8 4.21 (t, 2H, J=6.6 Hz), 3.38 (t, 2H, 6.4 Hz), 3.37 (t, 2H, J=6.7 Hz), 2.98 (s, 3H), 1.74 (m, 2H), 1.61—1.46 (m, 4H), 1.40-1.37 (m, 4H), 1.35-1.24 (m, 6H), 0.87 (t, 3H, J=6.8 Hz).
N—[6—(Hexyloxy)hexyl]phthalimide Rf0.40 (20% EA/Hex). 6—(Hexyloxy)hexan—l—amine 1H NMR (CDClg) 5 3.36 (m, 2H), 3.35 (t, 2H, J=6.8 HZ), 2.67 (m, 2H), 2.10 (br s, 2H, N?z), 1.78-1.19 (m, 16H), 0.85 (t, 3H, J=6.8 Hz).
A mixture of 6—(hexyloxy)hexan—1—amine (234 mg, 1.16 mmol), 4—chloroquinoline (235 mg, 1.44 mmol) and TEA (0.50 mL, 3.56 mmol) in 1 mL of NMP was heated at 160 0C for 16 hr. The mixture was cooled and partitioned between EA and 5% N212C03. The organic phases were washed with brine, dried over NaZSO4, and concentrated. SPE, washing with 40% EA/Hex and 4% MeOH/DCM and eluting with 8% MeOH/DCM, gave 137 mg of product as a solid. Rf 0.42 (7.5% MeOH/DCM); mp 41-44 0C (from EA/Hex); 1H NMR (CDC13) 8 8.45 (d, 1H, J=5.5 Hz), 7.92 (d, 1H, J=8.4 Hz), 7.86 (d, 1H, J=8.4 Hz), 7.55 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.33 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.35 (br s, 1H, NH), 3.37-3.22 (m, 6H), 1.72-1.19 (m, 16H), 0.83 (m, 3H).
Example 5: N-(6—Butoxyhexy1)quinolin—4—amine HN/\/\/\/O\/\/ : \J\T/ 6—Butoxyhexan—1—ol 60% Sodium hydride in mineral oil (3.56 g, 89 mmol) was washed twice with 20 mL of hexanes. Anhydrous DMF (250 mL) was added, the e was cooled with an ice bath, and 1,6—hexanediol (41.4 g, 351 mmol) was added. After 1.5 hr, l—bromobutane (4.71 mL, 43.7 mmol) was added . The e was warmed to room temperature. After 24 hr, the e was trated. The residue was taken up in EtZO (500 mL) and washed with saturated NaHC03 and H20 (400 mL each). The aqueous phases were extracted with Eth (3x400 mL). The combined organic phases were dried over NaZSO4, filtered, and concentrated to W0 2014/120995 2014/013992 give 6.55 g ess oil. Rf0.4 (30% EA/Hex); 1H NMR (CDC13) 5 3.6 (t, 2H), 3.4—3.3 (m, 4H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 6H), 0.8 (t, 3H). 6—Butoxyhexyl methanesulfonate A mixture of 6—butoxyhexan—l—ol (6.55 g, 37.6 mmol) and TEA (5.51 mL, 39.5 mmol) in 100 mL of DCM was cooled using an ice bath. Then, methanesulfonyl chloride (3.06 mL, 39.5 mmol) was added. After 1.5 hr, the mixture was washed with H2O, saturated , H2O, 1M HCl, and H20 (50 mL each). The organic phase was dried over Na2SO4, filtered through a pad of silica gel, and trated to give 9.24 g of colorless oil. 1H NMR (CDC13) 8 4.2 (t, 2H), 3.4—3.3 (m, 4H), 2.9 (s, 3H), 1.7 (m, 2H), 1.6—1.2 (m, 10H), 0.8 (t, 3H). 1-Butoxy—6—iodohexane A mixture of 6-butoxyhexyl methanesulfonate (9.23 g, 36.6 mmol) and sodium iodide (5.5 g, 36.6 mmol) in 300 ml of acetone was heated at re?ux for 3 hr. The e was cooled, filtered, and concentrated. The residue was taken up in EA (400 mL) and washed with saturated NaHC03 and brine (100 mL each). The organic phase was dried over Na2SO4, ?ltered, and concentrated to give 10.4 g of yellow liquid. utoxyhexyl)phthalimide 1-Butoxyiodohexane (10.4 g, 36.6 mmol) and potassium phthalimide (6.78 g, 36.6 mmol) in 300 mL of DMF were mixed at 60—80 °C for 12 hr. The cooled mixture was concentrated, and the residue was partitioned between EA (3x300 mL) and 5% Na2S203, H20, and brine (100 mL each). The combined organic phases were dried over Na2SO4, ?ltered, and concentrated to give 7.2 g of solid. 1H NMR (CDC13) 5 7.8 and 7.7 (m, 4H, AA’BB’), 3.6 (t, 2H), 3.4—3.3 (m, 4H), 2 (m, 12H), 0.8 (t, 3H). 6—Butoxyhexan—1—amine Hydrazine monohydrate (1.3 mL, 27 mmol) was added to a mixture of N—(6—butoxyhexyl)phthalimide (6.72 g, 22.2 mmol) and 100 mL of EtOH. The mixture was heated at re?ux for 16 hr. Then, the mixture was cooled with an ice bath and stirred vigourously while 200 mL of Et2O were added. The precipitate was filtered and washed with Et2O, and the organic phases were concentrated to give 4.2 g of amber oil. 1H NMR (CDgOD) 3.5—3.4 (m, 4H), 2.9 (t, 2H), 1.7-1.3 (m, 12H), 0.9 (t, 3H).
N—(6—Butoxyhexyl)quinolin—4—amine A mixture of 6—butoxyhexan—l—amine (0.5 g, 2.9 mmol), 4— chloroquinoline (711 mg, 4.4 mmol), TEA (5 mL, 36 mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 0C for 4 days. The mixture was cooled and partitioned between EA and 5% Na2C03 and brine, dried over NaZSO4, filtered, and concentrated. Purification by EC (60% EA/Hex + 2% TEA) gave 220 mg of amber oil. 1H NMR (CDC13) 5 8.4 (d, 1H), 8.3-8.1 (m, 3H), 7.6 (m, 1H), 7.4 (m, 1H), 6.4 (d, 1H), 3.5 (m, 2H), 3.4— 3.3 (m, 4H), 1.8 (m, 2H), l.7-l.3 (m, 10H), 0.9 (t, 3H).
Alternative Synthesis 6-Butoxyhexan—1—ol 60% Dispersion of sodium hydride in mineral oil (14 g, 350 mmol) was washed with two 50 mL portions of Hex, and then dried in vacuo. While cooling with an ice bath, IPA (50 mL) and 1,6-hexanediol (200 g, 1700 mmol) were added cautiously, with gas evolution observable. The mixture was allowed to warm to room ature, and 1- bromobutane (25.0 mL, 234 mmol) was added. The mixture was warmed at 45 0C for 3 days.
Then, 6.6 mL of acetic acid were added, and distillation of volatile components was carried out until bp 90 0C was attained. The residue was loaded onto silica gel. Two rounds of SPE (50% EA/Hex) gave 36.7 g of pale yellow liquid. Rf 0.40 (50% EA/Hex). 6—Butoxyhexyl methanesulfonate 6—Butoxyhexanol (36.7 g, 211 mmol) was taken up in 600 mL of EtzO cooled by an ice bath. esulfonyl chloride (19.8 mL, 253 mmol) and TEA (35.5 mL, 253 mmol) were added, anied by immediate precipitate formation. After 1.5 hr, 100 mL of H20 were added, and the phases were separated. The aqueous phase was extracted with EA (2x150 mL), and the organic phases were washed with saturated NaHCOg, H20, 1M HCl, H20, and brine (100 mL each). The organic phases were dried over anhydrous NaZSO4, filtered through a pad of silica gel, and trated to 52.2 g of pale yellow liquid. Rf 0.55; 1H NMR(CDC13) 5 4.19 (m, 2H), .34 (m, 4H), 2.97 (s, 3H), 1.72 (m, 2H), 1.56-1.50 (m, 4H), 1.50—1.30 (m, 6H), 0.88 (t, 3H); 13C NMR(CDC13)5 70.8, 70.7, 70.2, 37.4, 32.0, 29.7, 29.2, .8, 25.4, 19.5, 14.0. 1—Butoxy—6—iodohexane A mixture of xyhexyl methanesulfonate (52.2 g, 207 mmol) and sodium iodide (40 g, 267 mmol) in 400 ml of acetone was heated at re?ux for 1 hr. The e was cooled, concentrated, and partitioned between EA (3x300 mL) and H20, 5% N328203, H20, and brine (150 mL each). The organic phases were dried over NaZSO4 and concentrated to give the product as a yellow liquid that ned 13 mol% of the starting material. 1H NMR ) 5 .35 (m, 4H), 3.16 (t, 2H, J=7.0 Hz), 1.80 (m, 2H), .48 (m, 4H), 1.40-1.30 (m, 6H), 0.88 (t, 3H, J=7.3 Hz); 13C NMR (CDC13) 5 70.8, 70.7, 33.6, 32.0, .5, 29.7, 25.3, 19.5, 14.1, 7.2.
N—(6—Butoxyhexyl)phthalimide Crude 1—butoxy—6—iodohexane and potassium phthalimide (46 g, 249 mmol) in 300 mL of DMF were mixed at room temperature for 41 hr and at 60—80 0C for 24 hr. The cooled mixture was concentrated, and the residue was partitioned between EA (3x350 mL) and H20, 5% Na28203, H20, and brine (100 mL each). The combined organic phases were dried over NaZSO4, ed through a pad of silica gel, and concentrated. SPE (10% EA/Hex) gave 51.6 g of colorless liquid. Rf 0.38 (20% EA/Hex); 1H NMR (CDClg) 8 7.77 and 7.65 (m, 4H, AA’BB’), 3.62 (t, 2H, J=7.3 Hz), 3.34-3.31 (m, 4H), 1.63 (m, 2H), 1.52-1.44 (m, 4H), 1.35-1.25 (m, 6H), 0.85 (m, 3H); 13C NMR (CDC13) 5 168.5, 133.9, 132.3, 123.2, 70.8, 70.7, 38.0, 31.9, 29.7, 28.7, 26.8, 25.9, 19.4, 14.0. 6—Butoxyhexan-1—amine Hydrazine monohydrate (9.1 mL, 187 mmol) was added to a mixture of N—(6—butoxyhexyl)phthalimide (51.6 g, 170 mmol) and 900 mL of EtOH. The mixture was heated at re?ux for 12 hr, and allowed to stand at room temperature for 3 days. Then, 250 mL of volatile material was removed by distillation. 1M HCl (200 mL) was added to the still— warm pot e. After cooling to room temperature, the precipitate was removed by filtration, washing with three 200 mL portions of 50% aqueous EtOH. The filtrate was adjusted to pH 10 by adding NaOH pellets, concentrated, and taken up in 800 mL of DCM. The aqueous phase was separated, and the organic phase was dried over anhydrous NaZSO4 and concentrated. SPE, washing with DCM and 5% MeOH/DCM and eluting with 8% MeOH/DCM + 3% NH4OH, gave ninhydrin (+) t fractions. The product fractions were concentrated and taken up in DCM. The organic phase was separated, dried over anhydrous NaZSO4, and concentrated to give 29.1 g of yellow liquid. Rf 0.09 (10% MeOH/DCM); 1H NMR (CDCl3) 5 3.26 (t, 2H, J=6.6 Hz), 3.25 (t, 2H, J=6.6 Hz), 2.55 (t, 2H, J=6.9 Hz), 1.46—1.38 (m, 4H), 1.32 (m, 2H), 1.34 (br s, 2H, N?z), 1.26-1.20 (m, 6H), 0.78 (t, 3H, J=7.4 Hz); 13C NMR (CDC13) 5 70.7, 70.6, 42.1, 33.6, 31.8, 29.7, 26.7, 26.0, 19.3, 13.8.
N—(6—Butoxyhexyl)quinolin—4—amine 6—Butoxyhexan—1—amine (6.05 g, 34.6 mmol) was taken up in 150 mL of 1—pentanol, and 15 mL was removed by distillation. Tripropylamine (15.8 mL, 82.9 mmol) and 4—chloroquinoline (8.20 g, 50.3 mmol) were added, and the mixture was heated at re?ux for 25 hr and allowed to stand at room temperature for 2 days. Then, most of the le components were ated, and 30 mL of 1N NaOH and 60 mL of 5% Na2C03 were added.
The mixture was extracted with DCM (3x150 mL), and the organic phases were dried over NaZSO4 and evaporated onto silica gel. SPE, washing with 50% EA/Hex and g with 5% MeOH/DCM + 2% TEA, gave a brown oil. Upon cooling below 0 0C, the oil solidified. The solid was washed with cold 10% EA/Hex and dried in vacuo to give 6.62 g of colorless solid. Rf 0.07 (50% EA/Hex) 0.35 (10% CM); mp 62.5-65.0 0C; 1H NMR (CDClg) 8 8.52 (d, 1H, J=5.5 Hz), 7.99 (dd, 1H, J=0.7, 8.4 Hz), 7.77 (dd, 1H, J=0.7, 8.4 Hz), 7.62 (ddd, 1H, J=1.5, 7.0, 8.4 Hz), 7.42 (ddd, 1H, J=1.4, 6.9, 8.4 Hz), 6.42 (d, 1H, J=5.5 Hz), 5.26 (br s, 1H, NH), 3.41 (t, 2H, J=6.6 Hz), 3.40 (t, 2H, J=6.6 Hz), 3.33 (m, 2H), 1.78 (m, 2H), 1.64—1.31 (m, 10H), 0.91 (t, 3H, J=7.3 Hz); 13C NMR(CDC13)5150.5, 150.3, 147.8, 129.5, 129.4, 124.9, 119.6, 118.8, 98.9, 70.9, 70.8, 43.4, 32.0, 29.9, 29.1, 27.2, 26.2, 19.6, 14.1.
Example 6: N—[10—(Hexyloxy)decyl]quinolin—4—amine HN/\/\/\/\/\/O\/\/\/ C(i/N 10—(Hexyloxy)decan—1—ol 60% Sodium hydride dispersion in l oil (1.08 g, 27 mmol) was washed with hexane. 2—Propanol (150 mL) was added, slowly at first. Then, 1,10—decanediol (31.3 g, 180 mmol) was added, and the mixture was warmed slightly to attain homogeneity. l— exane (2.50 mL, 17.9 mmol) was added dropwise. After being d at room temperature overnight, the mixture was heated at re?ux for 2 hr and then 100 mL of volatile components were removed by distillation. 1M HCl (10 mL) was added, and then the remainder of the t was removed by distillation. Puri?cation by solid phase extraction, g with 12% EA/Hex, gave 1.20 g of 10—(hexyloxy)decan—l—ol as a colorless liquid. Rf 0.22 (20% EA/Hex); 1H NMR (CDC13) 5 3.63 (m, 2H), 3.40—3.35 (m, 4H), 1.65-1.55 (m, 6H), 1.40—1.20 (m, 18H), 0.87 (m, 3H).
—(Hexyloxy)decan—l—amine Methanesulfonyl de (0.50 mL, 6.39 mmol) was added to a mixture of 10—(hexyloxy)decan—1—ol (1.20 g, 4.65 mmol) and triethylamine (0.98 mL, 6.99 mmol) in 100 mL of DME cooled by an ice bath. After 1 hr, the mixture was partitioned between EA (3x100 mL) and H20, saturated NaHCOg, H20, 0.1M HCl, and brine (50 mL each), and the organic phases were dried over NaZSO4, filtered through a pad of silica gel, and concentrated.
The residue was taken up in 150 mL of acetone, sodium iodide (1.27 g, 8.47 mmol) was added, and the mixture was heated at re?ux for 3 hr. Then, the mixture was , the solvent was evaporated, and the residue was partitioned between EA (3x100 mL) and 5% NaZSZOg and H20 (50 mL of each), and the organic phases were dried over Na2804, filtered through a pad of silica gel, and concentrated. The residue was taken up in 20 mL of NMP and potassium phthalimide (1.66 g, 8.97 mmol) was added. After the iodide was consumed, as observed by TLC, the mixture was partitioned between EA (3x100 mL) and 0.1M HCl and brine (50 mL of each), and the organic phases were dried over NaZSO4, filtered through a pad of silica gel, and concentrated.
The e was taken up in 30 mL of ethanol, hydrazine monohydrate (0.60 mL, 12.5 mmol) was added, and the mixture was heated at re?ux for 8 hr. Then, the volatile components were ated, the residue was partitioned between DCM (3x60 mL) and 5% Na2C03 (50 mL), and the organic phases were dried over NaZSO4 and concentrated to give 964 mg of 10— (hexyloxy)decan—l—amine as an oil that solidified upon standing. 1H NMR ) 5 3.45—3.36 (m, 4H), 2.72 (m, 2H), 1.65-1.45 (m, 6H), 1.45—1.25 (m, 18H), 0.89 (m, 3H).
N—[10—(Hexyloxy)decyl]quinolin—4—amine A mixture of lO—(hexyloxy)decan—l—amine (256 mg, 1.00 mmol), 4—chloroquinoline (240 mg, 1.47 mmol), and a particle of prilled DMAP in 1.5 mL of DIEA were heated at 150 0C in a sealed tube for 24 hr. The cooled mixture was partitioned between DCM (3x60 mL) and 5% NazCO3 (50 mL), and the organic phases were dried over NaZSO4 and concentrated. Purification by solid phase extraction, washing with 50% EA/Hex and then eluting the product with 50% EA/Hex + 2% TEA, gave 175 mg of the product as a solid. Rf 0.42 (50% EA/Hex + 0.5% TEA); 1H NMR (CDC13) 5 8.51 (d, 1H, J=5.2 Hz), 7.94 (dd, 1H, J=1.0, 8.4 Hz), 7.74 (d, 1H, J=8.2 Hz), 7.57 (ddd, 1H, J=l.5, 6.9, 8.4 Hz), 7.36 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 6.37 (d, 1H, J=5.4 Hz), 5.23 (br s, 1H, NH), 3.36 (t, 4H, J=6.7 Hz), 3.25 (m, 2H), 1.70 (m, 2H), 1.56-1.26 (m, 22H), 0.85 (m, 3H).
Example 7: N—(10—Butoxydecyl)quinolin-4—amine HNWWVOW CK?/N 1-Bromobutoxydecane 60% Sodium hydride dispersion in mineral oil (1.7 g, 42 mmol) was washed with hexane. While cooling with an ice bath, a mixture of 1—butanol (10 mL, 109 mmol) and DMF (40 mL) was added, slowly at ?rst. After gas ion ceased, a e of ibromodecane (47.1 g, 157 mmol) and 100 mL of DCM and 40 mL of DMF were added in one portion. The mixture was d to come to room temperature ght. Then, the DCM was evaporated, and the residue was partitioned between EA (3x250 mL) and 0.1M HCl and brine (100 mL each), and the organic phases were dried over NaZSO4 and concentrated.
Purification by SPE, washing with Hex to recover excess dibromide and then eluting with 10% EA/Hex gave 10.7 g of l—bromo—lO—butoxydecane contaminated with 1,10—dibutoxydecane. Rf 0.39 (10% EA/Hex); 1H NMR ) 5 3.40—3.36 (m, 6H), 1.82 (m, 2H), 1.57—1.47 (m, 4H), 1.41—1.26 (m, 14H), 0.89 (m, 3H). lO—Butoxydecan—l—amine A e of 1—bromo—10—butoxydecane (21.1 g, 72 mmol) and sodium azide (5.1 g, 78 mmol) in 30 mL of DMF was stirred at room temperature until the bromide was consumed, as observed by TLC. The mixture was partitioned between EA (3x350 mL) and H20 (3x100 mL) and brine (100 mL), and the organic phases were dried over NaZSO4 and trated. Purification by SPE using 10% EA/Hex gave 19.6 g of the azide product. The azide was taken up in 40 mL of EA and 40 mL of MeOH under a blanket of argon, 2.0 g of 5% Pd/C were added, and the mixture was stirred under an atmosphere of hydrogen until the azide was consumed, as ed by TLC. The catalyst was removed by filtration and the volatile components were evaporated. Purification by SPE, washing with 50% EA/Hex and then eluting with 15% MeOH/DCM + 2% TEA, gave 7.0 g of 10—butoxydecan—1—amine as a colorless solid. 1H NMR (CDCl3) 5 3.40-3.34 (m, 4H), 2.55 (m, 2H), 2.1 (br s, 2H, N?z), 1.58-1.26 (m, 20H), 0.90 (m, 3H).
N—(10-Butoxydecyl)quinolinamine A mixture of 10-butoxydecanamine (312 mg, 1.36 mmol), 4-chloroquinoline (375 mg, 2.30 mmol) and DIEA (0.50 mL, 2.87 mmol) in 3 mL of 2-propanol was heated at 130 0C for 3 days and the 160 0C for 1 day. The volatile components were ated. The mixture was partitioned between DCM (3x60 mL) and 5% N32C03 (50 mL), and the c phases were dried over Na2$O4 and concentrated. cation by long- column FC (10% MeOH/DCM) gave N—(10—butoxydecy1)quinolin—4—amine. Rf 0.34 (10% MeOH/DCM); 1H NMR (CDC13) 8 8.52 (d, 1H, J=5.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.75 (d, 1H, J=8.4 Hz), 7.60 (dd, 1H, J=7.0, 8.2 Hz), 7.39 (dd, 1H, J=6.9, 8.4 Hz), 6.39 (d, 1H, J=5.2 Hz), .20 (br s, 1H, NH), 3.41-3.35 (m, 4H), 3.28 (m, 2H), 1.73 (m, 2H), 1.59—1.28 (m, 18H), 0.89 (m, 3H).
Example 8: N—(5—Methoxypentyl)quinolin—4—amine /\/\/\ HN 00 H3 N 1—Bromo—5—methoxypentane MeOH (20 mL) was added drop—wise to hexane—washed sodium hydride (61.8 mmol) while cooling with an ice bath. The mixture was added drop—wise to a 2014/013992 mixture of l,5—dibromopentane (99.44 g, 0.432 mol) and 100 mL of 1:1 MeOH and THF. After 42 hr, most of the solvent was removed by distillation at room pressure. Then, gentle vacuum distillation gave approximately 20 mL of , which was comprised of a 1:1 mixture of 1,5— dibromopentane and l—bromo—5—methoxypentane. The pot was partitioned between DCM and H20, and the organic phase was dried over MgSO4 and concentrated by distillation at room pressure to leave 96 g of a 21:1 mixture of 1,5—dibromopentane and DCM. The ide was retreated with sodium methoxide. The crude 1—bromo—5—methoxypentane mixtures were ed and separated by SPE, washing with pentane to recover l,5—dibromopentane and eluting with 10% Eth/pentane to get 8.40 g of colorless liquid after concentration by distillation.
Rf0.53 (5% EA/Hex) 0.44 (10% EtZO/Hex); 1H NMR (CDC13) 5 3.4-3.3 (m, 4H), 3.31 (s, 3H), 1.86 (m, 2H), 1.6 (m, 2H), 1.3 (m, 2H). 1-Azido—5—methoxypentane A mixture of 1-bromo—5—methoxypentane 2.76 g, 15.2 mmol) and sodium azide (1.14 g, 17.5 mmol) in 10 mL of DMF was stirred at room temperature for 16 hr.
Then, the mixture was partitioned between Et20 (3x70 mL) and H20 (3x50 mL) and brine. The organic phases were dried over NaZSO4 and the mixture was carried on. Rf 0.36 (10% Eth/Hex).
-Methoxypentanamine A mixture of 1-azidomethoxypentane in Eth and 286 mg of % Pd—C was stirred under a blanket of en for 24 hr. The mixture was blanketed with argon and filtered through a pad of Celite. Most of the Et20 was removed by distillation at atmospheric pressure. 1H NMR (CDC13) 8 3.35 (t, 2H), 3.3 (s, 3H), 2.6 (m, 2H), 3 (m, 6H). ethoxypentyl)quinolin—4—amine A mixture of 5—methoxypentan—1—amine, 4— chloroquinoline (900 mg, 5.52 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated at 130 0C in a sealed tube for 24 hr. The mixture was cooled and partitioned n EA and 5% N32C03 and brine. The organic phases were dried over anhydrous NaZSO4 and concentrated. SPE, washing with 40% EA/Hex + 2% TEA and eluting with 80% EA/Hex + 2% TEA, gave a solid. Rf0.20 (80% EA/Hex + 2% TEA); 1H NMR(CDC13)8 8.46 (d, 1H, J=5.2 Hz), 7.90 (dd, 1H, J=l.0, 8.4 Hz), 7.77 (m, 1H), 7.51 (ddd, lH, J=l.5, 6.9, 8.4 Hz), 7.28 (ddd, lH, J=l.2, 6.9, 8.1 Hz), 6.31 (d, 2014/013992 1H, J=5.4 HZ), 5.55 (m, 1H, NH), 3.30 (t, 2H, J=6.2 Hz), 3.25 (s, 3H), 3.20 (m, 2H), 1.65 (p, 2H, J=7 Hz), 1.57—1.42 (m, 4H).
Example 9: N—[8—(Hexyloxy)octyl]—2—methquuinolin—4—amine HN/VVWOM m/N CH3 N—[8—(Hexyloxy)octyl]—2—methquuinolin—4—amine A mixture of 8—(hexyloxy)octan—1—amine (479 mg, 2.09 mmol), 4—chloroquinaldine (575 mg, 3.25 mmol), and DIEA (1.00 mL, 5.74 mmol) was heated at 140 0C in a sealed tube for 4 days. Then, the volatile material was evaporated, and the residue was purified by PC (7% CM) to give 217 mg of N—[8— (hexyloxy)octyl]—2—methquuinolin—4—amine. 1H NMR (CDClg) 5 7.87 (d, 1H, J=8.4 Hz), 7.67 (d, 1H, J=8.0 Hz), 7.53 (m, 1H), 7.29 (m, 1H), 6.26 (s, 1H), 5.10 (m, 1H, NH), 3.35 (t, 4H, J=6.5 Hz), 3.21 (m, 2H), 2.57 (s, 3H), 1.73-1.21 (m, 20H), 0.85 (m, 3H).
Example 10: 7-Chloro-N—[8-(hexyloxy)octyl]quinolinamine H NWOW CIm/N 7—Chloro—N—[8-(hexyloxy)octy1]quinolin—4—amine A mixture of 8—(hexyloxy)octan—1—amine (537 mg, 2.34 mmol), 4,7—dichloroquinoline (565 mg, 2.85 mmol), DIEA (0.50 mL, 287 mmol), and 1 mL of NMP was heated at 140 °C in a sealed tube for 24 hr. Then, the volatile material was evaporated, and the residue was ed by SPE (5% MeOH/DCM and then 30% EA/Hex + 2% TEA) to give 358 mg of 7—chloro—N—[8—(hexyloxy)octyl]quinolin—4—amine. Rf 0.20 (5% MeOH/DCM), 0.31 (30% EA/Hex + 2% TEA); 1H NMR (CDClg) 8 8.43 (d, 1H, J=5.4 Hz), 7.87 (d, 1H, J=2.0 Hz), 7.68 (d, 1H, J=8.9 Hz), 7.22 (dd, 1H, J=2.2, 8.9 Hz), 6.30 d, 1H, J=5.4 Hz), .46 (t, 1H, J=4.8 Hz, NH), 3.33 (t, 4H, J=6.7 Hz), 3.19 (m, 2H), 1.70—1.23 (m, 20H), 0.82 (m, 3H).
Example 11: 8—Chloro—N—[8—(hexyloxy)octyl]quinolin—4—amine HN/\/\/\/\/O\/\/\/ 8—Chloro—N—[8—(hexyloxy)octyl]quinolin—4—amine A mixture of 8—(hexyloxy)octan—1—amine (456 mg, 1.99 mmol), 4,8—dichloroquinoline (480 mg, 2.42 mmol), DIEA (0.43 mL, 2.47 mmol), and 1 mL of NMP was heated at 140 0C in a sealed tube for 24 hr. Then, the volatile material was evaporated, and the residue was purified by SPE (5% MeOH/DCM and then 30% EA/Hex + 2% TEA) to give 338 mg of 8—chloro—N—[8—(hexyloxy)octyl]quinolin—4—amine. Rf 0.28 (5% MeOH/DCM), 0.38 (30% EA/Hex + 2% TEA); 1H NMR (CDC13) 8 8.61 (d, 1H, J=5.5 Hz), 7.72—7.64 (m, 2H), 7.26 (m, 1H), 6.41 (d, 1H, J=5.4 Hz), 5.19 (t, 2H, J=4.7 Hz, NH), .33 (m, 4H), 3.26 (m, 2H), 1.76 (m, 20H), 0.85 (m, 3H).
Example 12: N-[8-(Hexyloxy)octyl] (tri?uoromethyl)quinolinamine HNWOW / F3C’ : :N: A mixture of 8-(hexyloxy)octan—1—amine (546 mg, 2.38 mmol), 4—chloro—7— trifluoromethquuinoline (711 mg, 3.06 mmol), DIEA (0.50 mL, 2.87 mmol), and 1 mL of NMP was heated at 0 0C in a sealed tube for 24 hr. Then, the residue was partitioned between EA and 5% Na2C03 and brine, and the c phases were dried over NaZSO4 and concentrated.
Purification by SPE failed, but FC (25% EA/Hex) gave 626 mg of a yellow oil that solidi?ed upon standing. Rf0.10 (20% EA/Hex); 1H NMR ) 5 8.53 (d, l, J=5.4 Hz), 8.19 (s, 1), 7.87 (d, 1, J=8.9 Hz), 7.47 (dd, 1,J=l.7, 8.9 Hz), 6.42 (d, 1, J=5.5 Hz), 5.47 (m, 1), 3.36—3.32 (m, 4), 3.25 (m, 2), 1.81—1.17 (m, 20), 0.83 (m, 3).
Example 13: N—[8—(Hexyloxy)octyl]—8—(tri?uoromethyl)quinolin—4—amine HN/\/\/\/\/O\/\/\/ N—[8—(Hexyloxy)octyl]—8—(tri?uoromethyl)quinolin—4—amineA e of 8—(hexyloxy)octan—l— amine (590 mg, 2.58 mmol), 4—chloro—8—(tri?uoromethyl)quinoline (780 mg, 3.36 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP was heated in a heavy walled sealed tube at 140— 150 0C for 48 hr. Then, the residue was partitioned between EA and 5% Na2C03 and brine, and the organic phases were dried over NaZSO4 and concentrated. FC (20% EA/Hex) gave 793 mg of yellow oil. Rf0.28 (20% EA/Hex); 1H NMR (CDC13) 5 8.60 (d, 1, J=5.4 HZ), 7.94 (d, 1, J=8.6 Hz), 7.91 (d, 1, J=7.4 Hz), 7.35 (m, 1), 6.42 (d, 1, J=5.4 Hz), 5.23 (m, 1, NH), 3.36 (t, 4, J=6.6 Hz), 3.23 (m, 2), 1.74-1.25 (m, 20), 0.85 (m, 3).
Example 14: N-{ 5-[3-(Hexyloxy)propoxy]pentyl}quinolinamine : \ yloxy)propan—1—ol One mole of sodium metal was added in portions to 250 g of 1,3- ediol cooled by an ice bath and blanketed with argon. After the metal had dissolved, 0.466 mole of l—iodohexane mixed in 100 mL of DMF was added dropwise. The e was allowed to warm to room temperature overnight. Then, the mixture was warmed to 60 °C for 2 hr. Then, the mixture was cooled to room temperature and treated with 10 mL of concentrated NH4OH for 1 hr. Then, the mixture was partitioned between EA (3x250 mL) and 1.5 L H20 + H3PO4 (pH~10), H20, 1M HCl, 2x0.1M HCl, and brine. The organic phases were dried over MgSO4 and concentrated. Purification by SPE, washing with 10% EA/Hex and eluting with 30% EA/Hex, gave 44.2 g of 3—(hexyloxy)propan—1—ol as a pale yellow liquid. Rf 0.28 (30% EA/Hex); 1H NMR(CDC13) 5 3.74 (t, 2H), 3.60 (t, 2H, J=5.7 Hz), 3.39 (t, 2H), 2.66 (s, 1H, OH), 1.80 (m, 2H), 1.53 (m, 2H), 1.56—1.20 (m, 6H), 0.85 (m, 3H).
WO 20995 3—(Hexyloxy)propyl methanesulfonate was prepared by the method used for the preparation of 3— phenoxybenzyl esulfonate, using 44.2 g of 3—(hexyloxy)propan—l—ol, 43 mL of TEA, and 24 mL of methanesulfonyl chloride in 540 mL of DCM. The crude al was taken up in 450 mL of acetone and reacted with 55.7 g of sodium iodide at re?ux for 4 hr. Then, the mixture was cooled and diluted with 1 volume of hexanes. The solid was filtered, and the filtrate was concentrated. The residue was taken up in 350 mL of DCM and washed with 5% 3 (to remove color) and H20. The organic phase was dried over NaZSO4 and concentrated to give crude l—(3—iodopropoxy)hexane. 1,5—Pentanediol (230 mL) was ted with argon, and 22.6 g of potassium metal was added in portions. The exothermic evolution of gas was ted by cooling with an ice bath. Then, at room temperature, a mixture of the crude 1-(3—iodopropoxy)hexane and 100 mL of DMA was added dropwise. After being stirred overnight, unreacted iodide was observed by TLC. Sodium hydride (7.4 g) was added in 2-gram portions with cooling by an ice bath. The mixture was allowed to stir at room temperature for 60 hr. Then, the mixture was cooled with an ice bath and neutralized by the addition of concentrated HCl. The mixture was partitioned between EA and H20, and the organic phases were washed with 5% N328203 (to remove color) and brine, dried over Na2SO4, and concentrated. Purification by SPE, g with 5% EA/Hex and then eluting with 30% EA/Hex, gave 39.0 g of 5—[3—(hexyloxy)propoxy]pentan—1—ol as a colorless oil. Rf 0.19 (30% ), 0.31 (40% EA/Hex); 1H NMR (CDC13) 5 3.60 (t, 2H, J=6.6 Hz), 3.48—3.34 (m, 8H), 1.8 (m, 2H), 1.6—1.5 (m, 4H), 1.5—1.2(m, 10H), 0.85 (t, 3H, J=6.7 Hz). —[3—(Hexyloxy)propoxy]pentyl methanesulfonate (51.0 g) was prepared by the method used for 3—(hexyloxy)propyl methanesulfonate, using 39.0 g of 5—[3—(hexyloxy)propoxy]pentan—1—ol, 24.4 mL of TEA, 13.6 mL of esulfonyl chloride, and 420 mL of DCM. Rf 0.38 (40% EA/Hex); 1H NMR (CDC13) 5 4.23 (t, 2H, J=6.4 Hz), 3.5-3.3 (m, 8H), 2.98 (s, 3H), 1.8—1.7 (m, 4H), 1.7—1.4 (m, 6H), 1.4-1.2 (m, 6H), 0.9 (t, 3H).
—Azidopentyl 3—(hexyloxy)propyl ether (29.3 g) was produced from the reaction of 5—[3— (hexyloxy)propoxy]pentyl methanesulfonate (51 g) and sodium azide (11.3 g) in 80 mL of DMF at room temperature following the method used for 8—(3—ethoxypropoxy)octan— l—amine. Rf0.20 (5% EA/Hex); 1H NMR (CDCl3) 5 3.4-3.3 (m, 8H), 3.22 (t, 2H), 1.7 (m, 2H), 1.6-1.2 (m, 14H), 0.84 (t, 3H). —[3—(Hexyloxy)propoxy]pentan—l—amine (26.4 g) was prepared from 5—azidopentyl 3— (hexyloxy)propyl ether using LAH by the method used to prepare [4— (hexyloxy)phenyl]methanamine. 1H NMR (CDC13) 5 3 (m, 8H), 2.65 (t, 2H, J=6.4 Hz), 1.8 (m, 2H), 1.7—1.2 (m, 14H), 0.84 (t, 3, J=6.8 Hz).
N—{5—[3—(Hexyloxy)propoxy]pentyl}quinolin—4—amine A mixture of 5—[3— (hexyloxy)propoxy]pentan—1—amine (482 mg, 1.97 mmol), 4—chloroquinoline (345 mg, 2.12 mmol), DIEA (0.80 mL, 4.59 mmol), and 2 mL of NMP were heated at 160 0C for 3 days in a sealed tube. Then, the e was cooled, the le material was evaporated, the residue was partitioned between DCM and 5% N32C03, and the organic phase was dried over Na2$O4 and concentrated. SPE, washing with 50% EA/Hex and then eluting with 60% EA/Hex + 2% TEA, gave 502 mg of N—{5-[3-(hexyloxy)propoxy]pentyl}quinolinamine as an amber oil. Rf 0.20 (60% EA/Hex + 2% TEA); 1H NMR (CDClg) 8 8.48 (d, 1H, J=5.4 Hz), 7.91 (dd, 1H, 1.2, 8.4 Hz), 7.76 (m, 1H), 7.54 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.32 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 6.34 (d, 1H, J=5.4 Hz), 5.42 (t, 1H, J=5.0 Hz), 3.46—3.20 (m, 10H), 1.83—1.39 (m, 10H), .15 (m, 6H), 0.81 (m, 3H).
Example 15: N—{ 3—[5—(Hexyloxy)pentyloxy]propyl }quinolin—4—amine HN/\/\O/\/\/\O/\/\/\ —(Hexyloxy)pentyloxy]propyl}quinolin—4—amine (426 mg) was made by a method analogous to that used for the preparation of N—{ 5—[3—(hexyloxy)propoxy]pentyl}quinolin—4— amine but the two diols were reacted in the reverse sequence. Rf 0. 18 (60% EA/Hex + 2% TEA); 1H NMR (CDC13) 5 8.47 (d, 1H, J=5.5 Hz), 7.90 (dd, 1H, J=0.7, 8.4 Hz), 7.70 (m, 1H), 7.54 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.32 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.30 (d, 1H, J=5.4 Hz), 6.19 (m, 1H), 3.57 (m, 2H), 3.44—3.24 (m, 8H), 1.96 (m, 2H), .16 (m, 14H), 0.81 (m, 3H).
Example 16: N—[8—(3—Ethoxypropoxy)octyl]quinolin—4—amine /O\/\/O\/ d?/N 1—Bromo—8—(3—ethoxypropoxy)octane60% Dispersion of sodium hydride in mineral oil (1.4 g, 35 mmol) was washed twice with 20 mL of hexane. Anhydrous NMP (50 mL) and DME (50 mL) were added, the mixture was cooled with an ice bath, and 3—ethoxy—1—propanol (2.00 mL, 17.4 mmol) was added. After evolution of gas ceased, 1,8—dibromooctane (25.7 mL, 139 mmol) was added in one portion. After 16 hr at room ature, the mixture was heated at re?ux for 1.5 hr. Then, the volatile components were evaporated, and the residue was diluted with 150 mL of H20 and extracted with DCM (2x25 mL). The combined organic phases were washed with 0.05M HCl, dried over ous MgSO4, and concentrated. SPE, washing with hexane to recover 1,8-dibromooctane and then eluting with 10% EA/Hex, gave 4.15 g of o(3- ethoxypropoxy)octane. Rf0.28 (10% EA/Hex); 1H NMR (CDCl3) 5 3.50-3.31 (m, 10H), 1.88- 1.77 (m, 4H), 1.56-1.38 (m, 10H), 1.17 (t, 3H, J=6.9 Hz). 1—Azido—8—(3-ethoxypropoxy)octane 1—Bromo—8—(3—ethoxypropoxy)octane (4.15 g, 14.1 mmol) was taken up in 50 mL of DMF, and sodium azide (1.09 g, 16.8 mmol) and catalytic sodium iodide were added. After 88 hr, the e was partitioned between EA (150 mL) and H20 (50 mL), and the organic phase was washed with brine (50 mL), dried over NaZSO4, and concentrated. FC (5% EA/Hex) gave 2.55 g of colorless liquid. Rf 0.37 (10% EA/Hex); 1H NMR (CDClg) 5 3.50—3.42 (m, 6H), 3.38 (t, 2H, J=6.7 Hz), 3.24 (t, 2H, J=6.9 Hz), 1.82 (m, 2H), 1.64- 1.49 (m, 4H), 1.31 (br m, 8H), 1.18 (t, 3H, J=6.9 Hz). 8—(3—Ethoxypropoxy)octan—1—amine 1—Azido-8—(3—ethoxypropoxy)octane (2.55 g, 9.84 mmol) was taken up in 100 mL of EA. The mixture was placed under an atmosphere of argon, 10% Pd/C (200 mg) was added, and the argon was replaced by hydrogen. When the starting material was consumed, as observed by TLC, the hydrogen was ed by argon, and the mixture was filtered through Celite, washing with EA. The filtrate was concentrated to give 1.0 g of yellow oil. 1H NMR (CDC13) 5 3.6-3.3 (m, 8H), 2.6 (m, 1H), 2.4 (m, 1H), 1.8 (m, 2H), 1 (m, 15H).
N—[8—(3—Ethoxypropoxy)octyl]quinolin—4—amine A mixture of 8—(3—ethoxypropoxy)octan—1— amine (1.0 g, 4.4 mmol), 4—chloroquinoline (1.46 g, 9.0 mmol), TEA (4.0 mL, 28 mmol), and 0.2 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 0C for 4 days. The mixture was cooled and partitioned between EA and 5% NaZCO3 and brine, dried over NaZSO4, ?ltered, and concentrated. Purification by EC (60% EA/Hex + 2% TEA) gave 147 mg of amber oil. 1H NMR(CDC13) 5 8.4 (d, 1H), 8.1-7.9 (m, 2H), 7.6 (m, 1H), 7.4 (m, 1H), 6.4 (d, 1H), 6.2 (br s, 1H, NH), 3.6—3.3 (m, 10H), 7 (m, 6H), 2 (m, 8H), 1.2 (m, 3H).
Example 17: 2-Propoxyethoxy)octyl]quinolinamine HN/W\/\/O\/\O/\/ : :kT/ N N—[8-(2-Propoxyethoxy)octyl]quinolinamine (550 mg) was made using ethylene glycol monopropyl ether (2.00 mL, 17.5 mmol), 1,8—dibromooctane (25.7 mL, 139 mmol), and 4— chloroquinoline (1.42 g) using the method for the preparation of N—[8—(3— ethoxypropoxy)octyl]quinolin—4—amine. 1—Bromo—8-(2—propoxyethoxy)octane: Rf 0.29 (10% EA/Hex); 3.55 (br s, 4H, Asz), 3.46—3.34 (m, 6H), 1.81 (m, 2H), 1.65-1.52 (m, 4H), 1.42—1.30 (m, 8H), 0.88 (t, 3H, J=7.4 Hz). 1—Azido—8-(2—propoxyethoxy)octane: Rf 0.37 (10% EA/Hex); 3.55 (br s, 4H, AZBZ), 3.43 (t, 2H, J=6.7 Hz), 3.40 (t, 2H, J=6.8 HZ), 3.22 (m, 2H, J=6.9 Hz), 1.65—1.52 (m, 6H), 1.29—1.20 (m, 8H), 0.88 (t, 3H, J=7.4 Hz).
N—[8—(2—Propoxyethoxy)octyl]quinolin—4—amine: 1H NMR (CDCl3) 5 8.3 (m, 2H), 8.1 (d, 1H), 7.6 (m, 1H), 7.4 (m, 2H), 6.4 (d, 1H), 3.55 (br s, 4H, Ang), 3.45-3.35 (m, 6H), 1.8 (m, 2H), 1.6— 1.2 (m, 12H), 0.9 (t, 3H).
Example 18: N—[8—(Benzyloxy)octyl]quinolin—4—amine HN/VWVOQ CK?/N 8—(Benzyloxy)octan—l—amine (880 mg) was prepared from 8—(benzyloxy)octan—1—ol (4.23 g) following the method used in the preparation of 10—(hexyloxy)decan—1—amine.
A mixture of zyloxy)octanamine (235 mg, 1.00 mmol), 4-chloroquinoline (201 mg, 1.23 mmol), DIEA (0.50 mL, 2.87 mmol), and 2 mL of IPA was heated in a heavy walled glass tube at 150 0C for 4 days. The mixture was cooled and partitioned between DCM and 5% N32CO3, and the organic phase was dried over N32SO4, and concentrated. SPE, washing with 3% MeOH/DCM and g with 8% MeOH/DCM, gave 150 mg of the product as a yellow oil. Rf 0.13 (5% MeOH/DCM); 1H NMR (CDClg) 8 8.49 (d, 1H, J=5.4 Hz), 7.97 (d, 1H, J=8.4 Hz), 7.86 (d, 1H, J=8.4 Hz), 7.58 (ddd, 1H, J=1.2, 7.0, 8.5 Hz), .21 (m, 6H), 6.38 (d, 1H, J=5.4 Hz), 5.68 (m, 1H), 4.48 (s, 2H), 3.44 (t, 2H, J=6 Hz), 3.27 (m, 2H), 1.75-1.52 (m, 4H), 1.37—1.32 (m, 8H).
Example 19: N—(6—Phenoxyhexyl)quinolin—4—amine (I5HN/W\/O\©/ N N—(6—Phenoxyhexyl)quinolin—4—amine (188 mg) was prepared starting from 1,6—dibromohexane (4.25 mL) and phenol (326 mg) ing the method used for the preparation of N—(8— phenoxyoctyl)quinolin—4—amine. (6—Bromohexyloxy)benzene (409 mg): Rf 0.46 (5% EA/Hex); 1H NMR (CDClg) 5 7.3 (m, 2H), 6.9 (m, 3H), 4.0 (m, 2H), 3.4 (m, 2H), 2.0-1.7 (m, 4H), 1.6-1.4 (m, 4H). (6—Azidohexyloxy)benzene (344 mg): 1H NMR (CDC13) 8 7.3 (m, 2H), 6.9 (m, 3H), 4.0 (m, 2H), 3.28 (t, 2H, J=6.8 Hz), 1.8 (m, 2H), 1.7-1.4 (m, 6H). 6—Phenoxyhexan—l—amine (224 mg): 1H NMR (CDCl3) 5 7.3 (m, 2H), 6.9 (m, 3H), 3.91 (t, 2H, J=6.4 Hz), 2.6 (m, 2H), 1.8-1.3 (m, 8H). henoxyhexyl)quinolin—4—amine: Rf 0.15 (50% EA/Hex + 2% TEA); 1H NMR ) 5 8.53 (d, 1H, J=5.2 Hz), 7.97 (m, 1H), 7.75 (m, 1H), 7.60 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 7.38 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.30—7.22 (m, 2H), 6.95—6.86 (m, 3H), 6.39 (d, 1H, J=5.5 Hz), 5.22 (t, 1H, J=4.7 Hz), 3.94 (t, 2H, J=6 Hz), 3.29 (m, 2H), 1.81-1.44 (m, 8H).
Example 20: N-(8-Phenoxyoctyl)quinolinamine HNWOQ : \J\T/ N (8—Bromooctyloxy)benzene A mixture of phenol (321 mg, 3.41 mmol), 1,8—dibromooctane (5.00 mL, 27.0 mmol), and K2C03 (1.41 g, 10.2 mmol) in 6 mL of DMF and 6 mL of 1,2— oxyethane was heated at 90 °C for 24 hr. The mixture was cooled and partitioned between ether (3x175 mL) and 0.1N NaOH (75 mL) and 1:1 0.1M HCl/brine (75 mL). The organic phases were dried over MgSO4 and concentrated. Purification by PC (5% EA/Hex) gave 533 mg of (8—bromooctyloxy)benzene as a colorless oil. Rf0.50 (5% EA/Hex); 1H NMR (CDClg) 8 7.31— 7.24 (m, 2H), 6.95—6.88 (m, 3H), 3.95 (t, 2H, J=6.5 Hz), 3.41 (t, 2H, J=6.8 Hz), 1.91-1.73 (m, 4H), 1.47—1.27 (m, 8H). (8—Azidooctyloxy)benzene (460 mg of a colorless oil) and then oxyoctan—l—amine (339 mg of a colorless solid) were ed following the method for lO—butoxydecan—l—amine using 533 mg of (8—bromooctyloxy)benzene and 170 mg of sodium azide. (8—Azidooctyloxy)benzene: 1H NMR (CDCl3) 8 .25 (m, 2H), 6.97—6.88 (m, 3H), 3.96 (m, 2H), 3.26 (t, 2H, J=7.0 Hz), 1.80 (m, 2H), 1.60 (m, 2H), 1.50—1.38 (m, 8H). 8—Phenoxyoctan—l—amine: 1H NMR (CDCl3) 5 7.26—7.20 (m, 2H), 6.91—6.84 (m, 3H), 3.90 (t, 2H, J=6.4 Hz), 2.63 (m, 2H), 1.74 (m, 2H), 1.5-1.2 (m, 10H).
N—(8—Phenoxyoctyl)quinolin—4—amineA mixture of 8—phenoxyoctan—1—amine (339 mg, 1.53 mmol), 4—chloroquinoline (328 mg, 2.01 mmol) and TEA (0.50 mL, 3.56 mmol) in 1 mL of NMP was heated at 160 °C for 24 hr. The mixture was cooled and partitioned between EA and % N32C03. The organic phases were washed with brine, dried over NaZSO4, and concentrated.
Purification by EC (50% EA/Hex + 2% TEA) gave 431 mg of N-(8-phenoxyoctyl)quinolin amine. Rf0.18 (50% EA/Hex + 2% TEA); 1H NMR (CDC13) 5 8.53 (d, 1H, J=5.4 Hz), 7.97 (dd, 1H, J=1.0, 8.4 Hz), 7.74 (m, 1H), 7.60 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.39 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.30-7.22 (m, 2H), 6.95-6.86 (m, 3H), 6.39 (d, 1H, J=5.4 Hz), 5.17 (br s, 1H, NH), 3.93 (t, 2H, J=6.5 Hz), 3.27 (m, 2H), 1.82—1.68 (m, 4H), 1.47-1.40 (m, 8H).
Example 21: N—{2—[2—(Hexyloxy)phenoxy]ethyl}quinolin—4—amine €35/ Hexyloxy)phenoxy]ethanol A mixture of yloxy)phenol (9.10 g, 46.9 mmol), ethylene carbonate (6.4 g, 72.7 mmol), and K2CO3 (10.0 g, 72.5 mmol) in 50 mL of DMF was heated at 70—75 0C for 17 hr and then 90 °C for 6 hr. The mixture was cooled, partly neutralized with 1M HCl, and partitioned between EA and 1M HCl, H20 (2x), and brine. The organic phases were dried over Mg804, filtered through a pad of silica gel, and concentrated to a brown oil.
SPE, washing with 10% EA/HeX and then eluting with 37% EA/HeX, gave 10.73 g of pale yellow . Rf0.15 (20% EA/HeX); 1H NMR (CDC13) 5 6.99-6.94 (m, 2H), 6.92—6.87 (m, 2H), 4.12 (m, 2H), 4.00 (t, 2H), 3.88 (m, 2H), 2.80 (s, 1H, OH), 1.82 (m, 2H), 1.46 (m, 2H), 1.38—1.31 (m, 4H), 0.90 (m, 3H); 13C NMR(CDC13)5150.2, 148.6, 122.8, 121.3, 117.2, 113.9, 72.5, 69.3, 61.5, 31.8, 29.4, 25.9, 22.8, 14.2. 2—[2—(Hexyloxy)phenoxy]ethyl methanesulfonate The crude 2—[2—(hexyloxy)phenoxy]ethanol (10.73 g, 45.1 mmol) was taken up in 170 mL of 1,2—dimethoxyethane and cooled by an ice bath.
Methanesulfonyl chloride (4.90 mL, 62.6 mmol) and then TEA (9.40 mL 67.0 mmol) were added. After 2 hr, 5 mL of H20 were added, and the volatile components were evaporated. The residue was partitioned between EA and H20, saturated , H20, 1M HCl, H20 (2x), and brine. The organic phases were dried over MgSO4 and concentrated to give 13.67 g of colorless solid. Rf0.37 (30% EA/Hex); 1H NMR (CDClg) 8 6.99—6.86 (m, 4H), 4.60 (m, 2H), 4.25 (m, 2H), 3.98 (m, 2H), 3.16 (s, 3H), 1.78 (m, 2H), 1.46 (m, 2H), 1.38-1.30 (m, 4H), 0.90 (m, 3H); 13c NMR(CDC13)8149.7, 147.9. 122.8, 121.1, 115.5, 113.7, 69.1, 69.0, 67.6, 38.1, 31.8, 29.5, 25.9, 22.8, 14.2. -[2-(Hexyloxy)ethy1]phthalimide A mixture of 2-[2-(hexyloxy)phenoxy]ethyl methanesulfonate (13.67 g, 43.2 mmol), potassium phthalimide (15.5 g, 84 mmol), and sodium iodide (610 mg) in 50 mL of DMF was heated at 90 0C for 24 hr. The cooled e was partitioned between EA and 5% Na2C03 and brine. The organic phases were dried over Na2S04 and concentrated, and the residue was filtered through a pad of silica gel in 30% EA/Hex and ated to give a solid. Recrystallization from EtOH gave 10.4 g of colorless solid. 1H NMR (CDC13) 5 7.85 and 7.72 (m, 4H, AA’BB’), .82 (m, 4H), 4.26 and 4.12 (m, 4H, Asz), 3.88 (t, 2H), 1.71 (m, 2H), 1.42-1.27 (m, 6H), 0.90 (m, 3H); 13C NMR(CDC13) 5 168.3, 149.8, 148.6, 134.1, 132.4, 123.5, 122.3, 121.1, 115.6, 114.3, 69.3, 66.4, 37.7, 31.8, 29.4, 25.8, 22.8, 14.2. 2—[2—(Hexyloxy)phenoxy]ethanamineN—[2—(Hexyloxy)ethyl]phthalimide (10.4 g, 28.3 mmol) was taken up in 130 mL of EtOH, and hydrazine monohydrate (2.0 mL, 41 mmol) was added. The WO 20995 mixture was heated at re?ux for 16 hr. After heating was halted, 140 mL of 1M HCl was added to the still—warm mixture, and the mixture was stirred vigorously during cooling. The itate was ?ltered and washed with EtOH. The filtrate was concentrated. SPE, washing with 7% MeOH/DCM and then 7% MeOH/DCM + 2% TEA gave fractions containing 6.80 g of oily— solid ninhydrin (+) product. Rf 0.40 (5% MeOH/DCM + 2% TEA); 1H NMR (CDC13) 5 6.94— 6.82 (m, 4H), 4.00 (t, 2H, J=5.2 Hz), 3.97 (t, 2H, J=6.7 Hz), 3.05 (t, 2H, J=5.2 Hz), 1.80 (m, 2H), 1.54 (br s, 2H, N?z), 1.50—1.28 (m, 6H), 0.89 (m, 3H).
N- { 2—[2—(Hexyloxy)phenoxy] ethyl }quinolin—4—amine Crude 2— [2— (hexyloxy)phenoxy]ethanamine (6.8 g, 28.7 mmol) was taken up in 30 mL of DMA, and 25 mL was evaporated in vacuo. The residue was diluted with 5 mL of NMP, and 4—chloroquinoline (4.20 g, 25.8 mmol) and DIEA (10.0 mL, mmol) were added. The mixture was heated in a sealed tube at 160 0C for 24 hr. Then, the mixture was cooled, partitioned n EA and 5% N32C03 (3x) and brine. The organic phase was dried over NaZSO4 and trated to give a solid.
Trituration with Eth and drying gave 3.11 g of colorless solid. Rf 0.31 (10% CM); mp 1045-1060 0C; 1H NMR (CDC13) 8 8.55 (d, 1H, J=5.5 Hz), 8.04 (m, 1H), 7.85 (d, 1H, J=8.4 Hz), 7.66 (ddd, 1H, J=1.4, 6.9, 8.4 Hz), 7.44 (m, 1H), .97 (m, 2H), 6.95-6.89 (m, 2H), 6.50 (d, 1H, J=5.5 Hz), 6.00 (br s, 1H, NH), 4.37 (t, 2H, J=5.1 Hz), 4.02 (t, 2H, J=6.9 Hz), 3.71 (m, 2H), 1.79 (m, 2H), 1.40 (m, 2H), 1.28—1.20 (m, 4H), 0.83 (m, 3H).
Example 22: N—{ 3—[2—(Hexyloxy)phenoxy]propyl }quinolin—4—amine HNMO/qj C3) OM 2—(Hexyloxy)phenol A mixture of catechol (28.9 g, 263 mmol), K2C03 (37 g, 268 mmol), and 1—bromohexane (29.0 mL, 207 mmol) in 130 mL of DMA reacted at room temperature for 20 hr with the aid of mechanical stirring. TLC of an aliquot showed the presence of a substantial amount of catechol. The mixture was heated at 80 0C, and TLC of an aliquot showed good reaction progress. l—Bromohexane (5.9 mL, 42 mmol) and K2C03 (6 g, 43 mmol) were added, and heating ued for 10 hr. Then, the mixture was cooled, and most of the volatile components were evaporated. The residue was partitioned between EA (3x250 mL) and H20, %Na2C03 (2x), H20, 0.1M HCl, and brine (200 mL each). The combined organic phases were dried over MgSO4 and concentrated. SPE (5% EA/Hex) gave 34.8 g of a 4:1 mixture of 2— (hexyloxy)phenol and l,2—bis(hexyloxy)benzene as determined by 1H NMR. A sample was purified by SPE, washing with Hex to obtain the diether, and then eluting yloxy)phenol using 5% EA/Hex. Rf0.38 (5% EA/Hex); 1H NMR ) 8 7.0-6.8 (m, 4H), 5.7 (s, 1H), 4.0 (t, 2H), 1.9 (m, 2H), 1.5 (m, 2H), 1.4-1.3 (m, 4H), 1.9 (t, 3H).
N—{3—[2—(Hexyloxy)phenoxy]propyl}phthalimide A e of 2—(hexyloxy)phenol that contained 1,2—bis(hexyloxy)benzene (90 mol % pure, 61.8 g), K2CO3 (43.6 g, 316 mmol), and N— (3-bromopropyl)phthalimide (76.9 g, 287 mmol) in 150 mL of DMF was heated at 60 0C for 24 hr with the aid of ical stirring. TLC (5% BA, 45% toluene, 50% Hex) of an aliquot showed that substantial bromide starting material ed, so the temperature was raised to 100 0C. After 16 hr, the reaction was completed, as shown by TLC. Then, the mixture was cooled, and most of the volatile components were evaporated. The residue was partitioned between EA (3x250 mL) and H20 neutralized using H3PO4, 0.1M HCl, H20, and brine (200 mL each). The combined organic phases were dried over MgSO4 and concentrated to give 83 g of the product as a light tan solid that contained 2—(hexyloxy)phenol and 1,2-bis(hexyloxy)benzene, as shown by 1H NMR. Rf 0.21 (19:10 uene/Hex) 0.19 (10% EA/Hex); 1H NMR (CDC13) 8 7.82 and 7.71 (m, 4H, AA’BB’), 6.93—6.82 (m, 4H), 4.06 (t, 2H), 3.96-3.88 (m, 4H), 2.19 (m, 2H), 1.76 (m, 2H), 1.46-1.24 (m, 6H), 0.87 (m, 3H). 3—[2—(Hexyloxy)phenoxy]propan—l—amine Crude N—{ 3—[2— (hexyloxy)phenoxy]propyl}phthalimide was dissolved in 450 mL of warm IPA, and hydrazine monohydrate (24.8 mL, 327 mmol) was added. The mixture was heated at 80 0C for 12 hr with the aid of mechanical stirring, and then the mixture was allowed to stand at room temperature for 48 hr. The solid was broken up, diluted with 400 mL of EtZO, and stirred for 1 hr. The precipitate was filtered and washed with 50% tzO (2x200 mL). The ed filtrates were concentrated to give 73 g of amber liquid. The liquid was taken up in 400 mL of DCM and washed with 1N NaOH and H20 (100 mL each). The organic phase was concentrated. The e was separated by SPE. Elution with 1% MeOH/DCM gave 20 g of a mixture of 2— (hexyloxy)phenol and 1,2—bis(hexyloxy)benzene. Then, elution with 7% MeOH/DCM + 2% NH4OH gave the product. The partially concentrated fractions were washed with 200 mL of H20, the water phase was extracted with 150 mL of DCM, and the combined organic phases were dried over NaZSO4, filtered, and concentrated to give 33.6 g of an amber liquid. Rf 0.06 (5% CM, ninhydrin (+)); 1H NMR (CDC13) 5 6.91-6.87 (m, 4H), 4.09 (t, 2H), 3.98 (t, 2H, J=6.6 Hz), 2.93 (t, 2H), 1.95 (q, 2H), 1.80 (m, 2H), 1.50—1.31 (m, 6H), 0.90 (m, 3H); l3C NMR(CDC13)8121.5, 121.2, 114.4, 114.1, 69.3, 67.9, 40.0, 33.4, 31.8, 29.5, 25.9, 22.8, 14.2.
N— { Hexyloxy)phenoxy]propyl}quinolin—4—amine 3—[2—(Hexyloxy)phenoxy]propan— 1— amine (28.4 g, 113 mmol) was taken up in 230 mL of 1—pentanol, and 70 mL of le material was removed by distillation in order to ensure anhydrous conditions. The mixture was allowed to cool below re?ux temperature, and pylamine (43 mL, 226 mmol) and 4-chloroquinoline (23.9 g, 147 mmol) were added. Heating at re?ux was resumed. After 15 hr, TLC of an aliquot indicated no ninhydrin (+) starting al remained. After ng at room temperature for 48 hr, 120 mL of volatile material was removed by distillation. The cooled mixture was diluted with 350 mL of DCM and washed with 2N NaOH, H20, and 5% Na2C03 (100 mL each). The aqueous phases were extracted in turn with 350 mL of DCM. The combined organic phases were dried over Na2804, filtered, and concentrated. Purification by PC, eluting with a step gradient of 40, 50, and 60% EA/Hex + 2% TEA, gave pure product fractions, as shown by TLC and NMR.
The product e was trated, taken up in EA, washed with 5% N32C03 and brine, dried over NaZSO4, filtered, and concentrated to give a yellow oil. Standing under Et20 and cooling using an ice bath gave a colorless precipitate. The precipitate was collected by filtration and washed with ice—cold EtZO to give 33.9 g of the product after drying in vacuo. mp 61.0—62.0 0C; 1H NMR (CDC13) 5 8.55 (d, 1H, J=5.1 Hz), 7.95 (dd, 1H, J=0.8, 8.5 Hz), 7.84 (dd, 1H, 121.1, 8.4 Hz), 7.60 (m, 1H), 7.35 (m, 1H), 6.98—6.87 (m, 4H), 6.44 (d, 1H, J=5.5 Hz), 5.98 (t, 1H, J=4.4 Hz, NH), 4.21 (t, 1H, J=5.5 Hz), 4.02 (t, 2H), 3.58 (m, 2H), 2.27 (m, 2H), 1.75 (m, 2H), 1.40 (m, 2H), 1.27—1.21 (m, 4H), 0.84 (m, 3H); 13C NMR (CDC13) 8 151.2, 150.1, 149.6, 148.7, 148.6, 130.0, 129.0, 124.5, 122.3, 121.1, 120.2, 119.2, 115.2, 113.8, 98.7, 69.2, 69.2, 42.1, 31.6, 29.3, 28.5, 25.8, 22.7, 14.1.
Example 23: N— { 4— [2— (Hexyloxy)phenoxy]butyl lin—4—amine C3?/N N—(4—Bromobutyl)phthalimide A mixture of 1,4—dibromobutane (22 mL, 185 mmol) and potassium phthalimide (11.35 g, 61.4 mmol) in 60 mL of DMF was mixed at room temperature for 1 day. Then, the reaction mixture was extracted with hexane (3x150 mL). The hexane fractions were dried over MgSO4, filtered, and concentrated to give 30 g of a 1:22 molar mixture of recovered 1,4—dibromobutane and DMF. This mixture was d with 30 mL of DMF and ted with potassium phthalimide (4.80 g, 26 mmol) at room temperature for 1 day. The two reaction mixtures in DMF were partitioned between 1:1 EA/Hex (3x150 mL) and H20 (2x100 mL), 0.1M HCl (100 mL), and brine (100 mL).The organic phases were dried over MgSO4 and concentrated. SPE, eluting with 0% and 10% EA/Hex, gave 17.3 g of colorless solid. Rf 0.55 (40% EA/Hex); 1H NMR (CDClg) 8 7.86-7.81 (m, 2H), 7.73-7.69 (m, 2H), 3.71 (t, 2H), 3.43 (t, 2H), .80 (m, 4H); 13C NMR (CDC13) 8 168.5, 134.2, 132.3, 123.5, 37.2, 32.9, 30.1, 27.4.
N—{4—[2—(Hexyloxy)phenoxy]butyl}phthalimide A mixture of N—(4—bromobutyl)phthalimide (17.3 g, 61.3 mmol), 2—(hexyloxy)phenol (14.9 g, 61 mmol), and K2C03 (9.5 g, 69 mmol) in 80 mL of DMF was heated at 80 0C for 20 hr. Then, the mixture was cooled, partitioned between 40% EA/Hex (3x300 mL) and 0.25M HCl (340 mL), H20, 0.1M HCl, and brine (150 mL each), dried over MgSO4, concentrated, filtered through a pad of silica gel with 40% EA/Hex, and concentrated to give 25.7 g of pale yellow solid. 4—[2—(Hexyloxy)phenoxy]butan— l—amine Crude N— { 4— [2— (hexyloxy)phenoxy]butyl}phthalimide was taken up in 400 mL of IPA, and ine drate (4.40 mL, 91 mmol) was added. The mixture was heated at 80 0C for 12 hr. Then, the mixture was cooled, resulting in precipitation. Eth (400 mL) was added, and the heterogeneous mixture was stirred vigorously. The precipitate was removed by filtration h Celite, and the precipitate was washed with Eth (4x150 mL). The volatile components were evaporated to leave 14.2 g of colorless solid. 1H NMR ) 5 6.88—6.83 (m, 4H), 3.98 (t, 2H, J=6.2 Hz), 3.96 (t, 2H, J=6.7 Hz), 2.77 (t, 2H, J=6.9 Hz), 2.17 (br s, 2H), 1.89-1.74 (m, 4H), 1.64 (m, 2H), 1.50-1.23 (m, 6H), 0.89 (m, 3H).
N— { 4—[2—(Hexyloxy)phenoxy]butyl }quinolin—4—amine Crude 4— [2— (hexyloxy)phenoxy]butan—1—amine (14.2 g, 53.6 mmol) was taken up in 400 mL of 1—pentanol, and 100 mL was removed by distillation. The mixture was cooled below boiling, and tripropylamine (15 mL, 78.7 mmol) and 4-chloroquinoline (8.75 g, 53.7 mmol) were added.
Heating at re?ux was resumed for 18 hr. Then, the e was concentrated by distillation.
SPE, washing with 50% EA/Hex and then eluting with 10% MeOH/DCM gave a brown oil after concentration. The oil was taken up in DCM and washed with 5% Na2C03, dried over , and concentrated. Purification by PC (60% EA/Hex + 2% TEA), evaporation of solvents from the product fractions, and then ation of MeOH and drying gave 3.7 g of the product as a ess solid. 1H NMR(CDC13) 8 8.53 (d, 1H, J=5.5 Hz), 7.95 (dd, 1H, J=0.7, 8.4 Hz), 7.74 (m, 1H), 7.59 (ddd, 1H, J=1.1, 7.0, 8.1 Hz), 7.33 (m, 1H), 6.97-6.88 (m, 4H), 6.43 (d, 1H, J=5.2 Hz), 5.63 (t, 1H, NH), 4.11 (t, 1H), 4.00 (t, 2H), 3.49 (m, 2H), 2.01—1.94 (m, 4H), 1.74 (m, 2H), 1.39 (m, 2H), 1.23—1.16 (m, 4H), 0.80 (m, 3H); 13C NMR(CDC13)5151.3, 150.0, 149.5, 148.8, 148.8, 130.1, 129.1, 124.6, 121.8, 121.1, 119.8, 119.1, 114.4, 113.7, 98.8, 69.2, 69.2, 42.8, 31.7, 29.4, 26.8, 25.9, 25.8, 22.8, 14.1.
Example 24: N—[3—(2—Ethoxyphenoxy)propyl]quinolin—4—amine \ O\/ N—[3—(2—Ethoxyphenoxy)propyl]quinolin—4—amine (217 mg) was prepared ing the method for the preparation of N—{3—[4—(hexyloxy)phenoxy]propyl}quinolin—4—amine, starting with 2— ethoxyphenol (1.5 g) and N—(3—bromopropyl)phthalimide (2.91 g).
N—[3—(2—Ethoxyphenoxy)propyl]phthalimide (2.57 g): 1H NMR (CDC13) 5 7.85 and 7.75 (m, 4H, AA’BB’), 6.95-6.80 (m, 4H), 4.1-4.0 (m, 4H), 3.9 (t, 2H), 2.2 (m, 2H), 1.4 (t, 3H). 3—(2—Ethoxyphenoxy)propan—l—amine (0.76 g): 1H NMR (CDC13) 5 6.9 (m, 4H), 4.1—4.0 (m, 4H), 2.95 (t, 2H), 1.95 (m, 2H), 1.5 (br s, 2H, NH;), 1.4 (t, 3H).
N—[3—(2—Ethoxyphenoxy)propyl]quinolin—4-amine: 1H NMR (CDC13) 5 8.8 (br s, 1H, NH), 8.5 (m, 1H), 8.4 (m, 1H), 8.2 (d, 1H), 7.7 (m, 1H), 7.5 (m, 1H), 7.0-6.8 (m, 4H), 6.6 (d, 1H), 4.2 (m,2H), 4.1 , 3.8 (q, 2H), 2.4 (m,2H), 1.4 (t, 3H).
Example 25: N-[3-(2-Methoxyphenoxy)propyl]quinolinamine 3—(2—Methoxyphenoxy)propan—1—amine was prepared ing the method for the preparation of 3—[4—(Hexyloxy)phenoxy]propan—1—amine, starting with 2—methoxyphenol (1.5 g) and N—(3— bromopropyl)phthalimide (3.2 g).
N—[3—(2—Methoxyphenoxy)propyl]phthalimide (3.19 g): 1H NMR (CDC13) 5 7.8 and 7.7 (m, 4H, AA’BB’), 6.9-6.8 (m, 4H), 4.1 (t, 2H), 3.9 (t, 2H), 3.7 (s, 3H), 2.2 (m, 2H). 3—(2—Methoxyphenoxy)propan—l—amine (770 mg): 1H NMR ) 5 6.9—6.8 (m, 4H), 4.1 (t, 2H), 3.8 (s, 3H), 2.9 (t, 2H), 2.0 (m, 2H), 1.5 (br s, 2H, N?z).
N—[3—(2—Methoxyphenoxy)propyl]quinolin—4—amine A mixture of 3—(2— methoxyphenoxy)propan—l—amine (770 mg, 3.95 mmol), 4—chloroquinoline (777 mg, 4.77 mmol), 0.15 mL of NMP and 2 mL of TEA were heated at 130 0C in a sealed tube for 5 days.
Then, the mixture was cooled and concentrated in vacuo. Purification by preparative TLC (5% MeOH/DCM) gave the product. 1H NMR (CDC13) 5 8.4 (d, 1H), 8.2 (d, 1H), 8.1 (d, 1H), 7.7 (m, 1H), 7.4 (m, 1H), 7.1 (br s, 1H, NH), 7.0-6.9 (m, 4H), 6.5 (d, 1H), 4.3 (t, 2H), 3.9 (s, 3H), 3.7 (m, 2H), 2.3 (m, 2H). e 26: N—{ 3—[2—(Benyloxy)phenoxy]propyl }quinolin—4—amine .NMOQ $6 093 N—{3-[2-(Benyloxy)phenoxy]propyl}quinolinamine was prepared following the method for the preparation of N—{3-[4-(hexyloxy)phenoxy]propyl}quinolinamine, starting with 2- (benzyloxy)phenol (2.0 g) and N—(3-bromopropyl)phthalimide (2.68 g). 2-(Benzyloxy)phenoxy]propyl}phthalimide (3.6 g): 1H NMR (CDC13) 5 7.8 and 7.7 (m, 4H, AA’BB’), 7.5-7.3 (m, 4H), 7.0-6.8 (m, 5H), 5.1 (s, 2H), 4.1 (t, 2H), 3.9 (t, 2H), 2.2 (m, 2H). 3—[2—(Benzyloxy)phenoxy]propan—1—amine (1.92 g): 1H NMR ) 5 7.5—7.3 (m, 5H), 6.9—6.8 (m, 4H), 5.1 (s, 2H), 4.1 (t, 2H), 2.9 (t, 2H), 2.0 (m, 2H).
N—{3—[2—(Benyloxy)phenoxy]propyl}quinolin—4—amine: 1H NMR (CDC13) 5 8.5 (d, 1H), 7.9 (d, 1H), 7.8 (d, 1H), 7.5 (m, 1H), 7.4-7.2 (m, 6H), 7.0—6.9 (m, 4H), 6.4 (d, 1H), 6.0 (br s, 1H, NH), .1 (s, 2H), 4.2 (t, 2H), 3.6 (m, 2H), 2.3 (m, 2H).
Example 27: N—[8—(3—Methoxyphenoxy)octyl]quinolin—4—amine (>5/ 1—(8—Bromooctyloxy)—3—methoxybenzene (1.28 g) was prepared by the same method used for 1— (8—bromooctyloxy)—3—methylbenzene using 3—methoxyphenol (638 mg, 5.14 mmol), 1,8— dibromooctane (14.3 g, 53 mmol), and K2C03 (852 mg, 6.17 mmol) in 14 mL of NMP and 7 mL of DME heated for 24 hr. 1H NMR (CDC13) 5 7.2 (m, 1H), 6.46 (m, 3H), 3.9 (t, 2H), 3.4 (t, 2H, J=6.9 Hz), 1.9—1.7 (m, 4H), 2 (m, 8H). 1-(8—Iodooctyloxy)—3—methoxybenzene (1.47 g) was prepared from 1—(8—bromooctyloxy)—3— methoxybenzene (1.28 g, 6.78 mmol) and sodium iodide (601 mg) in 50 mL of acetone following the method used in the preparation of 10—(hexyloxy)decan—1—amine.
N—[8-(3-Methoxyphenoxy)octyl]phthalimide (1.0 g) was prepared from 1-(8-iodooctyloxy) methoxybenzene (1.47 g, 4.06 mmol) and potassium phthalimide (1.13 g) in 50 mL of DMF at 60-80 0C for 12 hr ing the method for N—[8-(hexyloxy)octyl]phthalimide. 1H NMR (CDC13) 8 7.85 (m, 2H), 7.7 (m, 2H), 7.2 (m, 1H), 6.7-6.5 (m, 3H), 3.9 (m, 2H), 3.8 (s, 3H), 3.65 (m, 2H), 1.8-1.6 (m, 4H), 1.5—1.3 (m, 8H). 8—(3—Methoxyphenoxy)octan—1—amine (438 mg, 1.74 mmol) was prepared from 3— methoxyphenoxy)octyl]phthalimide (1.0 g, 2.6 mmol) using hydrazine monohydrate (0.20 mL) in EtOH (50 mL) following the method for [3—(hexyloxy)phenyl]methanamine. 1H NMR (CDgOD) 5 7.1 (m, 1H), 4 (m, 3H), 3.9 (t, 2H), 3.7 (s, 3H), 2.7 (t, 2H), 1.8 (m, 2H), 1.6—1.4 (m, 10H).
N—[8—(3—Methoxyphenoxy)octyl]quinolin—4—amine (200 mg) was prepared from 8—(3— methoxyphenoxy)octan—l—amine (438 mg, 1.74 mmol), 4—chloroquinoline (572 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4— amine. 1H C13)5 8.5 (d, 1H), 8.0 (d, 1H), 7.75 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.15 (m, 1H), 6.5—6.4 (m, 4H), 5.1 (br s, 1H, NH), 3.9 (t, 2H), 3.3 (m, 2H), 1.8 (m, 4H), 3 (m, 8H).
Example 28: N—{4—[3—(Hexyloxy)phenoxy]butyl}quinolin—4—amine HN/\/\/0 co 00\/\/\/ N/ 1—(4—Bromobutoxy)—3—(hexyloxy)benzene A mixture of yloxy)phenol (1.21 g, 6.26 mmol), 1,4—dibromobutane (7.00 mL, 59 mmol), and K2C03 (950 mg, 6.88 mmol) in 14 mL of 1:1 NMP/1,2—dimethoxyethane was heated at gentle re?ux for 40 hr. The mixture was cooled and partitioned between DCM and 1M HCl. The organic phase was dried over MgSO4 and concentrated in vacuo with warming to remove excess dibromide. The residue was separated by SPE, washing with Hex and then eluting the product with 5% EA/Hex to give 1-(4- bromobutoxy)(hexyloxy)benzene (1.42 g). Rf0.40 (5% EA/Hex); 1H NMR (CDClg) 8 7.15 (m, 1H), 6.51-6.43 (m, 3H), 3.99-3.90 (m, 4H), 3.48 (t, 2H, J=6.6 Hz), 2.11 (m, 2H), 1.93 (m, 2H), 1.81 (m, 2H), 1.50—1.29 (m, 6H), 0.92 (m, 3H).
N— { 4—[3—(Hexyloxy)phenoxy]buty1}phtha1imide 1-(4-Bromobutoxy)—3—(hexyloxy)benzene (1.40 g, 4.26 mmol), potassium phthalimide (1.18 g, 6.38 mmol), and DMF (5 mL) were mixed at room temperature until the bromide was consumed, as observed by TLC of an aliquot. The mixture was partitioned n EA and H20 and brine, and the organic phase was dried over MgSO4 and concentrated. SPE (15% EA/Hex) gave 1.60 g of the product. Rf 0.40 (20% EA/Hex); 1H NMR (CDC13) 8 7.83 and 7.70 (m, 4H, AA’BB’), 7.12 (m, 1H), 6.48—6.42 (m, 3H), .88 (m, 4H), 3.76 (t, 2H, J=6.8 Hz), 1.92—1.70 (m, 6H), 1.49-1.25 (m, 6H), 0.89 (m, 3H). 4—[3-(Hexyloxy)phenoxy]butan—1—amine A mixture of the 3— (hexyloxy)phenoxy]butyl}phthalimide (1.60 g, 4.05 mmol), hydrazine monohydrate (0.30 mL, 6.3 mmol), and 15 mL of EtOH were heated at re?ux for 8 hr. The mixture was cooled and 2014/013992 partitioned between EA and 5% K2C03 and brine, and the organic phases were dried over NaZSO4 and concentrated. SPE, washing with 5% MeOH/DCM and eluting with 10% MeOH/DCM + 2% TEA gave 1.05 g of the amine as a colorless solid. 1H NMR (CD30D + CDC13) 8 7.01 (t, 1H, J=7.8 Hz), 6.37—6.32 (m, 3H), .76 (m, 4H), 2.66 (t, 2H), 1.74—1.50 (m, 6H), 1.34-1.17 (m, 6H), 0.77 (m, 3H). 3—(Hexyloxy)phenoxy]butyl}quinolin-4—amine A mixture of the 4—[3— (hexyloxy)phenoxy]butan—l—amine (300 mg, 1.20 mmol), 4—chloroquinoline (283 mg, 1.74 mmol), DIEA (0.50 mL, 2.87 mmol), and 1.5 mL of IPA was sealed in a heavy walled glass tube and mixed at 180 0C for 3 days. The mixture was cooled and partitioned between EA and 5% Na2C03 and brine, dried over NaZSO4, and concentrated. SPE, washing with 3% MeOH/DCM and eluting with 10% MeOH/DCM, gave 293 mg of the product as a solid. Rf 0.26 (10% MeOH/DCM); 1H NMR (CDC13) 8 8.52 (d, 1, J=5.2 Hz), 7.97 (d, 1, J=8.4 Hz), 7.72 (d, 1, J=8.4 Hz), 7.61 (m, 1H), 7.37 (m, 1H), 7.17 (t, 1, J=8 Hz), 6.53-6.47 (m, 3), 6.42 (d, 1, J=5.5 Hz), 5.35 (br s, 1H, NH), 4.03 (m, 2H), 3.91 (m, 2H), 3.40 (m, 2H), 1.96-1.95 (m, 4), 1.75 (m, 2H), 1.46- 1.31 (m, 6), 0.89 (m, 3).
Example 29: N-{ 3-[3-(Hexyloxy)phenoxy]propyl linamine HNMO CED dam 3—(Hexyloxy)phenol A mixture of resorcinol (7.1 g), K2C03 (1.13 g), and 1—bromohexane (1.0 mL) in 60 mL of NMP reacted at 50—60 °C for 20 hr with the aid of mechanical stirring. Then, the e was cooled, and most of the volatile components were evaporated. The residue was partitioned between EA (3x250 mL) and H20, 5% Na2C03 (2x), H20, 0.1M HCl, and brine (200 mL each). The combined organic phases were dried over MgSO4 and concentrated. SPE (5% EA/Hex) gave 1.29 g of 3—(hexyloxy)phenol. 1H NMR (CDC13) 5 7.10 (m, 1H), 6.48 (m, 1H), 6.42—6.38 (m, 2H), 3.91 (t, 2H, J=6.7 Hz), 1.75 (m, 2H), 1.48—1.31 (m, 6H), 0.89 (m, 3H).
W0 2014/120995 N—{3—[3—(Hexyloxy)phenoxy]propyl}phthalimide A mixture of yloxy)phenol (9.8 g), K2C03 (9.8 g), and N—(3—bromopropyl)phthalimide (15.5 g) in 150 mL of 2—butanone was heated at re?ux for 24 hr with the aid of mechanical ng. Then, the mixture was cooled, and most of the volatile components were evaporated. The residue was ioned between EA (3x250 mL) and H20 neutralized using H3PO4, 0.1M HCl, H20, and brine (200 mL each). The combined organic phases were dried over MgSO4 and concentrated to give 7.58 g of the t. 1H NMR (CDC13) 5 7.81 and 7.68 (m, 4H, AA’BB’), 7.09 (t, 1H, J=8.2 Hz), 6.45 (ddd, 1H, J=1.0, 2.5, 8.4 Hz), 6.39—6.32 (m, 2H), 3.99 (t, 2H, J=6.0 Hz), 3.91—3.83 (m, 4H), 2.16 (m, 2H), 1.73 (m, 2H), 1.45—1.21 (m, 6H), 0.90 (m, 3H). 3-[3—(Hexyloxy)phenoxy]propan—1—amine Crude N— { 3— [3—(hexyloxy)phenoxy]propyl} phthalimide (1.20 g) was dissolved in 50 mL of EtOH, and ine monohydrate (0.22 mL) was added. The mixture was heated at re?ux for 12 hr, and then the mixture was allowed to stand at room temperature for 48 hr. The solid was broken up, diluted with 50 mL of ether, and stirred for 1 hr. The precipitate was filtered and washed with 50% MeOH/ether (2x40 mL). The combined filtrates were concentrated. The liquid was taken up in 100 mL of DCM and washed with 1N NaOH and H20 (10 mL each). The organic phase was concentrated. SPE, washing with 1% MeOH/DCM and then eluting with 7% MeOH/DCM + 2% NH4OH, gave the product. The partially concentrated fractions were washed with 20 mL of H20, the water phase was extracted with 40 mL of DCM, and the combined organic phases were dried over Na2SO4 and concentrated to give 763 mg of an amber . 1H NMR ) 5 7.13 (m, 1H), 6.49—6.43 (m, 3H), 4.00 (t, 2H, J=6.1 Hz), 3.90 (t, 2H), 2.89 (t, 2H, J=6.7 Hz), 1.96-1.84 (m, 4H), 1.74 (m, 2H), 1.48—1.28 (m, 6H), 0.89 (m, 3H).
N—{3—[3—(Hexyloxy)phenoxy]propyl}quinolin—4—amine A mixture of 3—[3— oxy)phenoxy]propan—l—amine (763 mg, 3.04 mmol), 4—chloroquinoline (746 mg, 4.58 mmol), DIEA (1.0 mL, 5.74 mmol), and 0.1 mL of DMF was sealed in a heavy walled glass tube and heated at 130 0C for 4 days. The mixture was cooled. SPE, washing with 50% EA/Hex and eluting with 10% MeOH/DCM, gave the product contaminated by ninhydrin (+) material. FC (8% to 9% MeOH/DCM) resulted in partial purification. SPE (60% EA/Hex + 1% TEA) gave 389 mg of product as an oil that solidified upon standing. Rf 0.25 (10% MeOH/DCM); 1H NMR (CDC13) 8 8.52 (d, 1H, J=5.2 Hz), 7.96 (dd, 1H, J=0.8, 8.4 Hz), 7.77 (dd, 1H, J=1.0, 8.4 Hz), 7.61 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.40 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.17 (m, 1H), 6.53—6.48 (m, 3), 6.42 (d, 1H, J=5.4 Hz), 5.74 (br s, 1H, NH), 4.14 (m, 2H), 3.90 (m, 2H), 3.54 (m, 2H), 2.23 (m, 2H), 1.76 (m, 2H), 1.49-1.24 (m, 6), 0.89 (m, 3).
Example 30: N—{2—[3—(Hexyloxy)phenoxy]ethyl }quinolin—4—amine @0H\©/N/\/OO\/\/\/ 3-(Hexyloxy)phenol (2.5 g), N—(2—bromoethy1)phthalimide (3.27 g), and K2C03 (1.95 g) in acetone (50 mL) at re?ux and uent treatment with hydrazine monohydrate (3.5 mL) in EtOH (24 mL) at re?ux gave 226 mg of ninhydrin (+) 2—[3—(hexyloxy)phenoxy]ethan-1—amine. 1H NMR (CDC13) 5 7.10 (m, 1H), 6.55-6.40 (m, 3H), 4.00-3.80 (m, 4H), 3.00 (br s, 2H), 1.90- 1.70 (m, 4H), .30 (m, 6H), 0.90 (m. 3H).
N—{2-[3-(Hexyloxy)phenoxy]ethyl}quinolinamine A mixture of 2-[3- (hexyloxy)phenoxy]ethan—1—amine (226 mg, 0.95 mmol), 4-chloroquinoline (233 mg, 1.43 mmol), DIEA (1.0 mL, 5 .74 mmol), and 0.15 mL of DMF was sealed in a heavy walled glass tube and stirred at 140 OC and mixed for 5 days. The cooled mixture was concentrated and separated by FC (7% MeOH/DCM) to give 150 mg of t as a pink solid. Rf 0.32 (10% MeOH/DCM); 1H NMR ) 8 8.50 (d, 1H, J=5.5 Hz), 7.99 (d, 1H, J=8.2 Hz), 7.93 (d, 1H, J=8.1 Hz), 7.62 (m, 1H), 7.42 (m, 1H), 7.16 (m, 1H), 6.54—6.47 (m, 4), 6.21 (br s, 1H, NH), 4.28 (t, 2H, J=5.2 Hz), 3.92 (m, 2H), 3.75 (m, 2H), 1.75 (m, 2H), 1.48—1.24 (m, 6), 0.88 (t, 3, J26? Hz).
Example 31: N—[8—(4—Methoxyphenoxy)octyl]quinolin—4—amine HNWOO 1—(8—Bromooctyloxy)—4—methoxybenzene A mixture of 4—methoxyphenol (5.08 g, 41.0 mmol) and KZCO3 (6.12 g, 44.3 mmol) in 40 mL of DMF was stirred for 1.25 hr. Then, a mixture of bromooctane (86.0 g, 316 mmol) in 40 mL of DMF was added. The mixture was stirred for 24 hr and then it was allowed to stand for 6 days. The mixture was partitioned between 1:1 EA/Hex and H20 (3x), 0.1M HCl, and brine, and the organic phases were dried over NaZSO4, filtered, and concentrated. The e in 10% EA/Hex was filtered through a pad of silica gel, and then most of the solvents were ated. Vacuum distillation was performed to remove most of the excess dibromide, and the pot residue consisted of almost colorless solid and a small amount of liquid. The pot was rinsed twice with Hex and the solid was dried in vacuo. Rf 0.42 (10% EA/Hex); 1H NMR (CDC13) 8 6.82 (s, 4H), 3.89 (t, 2H), 3.76 (s, 3H), 3.40 (t, 2H, J=6.8 Hz), .70 (m, 4H), 1.48-1.33 (m, 8H).
N—[8-(4-Methoxyphenoxy)octyl]phthalimide A mixture of crude 1-(8-bromooctyloxy) methoxybenzene and potassium phthalimide (7.59 g, 41.0 mmol) in 60 mL of NMP was stirred at room temperature until the bromide was consumed, as shown by TLC analysis of an aliquot.
Then, 30 mL of H20 was added, and much of the volatile material was evaporated in vacuo. The residue was ioned n 1:1 EA/Hex and H20 and brine. The organic phases were dried over N32SO4, filtered, and concentrated to give 14.88 g of a colorless solid. Rf 0.11 (10% EA/Hex). 8—(4—Methoxyphenoxy)octan—l—amine Hydrazine monohydrate (4.00 mL, 84mmol) was added to a e of N—[8—(4—methoxyphenoxy)octyl]phthalimide (14.8 g, 38.8 mmol) and 125 mL of denatured EtOH using mechanical stirring. The mixture was heated at re?ux for 15 hr, during which time a colorless precipitate formed. The mixture was concentrated by evaporation, and the residue was partitioned between pyl acetate (300, 2x125 mL) and 5% N212CO3 (200, 3x100 mL) and brine (100 mL). The combined organic phases were dried over NaZSO4, filtered, and concentrated to give 8.63 g of white solid after drying in vacuo. 1H NMR (CDC13) 5 6.79 (s, 4H), 4.66 (s, 3H), 3.86 (t, 2H, J=6.4 Hz), 3.72 (s, 3H), 2.72 (t, 2H, J=7.4 Hz), 1.71 (m, 2H), 1.55—1.33 (m, 10H).
N—[8—(4—Methoxyphenoxy)octyl]quinolin—4—amine 8—(4—Methoxyphenoxy)octan—1—amine (4.60 g, 18.3 mmol) was taken up in 100 mL of 1—pentanol, and 30 mL of volatile material was removed by distillation. The e was cooled below boiling, and tripropylamine (7.00 mL, 36.7 mmol) and 4—chloroquinoline (3.28 g, 20.1 mmol) were added. Heating at re?ux was resumed. After 26.25 hr, the mixture was cooled, and 20 mL of 1N NaOH was added. Volatile material was removed by ation. The mixture was diluted with DCM (350 mL) and washed with 5% N32C03 (50 mL). The aqueous phase was extracted with DCM (100 mL). The ed organic phases were dried over NaZSO4, filtered, and concentrated. SPE, washing with 50% EA/Hex and then g with 50% EA/Hex + 2% TEA, gave product fractions that were combined and concentrated. The e was partitioned between DCM and 5% Na2C03. The combined organic phases were dried over , filtered, and concentrated to afford a yellow solid. The solid was triturated with ice-cold 20% EtzO/Hex and dried in vacuo. The solid had mp 1410-1440 0C. The solid was dissolved in minimal hot butanone and then the mixture was allowed to cool to room temperature. After chilling in an ice bath for 2 hr, the precipitate was collected and washed with ice—cold butanone to give 3.98 g of a tan solid. Rf 0.23 (5% MeOH/DCM + 2% TEA); mp 455 0C; 1H NMR (CDC13) 5 8.56 (d, 1H, J=5.1 Hz), 7.98 (dd, 1H, J=0.7, 8.5 Hz), 7.72 (m, 1H), 7.62 (m, 1H), 7.42 (m, 1H), 6.85—6.80 (m, 4H, AA’BB’), 6.42 (d, 1H, J=5.5 Hz), 4.97 (br s, 1H, NH), 3.90 (t, 2H, J=6.6 Hz), 3.76 (s, 3H), 3.31 (m, 2H), 1.80—1.73 (m, 4H), 1.48—1.39 (m, 8H); 13C NMR(CDC13)5153.9, 153.5, 151.3, 149.8, 148.7, 130.3, 129.1, 124.8, 119.3, 118.9, 115.6, 114.8, 99.0, 68.8, 56.0, 43.4, 29.6, 29.5, 29.5, 29.2, 27.3, 26.2.
Example 32: N—[6—(4—Methoxyphenoxy)hexyl]quinolin—4—amine 1—(6—Bromohexyloxy)—4—methoxybenzene A mixture of bromohexane (2.4 mL, 15.7 mmol), 4—methoxyphenol (243 mg, 1.96 mmol), and K2CO3 (550 mg, 3.99 mmol) in 4 mL of DMF and 3 mL of DME was d 16 hr at room temperature, 4 hr at 80 0C, and 64 hr at room temperature. The mixture was diluted with EA and washed with H20, 5% Na2C03, H20, 0.1M HCl, and brine. The organic phase was dried over anhydrous NaZSO4, filtered through a pad of silica gel, and concentrated. SPE, washing with Hex and then eluting with 15% EA/Hex, gave 623 mg of the product as a colorless solid. Rf0.29 (5% ); 1H NMR (CDClg) 8 6.82 (s, 4H, AA’BB’), 3.90 (t, 2H, J=6.3 Hz), 3.76 (s, 3H), 3.41 (m, 2H, AB), 1.88 (m, 2H), 1.76 (m, 2H), 1.56—1.39 (m, 4H). 1-(6-Azidohexyloxy)methoxybenzene A mixture of 1-(6-bromohexyloxy) methoxybenzene 623 mg, 2.17 mmol) and sodium azide (210 mg, 3.23 mmol) in 5 mL of DMF was stirred at room temperature for 48 hr. Then, the mixture was diluted with EA and washed with H20 and brine. The organic phase was dried over MgSO4 and concentrated to give 500 mg of oily solid. Rf0.50 (15% Et20/Hex); 1H NMR (CDCl3) 5 6.82 (s, 4H, AA’BB’), 3.89 (t, 2H, J=6.5 Hz), 3.74 (s, 3H), 3.25 (t, 2H, J=6.9 Hz), 1.76 (m, 2H), 1.62 (m, 2H), 1.55—1.36 (m, 4H). 6—(4—Methoxyphenoxy)hexan—l—amine A mixture of zidohexyloxy)—4— methoxybenzene (500 mg) and 65 mg of 5% Pd—C in 25 mL of MeOH was stirred under a blanket of hydrogen for 16 hr. The mixture was blanketed with argon and filtered through a pad of Celite. The filtrate was concentrated to give 448 mg of oil. 1H NMR (CDClg) 8 6.77 (s, 4H, ), 3.84 (m, 2H), 3.70 (s, 3H), 2.64 and 2.56 (m, 2H, AB), 1.71 (m, 2H), 1.51-1.31 (m, 6H). 4—Methoxyphenoxy)hexyl]quinolin—4—amine Four mL of ne was evaporated from 6— (4—methoxyphenoxy)hexan—l—amine (448 mg, 2.01 mmol). Then, a mixture of the amine, 4— chloroquinoline (424 mg, 2.60 mmol), DIEA (0.80 mL, 4.59 mmol), and 1.5 mL of NMP was heated at 160 0C in a sealed tube for 24 hr. The e was cooled and partitioned between DCM and 5% N212CO3. The organic phase was dried over anhydrous NaZSO4 and concentrated.
FC (50% EA/Hex + 2% TEA) gave an oil that contained residual NMP, as observed by NMR.
Dilution with EtOH and evaporation under high vacuum was ed until NMP was undetectable by NMR. Rf 0.12 (50% EA/Hex + 2% TEA); 1H NMR ) 8 8.52 (d, 1H, J=5.2 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.59 (ddd, lH, J=1.2, 6.9, 8.4 Hz), 7.37 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 6.82-6.80 (m, 4H), 6.39 (d, 1H, J=5.4 Hz), 5.20 (m, 1H, NH), 3.89 (t, 2H, J=6.3 Hz), 3.74 (s, 3H), 3.31 (m, 2H), 1.78—1.75 (m, 4H), 1.52-1.49 (m, 4H).
Example 33: N—{2—[4—(Hexyloxy)phenoxy]ethyl }quinolin—4—amine (>290o/W\ 4-(Hexyloxy)phenol was prepared by methods similar to that used for the preparation of 3- (hexyloxy)phenol. 4-(Benzyloxy)phenol (11.45 g), K2CO3 (8.68 g), 1-bromohexane (10.4 mL), and DMF (50 mL) at 80—100 °C gave 1—(benzyloxy)—4-(hexyloxy)benzene (12.97 g). Rf 0.68 (20% EA/Hex); 1H NMR (CDC13) 8 7.44—7.28 (m, 5H), 6.91—6.76 (m, 4H), 5.00 (s, 2H), 3.89 (t, 2H, J=6.6 Hz), 1.74 (m, 2H), 1.49—1.24 (m, 6H), 0.89 (m, 3H). 4—(Hexyloxy)phenol A mixture of 1—(benzyloxy)—4—(hexyloxy)benzene (12.97 g) and 5% Pd/C (1.2 g) in 200 mL of 1:1 MeOH/EA was d under en for 16 hr. Starting material was consumed, as seen by TLC analysis. The reaction mixture was filtered through Celite, the solvents were exchanged to 12% EA/Hex, and the mixture was filtered through a pad of silica gel and concentrated to give 8.84 g of 4—(hexyloxy)phenol. Rf 0.21 (10% EA/Hex); 1H NMR (CDC13)5 6.80—6.72 (m, 4H), 3.88 (t, 2H, J=6.7 Hz), 1.79—1.68 (m, 2H), 1.48—1.30 (m, 6H), 0.91— 0.86 (m, 3H). 2—[4—(Hexyloxy)phenoxy]ethanol A mixture of 4—(hexyloxy)phenol (11.0 g, 56.7 mmol), ethylene ate (7.5 g, 85 mmol), and K2C03 (11.7 g, 85 mmol) in 60 mL of DMF was heated at 60 0C for 16 hr. The mixture was partitioned between EA and H20, 0.1M HCl, H20, and brine. The organic phases were dried over MgSO4 and concentrated. SPE, washing with 10% EA/Hex (which gave 5.8 g of recovered starting ) and eluting with 37% EA/Hex, gave the t as colorless solid. The recovered ng material was retreated with the reagents. The combined t yield was 11.4 g of colorless solid. Rf 0.20 (20% EA/Hex); 1H NMR (CDCl3) 8 6.83—6.81 (m, 4H, ), 4.03 and 3.93 (m, 4H, AZBZ), 3.90 (t, 2H, J=6.6 Hz), 1.79—1.72 (m, 2H), 1.45 (m, 2H), 1.36-1.30 (m, 4H), 0.90 (m, 3H); 13C NMR(CDC13) 5 153.9, 152.9, 115.8, 115.7, 70.2, 68.9, 61.8, 31.8, 29.6, 25.9, 22.8, 14.2. 2-[4—(Hexyloxy)phenoxy]ethanamine was prepared by the method used for the preparation of [3— (hexyloxy)phenyl]methanamine. 2-[4-(Hexyloxy)phenoxy]ethanol (11.4 g), methanesulfonyl chloride (5.60 mL), TEA (11.0 mL), and DCM (150 mL) at 0 OC gave 2-[4-(hexyloxy)phenoxy]ethyl methanesulfonate (13.9 g). 1H NMR(CDC13) 5 6.85—6.81 (m, 4H, AA’BB’), 4.54 and 4.19 (m, 4H, A2B2), 3.90 (t, 2H, J=6.6 Hz), 3.08 (s, 3H), 1.76 (m, 2H), 1.44 (m, 2H), 1.36—1.30 (m, 4H), 0.90 (m, 3H); 13C NMR (CDC13)5154.3, 152.2, 116.0, 115.8, 68.9, 68.4, 66.9, 38.0, 31.8, 29.5, 25.9, 22.8, 14.2. 2—[4—(Hexyloxy)phenoxy]ethyl methanesulfonate (13.9 g), potassium phthalimide (8.57 g), and DMF (40 mL) at 60 OC gave N—{2—[4—(hexyloxy)phenoxy]ethyl}phthalimide (11.58 g after recrystallization from EtOH/HZO). Rf 0.40 (30% EA/Hex); 1H NMR (CDCl3) 5 7.85 and 7.71 (m, 4H, AA’BB’), 6.79 (m, 4H, AA’BB’), 4.18 and 4.08 (m, 4H, Asz), 3.86 (t, 2H, J=6.6 Hz), 1.73 (m, 2H), 1.42 (m, 2H), 1.34-1.28 (m, 4H), 0.89 (m, 3H); 13C NMR(CDC13) 5 168.4, 153.9, 152.6, 134.2, 132.3, 123.5, 115.9, 115.6, 68.8, 65.7, 37.7, 31.8, 29.5 25.9, 22.8, 14.2. 2— [4—(Hexyloxy)phenoxy]ethanamine N—{ 2—[4—(Hexyloxy)phenoxy]ethyl }phthalimide (11.6 g), hydrazine monohydrate (2.25 mL), IPA (125 mL), and EtOH (50 mL) at re?ux gave a colorless solid (7.50 g). 1H NMR (CDC13) 5 6.73 (s, 4H, ), 3.80 (t, 2H, J=5.2 Hz), 3.79 (t, 2H, J=6.7 Hz), 2.93 (t, 2H), 1.66 (m, 2H), 1.41—1.21 (m, 6H), 0.85—0.80 (m, 3H).
N— { 2—[4—(Hexyloxy)phenoxy] ethyl }quinolin—4—amine Crude 2— [4— (hexyloxy)phenoxy]ethanamine (7.40 g, 31.2 mmol) was taken up in 30 mL of DMA, and then 25 mL was evaporated. The residue was transferred to a heavy—walled sealed tube, and 5 mL of NMP, 4—chloroquinoline (5.09 g, 31.2 mmol), and DIEA (10.8 mL, 62 mmol) were added. The mixture was heated at 160 0C for 16 hr. After cooling, dilution of the mixture with 5% N32C03 resulted in the ion of a precipitate. The precipitate was filtered and washed with H20. The precipitate was recrystallized from MeOH/HZO and then from MeOH to give 7.50 g of colorless solid. Rf0.20 (5% MeOH/DCM); mp 1315-1320 0C; 1H NMR (CDC13) 5 8.58 (d, 1H. J=5.2 HZ), 8.00 (dd, 1H, J=0.8, 8.4 Hz), 7.79 (dd, 1H, J=0.8, 8.4 Hz), 7.66-7.62 (m, 1H), 7.44 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 6.86 (m, 4H, AA’BB’), 6.49 (d, 1H, J=5.5 Hz), 5.60 (br s, 1H, NH), 4.25 (t, 2H), 3.90 (t, 2H, J=6.6 Hz), 3.70 (m, 2H), 1.74 (m, 2H), 1.45 (m, 2H), 1.36-1.30 (m, 4H), 0.90 (m, 3H); 13C NMR(CDC13)8154.2, 1526,1510, 149.9, 148.5, 130.0, 129.4. 125.1. 119.7, 119.1, 115.9, 115.8, 99.2, 68.9, 66.9, 42.9, 31.8, 29.5, 25.9, 22.8, 14.2.
Example 34: N-{ Hexyloxy)phenoxy]propyl }quinolinamine HN/\/\O00W CK?/ N—{3—[4—(Hexyloxy)phenoxy]propyl}phthalimide A mixture of 4—(hexyloxy)phenol (1.04 g, 5.36 mmol), N—(3—bromopropyl)phthalimide (1.44 g, 5.37 mmol), K2C03 (1.12 g, 8.12 mmol), and 10 mL of DMF was reacted for 26 hr. Then, the mixture was diluted with EA and washed with H20, 0.1M HCl, and brine, dried over anhydrous NaZSO4, and concentrated. The residue was filtered h a pad of silica gel using 20% EA/Hex, and the filtrate was concentrated to give 1.96 g of a pale yellow solid. Rf 0.20 (15% EA/Hex), 0.38 20% EA/Hex + 2% DIEA); 1H NMR(CDC13) 5 7.83 and 7.69 (m, 4H, AA’BB’), 6.79—6.71 (m, 4H, AA’BB’), 3.96 (t, 2H, J=6.2 Hz), 3.91—3.81 (m, 4H), 2.14 (m, 2H), 1.73 (m, 2H), .28 (m, 6H), 0.89 (m, 3H). 3—[4—(Hexyloxy)phenoxy]propan—l—amine A mixture of N—{ 3—[4— (hexyloxy)phenoxy]propyl}phthalimide (1.96 g) and hydrazine drate (0.40 mL, 8.24 mmol) in 40 mL of EtOH was heated at re?ux for 20 hr. Then, the volatile components were evaporated. SPE, washing with 5% MeOH/DCM and then g with 5% MeOH/DCM + 2% TBA, gave 632 mg of colorless solid. Rf 0.21 (5% MeOH/DCM + 25 DIEA); 1H NMR (CDC13) 8 6.75 (br s, 4H), 3.92 (t, 2H, J=6.0 Hz), 3.83 (t, 2H, J=6.7 Hz), 3.00 (br m, 2H, NH;), 2.82 (t, 2H, J=6.8 Hz), 1.87 (m, 2H), 1.68 (m, 2H), 1.43—1.23 (m, 6H), 0.83 (m, 3H).
N—{3—[4—(Hexyloxy)phenoxy]propyl}quinolin—4—amine A mixture of 3—[4— (hexyloxy)phenoxy]propan—1—amine (476 mg, 1.90 mmol), 4—chloroquinoline (416 mg, 2.55 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP was heated at 150 0C in a sealed tube for 18 hr. Then, the e was cooled and partitioned between EA and 5% Na2C03 and brine.
The organic phase was dried over NaZSO4 and concentrated. SPE, washing with 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 633 mg of solid. Rf 0.28 (10% CM); mp 84.5-86.0 °C (from EA/Hex); 1H NMR (CDC13) 5 8.51 (d, 1H, J=5.4 Hz), 7.95 (dd, 1H, 121.0, 8.5 Hz), 7.79 (m, 1H), 7.57 (ddd, 1H, 121.5, 6.9, 8.4 Hz), 7.35 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 6.82 (br s, 4H, AA’BB’), 6.38 (d, 1H, J=5.4 Hz), 5.97 (m, 1H, NH), 4.03 (t, 2H, J=5.4 Hz), 3.86 (t, 2H, J=6.4 Hz), 3.47 (m, 2H), 2.15 (m, 2H), 1.73 (m, 2H), 1.47—1.25 (m, 6H), 0.88 (m, 3H).
Example 35 : N—{4—[4—(Hexyloxy)phenoxy]butyl }quinolin—4—amine Q5?HN/\/\/O\©\0W/ 1—(4—Bromobutoxy)—4—(hexyloxy)benzene 4—(Hexyloxy)phenol (1.52 g, 7.84 mmol), 1,4— dibromobutane (7.4 mL, 62 mmol), and K2C03 (1.22 g, 8.84 mmol) in 8 mL of DMF was mixed WO 20995 for 16 hr. The mixture was partitioned between EA and 0.1M HCl and brine, and the organic phases were dried over MgSO4, filtered, and concentrated. SPE, washing with 1% EA/Hex and then g with 5% EA/Hex gave 2.36 g of colorless solid. Rf 0.59 (15% EA/Hex); 1H NMR (CDC13) 5 6.80 (br s, 4H, AA’BB’), 3.93 (t, 2H, J=6.0 Hz), 3.88 (t, 2H, J=6.7 Hz), 3.48 (m, 2H), 2.05 (m, 2H), 1.90 (m, 2H), 1.74 (m, 2H), 1.48—1.28 (m, 6H), 0.89 (m, 3H).
N— { 4—[4—(Hexyloxy)phenoxy]butyl limide 1—(4—Bromobutoxy)—4—(hexyloxy)benzene (2.36 g, 7.17 mmol) and potassium phthalimide (2.0 g, 10.8 mmol) in 12 mL of DMF was mixed for 60 hr. The mixture was partitioned between EA and 0.1M HCl and brine, and the organic phases were dried over MgSO4, filtered, and trated. SPE, washing with 5% EA/Hex and then g with 15% EA/Hex gave 2.64 g of colorless solid. Rf 0.31 (15% EA/Hex); 1H NMR (CDC13) 5 7.83 and 7.70 (m, 4H, AA’BB’), 6.78 (br s, 4H, AA’BB’), 3.92 (t, 2H, J=6.1 Hz), 3.87 (t, 2H, J=6.7 Hz), 3.75 (t, 2H, J=7.0 Hz), 1.92—1.68 (m, 6H), 1.48-1.22 (m, 6H), 0.89 (m, 3H). 4-[4-(Hexyloxy)phenoxy]butanamine A mixture of N-{4-[4- (hexyloxy)phenoxy]butyl}phthalimide (2.64 g, 6.68 mmol) and hydrazine monohydrate (0.65 mL, 13.4 mmol) in 60 mL of EtOH was heated at re?ux for 20 hr. The mixture was cooled, concentrated, and partitioned between EA and 5% N32CO3 and brine. The organic phases were dried over Na2804, filtered, and concentrated. SPE, washing with 4% MeOH/DM and then eluting with 6% MeOH/DCM + 2% DIEA gave product-containing fractions. These fractions were trated, taken up in DCM and washed with 5% Na2C03, dried over NaZSO4, filtered, and concentrated to give 1.69 g of colorless solid. Rf 0.20 (5% MeOH/DCM + 2% DIEA, ninhydrin (+)); 1H NMR(CDC13) 8 6.80 (br s, 4H, AA’BB’), 3.93—3.85 (m, 4H), 2.75 (t, 2H, 127 Hz), 1.87—1.26 (m, 14H), 0.89 (m, 3H).
N—{4—[4—(Hexyloxy)phenoxy]butyl}quinolin—4—amine A mixture of 4—[4— (hexyloxy)phenoxy]butan—1—amine (499 mg, 1.88 mmol), 4—chloroquinoline (3999 mg, 2.45 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP was heated at 150 0C in a sealed tube for 18 hr. Then, the e was cooled and partitioned between EA and 5% N32C03 and brine.
The organic phase was dried over NaZSO4 and concentrated. SPE, washing with 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 633 mg of solid. Rf 0.25 (10% MeOH/DCM); mp 11301 14.0 0C (from EA/Hex); 1H NMR (CDCl3) 5 8.53 (d, 1H, J=5.2 Hz), 7.95 (m, 1H), 7.70 (d, 1H, J=7.6 Hz), 7.58 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.34 (ddd, 1H, J=l.2, 6.9, 8.2 Hz), 6.82 (br s, 4H, AA’BB’), 6.40 (d, 1H, J=5.4 Hz), 5.38 (br t, 1H, NH), 3.96 (t, 2H, J=5.6 Hz), 3.88 (t, 2H, J=6.5 Hz), 3.36 (br m, 2H), 1.92-1.90 (m, 4H), 1.74 (m, 2H), 1.48—1.28 (m, 6H), 0.89 (m, 3H).
Example 36: N—[8—(m—Tolyloxy)octyl]quinolin—4—amine HN/\/\/\/\/O CH3 (>5 0 1-(8—Bromooctyloxy)—3—methylbenzene A mixture of m—cresol (1.00 mL, 9.54 mmol), 1,8— dibromooctane (15.0 mL, 81 mmol), and K2CO3 (2.6 g, 18.8 mmol) in 20 mL of NMP and 10 mL of DME was heated at re?ux for 66 hr. Then, the mixture was cooled, diluted with DCM (20 mL), and extracted with 0.05N NaOH (150, 100 mL) and 1M HCl (100 mL). The aqueous phases were ted with DCM (20 mL), and the combined c phases were dried over MgSO4 and concentrated. SPE, washing with Hex to r dibromide and then eluting with 3% EA/Hex, gave 1.7 g of 1-(8-bromooctyloxy)methylbenzene. Rf 0.39 (5% ); 1H NMR (CDC13) 5 7.15 (t, 1H), 68-665 (m, 3H), 3.95 (t, 2H), 3.4 (t, 2H), 3.3 (s, 3H), 1.9—1.7 (m, 4H), 1.5—1.2(m, 8H). 1—(8—Azidoocyloxy)—3—methylbenzene (1.7 g) was prepared from 1—(8—bromooctyloxy)—3— methylbenzene (1.7 g, 5.69 mmol) and sodium azide (740 mg, 11.4 mmol) in 50 mL of DMF following the method for the preparation of 10—butoxydecan—1—amine. 8—(m—Tolyloxy)octan—l—amine (0.6 g) was prepared from 1—(8—azidoocyloxy)—3—methylbenzene (1.7 g) by the method used for the ation of lO-butoxydecan—l—amine. 1H NMR (CDCl3) 5 7.1 (m, 1H), 6.6 (m, 3H), 3.9 (m, 2H), 2.7 (t, 1H), 2.3 (m, 4H), 1.8-1.6 (m, 4H), 1.5-1.3 (m, 8H).
N—[8—(m—Tolyloxy)octyl]quinolin—4—amine (166 mg) was prepared from 8—(m—tolyloxy)octan—l— amine (0.6 g), 4—chloroquinoline (840 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4—amine. 1H NMR (CDClg) 5 8.6 (m, 2H), 8.05 (m, 2H), 7.6 (t, 1H), 7.4 (t, 1H), 7.1 (t, 1H), 6.8-6.6 (m, 3H), 6.4 (d, 1H), 3.9 (t, 2H), 3.5 (m, 2H), 2.3 (s, 3H), 1.9-1.7 (m, 4H), 1.5—1.3 (m, 8H).
Example 37: N—[8—(p—Tolyloxy)octyl]quinolin—4—amine (if? C”3 1-(8—Bromooctyloxy)—4—methylbenzene (1.9 g) was prepared by the same method used for 1—(8— bromooctyloxy)—3—methylbenzene using p-cresol (1.00 mL, 9.54 mmol), bromooctane (15.0 mL, 51 mmol), and K2CO3 (2.6 g, 18.8 mmol) in 20 mL of NMP and 10 mL of DME heated for 66 hr. 1H NMR (CDClg) 8 7.0 (d, 2H), 6.8 (d, 2H), 3.9 (t, 2H), 3.4 (t, 2H), 2.3 (s, 3H), 1.9-1.7 (m, 4H), 1.5-1.2 (m, 8H). zidooctyloxy)methylbenzene (1.9 g) was prepared from 1-(8-bromooctyloxy) methylbenzene (1.9 g, 6.36 mmol) and sodium azide (830 mg, 12.7 mmol) in 50 mL of DMF following the method for the preparation of 10—butoxydecan—1—amine. 8—(p—Tolyloxy)octan—1—amine (0.6 g) was prepared 1-(8-azidooctyloxy)—4—methylbenzene (1.9 g) by the method used for the preparation of 10—butoxydecan—1—amine. 1H NMR (CDClg) 8 7.05 (d, 2H), 6.75 (d, 2H), 3.9 (m, 2H), 2.7 (m, 1H), 2.35 (t, 1H), 2.3 (s, 3H), 1.8-1.2 (m, 12H).
N—[8—(p—Tolyloxy)octyl]quinolin—4—amine (161 mg) was prepared from olyloxy)octan—l— amine (0.6 g), 4—chloroquinoline (840 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4—amine. 1H NMR (CDC13)5 8.5 (d, 1H), 8.0 (d, 1H), 7.85 (d, 1H), 7.6 (t, 1H), 7.4 (t, 1H), 7.1 (m, 3H), 6.8 (m, 3H), 6.4 (d, 1H), 3.9 (t, 2H), 3.4 (m, 2H), 2.3 (s, 3H), 7 (m, 4H), 1.5-1.3 (m, 8H).
Example 38: N—[8—(0—Tolyloxy)octyl]quinolin—4—amine HNWOI) 1—(8—Bromooctyloxy)—2—methylbenzene (1.3 g) was prepared by the same method used for l—(8— bromooctyloxy)—3—methylbenzene using 0—Cresol (696 mg, 6.44 mmol), 1,8—dibromooctane (14 g, 81 mmol), and K2CO3 (1.00 g, 7.25 mmol) in 12 mL of NMP and 12 mL of DME heated for 16 1-(8—Iodooctyloxy)—2—methylbenzene (1.3 g) was prepared from 1—(8—bromooctyloxy)-2— methylbenzene (1.3 g, 4.35 mmol) and sodium iodide (652 mg, 4.35 mmol) in 50 mL of acetone following the method used in the preparation of 10—(hexyloxy)decan—1—amine.
N—[8-(0-Tolyloxy)octyl]phthalimide (1.3 g) was prepared from 1-(8-iodooctyloxy) benzene (1.3 g) and potassium phthalimide (1.0 g, 5.4 mmol) in 50 mL of DMF following the method for N—[8-(hexyloxy)octyl]phthalimide. 1H NMR (CDClg) 5 7.85 (m, 2H), 7.7 (m, 2H), 7.15 (m, 2H), 6.8 (m, 2H), 3.95 (m, 2H), 3.7 (m, 2H), 2.2 (m, 3H), 1.9-1.6 (m, 4H), 16-125 (m, 8H). 8—(0—Tolyloxy)octan—l—amine (390 mg) was prepared from N—[8—(0—tolyloxy)octy1]phthalimide (1.0 g, 2.74 mmol) using hydrazine monohydrate (0.2 mL) in EtOH (50 mL) following the method for [3—(hexyloxy)phenyl]methanamine. 1H NMR (DMSO—d6) 5 7.1 (m, 2H), 6.9—6.75 (m, 2H), 3.9 (t, 2H), 2.5 (m, 2H), 2.15 (s, 3H), 1.75 (m, 2H), 1.5—1.2 (m, 10H). 0—Tolyloxy)octyl]quinolin—4—amine (300 mg) was prepared from olyloxy)octan—l— amine (390 mg), 4-Chloroquinoline (544 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4—amine. 1H NMR (CDCl3) 5 8.55 (d, 1H), 8.0 (d, 1H), 7.75 (d, 1H), 7.65 (m, 1H), 7.45 (m, 1H), 7.15 (m, 2H), 6.8 (m, 2H), 6.4 (d, 1H), 3.95 (t, 2H), 3.35 (m, 2H), 2.3 (s, 3H), 1.8 (m, 4H), 1.6—1.3 (m, 8H). e 39: N—[8—(4—tert—Butylphenoxy)octyl]quinolin—4—amine HNWOO 1—(8—Bromooctyloxy)—4—tert—butylbenzene (900 mg) was prepared by the same method used for 1—(8—bromooctyloxy)—3—methylbenzene using 4—tert—butylphenol (647 mg, 4.31 mmol), 1,8— dibromooctane (11.7 g, 43 mmol), and K2C03 (714 mg, 5.17 mmol) in 12 mL of NMP and 6 mL of DME heated for 24 hr. 1H NMR (CDClg) 5 7.28 and 6.82 (m, 4H, AA’BB’), 3.93 (m, 2H), 3.40 (t, 2H, J=6.8 Hz), 1.90-1.71 (m, 4H), .22 (m, 8H), 1.29 (s, 9H). 1-tert-Butyl(8-iodooctyloxy)benzene (900 mg) was prepared from 1-(8-bromooctyloxy) tert-butylbenzene (900 mg) and sodium iodide (400 mg) in 50 mL of acetone ing the method for the preparation of 10-(hexyloxy)decan-l-amine.
N—[8—(4—tert-Butylphenoxy)octyl]phthalimide (1.3 g) was prepared from 1—tert—butyl—4—(8— iodooctyloxy)benzene (900 mg) and potassium phthalimide (860 mg) in 50 mL of DMF following the method for the preparation of N—[8—(hexyloxy)octy1]phthalimide. 1H NMR (CDC13) 8 7.85 and 7.70 (m, 4H, AA’BB’), 7.3 and 6.8 (m, 4H, AA’BB’), 3.9 (t, 2H), 3.65 (m, 2H), 1.8- 1.6 (m, 4H), 1.6—1.3 (m, 17H). 8—(4—tert—Butylphenoxy)octan—1—amine (590 mg) was prepared from 4—tert— butylphenoxy)octyl]phthalimide (900 mg) and hydrazine monohydrate (0.17 mL) in 50 mL of EtOH following the method for the preparation of [3—(hexyloxy)phenyl]methanamine. 1H NMR (DMSO—d6) 5 7.25 and 6.80 (m, 4H, AA’BB’), 3.9 (t, 2H), 2.5 (m, 2H), 1.68 (m, 2H), 1.5—1.2 (m, 19H). 4—tert—Butylphenoxy)octyl]quinolin—4—amine A mixture of 8—(4—tert—butylphenoxy)octan— l—amine (510 mg, 1.84 mmol), 4—chloroquinoline (604 mg, 3.70 mmol), TEA (4.0 mL, 28 mmol), and 0.4 mL of NMP was heated in a heavy walled glass tube at 130 0C for 4 days. The e was cooled and partitioned between EA and 5% N32CO3 and brine, dried over NaZSO4, filtered, and concentrated. Purification by EC (60% EA/Hex + 2% TEA) gave 320 mg of solid.
Mp 108—110 0C (from MeOH); 1H NMR (CDC13) 5 8.4 (d, 1H), 8.0 (d, 1H), 7.8 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.3 and 6.8 (m, 4H, AA’BB’), 6.4 (d, 1H), 5.2 (br s, 1H, NH), 3.9 (m, 2H), 3.3 (m, 2H), 1.8—1.6 (m, 4H), 1.6-1.3 (m, 8H), 1.3 (s. 9H).
Example 40: N—[8—(4—Fluorophenoxy)octyl]quinolin—4—amine ()5HN/VWVOOF/ N romooctyloxy)?uorobenzene (2.75 g) was prepared by the same method used for 1-(8- bromooctyloxy)methylbenzene using 4-?uorophenol (1.33 g, 12.1 mmol), 1,8-dibromooctane (20 mL, 108 mmol), and K2C03 (1.77 g, 14.3 mmol) in 20 mL of NMP and 10 mL of DME heated for 24 hr. 1H NMR ) 8 7.0-6.9 (m, 2H), 6.8 (m, 2H), 3.89 (t, 2H, J=6.4 Hz), 3.40 (t, 2H. J=6.8 Hz), 1.9—1.7 (m, 4H), 1.6-1.2 (m, 8H). 1—F1uoro—4—(8-iodooctyloxy)benzene was prepared from 1(8—bromooctyloxy)—4—?uorobenzene (2.75 g, 9.08 mmol) and sodium iodide (1.63 g, 10.9 mmol) in 70 mL of acetone following the method used in the preparation of 10—(hexyloxy)decan-1—amine.
N—[8—(4—Fluorophenoxy)octyl]phthalimide (2.19 g) was prepared from l—?uoro—4—(8— iodooctyloxy)benzene and potassium phthalimide (2.52 g, 13.6 mmol) in 50 mL of DMF at 60- 80 0C for 12 hr following the method for N—[8—(hexyloxy)octyl]phthalimide. 1H NMR (CDC13) 5 7.85 (m, 2H), 7.7 (m, 2H), 6.9 (m, 2H), 6.8 (m, 2H), 3.9 (t, 2H), 3.7 (t, 2H), 1.8-1.6 (m, 4H), 1.5- 1.3 (m, 8H).
WO 20995 8—(4—F1uorophenoxy)octan—l—amine (657 mg, 2.75 mmol) was prepared from N—[8—(4— ?uorophenoxy)octyl]phthalimide (2.19 g, 5.94 mmol) using hydrazine monohydrate (0.43 mL) in EtOH (50 mL) ing the method for [3—(hexyloxy)phenyl]methanamine. 1H NMR (CD3OD) 5 7.0—6.8 (m, 4H), 3.9 (t, 2H), 2.7 (t, 2H), 1.75 (m, 2H), 1.6—1.3 (m, 10H).
N—[8—(4—Fluorophenoxy)octyl]quinolin—4—amine was prepared from 8—(4—?uorophenoxy)octan—1— amine (657 mg, 2.75 mmol), 4—chloroquinoline (676 mg), TEA (2 mL), and NMP (0.2 mL) at 130 0C in a sealed tube for 5 days following the method for N—[8—(3— ethoxypropoxy)octyl]quinolin—4—amine. 1H NMR (CDC13) 5 8.5 (d, 1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.65 (m, 1H), 7.4 (m, 1H), 7.1-6.8 (m, 4H), 6.4 (d, 1H), 5.6 (br s, 1H, NH), 4.0 (t, 2H), 3.35 (m, 2H), 1.8 (m, 2H), 1.7-1.2 (m, 10H).
Example 41: N—[8—(3—Fluorophenoxy)octyl]quinolin—4—amine (>5HN/\/\/\/\/O\©/F/N romooctyloxy)?uorobenzene (2.06 g) was prepared by the same method used for 1-(8- bromooctyloxy)methylbenzene using 3-?uorophenol (1.60 g, 14.3 mmol), 1,8-dibromooctane (25 mL, 135 mmol), and K2C03 (2.56 g, 18.5 mmol) in 25 mL of NMP and 12 mL of DME heated for 24 hr. Rf 0.42 (5% EA/Hex); 1H NMR (CDC13) 5 7.2 (m, 1H), 6.7-6.6 (m, 3H), 3.9 (t, 2H), 3.4 (t, 2H), 7 (m, 4H), 1.6—1.2 (m, 8H). 1—Fluoro—3-(8—iodooctyloxy)benzene was prepared from 1—(8—bromooctyloxy)—3—fluorobenzene (2.06 g, 6.78 mmol) and sodium iodide (1.22 g, 8.13 mmol) in 60 mL of acetone following the method used in the preparation of lO—(hexyloxy)decan—1—amine.
N—[8—(3—Fluorophenoxy)octyl]phthalimide (1.85 g) was ed from l—?uoro—3—(8— iodooctyloxy)benzene and potassium phthalimide (1.9 g, 10.3 mmol) in 50 mL of DMF at 60—80 °C for 12 hr following the method for N—[8—(hexyloxy)octyl]phthalimide. 1H NMR (CDClg) 5 7.85 (m, 2H), 7.7 (m, 2H), 7.2 (m, 1H), 6.7—6.5 (m, 3H), 3.9 (t, 2H), 3.7 (t, 2H), 1.8—1.6 (m, 4H), 1.5—1.3 (m, 8H). 8—(3—F1uorophenoxy)octan—l—amine (874 mg, 3.66 mmol) was prepared from N—[8—(3— ?uorophenoxy)octyl]phthalimide (1.85 g, 5.01 mmol) using hydrazine drate (0.36 mL) in EtOH (50 mL) following the method for [3-(hexyloxy)phenyl]methanamine. 1H NMR (CD3OD) 5 7.25 (m, 1H), 6 (m, 3H), 3.9 (t, 2H), 2.7 (t, 2H), 1.8 (m, 2H), 1.6—1.3 (m, 10H).
N—[8—(3—Fluorophenoxy)octyl]quinolin—4—amine was prepared from 8—(3—fluorophenoxy)octan—l— amine (874 mg, 3.66 mmol), 4—chloroquinoline (900 mg), TEA (2 mL), and NMP (1 mL) at 130 0C in a sealed tube for 5 days following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4— amine. 1H NMR ) 8 8.5 (d, 1H), 8.0 (d, 1H), 7.85 (d, 1H), 7.65 (m, 1H), 7.4 (m, 1H), 7.15 (m, 1H), 6.7—6.5 (m, 3H), 6.5 (d, 1H), 5.6 (br s, 1H, NH), 3.9 (t, 2H), 3.35 (m, 2H), 1.8 (m, 4H), 1.6-1.3 (m, 8H).
Example 42: N-[8-(2-Fluorophenoxy)octyl]quinolinamine CmHN/VWVO:©F/N 1—(8—Bromooctyloxy)—2—f1uorobenzene (2.97 g) was ed by the same method used for 1—(8- bromooctyloxy)—3—methylbenzene using 2—?uorophenol (1.69 g, 15.1 mmol), 1,8—dibromooctane (38.3 g, 141 mmol), and K2C03 (2.76 g, 20 mmol) in 25 mL of NMP and 20 mL of DME heated for 24 hr. Rf0.33 (5% EA/Hex); 1H NMR (CDCl3) 5 7.10-6.83 (m, 4H), 4.0 (m, 2H), 3.38 (t, 2H, J=6.9 Hz), 1.91-1.76 (m, 4H), 1.47-1.32 (m, 8H). 1—Fluoro—2-(8—iodooctyloxy)benzene (3.43 g) was prepared from l—(8—bromooctyloxy)—2— fluorobenzene (2.97 g, 9.80 mmol) and sodium iodide (1.76 g, 11.7 mmol) in 70 mL of acetone following the method used in the preparation of lO—(hexyloxy)decan—l—amine.
N—[8—(2—Fluorophenoxy)octyl]phthalimide (2.84 g) was ed from l—?uoro—2—(8— iodooctyloxy)benzene (3.43 g) and potassium phthalimide (2.72 g, 14.7 mmol) in DMF at 60—80 0C for 12 hr ing the method for N—[8—(hexyloxy)octyl]phthalimide. 1H NMR (CDC13) 5 7.85 and 7.70 (m, 4H, AA’BB’), 7.10-6.80 (m, 4H), 4.00 (t, 2H), 3.70 (t, 2H), 1.90-1.60 (m, 4H), 1.55—1.25 (m, 8H). 8—(2—F1uorophenoxy)octan—l—amine (1.27 g, 5.32 mmol) was prepared from N—[8—(2— ?uorophenoxy)octyl]phthalimide (2.84 g, 7.70 mmol) using hydrazine monohydrate (0.50 mL) in EtOH (50 mL) following the method for [3—(hexyloxy)phenyl]methanamine.
N—[8—(2—Fluorophenoxy)octyl]quinolin—4-amine (100 mg) was prepared from 8—(2- ?uorophenoxy)octan—1—amine (1.27 g, 5.32 mmol), 4—chloroquinoline (1.3 g, 7.98 mmol), TEA (2 mL), and NMP (1 mL) at 130 0C in a sealed tube for 5 days ing the method for N—[8—(3— ethoxypropoxy)octyl]quinolinamine. 1H NMR (CDClg) 5 8.4 (d, 1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.0-6.7 (m, 4H), 6.4 (d, 1H), 5.9 (br s, 1H, NH), 3.9 (t, 2H), 3.3 (m, 2H), 1.9-1.2 (m, 12H).
Example 43: N-(Biphenylyl)quinolinamine A e of 4—biphenylamine (200 mg, 1.18 mmol), roquinoline (228 mg, ), and DIEA (0.25 mL, 1.43 mmol) in 1 mL of NMP was heated at 150 0C in a sealed tube for 24 hr. The cooled mixture was diluted with EA, washed with 5% Na2C03 (2x) and brine, dried over anhydrous Na2804, and concentrated. SPE, eluting with a step gradient of 1%, 3%, and 5% MeOH/DCM, gave fractions that were concentrated to give a brown solid. The solid was washed with MeOH and dried in vacuo. Rf 0.21 (5% MeOH/DCM); mp 222—226 0C; 1H NMR (20% CDC13) 5 8.38 (d, 1H, J=5.7 HZ), 8.06 (m, 1H), 7.91 (m, 1H), 7.67-7.26 (m, 11H), 6.98 (d, 1H, J=5.5 HZ).
Example 44: exylphenyl)quinolin—4—amine .NQW A mixture of 4—hexylaniline (197 mg, 1.11 mmol), 4—chloroquinoline (210 mg) and DIEA (0.24 mL) in 1 mL of NMP was heated at 150 0C in a sealed tube for 24 hr. The mixture was cooled and partitioned between EA and 5% . The organic phases were washed with brine, dried over Na2S04, and concentrated. Purification by SPE (step gradient 1, 2, 3, 5, 6% CM) gave fractions yielding a yellow solid. Recrystallization from MeOH gave 229 mg of a colorless solid. Rf0.14 (5% MeOH/DCM); mp 132.5-133.0 0C; 1H NMR (CDCl3) 8 8.52 (d, 1H, J=5.7 Hz), 8.03 (dd, 1H, J=0.7, 8.4 Hz), 7.85 (d, 1H, J=7.6 Hz), 7.64 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.44 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 6.88-6.81 (m, 4H), 6.50 (d, 1H, J=5.7 Hz), 5.92 (br s, 1H, NH), 4.26 (t, 2H, J=5 Hz), 3.89 (t, 2H, J=6 Hz), 3.73 (q, 2H, J=5.2 Hz), 1.74 (m, 2H), 1.48-1.28 (m, 6H), 0.89 (m, 3H).
Example 45: Hexyl 4—(quinolin—4—y1amino)benzoate Hexyl 4—aminobenzoate (282 mg), prepared from l—hexanol and 4—nitrobenzoyl chloride in two unremarkable steps, was reacted with 4—chloroquinoline (322 mg) and DIEA (0.50 mL) in 2 mL of NMP heated at 160 0C in a sealed tube for 16 hr. The mixture was cooled and partitioned between EA and 5% N32CO3. The organic phases were washed with brine, dried over NaZSO4, and concentrated. Purification by SPE, washing with 20% EA/Hex and then eluting with 55% EA/Hex, gave a yellow solid. Recrystallization from EA/Hex gave a colorless solid. Rf0. 14 (50% EA/Hex); 1H NMR (CDC13) 5 8.61 (d, 1H, J=5.2 Hz), 8.09-8.03 (m, 4H), 7.70 (ddd, 1H, J=l.2, 6.9, 8.4 Hz), 7.52 (ddd, 1H,J=1.2, 6.9, 8.4 Hz), 7.34-7.31 (m, 2H), 7.19 (d, 1H, J=5.2 Hz), 4.30 (t, 2H, J=6.6 Hz), 1.76 (m, 2H), 1.47-1.24 (m, 6H), 0.89 (m, 3H).
Example 46: N—(4—Phenoxyphenyl)quinolin—4—amine .Nooo A mixture of 4—phenoxyaniline (182 mg, 0.98 mmol), 4—chloroquinoline (175 mg, 1.07 mmol), and DIEA (0.50 mL, 2.87 mmol) in 1 mL of NMP was heated at 140—150 0C in a sealed tube for 24 hr. Then, the mixture was cooled and partitioned between DCM and 5% N32CO3. The organic phase was dried over Na2804 and concentrated. SPE, washing with 50% EA/Hex and g with 5% MeOH/DCM, gave a solid. Recrystallization from EA/Hex gave 111 mg of tan solid. A second crop of 111 mg light tan solid was obtained from MeOH. The two crops had comparable NMR spectra. Rf 0.19 (5% MeOH/DCM); mp 170-172 0C (from MeOH); 1H NMR (CDClg) 5 8.51 (d, 1H, J=5.5 Hz), 8.05 (d, 1H, J=8.7 Hz), 7.99 (d, 1H, J=8.4 Hz), 7.68 (ddd, 1H, J=1.3, 6.9, 8.2 Hz), 7.50 (ddd, 1H, J=1.3, 6.9, 8.2 Hz), .25 (m, 5H), 7.22—6.99 (m, 5H), 6.83 (d, 1H, J=5.4 Hz).
Example 47: N—(3—Phenoxyphenyl)quinolin—4—amine A mixture of 3—phenoxyaniline (307 mg, 1.66 mmol), 4—chloroquinoline (296 mg, 1.82 mmol), and DIEA (0.32 mL, 1.84 mmol) in 1 mL of NMP was heated at 140—150 0C in a sealed tube for 24 hr. Then, the mixture was cooled and partitioned between DCM and 5% . The organic phase was dried over NaZSO4 and concentrated. SPE, washing with 20% EA/Hex, 20% EA/Hex + 2% TEA, and 35% EA/Hex + 2% TEA, then eluting with 50% EA/Hex + 2% TEA, gave 208 mg of yellow solid. Rf0.26 (7.5% MeOH/DCM); mp 189—192 0C (from MeOH); 1H NMR (CDC13) 5 8.40 (d, 1H, J=5.2 Hz), 7.98-7.91 (m, 2H), 7.62 (m, 1H), 7.45 (m, 1H), .26 (m, 3H), 7.10—6.98 (m, 6H), 6.90 (t, 1H, J=2.2 Hz), 6.75 (dd, 1H, J=2.5, 8.1 Hz). e 48: N—(2—Phenoxyphenyl)quinolin—4—amine Cd: 0o A mixture of 2—phenoxyaniline (286 mg, 1.54 mmol), 4—chloroquinoline (278 mg, 1.70 mmol), and 4—methylmorpholine (0.19 mL, 1.73 mmol) in 0.5 mL of NMP was heated in a heavy walled sealed tube at 130 0C for 20 hr. The mixture was cooled and partitioned between EA and 5% Na2C03 and brine. The organic phases were dried over NaZSO4 and trated. FC (7.5% MeOH/DCM) gave a dark oil that contained residual 4-methylmorpholine. The oil was filtered through a pad of silica gel using 30% EA/Hex + 2% TEA to give 402 mg of solid. Rf 0.10 (5% MeOH/DCM); 1H NMR(CDC13) 8 8.61 (d, 1H, J=5.2 Hz), 8.03 (dd, 1H, J=0.7, 8.4 Hz), 7.85- 7.81 (m, 1H), 7.64 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.59 (m, 1H), 7.43 (m, 1H), 7.34—7.24 (m, 2H), 7.19—6.98 (m, 8H).
Example 49: Quinolin—4—ylamino)phenyl]hexanamide N—(4—Nitrophenyl)hexanamide Hexanoyl chloride ((0.81 mL, 5.8 mmol) was added slowly to a mixture of 4—nitroaniline ((800 mg, 5.79 mmol) in 5 mL of pyridine and 15 mL of DMF cooled by an ice bath. After 30 min, the mixture was warmed to room temperature. After an onal 2 hr, the volatile components were evaporated. The residue was taken up in EA (100 mL) and washed with ted NaHC03 (2x75 mL), H20 (2x50 mL), 0.1N HCl (2x25 mL), and H20. The organic phase was concentrated in vacuo to give 1.50 g product. 1H NMR (CDC13) 5 8.2 (m, 2H), 7.7 (m, 2H), 7.4 (br s, 1H, NH), 2.4 (m, 2H), 1.8 (m, 2H), 1.4-1.3 (m, 4H), 0.9 (m, 3H).
N—(4—Aminophenyl)hexanamide A mixture of N—(4—nitrophenyl)hexanamide (1.50 g), 10% Pd—C (200 mg), and 75 mL of MeOH was stirred under a blanket of hydrogen until the starting material was consumed, as observed by analytical TLC. Then, the atmosphere was purged with argon, and the mixture was ed through a pad of . Evaporation of the solvent gave 1.22 g of product. 1H NMR (CDC13) 8 7.2 (m,3H), 7.0 (br s, 1H, NH), 6.6 (m, 2H), 3.6 (br s, 2H, N?z), 2.3 (m, 2H), 1.7 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
N—[4-(Quinolinylamino)phenyl]hexanamide A mixture of 4-chloroquinoline (358 mg, 2.20 mmol), N—(4-aminophenyl)hexanamide (300 mg, 1.46 mmol), and TEA (1 mL) was heated at 130 0C in a sealed tube for 5 days. Then the volatile components were evaporated. The e was purified by preparative TLC (10% MeOH/DCM) to give 329 mg of product. Rf 0.3 (10% MeOH/DCM); 1H NMR (CDC13) 8 8.56 (d, 1H, J=5.5 Hz), 8.04 (d, 2H, J=8.9 Hz), 8.05-7.99 (m, 2H), 7.69 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 7.51 (ddd, 1H, 121.5, 6.9, 8.4 Hz), 7.30 (d, 2H, J=8.9 Hz), 7.18 (d, 1H, J=5.4 Hz), 4.35 (q, 2H, J=7 Hz), 1.38 (t, 3H, J=7 Hz).
Example 50: N—[3—(Quinolin—4—ylamino)phenyl]hexanamide HNOHM N—[3—(Quinolin—4—ylamino)phenyl]hexanamide was prepared following the method for N—[4— (quinolin—4—ylamino)phenyl]hexanamide, starting with 3—nitroaniline (800 mg) and hexanoyl de (0.81 mL) and using 4—chloroquinoline (358 mg).
N—(4—Nitrophenyl)hexanamide (1.50 g): 1H NMR (CDC13) 5 8.4 (m, 1H), 8.0—7.9 (m, 2H), 7.8 (br s, 1H, NH), 7.5 (m, 1H), 2.4 (m, 2H), 1.8 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
N—(4—Aminophenyl)hexanamide (1.34 g): 1H NMR (CDC13) 5 7.4 (br s, 1H, NH), 7.2 (br s, 1H), 7.0 (t, 1H), 6.7 (d, 1H), 6.4 (d, 1H), 3.5 (br s, 2H, N?z), 2.3 (t, 2H), 1.7 (m, 2H), 2 (m, 4H), 0.9 (m, 3H).
N—[3—(Quinolin—4—ylamino)phenyl]hexanamide: Rf0.2 (10% MeOH/DCM); 1H NMR (CD3OD) 5 8.5 (d. 1H), 8.4 (d, 1H), 8.0-7.8 (m, 3H), 7.7 (m, 1H), 3 (m, 2H), 7.1 (m, 1H), 7.0 (d, 1H), 2.4 (t, 2H), 1.7 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
Example 51: N—Hexy1—4—(quinolin—4-ylamino)benzamide HN@NWH (:6?/N N—Hexyl(quinolinylamino)benzamide 4-Amino-N-hexylbenzamide (220 mg), prepared from l—aminohexane (0.70 mL) and 4—nitrobenzoyl de (450 mg) in two unremarkable steps, was reacted with 4—chloroquinoline (239 mg) and DIEA (0.50 mL) in 1 mL of IPA heated at 130- 180 0C in a sealed tube for 8 days. The mixture was cooled and partitioned between DCM and % . The organic phases were dried over NaZSO4, and concentrated. Purification by SPE, washing with 3% MeOH/DCM and then eluting with 15% MeOH/DCM, gave 105 mg of a solid.
Rf0.08 (5% MeOH/DCM); 1H NMR (20% CD30D/CDC13) 5 8.39 (d, 1H, J=5.4 Hz), 8.15 (dd, 1H, 120.7, 8.4 Hz), 7.89 (dd, 1H, J=0.7, 8.4 Hz), 7.80—7.75 (m, 2H), 7.65 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.47 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.36—7.30 (m, 2H), 7.07 (d, 1H, J=5.5 Hz), 3.35 (m, 2H, AB), 1.57 (m, 2H), 1.32—1.21 (m, 6H), 0.84 (t, 3H, J=6 Hz).
N—Hexyl—4—nitrobenzamide (467 mg): 1H NMR (CDC13) 5 8.17 (d, 2H, J=8.7 Hz), 7.91 (d, 2H, J=8.7 Hz), 7.00 (br s, 1H, NH), 3.39 (m, 2H), 1.56 (m, 2H), 1.4-1.1 (m, 6H), 0.81 (m, 3H). o—N—hexylbenzamide: Rf 0.22 (5% MeOH/DCM); 1H NMR (CDCl3) 5 7.56 (m, 2H), 6.58 (m, 2H), 6.56 (br s, 1H, NH), 4.12 (br s, 2H, NH;), 3.57 (m, 2H), 1.53 (m, 2H), 1.47-1.22 (m, 6H), 0.84 (m, 3H).
Example 52: N—Hexyl—3—(quinolin—4—ylamino)benzamide N—Hexyl—3—(quinolin—4—ylamino)benzamide (117 mg) was prepared following the method for N— hexyl—4—(quinolin—4—ylamino)benzamide, starting from 3—nitrobenzoic acid (1.17 g) and 1— hexylamine (1.02 mL) and using 4—chloroquinoline (225 mg).
N—Hexylnitrobenzamide: 1H NMR (CDClg) 8 8.56 (m, 1H), 8.28 (m, 1H), 8.13 (ddd, 1H, J=1.2, 1.7, 7.7 Hz), 7.58 (t, 1H, J=7.9 Hz), 6.84 (br s, 1H, NH), 3.44 (m, 2H), 1.60 (m, 2H), 1.39- 1.23 (m, 6H), 0.84 (t, 3H, J=7.0 Hz). 3—Amino—N—hexylbenzamide (1.47 g): Rf 0.25 (5% MeOH/DCM); 1H NMR (CDC13) 8 7.14—7.00 (m, 3H), 6.71 (m, 1H), 6.42 (br s, 1H, NH), 3.80 (br s, 2H, N?z), 3.34 (m, 2H), 1.53 (m, 2H), 1.48—1.21 (m, 6H), 0.84 (m, 3H).
N—Hexyl—3—(quinolin—4—ylamino)benzamide: Rf 0.05 (5% MeOH/DCM); 1H NMR (20% CD30D/CDC13) 5 8.34 (d, 1H, J=5.6 Hz), 8.18 (dd, 1H, J=0.7, 8.4 Hz), 7.91-7.88 (m, 1H), 7.70- 7.64 (m, 2H), 7.53—7.38 (m, 4H), 6.93 (d, 1H, J=5.7 Hz), 3.35 (m, 2H), 1.57 (m, 2H), 1.32—1.20 (m, 6H), 0.84 (m, 3H).
Example 53: ethoxyphenyl)quinolin—4—amine CK?/ A mixture ofp—anisidine (138 mg, 1.12 mmol), 4—chloroquinoline (235 mg, 1.44 mmol), and DIEA (0.50 mL, mmol) was heated at 130 0C in a sealed tube for 40 hr. The cooled mixture was partitioned between EA (3x) and 5% N32C03 (3x) and brine, and the organic phases were dried over anhydrous NaZSO4 and trated to give 385 mg of brown oil. Purification by preparative TLC (10% MeOH/DCM) gave 294 mg of brown oil that fied upon standing. 1H NMR(CDC13) 5 8.48 (d, 1H, J=5.4 Hz), 7.99 (d, 1H, J=8.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.64 (ddd, 1H, J=1.3, 7.0, 8.5 Hz), 7.45 (m, 1H), 7.21 (m, 2H), 6.93 (m, 2H), 6.68 (d, 1H, J=5.2 Hz), 3.82 (s, 3H).
Example 54: N-[4-(Benzyloxy)phenyl]quinolinamine 00 V CK)/ A mixture of 4-(benzyloxy)aniline (197 mg, 0.99 mmol), 4—chloroquinoline (169 mg, 1.04 mmol), and DIEA (0.18 mL, 1.03 mmol) in 1 mL of NMP was heated at 150 °C in a sealed tube for 24 hr. Then, the mixture was cooled and partitioned between EA (2x) and 5% N32C03 (2x) and brine. The organic phase was dried over Na2S04 and concentrated. SPE, washing with 1% MeOH/DCM and eluting with 5% MeOH/DCM while cutting fractions, gave 152 mg of colorless solid. Rf 0.18 (5% MeOH/DCM); mp 201—202 0C (from MeOH); 1H NMR (CDC13) 5 8.49 (d, 1H, J=5.4 Hz), 8.02 (dd, 1H, J=1.0, 8.6 Hz), 7.91 (dd, 1H, J=0.7, 8.4 Hz), 7.66 (ddd, 1H, J=1.2, 6.9, 8.4 HZ), 7.51—7.31 (m, 6H), 7.26—7.20 (m, 2H), 7.06-6.98 (m, 2H), 6.71 (d, 2H, J=5.2 Hz), 5.09 (s, 2H).
Example 55: N—(4—Butoxyphenyl)quinolin—4—amine A mixture of xyaniline (236 mg, 1.43 mmol), 4—chloroquinoline (236 mg, 1.45 mmol), and DIEA (0.26 mL, 1.49 mmol) in 1 mL of NMP was heated at 150 0C in a sealed tube for 24 hr.
The cooled mixture was partitioned between EA (2x) and 5% N32CO3 (2x) and brine, and the organic phases were dried over anhydrous NaZSO4 and concentrated to give a solid. SPE, washing with 1% MeOH/DCM and eluting with 5% MeOH/DCM, gave fractions affording a solid after concentration. tallization from MeOH gave 177 mg. Rf 0. 18 (5% MeOH/DCM); mp 181—185 0C; 1H NMR (CDC13) 5 8.45 (d, 1H, J=5.4 Hz), 8.03 (dd, 1H, J=1.0, 8.7 Hz), 7.97 (d, 1H, J=8.4 Hz), 7.67 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.48 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.22 and 6.95 (m, 4H, ), 6.67 (d, 1H, J=5.4 Hz), 3.98 (t, 2H, J=6.5 Hz), 1.79 (m, 2H), 1.51 (m, 2H), 0.99 (t, 3H, J=7.3 Hz).
Example 56: N-[4—(Hexyloxy)pheny1]quinolin—4—amine 1—(Hexyloxy)—4—nitrobenzene A mixture of 4—nitrophenol (480 mg, 3.45 mmol), 1—bromohexane (0.43 mL, 3.08 mmol), K2C03 (481 mg, 3.57 mmol), and 20 mg sodium iodide in 5 mL of DMF was heated at 60 0C for 18 hr. The cooled mixture was diluted with EtZO and washed with 5% N212C03 and brine, repetitively, until the aqueous phase was colorless. The organic phase was dried over MgSO4 and concentrated to obtain 532 mg of yellow oil. Rf 0.21 (5% EA/Hex); 1H NMR(CDC13) 5 8.19-8.13 (m, 2H, ), 6.94—6.88 (m, 2H, AA’BB’), 4.02 (t, 2H), 1.80 (m, 2H), 1.50—1.29 (m, 6H), 0.89 (m, 3H). 4—(Hexyloxy)aniline A mixture of 1—(hexyloxy)—4—nitrobenzene (532 mg, 2.38 mmol) and 5% Pd/C (60 mg) in 20 mL of MeOH was stirred under a hydrogen atmosphere for 3 hr. Then, the mixture was ed through a pad of Celite and concentrated to give 458 mg of oil. 1H NMR (CDC13) 5 6.78—6.72 (m, 2H, AA’BB’), 6.65-6.59 (m, 2H, AA’BB’), 3.88 (t, 2H), 3.44 (br s, 2H, NH;), 1.75 (m, 2H), 1.50-1.28 (m, 6H), 0.92 (m, 3H).
N—[4—(Hexyloxy)phenyl]quinolin—4—amine A mixture of 4—(hexyloxy)aniline (430 mg, 2.23 mmol), 4—chloroquinoline (431 mg, 2.64 mmol), and DIEA (1.0 mL, 5.74 mmol) in 1 mL of NMP was heated in a heavy walled sealed tube at 160 0C for 24 hr. The e was cooled and partitioned between EA and 5% Na2C03 and brine. The organic phases were dried over Na2S04 and concentrated to give a solid that was tallized from EtOH to give a colorless solid. 1H NMR (CDC13) 5 8.49 (d, 1, J=5.2 Hz), 8.02 (dd, 1, J=0.7, 8.4 Hz), 7.91 (d, 1, J=8.4 Hz), 7.67 (ddd, 1, J=1.5, 6.9, 8.4 Hz), 7.48 (ddd, 1, J=1.5, 6.9, 8.4 Hz), 7.25-7.18 (m, 2H), 6.98-6.92 (m, 2H), 6.69 (d, 1, J=5.5 Hz), 6.64 (br s, 1H), 3.97 (t, 2H, J=6 Hz), 1.80 (m, 2H), 1.50-1.30 (m, 6), 0.92 (m, 3).
Example 57: N-[3-(Benzyloxy)phenyl]quinolinamine A mixture of 3—(benzyloxy)aniline (312 mg, 1.57 mmol), 4—chloroquinoline (280 mg, 1.72 mmol), and DIEA (0.30 mL, 1.72 mmol) in 1 mL of NMP was heated at 150 °C in a sealed tube for 24 hr. Then, the mixture was cooled and partitioned between DCM and 5% N32C03. The organic phase was dried over NaZSO4 and concentrated. SPE, washing with 20% , 20% EA/Hex + 2% TEA, and 35% EA/Hex + 2% TEA, then eluting with 50% EA/Hex + 2% TEA, gave 528 mg of yellow solid. tallization from MeOH gave 390 mg of pale yellow solid. Rf 0.26 (7.5% MeOH/DCM); mp 77—80 0C (from MeOH); 1H NMR (CDC13) 5 8.45 (d, 1H, .1255 Hz), 8.04 (d, 1H, J=8.4 Hz), 7.98 (d, 1H, J=8.4 Hz), 7.67 (m, 1H), .24 (m, 8H), 6.94—6.79 (m, 4H), 5.08 (s, 2H).
Example 58: N—[3—(Hexyloxy)phenyl]quinolin—4—amine 1—(Hexyloxy)—3—nitrobenzene A mixture of 3—nitrophenol (553 mg, 3.98 mmol), 0hexane (0.50 mL, 3.58 mmol), and K2C03 (618 mg, 4.48 mmol) in 5 mL of DMF was heated at 60—80 0C for 12 hr. The cooled mixture was diluted with EtZO and washed with 5% N32C03 and brine, repetitively, until the aqueous phase was colorless, and then with 0.1M HCl and brine. The organic phase was dried over MgSO4 and concentrated to obtain 756 mg of oil. 1H NMR )8 7.78 (ddd, 1H, J=1.0, 2.0, 7.9 Hz), 7.70 (m, 1H), 7.39 (m, 1H), 7.19 (ddd, 1H, J=1.0, 2.4, 8.1 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.80 (m, 2H), 1.58-1.30 (m, 6H), 0.89 (m, 3H). 3-(Hexyloxy)aniline A mixture of 1-(hexyloxy)nitrobenzene (756 mg, 3.39 mmol) and 5% Pd/C (90 mg) in 20 mL of MeOH was stirred under a hydrogen atmosphere for 3 hr. Then, the mixture was filtered through a pad of Celite and concentrated to give 660 mg of light orange oil. 1H NMR (CDC13) 5 7.04 (m, 1H), 6.34—6.23 (m, 3H), 3.90 (t, 2H), 3.62 (br s, 2H, N?z), 1.75 (m, 2H), 1.49—1.26 (m, 6H), 0.90 (m, 3H).
N—[3—(Hexyloxy)phenyl]quinolin—4—amine Anhydrous pyridine (4 mL) was evaporated from the crude 3-(hexyloxy)aniline (406 mg, 2.10 mmol), then 4—chloroquinoline (420 mg, 2.58 mmol), DIEA (0.80 mL, 4.59 mmol), and 1.5 mL of NMP were added, and the mixture was heated at 160 0C in a heavy walled sealed tube for 24 hr. The mixture was cooled and partitioned n EA and 5% N32CO3 and brine. The organic phases were dried over NaZSO4 and concentrated. SPE, washing with 20% EA/Hex and then g with 50% EA/Hex + 2% TEA, gave the product as a brown oil that contained residual NMP. Crystallization from EA/Hex gave 410 mg of light tan solid. Rf0.32 (50% 50% EA/Hex + 2% TEA); 1H NMR (CDClg) 5 8.55 (d, l, J=5.2 HZ), 8.03—7.96 (m, 2H), 7.63 (ddd, 1, J=l.2, 6.9, 8.4 Hz), 7.43 (ddd, l, J=l.2, 6.7, 8.2 Hz), 7.26 (m, 1H), 7.14 (br s, 1H), 7.04 (d, 1, J=5.5 HZ), 6.87-6.83 (m, 2H), 6.69 (m, 1H), 3.90 (t, 2H, J=6 Hz), 1.75 (m, 2H), .30 (m, 6), 0.89 (m, 3).
Example 59: N—[2—(Benzyloxy)phenyl]quinolin—4—amine A mixture of 2—(benzyloxy)aniline (301 mg, 1.51 mmol), 4—chloroquinoline (268 mg, 1.64 mmol), and ylmorpholine (0.18 mL, 1.64 mmol) in 0.5 mL of NMP was heated in a heavy walled sealed tube at 130 °C for 20 hr. The mixture was cooled and partitioned between EA and % N32CO3 and brine. The organic phases were dried over NaZSO4 and concentrated. FC (7.5% MeOH/DCM) gave a dark oil that contained residual 4-methylmorpholine. The oil was filtered through a pad of silica gel using 30% EA/Hex + 2% TEA to give 268 mg of tan solid. Rf0.12 (5% MeOH/DCM); 1H NMR(CDC13) 8 8.60 (d, 1H, J=5.4 Hz), 8.05 (dd, 1H, 1.0, 8.4 Hz), 7.88 (dd, 1H, J=0.8, 8.4 Hz), 7.66 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), .40 (m, 2H), 7.37-7.29 (m, 5H), 7.15 (d, 1H, J=5.2 Hz), 7.07-6.98 (m, 3H), 5.17-5.10 (m, 2H, AB).
Example 60: N-[2—(Hexyloxy)pheny1]quinolin—4—amine HN ; C6?OM/N 1—(Hexyloxy)—2—nitrobenzene 2—Nitrophenol (1.38 g, 9.93 mmol), l—bromohexane (1.30 mL, 9.30 mmol), and K2C03 (1.38 g, 10.0 mmol) in 6 mL of DMF was mixed at room temperature for 3 days. The mixture was diluted with EtzO and washed with 0.25N NaOH until the aqueous phase was colorless, and then with brine. The organic phase was dried over MgS O4 and concentrated.
Rf0.39 (5% EA/Hex); 1H NMR (CDCl3) 5 7.78 (dd, 1H, J=l.7, 8.2 Hz), 7.48 (ddd, 1H, J=l.8, 7.3, 8.9 HZ), 7.04 (dd, 1H, J=l.0, 8.5 Hz), 6.97 (ddd, 1H, 1.2, 7.4, 8.2 Hz), 4.07 (t, 2H, J=6.4 Hz), 1.80 (m, 2H), 1.51—1.28 (m, 6H), 0.90 (m, 3H). 2—(Hexyloxy)aniline A mixture of the l—(hexyloxy)—2—nitrobenzene and 5% Pd/C (94 mg) in 15 mL of MeOH and 15 mL of EA was stirred under a hydrogen atmosphere for 5 hr. Then, the mixture was filtered through a pad of Celite and concentrated. The residue was ed through silica gel using 30% EA/Hex to give 1.51 g of brown oil that contained residual 1—bromohexane, as shown by NMR is. SPE, washing with hexane and eluting with 30% EA/Hex gave 1.38 g of red—brown oil. Rf0.26 (5% EA/Hex); 1H NMR (CDC13) 8 6.81—6.68 (m, 4H), 3.98 (t, 2H, J=6.4 Hz), 3.76 (br s, 2H, NH;), 1.81 (m, 2H), 1.53—1.23 (m, 6H), 0.91 (m, 3H).
N—[2—(Hexyloxy)phenyl]quinolin—4—amine A mixture of 2—(hexyloxy)aniline (282 mg, 1.46 mmol), 4—chloroquinoline (258 mg, 1.58 mmol), and 4—methylmorpholine (0.18 mL, 1.64 mmol) in 0.5 mL of NMP was heated in a heavy walled sealed tube at 130 0C for 20 hr. The mixture was cooled and ioned between EA and 5% Na2C03 and brine. The organic phases were dried over NaQSO4 and concentrated. FC (7.5% MeOH/DCM) gave a dark oil that contained residual 4-methylmorpholine. The oil was filtered through a pad of silica gel using 30% EA/Hex + 2% TEA to give 416 mg of tan solid. Rf0.13 (5% MeOH/DCM) 0.50 (10% MeOH/DCM); 1H NMR(CDC13) 5 8.59 (dd, 1H, J=6.3, 11.5 Hz), 8.05 (m, 1H), 7.95 (m, 1H), 7.65 (ddd, 1H, J=1.3, 6.7, 9.7 Hz), 7.50—7.44 (m, 2H), 7.19-7.13 (m, 2H), .91 (m, 3H), 3.99 (t, 2H, J=6.4 Hz), 1.75 (m, 2H), 1.45—1.17 (m, 6H), 0.83 (m, 3H).
Example 61: N—[2—Fluoro—4—(hexyloxy)pheny1]quinolin—4—amine 2—Fluoro—4—(hexyloxy)—l—nitrobenzene (2.6 g) was prepared from o—4—nitrophenol (5.0 g, 31.5 mmol), 60% sodium hydride (1.9 g), l—bromohexane (4.75 mL), and 30 mL of DMF 2014/013992 following the method for romooctyloxy)—3—methylbenzene. 1H NMR (CDCl3) 5 8.05 (t, 1H), 6.7 (m, 2H), 4.0 (t, 2H), 1.8 (m, 2H), 161.3 (m, 6H), 0.9 (m, 3H). 2—Fluoro—4—(hexyloxy)aniline (1.6 g) was prepared from 2—?uoro—4—(hexyloxy)—l—nitrobenzene (2.6 g) following the method for 8—(3—ethoxypropoxy)octan—l—amine. 1H NMR (CDCl3) 8 6.75— 6.5 (m, 3H), 3.85 (t, 2H), 3.4 (br s, 2H, NH;), 1.75 (m, 2H), 15-12 (m, 6H), 0.9 (m, 3H).
N—[2—Fluoro—4—(hexyloxy)phenyl]quinolin—4—amine (114 mg) was prepared from 2—?uoro—4— (hexyloxy)aniline (1.6 g), roquinoline (1.33 g), TEA (5 mL), and NMP (0.5 mL) at 130 0C in a sealed tube for 5 days following the method for N—[8—(3—ethoxypropoxy)octyl]quinolin—4— amine. 1H NMR(CDC13)5 8.55 (d, 1H), 8.05 (d, 1H), 7.95 (d, 1H), 7.7 (m, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 6.75 (m, 2H), 6.65 (d, 1H), 6.4 (br s, 1H, NH), 3.95 (t, 2H), 1.8 (m, 2H), 1.6-1.3 (m, 6H), 0.9 (m, 3H).
Example 62: N-Benzquuinolinamine A mixture of benzylamine (166 mg, 1.55 mmol), 4—chloroquinoline (268 mg, 1.64 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated in a heavy walled sealed tube at 130 °C for 40 hr. The mixture was cooled, a mixture of EtOH and H20 was added, and the sealed mixture was heated for 16 hr. Then, the mixture was cooled and partitioned n EA (3x) and 5% N32C03 (3x) and brine. The organic phases were dried over Na2S04 and concentrated to give 385 mg of oil.
Purification by preparative TLC (10% MeOH/DCM) gave 294 mg of brown oil. Rf 0.33 (10% MeOH/DCM); 1H NMR (CDC13) 8 8.49 (d, 1H, J=5.2 Hz), 7.98 (dd, 1H, J=0.8, 8.4 Hz), 7.82 (d, 1H, J=8.4 Hz), 7.61 (ddd, 1H, J=l.2, 6.9, 8.4 Hz), 7.42—7.27 (m, 6H), 6.41 (d, 1H, J=5.4 Hz), .76 (br s, 1H), 4.51 (m, 2H, AB). e 63: N—Phenethquuinolin—4—amine A mixture of 2—phenethylamine (177 mg, 1.46 mmol), 4—chloroquinoline (258 mg, 1.58 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated at 130 0C in a sealed tube for 40 hr. The cooled mixture was partitioned between EA (3x) and 5% N32C03 (3x) and brine, and the organic phases were dried over anhydrous NaZSO4 and trated to give a solid. Washing with EtZO gave 230 mg of red solid. 1H NMR (CDC13) 5 8.55 (d, 1H, J=5.4 Hz), 7.98 (m, 1H), 7.64-7.58 (m, 2H), 7.42—7.24 (m, 6H), 6.48 (d, 1H, J=5.4 Hz), 5.17 (br s, 1H, NH), 3.60 (m, 2H), 3.06 (t, 2H, J=6.9 Hz).
Example 64: N—[4-(Hexyloxy)benzyl]quinolinamine co“(10W/N 4-(Hexyloxy)benzonitrile A mixture of 4-cyanophenol (25.2 g, 212 mmol), K2CO3 (24.7 g, 233 mmol), and l-bromohexane (29.6 mL, 212 mmol) in 150 mL of DMF was d at room temperature for 24 hr and then at 55 °C for 24 hr. 4—Cyanophenol remained, as shown by TLC.
Na2C03 (7.0 g, 66 mmol), and 1—bromohexane (3.0 mL, 21 mmol) were added, and, after 24 hr, the temperature was lowered to 40 °C and additional Na2C03 (12.4 g, 117 mmol) and 1— bromohexane (10.0 mL, 72 mmol) were added. r, after 24 hr, no consumption of the ing 4-cyanophenol was apparent. The mixture was cooled to room temperature and 6 mL of concentrated NH4OH was added. After standing for 3 days, the mixture was partitioned between EA (3x250 mL) and H20 (300 and 200 mL), 1M HCl (100 mL), and brine (150 mL).
The combined organic phases were dried over MgSO4 and concentrated. SPE (10% EA/Hex) gave 35.8 g of colorless oil that solidified upon standing. Rf 0.63 (20% EA/Hex); 1H NMR (CDC13)5 7.55 and 6.92 (m, 4H, AA’BB’), 3.98 (t, 2H, J=6.6 Hz), 1.78 (m, 2H), 1.43 (m, 2H), 1.35—1.30 (m, 4H), 0.89 (m, 3H); 13C NMR ) 5 162.6, 134.1, 119.5, 115.4, 103.8, 68.6, 31.7, 29.1, 25.8, 22.7, 14.2. [4—(Hexyloxy)phenyl]methanamine 4—(Hexyloxy)benzonitrile (35.8 g, 176 mmol) was taken up in 350 mL of THF, and the mixture was cooled by an ice bath. LAH (7 g, 184 mmol) was added cautiously in ns. After 1 hr, the mixture was heated at re?ux. After 15 hr, the mixture was cooled with an ice bath. Cautiously, with thorough ng, in portions and in sequence, 7 mL of H20, 7 mL of 15% NaOH, and 21 mL of H20 were added to the ice—cold mixture. The resultant heterogenous mixture was diluted with 350 mL of IPA. The mixture was filtered through a bed of Celite, and the solids were washed with 200 mL of IPA. The filtrate was trated to give 34.4 g of the product that contained residual IPA. Rf 0.25 (5% MeOH/DCM + 2% TEA, ninhydrin (+)); 1H NMR (CDCl3) 8 7.17 and 6.83 (m, 4H, ), 3.90 (t, 2H, J=6.7 Hz), 3.74 (s, 2H), 2.00 (br s, 2H, N?z), 1.78 (m, 2H), 1.48—1.27 (m, 6H), 0.88 (m, 3H).
N—[4-(Hexyloxy)benzyl]quinolinamine [4-(Hexyloxy)phenyl]methanamine (166 mmol) was taken up in 400 mL of 1-pentanol, and 150 mL of volatile material was removed by distillation in order to ensure anhydrous conditions. The mixture was allowed to cool to 70 OC, and tripropylamine (63 mL, 330 mmol) and 4-chloroquinoline (28 g, 172 mmol) were added.
Heating at re?ux was resumed. After 16 hr, TLC of an aliquot indicated very little ninhydrin (+) ng material ed. Volatile material was removed by distillation and evaporation. The cooled mixture was diluted with 1:2 DCM/EA and washed with 3N NaOH (60 mL), H20, and brine. The combined organic phases were dried over NaZSO4, filtered, and concentrated. SPE, eluting with 50% EA/Hex and then 15% EtOH/DCM, gave a brown oil. The oil was taken up in EA and washed with 5% Na2C03 and brine. The organic phase was dried over Na2804, filtered, and concentrated. EA (10 mL) and then s (20 mL) were added to the e. A precipitate was obtained. The colorless precipitate was collected by filtration and washed with 100 mL of 50% EA/Hex and then 50 mL of 30% EA/Hex. A second crop was obtained from the combined filtrates. The crops were combined and dried in vacuo to give 38.4 g. Rf 0.25 (5% MeOH/DCM); mp 1035—1040 0C; 1H NMR(CDC13) 5 8.55 (d, 1H, J=5.5 Hz) 8.00 (d, 1H, J=0.7 Hz), 7.98 (d, 1H, J=0.7 Hz), 7.74 (m, 1H), 7.65—7.61 (m, 1H), 7.41 (m, 1H), 7.30 and 6.90 (m, 4H, AA’BB’), 6.46 (d, 1H, J=5.1 Hz), 5.33 (m, 1H), 4.43 (m, 2H, AB), 3.96 (t, 2H, J=6.6 Hz), 1.79 (m, 2H), 1.46 (m, 2H), 1.39—1.30 (m, 4H), 0.90 (m, 3H); 13C NMR(CDC13) 8 159.2, 151.4, 149.6, 148.7, 130.3, 129.5, 129.2, 129.1, 124.9, 119.5, 119.0, 115.2, 99.5, 68.4, 47.4, 31.8, 29.4, .9, 22.8, 14.2.
Example 65: N—[3—(Hexyloxy)benzyl]quinolin—4—amine 3—(Hexyloxy)benzaldehyde A mixture of 3—hydroxybenzaldehyde (10.3 g, 84.4 mmol), K2C03 (13.9 g, 100.7 mmol), and 1—bromohexane (11.2 mL, 80.0 mmol) in 90 mL of DMF was heated at 60 °C for 12 hr. The mixture was cooled to room temperature, poured into 30% , and washed with H20, 5% Na2C03, H20, 0.1M HCl, and brine. The organic phases were dried over NagSO4, filtered h a pad of silica gel, and concentrated to give 15.8 g of brown oil. Rf 0.56 (20% EA/Hex), 1H NMR (CDC13) 8 9.94 (s, 1H), 7.43-7.36 (m, 3H), 7.14 (m, 1H), 3.99 (t, 2H, J=6.6 Hz), 1.79 (m, 2H), 1.45 (m, 2H), 1.37-1.28 (m, 4H), 0.89 (m, 3H); 13C NMR (CDC13) 8 192.4, 159.9, 137.9, 130.1, 123.4, 122.1, 113.0, 68.4, 31.7, 29.2, 25.8, 22.7, 14.2. xyloxy)phenyl]methanol 3—(Hexyloxy)benzaldehyde was taken up in 160 mL of MeOH, and the mixture was cooled using an ice bath. NaBH4 (3.17 g, 83 mmol) was added in three portions, during which gas was evolved from the mixture. Three hours after the final addition, 10 mL of acetone was added, and the mixture was allowed to stand for 3 days. Then, the volatile material was evaporated, and the residue was partitioned between 1:1 EA/Hex and H20, 5% Na2C03 (2x), H20, 0.1M HCl (2x), and brine. The c phases were dried over Na2804, ?ltered through a pad of silica gel, and concentrated to give 15.3 g of light brown oil. Rf 0.28 (20% ); 1H NMR(CDC13) 8 8.16 (m, 1H), 7.83—7.81 (m, 2H), 7.73 (m, 1H), 5.55 (s, 2H), 4.86 (t, 2H, J=6.6 Hz), 2.86 (br s, 1H, OH), 2.69 (m, 2H), 2.37 (m, 2H), 2.27—2.23 (m, 4H), 1.82 (t, 3H, J=7.0 Hz); 13C NMR(CDC13)8159.6, 142.7, 129.7, 119.1, 114.0, 113.1, 69.2, 65.4, 31.8, 29.4, 25.9, 22.8, 14.2.
WO 20995 3—(Hexyloxy)benzyl methanesulfonate [3—(Hexyloxy)phenyl]methanol was taken up in 180 mL of THF and 100 mL of EA and cooled using an ice bath. TEA (12.4 mL, 88 mmol) and then methanesulfonyl chloride (6.30 mL, 80 mmol) were added. A white precipitate formed y.
After 2 hr, 5 mL of H20 were added, and the volatile ents were evaporated. The residue was partitioned between EA (3x300 mL) and H20, saturated NaHC03, H20, 0.1M HCl, and brine (100 mL each). The combined organic phases were dried over Na2SO4, ed through a pad of silica gel, and concentrated to give 20.75 g of light brown oil. Rf 0.50 (30% EA/Hex); 1H NMR (CDC13) 8 7.3 (m, 1H), 6.9-6.8 (m, 3H), 5.2 (s, 2H), 4.0 (t, 2H, J=6.6 Hz), 2.9 (2s, 3H), 1.8 (m, 2H), 1.4 (m, 2H), 1.4-1.3 (m, 4H), 0.9 (m, 3H); 13C NMR(CDC13) 5 159.7, 134.9, 130.1, 120.9, 115.7, 114.9, 71.7, 68.3, 38.6, 31.7, 29.4, 25.9, 22.8, 14.2.
N—[3—(Hexyloxy)benzyl]phthalimide A mixture of 3—(hexyloxy)benzyl methanesulfonate and potassium phthalimide (15.4 g, 83.2 mmol) in 200 mL of DMF was stirred using a mechanical stirrer at room temperature for 4 hr and then at 50 0C for 4 hr. Then, H20 (100 mL) was added, and the volatile material was evaporated. The residue was partitioned between EA and 5% Na2C03 (2x), H2O, 0.1M HCl, and brine. The organic phases were dried over Na2SO4, filtered through a pad of silica gel, and trated. Crystallization from IPA gave 20.74 g of colorless solid. Rf0.56 (30% EA/Hex); 1H NMR (CDClg) 8 7.9 and 7.7 (m, 4H, AA’BB’), 7.2 (m, 1H), 7.0—6.9 (m, 2H), 6.8 (m, 1H), 4.8 (s, 2H), 3.9 (t, 2H, J=6.6 Hz), 1.8 (m, 2H), 1.5 (m, 2H), 1.3—1.2 (m, 4H), 0.9 (m, 3H); 13C NMR(CDC13) 8 168.2, 159.6, 138.0, 134.2, 132.3, 129.8, 123.6, 120.8, 114.8, 114.1, 68.1, 41.8, 31.8, 29.4, 25.9, 22.8, 14.2. xyloxy)phenyl]methanamine Hydrazine drate (2.20 mL, 45.3 mmol) was added to a mixture of N—[3—(hexyloxy)benzyl]phthalimide (10.1 g, 30.0 mmol) and 90 mL of denatured EtOH with mechanical stirring. The mixture was heated at re?ux for 15 hr, during which time a colorless precipitate formed. The mixture was concentrated by evaporation, and the residue was partitioned between DCM (150, 2x80 mL) and 5% Na2C03 (2x100 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. SPE, washing with 50% isopropyl acetate/Hex and then eluting with 3% MeOH/DCM + 2% TEA gave 4.40 g of the product as a pale yellow liquid, which was carried on without additional drying. Rf 0.26 (10% MeOH/DCM, ninhydrin (+)); 1H NMR (CDCl3) 5 7.22 (m, 1H), 6.87-6.84 (m, 2H), 6.76 (dd, 1H, J=2.4, 8.0 Hz), 3.94 (t, 2H, J=6.6 Hz), 3.82 (br s, 2H, AB), 1.76 (m, 2H), 1.59 (br s, 2H, N?z), 1.47—1.29 (m, 6H), 0.89 (t, 3H, J=6.8 Hz).
Hexyloxy)benzyl]quinolin—4—amine [3—(Hexyloxy)phenyl]methanamine (7.20 g, 34.8 mmol) was taken up in 100 mL of 1—pentanol, and then 25 mL of volatile material was removed by distillation. The mixture was cooled below g, and tripropylamine (10.0 mL, 52.4 mmol) and 4—chloroquinoline (5.67 g, 34.8 mmol) were added. Heating at re?ux was d. After 26 hr, volatile material was removed by evaporation. The mixture was diluted with DCM (350 mL) and washed with 1N NaOH (50 mL) and 5% N32CO3 (50 mL). The aqueous phases were ted with DCM (100 mL). The combined organic phases were dried over NaZSO4, ?ltered, and concentrated. SPE, washing with 50% EA/Hex and then eluting with 50% EA/Hex + 2% TEA, gave product fractions that were combined and concentrated. The residue was partitioned between EA (400, 175 mL) and 5% Na2C03 and brine (50 mL each). The combined organic phases were dried over Na2804, filtered, and concentrated to approximately 50 mL, pon substantial precipitate formed. The precipitate was recrystallized by heating and cooling, at the end of which 20 mL of hexanes was added. After standing overnight, the colorless precipitate was collected by filtration and washed with 30% . (The mother liquor contained imately 2.4 g of material, but it was not treated further.) Drying in vacuo gave 4.05 g. Rf 0.20 (10% MeOH/DCM); mp 1095—1100 0C; 1H NMR(CDC13) 5 8.55 (d, 1H, J=5.1 Hz), 8.00 (dd, 1H, 120.7, 8.4 Hz), 7.76 (dd, 1H, J=1.1, 8.5 Hz), 7.65 (ddd, 1H, J=1.4, 6.9, 8.4 Hz), 7.44 (m, 1H), 7.29 (t, 1H), 6.98—6.94 (m, 2H), 6.86 (dd, 1H, 121.8, 8.1 Hz), 6.46 (d, 1H, J=5.2 Hz), 5.34 (t, 1H, NH), 4.50 (m, 2H, AB), 3.94 (t, 2H, J=6.6 Hz), 1.80—1.73 (m, 2H), 1.46—1.40 (m, 2H), 1.35—1.30 (m, 4H), 0.91—0.87 (m, 3H); 13C NMR(CDC13)5160.0, 151.4, 149.6, 148.8, 139.4, 130.4, 130.2, 129.2, 125.0, 119.8, 119.5, 119.1, 114.2, 113.9, 99.7, 68.3, 47.9, 31.8, 29.5, 25.9, 22.8, 14.2.
W0 2014/120995 Example 66: N—[2—(Hexyloxy)benzyl]quinolin—4—amine HN/\© [2—(Hexyloxy)phenyl]methanol A mixture of 3—hydroxybenzyl alcohol (3.06 g, 24.7 mmol), 1—bromohexane (3.20 mL, 22.9 mmol), K2C03 (3.50 g, 25.4 mmol), and 10 mL of DMF was reacted for 40 hr. The mixture was partitioned between EA and H20, 5% Na2C03, H2O, 0.1M HCl, and brine. The organic phases were dried over anhydrous Na2SO4 and trated. SPE, washing with 5% EA/Hex and eluting with 15% EA/Hex, gave 2.86 g of product. Rf 0.31 (15% EA/Hex); 1H NMR ) 8 7.27—7.22 (m, 2H), 6.95-6.85 (m, 2H), 4.69 (s, 2H), 4.01 (t, 2H, J=6.5 Hz), 2.45 (br s, 1H, 0H), 1.81 (m, 2H), 1.52—1.32 (m, 6H), 0.91 (m, 3H).
N—[2-(Hexyloxy)benzyl]phthalimide DIEA (4.90 mL, 28.1 mmol) was added to a mixture of [2- (hexyloxy)phenyl]methanol (2.86 g, 13.8 mmol) and methanesulfonyl chloride (2.10 mL, 26.8 mmol) in 25 mL of dioxane and 10 mL of EA cooled by an ice bath. After 2 hr, the mixture was partitioned between EA and H20, saturated NaHCOg, H2O, 0.1M HCl, and brine. The organic phases were dried over anhydrous Na2SO4 and trated. The residue was filtered through a pad of silica gel using 50% EA/Hex and the filtrate was concentrated to give crude 2— (hexyloxy)benzyl methanesulfonate. The crude 2—(hexyloxy)benzyl methanesulfonate was taken up in 150 mL of acetone, sodium iodide (3.1 g, 21 mmol) was added, and the mixture was heated at re?ux for 1.5 hr. Then, the solvent was evaporated, and the solid residue was ioned between EA and H20. The c phase was decolorized with aqueous Na2S203 and washed with H20 and brine, dried over anhydrous MgSO4, and concentrated. The residue was ed through a pad of silica gel using 25% EA/Hex and the filtrate was concentrated to give crude 1- (hexyloxy)-2—(iodomethyl)benzene. A mixture of the crude 1—(hexyloxy)—2—(iodomethyl)benzene and potassium phthalimide (3.8 g, 20 mmol) in 12 mL of DMF was reacted at room temperature for 24 hr. The mixture was partitioned between EA and H20, aqueous Na2S203, H20, 5% Na2C03, H2O, 0.1M HCl, and brine, and the c phases were dried over ous MgSO4 and concentrated. SPE, washing with 5% EA/Hex and eluting with 15% EA/Hex, gave 2.30 g of oil. Careful TLC (avoiding overloading and using a longer plate) showed that the product contained a nearly co—migratory impurity. Rf0.37 (15% EA/Hex); 1H NMR (CDClg) 5 7.84 and 7.71 (m, 4H, AA’BB’), 7.27-7.14 (m, 2H), .81 (m, 2H), 4.91 (s, 2H), 3.96 (t, 2H, J=6.5 Hz), 1.77 (p, 2H, J=6.7 Hz), 1.46-1.22 (m, 6H), 0.88 (m, 3H). [2—(Hexyloxy)phenyl]methanamine Hydrazine monohydrate was added to a mixture of N—[2— (hexyloxy)benzyl]phthalimide and 80 mL of EtOH, and the mixture was heated at re?ux for 20 hr. The e was cooled, and the volatile components were evaporated. The residue was partitioned between EA and 5% Na2C03 and brine, dried over anhydrous NaZSO4, and concentrated. SPE, g with 18% EA/Hex followed by 4% MeOH/DCM and eluting with 6% MeOH/DCM + 2% TEA, gave the ninhydrin (+) product. Rf 0.61 (5% MeOH/DCM + 2% TEA).
N—[2-(Hexyloxy)benzyl]quinolinamine A mixture of [2-(hexyloxy)phenyl]methanamine (417 mg, 2.01 mmol), 4-chloroquinoline (430 mg, 2.64 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP was heated at 150 0C in a sealed tube for 18 hr. Then, the e was cooled and partitioned between EA and 5% N32C03 and brine. The organic phase was dried over N32804 and trated. SPE, washing with 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 545 mg of solid. Rf 0.20 (10% MeOH/DCM); mp 90—91°C (from EA/Hex); 1H NMR (CDC13) 5 1H NMR (CDC13) 8 8.52 (d, 1H, J=5.5 Hz), 7.98 (dd, 1H, J=0.7, 8.4 Hz), 7.77 (dd, 1H, 121.0, 8.4 Hz), 7.61 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.39 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.31—7.23 (m, 2H), 6.92-6.87 (m, 2H), 6.48 (d, 1H, J=5.2 Hz), 5.71 (bt, 1H, J=5.2 Hz, NH), 4.54 (m, 2H, AB), 4.02 (t, 2H, J=6.4 Hz), 1.84—1.74 (m, 2H), 1.50—1.17 (m, 6H), .81 (m, 3H).
Example 67: N—[3—Fluoro—4—(hexyloxy)benzyl]quinolin—4—amine WO 20995 3—Fluoro—4—(hexyloxy)benzonitrile (721 mg) was prepared from 3—?uoro—4—hydroxybenzonitrile (1.5 g, 10.9 mmol), 60% sodium e (654 mg), 1—bromohexane (1.30 mL), and 10 mL of DMF following the method for 1—(8—bromooctyloxy)—3—methylbenzene. 1H NMR (CDCl3) 5 7.5 (t, 1H), 6.8-6.6 (m, 2H), 3.95 (t, 2H), 1.8 (m, 2H), 1.5—1.2 (m, 6H), 0.9 (m, 3H). [3—Fluoro—4—(hexyloxy)phenyl]methanamine (212 mg, 0.9 mmol) was ed from 3—?uoro—(4— hexyloxy)benzonitrile (721 mg, 3.3 mmol) and LAH (6.6 mmol) in THF (50 mL) at 0 0C for 4 hr and room temperature for 12 hr following the method for [4—(hexyloxy)phenyl]methanamine. 1H NMR (CDC13) 5 7.15 (t, 1H), 6.7-6.5 (m, 2H), 3.9 (t, 2H), 3.75 (s, 2H), 1.75 (m, 2H), 1.6—1.2 (m, 8H), 0.9 (m, 3H).
N—[3—Fluoro—4—(hexyloxy)benzyl]quinolinamine (325 mg) was prepared from [3-fluoro—4— (hexyloxy)phenyl]methanamine (486 mg, 2.2 mmol), 4—chloroquinoline (541 mg, 3.3 mmol), TEA (4 mL), and NMP (0.5 mL) at 130 0C in a sealed tube for 5 days following the method for 3-ethoxypropoxy)octyl]quinolinamine. 1H NMR (CDC13) 5 8.5 (d, 1H), 8.0 (d, 1H), 7.8 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.25 (t, 1H), 6.6 (m, 2H), 6.45 (d, 1H), 5.8 (br s, 1H, NH), 4.5 (m, 2H, AB), 3.9 (t, 2H), 1.8 (m, 2H), 1.6-1.2 (m, 6H), 0.9 (m, 3H).
Example 68: N-[4—(Decyloxy)benzy1]quinolin—4—amine CK?HN/\©\OW/ 4—(Decyloxy)benzonitrile A mixture of 4—hydroxybenzonitrile ( 4.32 g, 36.3 mmol), 1— bromodecane (6.80 mL, 32.9 mmol), and K2C03 (6.61 g, 47.8 mmol) in 20 mL of DMF was reacted for 2 days. The solvent was evaporated in vacuo. The e was partitioned between 50% EA/HeX (3X150 mL) and 5% N212C03 (3X80 mL), H20 (40 mL), 0.1M HCl (40 mL), and brine (80 mL). The organic phases were dried over anhydrous NaZSO4 and concentrated to give 8.30 g of colorless oil that solidified upon standing. 1H NMR (CDCl3) 5 7.54 and 6.90 (m, 4H, AA’BB’), 3.97 (t, 2H, J=6.6 Hz), 1.78 (m, 2H), 1.42 (m, 2H), 1.34-1.25 (m, 12H), 0.86 (m, 3H); W0 20995 13C NMR(CDC13) 5 162.6, 134.0, 119.4, 115.3, 103.7, 68.5, 32.0, 29.6, 29.4, 29.4, 29.1, 26.0, 22.8, 14.2. [4—(Decyloxy)phenyl]methanamine Lithium aluminum hydride (2.0 g, 53 mmol) was added in ns to a mixture of 4—(decyloxy)benzonitrile (8.30 g, 32.0 mmol) and 80 mL of THF cooled by an ice bath. Then, the mixture was allowed to warm to room temperature. After 2 hr, the mixture was cooled by an ice bath, and 2 mL H20, 2 mL 15% NaOH, and 6 mL H20 were added sequentially and cautiously. The resulting solids were ed, and the solids were washed with % MeOH/DCM + 1% TBA. The te was concentrated, then taken up in DCM and washed with 5% N32CO3. The organic phase was dried over anhydrous NaZSO4 and concentrated. SPE, washing with 40% isopropyl acetate/Hex and eluting with 3% MeOH/DCM + 2% TEA, gave ninhydrin (+) fractions. These fractions were concentrated, and the residue was taken up in DCM, washed with 5% NaZC03, dried over anhydrous NaZSO4, and concentrated to give 7.61 g of colorless solid. Rf 0.11 (10% CM); 1H NMR ) 8 7.18 and 6.83 (m, 4H, AA’BB’), 3.90 (t, 2H, J=6.6 Hz), 3.76 (s, 2H), 1.75 (m, 2H), 1.56 (br s, 2H, N?z), 1.43 (m, 2H), .26 (m, 12H), 0.87 (t, 3H, J=6.9 Hz); 13C NMR (CDC13) 5 158.1, 135.4. 128.2, 114.5, 68.0, 46.0, 32.0, 29.6, 29.6, 29.5, 29.4, 26.1, 22.7, 14.2.
N—[4—(Decyloxy)benzyl]quinolin—4—amine [4—(Decyloxy)phenyl]methanamine (5.90 g, 22.4 mmol) was taken up in 100 mL of 1—pentanol, and 25 mL was removed by distillation. The mixture was cooled slightly, and tripropylamine (6.50 mL, 34.1 mmol) and 4—chloroquinoline (3.63 g, 22.3 mmol) were added. Heating at re?ux was continued for 24 hr. Then, the volatile components were evaporated, and the residue was partitioned between DCM and 5% NazCO3.
The organic phase was dried over anhydrous Na2S04 and concentrated onto silica gel. SPE, washing with 50% EA/Hex and then eluting with 10% MeOH/DCM, gave a solid. The solid was taken up in DCM, washed with 5% N32C03, dried over anhydrous NaZSO4, and concentrated to give a solid. Recrystallization from EA/Hex gave 3.70 g colorless solid. Rf 0.13 (10% MeOH/DCM); mp 96.5—97.0 0C; 1H NMR (CDC13) 5 8.55 (d, 1H, J=5.2 Hz), 7.99 (d, 1H, J=8.5 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.63 (m, 1H), 7.42 (m, 1H), 7.30 and 6.90 (m, 4H, AA’BB’), 6.47 (d, 1H, J=5.1 Hz), 5.30 (br s, 1H, NH), 4.44 (m, 2H, AB), 3.95 (m, 2H), 1.79 (m, 2H), 1.46 (m, 2H), 1.32—1.27 (m, 10H), 0.88 (m, 3H); 13C NMR ) 5 159.1, 151.3, 149.6, 148.7, 130.2, 129.4, 129.2, 129.2, 124.9, 119.5, 118.9, 115.1, 99.5, 68.3, 47.3, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 26.2, 22.9, 14.3. e 69: N—[3—(Decyloxy)benzyl]quinolin—4—amine \/\/ CK?/ N 3-(Decyloxy)benzaldehyde 1—Bromodecane (15.0 mL, 72.6 mmol) was added to a mixture of 3—hydroxybenzaldehyde (9.75 g, 79.9 mmol) and K2C03 (12.2 g, 88.4 mmol) in 80 mL of DMF heated at 50 0C using mechanical stirring. After 22 hr, the mixture was diluted with H20 (100 mL) and extracted with EA (3x100 mL), and the organic phases were washed with 5% N32C03 and H20 (100 mL each), 0.1M HCl (2x100 mL), and brine (100 mL), and dried over anhydrous NagSO4. Evaporation of the volatile components yielded 18.74 g of product as a brown oil. Rf 0.54 (10% EA/Hex); 1H NMR(CDC13) 8 9.96 (s, 1H), 7.44-7.37 (m, 3H), 7.18 (m, 1H), 4.00 (t, 2H, J=6.6 Hz), 1.80 (m, 2H), 1.46 (m, 2H), 1.36-1.23 (m, 12H), 0.88 (m, 3H); 13C NMR(CDC13) 8192.4, 159.9, 138.0, 130.2, 123.5, 122.2, 113.0, 68.5, 32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 26.2, 22.9, 14.3. cyloxy)phenyl]methanol Sodium borohydride (2.63 g, 69.2 mmol) was added to a mixture of 3-(decyloxy)benzaldehyde (18.74 g) and 160 mL of MeOH cooled by an ice bath.
After 1 hr, residual hydride was quenched by adding H20, and 80 mL of 1M HCl was added slowly, resulting in precipitation. The volatile components were evaporated, and the residue was partitioned between 50% EA/Hex and H20, 5% N32C03 (2x), H20, and brine. The organic phases were dried over anhydrous NaZSO4, filtered through a pad of silica gel, and concentrated to give 21.05 g of product as a light brown solid. Rf0.11 (10% EA/Hex) 0.28 (1:4:5 EA/toluene/Hex); 1H NMR (CDCl3) 5 7.24 (m, 1H), 6.90-6.88 (m, 2H), 6.81 (m, 1H), 4.60 (br s, 2H, AB), 3.94 (t, 2H, J=6.6 Hz), 2.55 (br s, 1H, OH), 1.78 (m, 2H), 1.46 (m, 2H), 1.38-1.24 (m, 12H), 0.91 (m, 3H); 13C NMR(CDC13)5159.5, 142.7, 129.6, 119.0, 113.8, 113.0, 68.1, 65.2, 32.0, 29.8, 29.7, 29.6, 29.5, 29.4, 26.2, 22.8, 14.3. 3—(Decyloxy)benzyl methanesulfonate Triethylamine (11.8 mL, 84.4 mmol) was added to a mixture of [3—(Decyloxy)phenyl]methanamine (21.05 g, mmol) and methanesulfonyl chloride (6.60 mL, 84.4 mmol) in 120 mL of THF cooled by an ice bath. A precipitate formed rapidly.
After 1 hr, 5 mL of H20 was added, and the volatile components were ated. The residue was partitioned between EA and H20, saturated NaHCOg, H20, 0.1M HCl, and brine. The organic phases were dried over anhydrous NaZSO4, filtered through a pad of silica gel, and trated to give 23.53 g of 3—(decyloxy)benzyl methanesulfonate as an amber oil that solidified upon standing. Rf 0.45 (1:4:5 EA/toluene/Hex) 0.35 (20% ); 1H NMR (CDC13) 8 7.29 (m, 1H), 6.98-6.90 (m, 3H), 5.19 (m, 2H, AB), 3.95 (t, 2H, J=6.6 Hz), 2.90 (s, 3H), 1.78 (m, 2H), 1.43 (m, 2H), 1.36-1.28 (m, 12H), 0.88 (m, 3H); 13C NMR(CDC13) 5 159.6, 134.9, 130.1, 120.8, 115.6, 114.8, 71.7, 68.2, 38.4, 32.0, 29.7, 29.7, 29.5, 29.4, 29.4, 26.2, 22.8, 14.3.
N—[3-(Decyloxy)benzyl]phthalimide A mixture of 3-(decyloxy)benzyl esulfonate (23.53 g, 68.8 mmol) and potassium phthalimide (14.00 g, 75.7 mmol) in 90 mL of DMF was reacted at room temperature for 16 hr and at 50-60 0C for 3 hr. The mixture was cooled, diluted with 350 mL H20, and ted with EA (3x400 mL). The c phases were washed with H20 (3x200 mL) and brine (2x200 mL), dried over anhydrous NazSO4, and concentrated to give a ess solid. The solid was broken up and washed with 10% EA/Hex to give 11.40 g of solid as a colorless solid. The washes were partially concentrated to give an additional 6.95 g of colorless solid. Rf0.50 (20% EA/Hex); 1H NMR (CDClg) 8 7.84 and 7.70 (m, 4H, AA’BB’), 7.21 (m, 1H), 7.00—6.96 (m, 2H), 6.79 (m, 1H), 4.81 (s, 2H, AB), 3.92 (t, 2H, J=6.6 Hz), 1.74 (m, 2H), 1.43 (m, 2H), 1.30—1.26 (m, 12H), 0.88 (m, 3H); 13C NMR(CDC13) 5 168.2, 159.6, 137.9, 134.2, 132.4, 129.9, 123.6, 120.8, 114.8, 114.1, 68.2, 41.8, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 29.5, 26.2, 22.9, 14.3. [3—(Decyloxy)phenyl]methanamine Hydrazine monohydrate (3.90 mL, 80.3 mmol) was added in three portions to a mixture of N—[3—(decyloxy)benzyl]phthalimide (5.12 g, 13.0 mmol) and IPA heated at re?ux. After the starting material was consumed as observed by TLC (30 hr), the mixture was cooled and concentrated. The residue was partitioned between pyl acetate and % Na2C03 and brine, and the organic phases were dried over anhydrous NaZSO4 and trated. SPE, washing with 50% isopropyl acetate/Hex and then eluting with 3% MeOH/DCM + 2% TEA, gave ninhydrin (+) material. Partial tration and washing of the te with 5% N32CO3 and drying over NaZSO4 gave 3.25 g of yellow oil after drying in vacuo.
N—[3—(Decyloxy)benzyl]quinolin—4—amine A mixture of [3—(decyloxy)phenyl]methanamine (2.54 g, 9.66 mmol), 4—chloroquinoline (1.73 g, 10.62 mmol), and tripropylamine (4.00 mL, 21.0 mmol) in 65 mL of 1—pentanol was heated at re?ux for 16 hr. Analytical TLC ted a substantial quantity of unreacted [3—(decyloxy)phenyl]methanamine. 4—Chloroquinoline (0.85 g, .21 mmol) and tripropylamine (2.00 mL, 10.5 mmol) were added. After 24 hr, the mixture was cooled and 15 mL of 1N NaOH were added. The volatile components were evaporated, the residue was taken up in DCM and washed with 5% N32CO3, and the organic phase was dried over anhydrous Na2804 and evaporated onto silica gel. SPE, washing with 70% EA/Hex and eluting with 50% EA/Hex + 2% TEA, gave 2.62 g of white solid after crystallization from IPA.
Recrystallization from 30% EA/Hex gave 2.00 g of N-[3-(decyloxy)benzyl]quinolinamine as a white powdery solid. Rf 0.24 (50% EA/Hex + 2% TEA) 0.40 (10% MeOH/DCM); mp 71.0- 72.0 0C; 1H NMR ) 5 8.55 (d, 1H, J=5.1 Hz), 8.00 (m, 1H), 7.77 (m, 1H), 7.64 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 7.43 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 7.28 (m, 1H), 6.97—6.93 (m, 2H), 6.85 (dd, 1H, J=1.8, 8.1 Hz), 6.45 (d, 1H, J=5.5 Hz), 5.38 (m, 1H, NH), 4.49 (m, 2H, AB), 3.94 (m, 2H), 1.77 (m, 2H), 1.42 (m, 2H), 1.34—1.26 (m, 10H), 0.87 (m, 3H); 159.9, 151.4, 149.6, 148.7, 139.3, 130.3, 130.2, 129.2, 125.0, 119.7, 119.5, 18.95, 114.1, 113.8, 99.6, 68.3, 47.8, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 26.3, 22.9, 14.3.
Example 70: N—(3—Phenoxybenzyl)quinolin—4—amine 2014/013992 3—Phenoxybenzyl methanesulfonate A mixture of 3—phenoxybenzyl alcohol (15.44 g, 77.2 mmol) and TEA (13.1 mL, 93.4 mmol) in 180 mL of THE and 100 mL of EA was cooled using an ice bath. Then, methanesulfonyl chloride (6.60 mL, 84.4 mmol) was added. A white precipitate formed rapidly. After 2 hr, 5 mL of H20 were added, and the volatile components were evaporated. The residue was partitioned between EA (3x300 mL) and H20, saturated NaHCOg, H20, 0.1M HCl, and brine (100 mL each). The combined organic phases were dried over NaZSO4, filtered h a pad of silica gel, and concentrated to give 22.02 g of colorless oil. Rf0.38 (30% EA/Hex); 1H NMR (CDC13) 8 7.4—7.3 (m, 3H), 7.2-7.1 (m, 2H), 7.1-7.0 (m, 4H), 5.2 (m, 2H, AB), 2.9 (s, 3H); 13C NMR (CDC13) 5 158.0, 156.7, 135.5, 130.4, 130.1, 124.0, 123.4,119.5,119.4,118.8, 71.0, 38.4.
N—(3—Phenoxybenzyl)phthalimide A mixture of 3—phenoxybenzyl methanesulfonate (22.5 g, 80.9 mmol) and potassium phthalimide (16.4 g, 88.6 mmol) in 200 mL of NMP was stirred at 50 0C for 17 hr using a mechanical stirrer. Then, H20 (100 mL) was added, and the volatile material was ated. The residue was partitioned between EA and 5% Na2C03 (2x), H20, 0.1M HCl, and brine. The c phases were dried over Na2SO4, filtered through a pad of silica gel, and concentrated. Crystallization from IPA gave 23.55 g of colorless solid. Rf 0.53 (30% EA/Hex); 1H NMR(CDC13) 5 7.85 and 7.73 (m, 4H, AA’BB’), .24 (m, 3H), 7.15-7.07 (m, 3H), 6.99—6.97 (m, 2H), 6.88—6.85 (m, 1H), 4.82 (m, 2H, AB); 13C NMR(CDC13) 5 168.1, 157.6, 157.1, 138.4, 134.5, 134.2, 132.2, 130.2. 129.9, 123.8, 123.6, 123.6, 123.2, 119.1. 119.1, 118.1, 41.4. noxyphenyl)methanamine Hydrazine drate (3.50 mL, 72.1 mmol) was added to a mixture of N—(3—phenoxybenzyl)phthalimide (6.28 g, 19.1 mmol) and 200 mL of IPA while using mechanical stirring. The mixture was heated at re?ux for 7 hr. After standing overnight, a precipitate had formed. The mixture was concentrated by evaporation, and the residue was partitioned between isopropyl acetate and 5% N32C03 and brine. The organic phases were dried over NagSO4, filtered, and concentrated. SPE, washing with 50% isopropyl acetate/Hex and then eluting with 3% CM + 2% TEA gave fractions that contained ninhydrin (+) t.
The combined product fractions were washed with 5% N32CO3, dried over NaZSO4, filtered, and concentrated to give 3.25 g of yellow oil. Rf 0.28 (10% MeOH/DCM); 1H NMR (CDC13) 5 7.36— 7.25 (m, 3H), 7.12—6.95 (m, 5H), 6.87 (ddd, 1H, J=l.0, 2.5, 8.2 Hz), 3.82 (br s, 2H), 2.15 (br s, 2H, NH;).
N—(3—Phenoxybenzyl)quinolin—4—amine (3—Phenoxyphenyl)methanamine (2.02 g, 10.2 mmol) was taken up in 60 mL of l—pentanol, and then 15 mL of volatile material was removed by distillation. The mixture was cooled below boiling, and tripropylamine (3.80 mL, 19.9 mmol) and roquinoline (1.65 g, 10.2 mmol) were added. Heating at re?ux was d. After 66 hr, volatile material was removed by evaporation. The e was partitioned between DCM (150, 100 mL) and 5% N32CO3 (80 mL). The combined organic phases were dried over Na2S04, filtered, and concentrated to give a solid. Recrystallization from EA/Hex gave 2.08 g of colorless solid. Rf0.34 (10% MeOH/DCM); mp 640 0C; 1H NMR (CDC13) 5 8.54 (d, 1H, J=5.5 Hz), 8.00 (m, 1H), 7.76 (d, 1H, J=8.1 Hz), 7.64 (m, 1H), 7.43 (m, 1H), 7.34-7.29 (m, 3H), 7.11 (m, 1H), 7.05 (s, 1H), 7.02-6.99 (m, 2H), 6.94 (dd, 1H, J=2.2, 8.0 Hz), 6.42 (d, 1H, J=5.5 Hz), .46 (br s, 1H, NH) 4.51 (m, 2H, AB); 13C NMR(CDC13)5158.2, 156.9, 151.3, 149.5, 148.7, 139.9, 130.5, 130.3, 130.0, 129.3, 125.0, 123.8, 122.2, 119.5, 119.3, 118.9, 118.0, 117.8, 99.7, 47.4.
Example 71: N-[3—(Benzyloxy)benzy1]quinolin—4—amine 3—(Benzyloxy)benzonitrile A mixture of oxybenzonitrile (504 mg, 4.24 mmol), benzyl chloride (607 mg, 4.78 mmol), and K2C03 (605 mg, 4.38 mmol) in 2 mL of DMF reacted for 42 hr. The mixture was diluted with 50% EA/Hex and washed with 5% N32CO3 (2x) and brine made acidic with 1M HCl. The organic phase was dried over anhydrous MgSO4 and concentrated. FC (15% EA/Hex) gave 780 mg of colorless oil. Rf 0.50 (20% EA/Hex); 1H NMR (CDClg) 5 7.43—7.31 (m, 6H), 7.26—7.17 (m, 3H), 5.08 (m, 2H, AB).
WO 20995 [3—(Benzyloxy)phenyl]methanamine A mixture of 3—(benzyloxy)benzonitrile and 30 mL of THF was cooled by an ice path. LAH (195 mg and then 190 mg) was added. The mixture was allowed to warm to room temperature. After 24 hr, the mixture was cooled by an ice bath, and 0.40 mL H20, 0.40 mL 15% NaOH, and 1.2 mL H20 were added in succession. The geneous mixture was diluted with 5% MeOH/DCM and preloaded on silica gel. SPE, washing with 5% MeOH and eluting with 10% MeOH/DCM + 2% TEA gave 672 mg of colorless oil that solidified upon ng. 1H NMR (CDCl3) 5 7.48—7.23 (m, 6H), 6.98-6.83 (m, 3H), 5.07 (m, 2H, AB), 3.83 (m, 2H, AB).
N—[3—(Benzyloxy)benzyl]quinolin—4—amine (600 mg) was prepared from [3— (benzyloxy)phenyl]methanamine (670 mg, 3.14 mmol), roquinoline (767 mg, 4.70 mmol), and DIEA (1.20 mL, 6.88 mmol) in 0.5 mL DMF heated in a sealed tube. FC (7% MeOH/DCM) gave 600 mg of product. Rf 0.38 (10% MeOH/DCM); 1H NMR (CDCl3) 5 8.43 (d, 1H, J=5.4 Hz), 8.01-7.96 (m, 2H), 7.62-7.56 (m, 1H), 7.40-7.22 (m, 7H), 6.99-6.88 (m, 3), 6.53 (br s, 1H, NH), 6.34 (d, 1H, J=5.5 Hz), 4.99 (s, 2H), 4.48 (m, 2H, AB).
Example 72: N-(3-Phenethoxybenzyl)quinolinamine N—(3—Phenethoxybenzyl)quinolin—4—amine was prepared by the method for N—[3— (benzyloxy)benzyl]quinolin—4—amine starting with 3-hydroxybenzonitrile (561 mg, 4.71 mmol), 2—bromoethylbenzene (1.34 g, 7.24 mmol), and K2C03 (1.00 g, 7.25 mmol) in 2 mL of DMF heated at 60 OC. 3—(Phenethoxy)benzonitrile (454 mg): Rf 0.46 (20% EA/Hex): 1H NMR (CDC13) 8 7.38—7.20 (m, 7H), 7.10 (m, 2H), 4.18 (t, 2H, J=6.9 Hz), 3.11 (t, 2H, J=6.9 Hz). (3—(Phenethoxyphenyl)methanamine (480 mg): 1H NMR (CDC13) 5 7.36—7.20 (m, 6H), 6.87 (m, 2H), 6.78 (m, 1H), 4.18 (t, 2H, J=7.2 Hz), 3.82 (m, 2H, AB), 3.10 (t, 2H, J=7.2 Hz), 2.16 (br s, 2H, NH;).
N—(3—Phenethoxybenzyl)quinolin—4—amine (358 mg): Rf 0.12 (5% MeOH/DCM); 1H NMR (CDC13) 5 8.39 (d, 1H, J=5.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.91 (d, 1H, J=8.4 Hz), 7.59 (m, 1H), 7.38 (m, 1H), 7.31—7.18 (m, 6H), 6.94—6.90 (m, 2H), 6.80 (dd, 1H, J=2.4, 8.1 Hz), 6.35 (d, 1H, J=5.5 Hz), 6.26 (br s, 1H), 4.48 (m, 2H, AB), 4.12 (t, 2H, J=7.0 Hz), 3.05 (m, 2H).
Example 73: N—[4—(Quinolin—4—ylamino)butyl]benzamide N N1-(Quinolinyl)butane-1,4-diamine A mixture of 1,4-butanediamine (1.54 g, 17.5 mmol), 4-chloroquinoline (357 mg, 2.19 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated at 130 0C in a sealed tube for 24 hr. The mixture was cooled, taken up in EA, and washed with 5% Na2C03 (3x) and brine. The organic phase was dried over NaZSO4 and concentrated. 1H NMR (20% CD3OD/CDC13) 5 8.33 (d, 1H, J=5.5 Hz), 7.86 (ddd, 1H, J=0.5, 1.5, 8.4 Hz), 7.81 (ddd, 1H, J=0.5, 1.2, 8.4 Hz), 7.53 (ddd, 1H, J=1.3, 6.7, 8.4 Hz), 7.33 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.29 (d, 1H, J=5.5 Hz), 3.20 (m, 2H), 2.66 (t, 2H, J=6.9 Hz), 1.69 (m, 2H), 1.51 (m, 2H).
N—[4—(Quinolin—4—ylamino)butyl]benzamide inolin—4—yl)butane—1,4—diamine (185 mg, 0.86 mmol) was taken up in 5 mL of pyridine, and the mixture was concentrated. The residue was taken up in 10 mL of DCM, cooled by an ice bath, and TEA (0.49 mL, 3.5 mmol) and then benzoyl chloride (0.40 mL, 3.43 mmol) were added. The mixture was allowed to warm to room temperature. After 2 hr, 3.43 mL of 1N NaOH were added, and the le ents were removed by distillation. The residue was partitioned between EA and 5% Na2C03 and brine. The organic phases were dried over NaZSO4 and concentrated. SPE, washing with 5% MeOH/DCM and eluting with 15% CM, gave an oily solid. Repurification by preparative TLC (15% CM) gave the product as a solid. Rf 0.21 (15% MeOH/DCM); 1H NMR (CDC13) 8 8.31 (d, 1H, J=5.7 Hz), 8.10 (m, 1H), 7.80-7.77 (m, 3H), 7.62 (ddd, 1H, J=l.2, 6.6, 8.4 Hz), 7.55—7.39 (m, 4H), 6.51 (d, 1H, J=5.5 Hz), 3.45 (q, 2H, J=7 Hz), 1.86-1.76 (m, 4H).
Example 74: N—[6—(Quinolin—4—ylamino)hexyl]benzamide /\/\/\/N N N1—(Quinolin—4—yl)hexane—1,6—diamine A mixture of 1,6—hexanediamine (2.05 g, 17.7 mmol) and 4—chloroquinoline (297 mg, 1.82 mmol) was heated at 130 0C in a sealed tube for 24 hr. The mixture was cooled, partitioned between EA (3x) and 5% Na2C03 (3x) and brine. The organic phases were dried over NaZSO4 and concentrated. 1H NMR (20% CDC13) 5 8.39 (d, 1H, J=5.4 Hz), 7.87 (d, 1H, J=8.1 Hz), 7.75 (d, 1H, J=8.4 Hz), 7.56 (ddd, 1H, J=1.3, 6.9, 8.4 Hz), 7.36 (m, 1H), 6.35 (d, 1H, J=5.4 Hz), 3.26 (m, 2H), 2.63 (m, 2H), 1.71 (m, 2H), 1.49-1.38 (m, 6H).
N—[6-(Quinolinylamino)hexyl]benzamide N1-(Quinolinyl)hexane-1,6-diamine (230 mg, 0.946 mmol) was taken up in 5 mL of pyridine, and the mixture was concentrated. The residue was taken up in 10 mL of DCM, cooled by an ice bath, and TEA (0.53 mL, 3.8 mmol) and then benzoyl chloride (0.44 mL, 3.78 mmol) were added. The mixture was allowed to warm to room temperature. After 2 hr, 3.78 mL of 1N NaOH were added. The e was partitioned between DCM and 5% N212C03. The organic phase was dried over NaZSO4 and concentrated. cation by preparative TLC (15% MeOH/DCM) gave the product. The residue from tration of the eluate was taken up in DCM, washed with 5% N32C03, dried over NaZSO4 and concentrated to give the product. Rf 0.23 (15% MeOH/DCM); 1H NMR (CDCl3) 5 8.30 (d, 1H, J=6.0 Hz), 8.09 (d, 1H, J=8.4 Hz), 7.91 (d, 1H, J=8.4 Hz), 7.82—7.78 (m, 2H), 7.55 (m, 1H), 7.45—7.30 (m, 4H), 6.94 (t, 1H, J=6 Hz), 6.81 (br s, 1H), 6.24 (d, 1H, J=6.2 Hz), 3.40 (m, 2H), 3.25 (m, 2H), 1.68— 1.54 (m, SH).
Example 75: N—[8—(Quinolin—4—ylamino)octyl]benzamide HN/VW\/ C6? 0 N—(8—Aminooctyl)benzamide A mixture of 1,8—octanediamine (3.27 g, 22.7 mmol) and methyl benzoate (0.40 mL, 3.20 mmol) was heated at 115 0C for 24 hr. The mixture was cooled and ioned between EA and H20. The organic phase, which contained a 1:1 molar ratio of diamine and monoamide, was concentrated. Reverse—phase SPE, washing with 20% MeOH/HZO and eluting with MeOH, gave the product fraction, which was concentrated, taken up in DCM, washed with 5% N32CO3, dried over NaZSO4, and concentrated to give 698 mg of product. 1H NMR (20% CD3OD/CDC13) 5 7.64-7.59 (m, 2H), 7.43 (br s, 1H, NH), .18 (m, 3H), 3.19 (m, 2H), 2.45 (m, 2H), 1.42 (m, 2H), 1.27-1.04 (m, 10H).
N—[8-(Quinolinylamino)octyl]benzamide A mixture of N-(8-aminooctyl)benzamide (357 mg, 1.44 mmol), 4-chloroquinoline (312 mg, 1.91 mmol), and DIEA (0.50 mL, 2.87 mmol) in 1 mL of NMP was heated at 160 °C in a sealed tube for 24 hr. The mixture was cooled, diluted with DCM, and washed with 5% . The organic phase was dried over NaZSO4 and concentrated. SPE, washing with 5% MeOH/DCM and eluting with 2.5% MeOH/DCM + 2% TEA, gave the product as an oil, which was crystallized from EtOH. Rf 0.33 (50% EA/Hex + 2% TEA); lH NMR(CDC13)5 8.33 (d, 1H, J=5.7 Hz), 7.87 (dd, 1H, J=0.7, 8.4 Hz), 7.80 (d, 1H, J=8.7 Hz), 7.74—7.71 (m, 2H), 7.58 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.48-7.34 (m, 4H), 6.38 (d, 1H, J=5.7 Hz), 3.38—3.26 (m, 4H), .35 (m, 12H).
Example 76: 3—Methoxy—N—[8—(quinolin—4—ylamino)octyl]benzamide HNW OCH3 C09 0 N—(8—Aminooctyl)—3—methoxybenzamide A mixture of methyl 3—methoxybenzoate (863 mg, .20 mmol) and l,8—octanediamine (6.90 g) was heated at 110—120 0C for 24 hr. The mixture was cooled and ioned between EA (3x60 mL) and H20, 2.5% N32CO3 (3x), and brine (60 mL each). The organic phases were dried over anhydrous NaZSO4 and concentrated. NMR showed the residue consisted of 2.3:1 ratio of amide and diamine. Reverse—phase SPE (ODS—silica gel), washing with 20% MeOH/HZO and then eluting with MeOH, gave 1.43 g yellow oil. NMR showed the oil consisted of 7.3:1 ratio of amide and diamine. 3—Methoxy—N—[8—(quinolin—4—ylamino)octyl]benzamide A mixture of N—(8—aminooctyl)—3— ybenzamide (540 mg, 1.94 mmol), 4—chloroquinoline (340 mg, 2.08 mmol), and DIEA (0.80 mL, 4.59 mmol) in 2.5 mL of NMP was heated at 160 0C in a sealed tube for 3 days. The e was cooled, diluted with EA, washed with 5% N32C03 and brine, dried over NaZSO4, and trated. SPE, washing with 1% MeOH/DCM and then eluting with 7.5% MeOH/DCM + 2% TEA, gave the product as a solid. Rf 0.19 (EA + 2% TEA); mp 162-165 0C (from MeOH); 1H NMR (20% CD3OD/CDC13) 8 8.38 (d, 1H, J=5.7 Hz), 8.04 (d, 1H, J=8.4 Hz), 7.92 (d, 1H, J=8.4 Hz), 7.57 (m, 1H), 7.40-7.21 (m, 4H), 6.95 (ddd, 1H, J=1.2, 2.7, 8.1 Hz), 6.85 (m, 1H), 6.36 (d, 1H, J=5.7 Hz), 6.31 (br s, 1H, NH), 3.75 (s, 3H), 3.41-3.25 (m, 4H), 1.72-1.16 (m, 12H).
Example 77: 4-Methoxy—N—[8—(quinolin—4—ylamino)octy1]benzamide HNWNYO/OCH3H Cd 0 N—(8—Aminooctyl)—4—methoxybenzamide A mixture of methyl 4—methoxybenzoate (874 mg, .26 mmol) and 1,8—octanediamine (6.18 g) was heated at 110—120 0C for 4 days. The mixture was cooled and partitioned between EA (3x60 mL) and H20, 2.5% N32CO3 (3x), and brine (60 mL each). The c phases were dried over anhydrous NaZSO4 and trated. Reverse— phase SPE (ODS—silica gel), washing with 20% MeOH/HZO and then eluting with MeOH, gave an oil. The oil was taken up in DCM and washed with 5% N32CO3, dried over Na2804, and concentrated to give 533 mg of sticky yellow solid. 1H NMR (CD3OD) 5 7.77 and 6.96 (m, 4H, AA’BB’), 4.88 (s, 3H), 3.34 (m, 2H), 3.13 (m, 1H, NH), 2.60 (m, 2H), 1.91 (2xs, 2H, N?z), 1.62—1.33 (m, 12H). 4—Methoxy—N—[8—(quinolin—4—ylamino)octyl]benzamide A mixture of N—(8—aminooctyl)—4— methoxybenzamide (533 mg, 1.92 mmol) and 7.5 mL of anhydrous ne was evaporated to dryness. Then, roquinoline (335 mg, 2.08 mmol) and DIEA (0.80 mL, 4.59 mmol) in 2.5 mL of NMP was added and the mixture was heated at 160 0C in a sealed tube for 3 days. The mixture was cooled, diluted with EA, washed with 5% N32C03 and brine, dried over NaZSO4, and concentrated. SPE, g with 1% MeOH/DCM and then g with 7.5% MeOH/DCM + 2% TEA, gave the product as a solid. Rf 0.00 (5% MeOH/DCM) 0.20 (EA + 2% TEA) ; 1H NMR (20% CD3OD/CDC13) 5 8.30 (d, 1H, J=5.7), 7.82—7.76 (m, 2H), 7.65 and 6.82 (m, 4H, AA’BB’), 7.53 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.33 (ddd, 1H, 121.2, 6.9, 8.4 Hz), 6.32 (d, 1H, J=5.5 Hz), 3.74 (s, 3H), 3.32-3.19 (m, 4H), .25 (m, 12H).
Example 78: 2-(Hexyloxy)-N—[2-(quinolinylamino)ethyl]benzamide \ OO\/\/\/ Methyl 2—(hexyloxy)benzoateA mixture of methyl salicylate (7.76 g, 51.1 mmol), K2C03 (8.8 g, 64 mmol), and 1—bromohexane (8.60 mL, 61.5 mmol) in 30 mL of DMF was heated at 50 0C for .5 hr. The e was partitioned between 1:1 EA/Hex (3x150 mL) and 0.2M HCl, 0.1M HCl, and brine (50 mL of each). The organic phases were dried over NaZSO4 and concentrated.
SPE, washing with Hex and eluting with 20% EA/Hex, gave 11.7 g colorless liquid.
N—(2—Aminoethyl)—2—(hexyloxy)benzamide A mixture of methyl 2—(hexyloxy)benzoate (2.11 g, 8.94 mmol) and 1,2—ethanediamine (5.40 mL, 81.0 mmol) was heated at 115 0C in a sealed tube for 72 hr. Then, the volatile components were evaporated in vacuo. The residue was taken up in mL of MeOH and evaporated in vacuo to give 2.34 g amber liquid. 1H NMR (CDgOD) 8 7.84 (m, 1H), 7.45 (ddd, lH, J=1.9, 7.4, 9.2 Hz), 7.09 (d, 1H, J=8.1Hz), 7.02 (m, 1H), 4.13 (t, 2H, J=6.5 Hz), 3.47 (m, 2H), 2.84 (m, 2H), 1.86 (m, 2H), 1.49 (m, 2H), 1.39—1.34 (m, 4H), 0.93 (m, 3H); 13C NMR (CD3OD) 5 169.0, 158.5, 134.1, 132.0, 123.7, 122.0, 114.0, 70.4, 43.5, 42.3, 32.9, 30.4, 27.2, 23.9, 14.6. 2—(Hexyloxy)—N—[2—(quinolin—4—ylamino)ethyl]benzamide N—(2—Aminoethyl)—2— (hexyloxy)benzamide (2.34 g, 8.86 mmol) was taken up in 65 mL of l—pentanol, and 15 mL was removed by distillation. The mixture was cooled slightly, and tripropylamine 3.40 mL, 17.8 mmol) and 4—chloroquinoline (1.60 g, 9.82 mmol) were added. The mixture was heated at re?ux for 63 hr. Then, the mixture was concentrated in vacuo. The residue was partitioned between DCM and 5% N212CO3, and the organic phase was dried over NaZSO4 and concentrated. FC (5% MeOH/DCM + 2% TBA) gave 1.84 g of brown syrup, which solidified upon standing. The solid was rinsed with 20%, 33%, and 50% EtzO/Hex and dried in vacuo to give 1.67 g of solid. Rf0.30 (5% MeOH/DCM + 2% TEA); 1H NMR (CDC13)8 8.56-8.51 (m, 2H), 8.28 (dd, 1H, J=1.8, 8.1 Hz), 7.92 (d, 1H, J=8.8 Hz), 7.60 (m, 1H), 7.46-7.41 (m, 2H), 7.08 (m, 1H), 6.93 (d, 1H, J=8.0 Hz), 6.77 (br s, 1H, NH), 6.33 (d, 1H, J=5.1 Hz), 4.06 (t, 2H, J=6.6 Hz), 3.90 (m, 2H), 3.50 (m, 2H), 1.77 (m, 2H), 1.42—1.23 (m, 6H), 0.87 (t, 3H, J=7 Hz); 13C NMR(CDC13) 8 168.1, 157.3, 151.2, 150.3, 148.6, 133.5, 132.5, 129.8, 129.1, 124.9, 121.5, 120.9, 120.6, 119.1, 112.5, 98.1, 69.3, 46.1, 39.1, 31.5, 29.2, 26.0, 22.7, 14.2.
Example 79: 2—(Hexyloxy)—N—[3—(quinolin—4—ylamino)propyl]benzamide HNMH%O\ yloxy)—N—[3—(quinolin—4—ylamino)propyl]benzamide (1.6 g) was prepared by the method for yloxy)—N—[4—(quinolin—4—ylamino)butyl]benzamide, ng with methyl 2— oxy)benzoate (2.13 g) and l,3—diaminopropane (6.00 mL) and using 4—chloroquinoline (1.70 g). minopropyl)—2—(hexyloxy)benzamide: 1H NMR (CDC13) 5 7.85 (dd, 1H, J=1.8, 7.7 Hz), 7.44 (ddd, 1H, J=1.8, 7.3, 9.2 Hz), 7.10 (d, 1H, J=8.4 Hz), 7.02 (m, 1H), 4.14 (m, 2H), 3.48 (m, 2H), 3.30 (m, 2H), 2.72 (m, 2H), 1.86 (m, 2H), 1.75 (m, 2H), 1.40-1.35 (m, 4H), 0.93 (m, 3H); 13C NMR (CDC13) 5 168.8, 158.5, 134.1, 132.0, 123.6, 122.0, 114.0, 70.4, 40.0, 38.2, 33.9, 32.9, .4, 27.2, 23.9, 14.6. 2—(Hexyloxy)—N—[3—(quinolin—4—ylamino)propyl]benzamide: Rf 0.08 (5% MeOH/DCM); 1H NMR ) 5 8.50 (d, 1H, J=5.5 Hz), 8.25 (dd, 1H, J=1.8, 7.7 Hz), 8.24-8.20 (m, 1H), 8.01— 7.98 (m, 1H), 7.93 (dd, 1H, J=0.7, 8.4 Hz), 7.58 (ddd, 1H, J=1.1, 7.0, 8.1 Hz), 7.44-7.36 (m, 2H), 7.10—7.06 (m, 1H), 6.92 (d, 1H, J=8.1 Hz), 6.49—6.46 (t, 1H, J=6 Hz, NH), 6.39 (d, 1H, J=5.5 Hz), 4.03 (t, 2H), 3.63-3.59 (m, 2H), 3.46-3.42 (m, 2H), 2.64 (br s, 1H, NH), 1.95-1.89 (m, 2H), .74 (m, 2H), 1.45-1.27 (m, 6H), 0.89-0.86 (m, 3H); 13C NMR(CDC13) 5 166.8, 157.2, 151.0, 150.0, 148.7, 133.1, 132.4, 129.7, 129.1, 124.7, 121.4, 21.3, 120.4, 119.3, 112.4, 98.3, 69.2, 39.6, 39.6, 36.8, 31.6, 29.3, 28.7, 26.0, 22.7, 14.1.
Example 80: 2-(Hexyloxy)-N-[4-(quinolinylamino)buty1]benzamide HNWNWKQH \ OO\/\/\/ N—(4—Aminobutyl)—2—(hexyloxy)benzamide A mixture of 1,4—diaminobutane (5.37 g, 61 mmol) and methyl 2-(hexyloxy)benzoate (1.80 g, 7.63 mmol) was heated at 110 0C in a sealed tube for 48 hr. The mixture was partitioned between isopropyl acetate (3x125 mL) and H20 (100 mL), 5% N32C03 (2x100 mL), and brine (100 mL). The organic phases were dried over anhydrous Na2804 and trated to give 2.10 g of colorless syrup. 1H NMR (CDC13) 5 8.15 (dd, 1H, J=7.7, 1.8 Hz), 8.01 (br s, 1H), 7.33 (ddd, 1H, J=9.2, 7.3, 1.8 Hz), 6.98 (m, 1H), 6.88 (d, 1H, J=8.4 Hz), 4.04 (m, 2H), 3.41 (m, 2H), 2.68 (m, 2H), 1.80 (m, 2H), 1.59 (m, 2H), 1.52-1.40 (m, 4H), 1.32—1.25 (m, 4H), 1.12 (br, s, 2H), 0.86 (m, 3H); 13C NMR (CDC13) 5 165.3, 157.0, 132.6, 132.2, 121.6, 121.1, 112.2, 69.0, 42.0, 39.6, 31.6, 31.3, 29.3, 27.1, 26.0, 22.6, 14.0. yloxy)—N—[4—(quinolin—4—ylamino)butyl]benzamide N—(4—Aminobutyl)—2— (hexyloxy)benzamide was taken up in 60 mL of 1—pentanol, and 15 mL of volatile liquid was removed by distillation. The mixture was cooled slightly, and tripropylamine (2.70 mL, 14.2 mmol) and 4—chloroquinoline (1.29 g, 7.91 mmol) were added. Heating at re?ux was resumed for 42 hr. The cooled mixture was concentrated and partitioned n DCM and 5% N212CO3, and the organic phase was dried over anhydrous NaZSO4 and concentrated. The residue was taken up in EA and then concentrated again. The resulting oil solidified upon standing. The solid was broken up and washed with 20%, 50%, and 100% x. Drying in vacuo gave 1.53 g of yellow—gray solid. Rf 0.21 (5% MeOH/DCM + 2% TEA); 1H NMR (CD3OD) 8 8.53 (d, 1H, J=5.5 Hz), 8.24 (dd, 1H, J=1.9, 7.7 Hz), 8.16 (m, 1H, NH), 7.95 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=8.4 Hz), 7.61 (m, 1H), 7.44-7.38 (m, 2H), 7.07 (m, 1H), 6.94 (d, 1H, J=8.4 Hz), 6.41 (d, 1H, J=5.1 Hz), 5.44 (br s, 1H, NH), 4.08 (m, 2H), 3.57 (m, 2H), 3.39 (m, 2H), 1.91-1.75 (m, 6H), 1.44 (m, 2H), 1.34-1.27 (m, 4H), 0.86 (m, 3H); 13C NMR (CDC13) 5 165.9, 157.2, 151.2, 149.9, 148.7, 133.0, 132.5, 130.1, 129.1, 124.8, 121.5, 121.4, 119.8, 119.0, 112.4, 98.9, 69.2, 43.2, 39.3, 31.7, 29.4, 28.0, 26.2, 26.1, 22.8, 14.2.
Example 81: N-[8-(Quinolinylamino)octyl]picolinamide H | /\/\/\/\/N \ HN \n/(Nj cm 0 N—(8—Aminooctyl)picolinamide A e of 1,8-octanediamine (8.19 g, 56.9 mmol) and methyl picolinate (970 mg, 7.08 mmol) was heated at 130 0C for 60 hr. The mixture was cooled, taken up in methanol, and evaporated onto silica gel. The pre—loaded silica gel was loaded on top of a ?ash column and eluted using 15% MeOH/DCM + 2% TEA. Concentration of the product— containing fractions gave 1.28 g of liquid. Rf 0.23 (15% MeOH/DCM + 2% TEA); 1H NMR (20% CD3OD/CDC13) 5 8.5 (ddd, 1H, J=1.0, 1.7, 4.9 Hz), 8.2 (m, 1H), 8.0 (br s, 1H, NH), 7.8 (m, 1H), 7.4 (ddd, 1H, J=1.5, 4.9, 7.7 Hz), 3.43 (m, 2H), 2.66 (m, 2H), 2.17 (br s, 2H,NH2), 1.65- 1.28 (m, 12H).
N—[8—(Quinolin—4—ylamino)octyl]picolinamide A mixture of minooctyl)picolinamide (557 mg, 2.24 mmol), 4—chloroquinoline (544 mg, 3.34 mmol), DlEA (1 mL, 6 mmol) and 0.5 mL of DMF was heated at 140 0C in a sealed tube for 89 hr. Then, the volatile components were evaporated, and the residue was purified by EC (8% MeOH/DCM) to give 520 mg of product. Rf 0.38 (10% MeOH/DCM); 1H NMR (CDC13) 5 8.6 (d, 1H), 8.4 (d, 1H), 8.1 (d, 1H), 9 (m, 3H), 7.7 (m, 1H), 7.5 (m, 1H), 7.30 (m, 1H), 6.3 (d, 1H), 3.4-3.3 (m, 4H), 1.7 (m, 2H), 1.5 (m, 2H), 1.3—1.0 (m, 8H).
Example 82: N—[8—(Quinolin—4—ylamino)octyl]nicotinamide WWH \ IN CKE O N N—(8-Aminooctyl)nicotinamide A mixture of 1,8-diaminooctane (9.78 g, 67.0 mmol) and methyl nicotinate (1.50 g, 10.9 mmol) was heated at 84 0C for 16 hr and 110-120 0C for an additional 56 hr. The cooled mixture was ted by SPE, washing with 5% MeOH/DCM + 2% TEA to remove the octane-1,8-bis(amide) and residual methyl nicotinate and then with 15% MeOH/DCM + 2% TEA to elute ninhydrin (+) product fractions. The product fractions were concentrated, taken up in DCM, washed with 5% N212C03, dried over Na2804, filtered, and dried to give 2.07 g of pale yellow solid. Rf 0.10 (15% MeOH/DCM + 2% TEA); 1H NMR (CD3OD) 5 8.95 (dd, 1H, J=0.8, 2.2 Hz), 8.67 (m, 1H), 8.23 (m, 1H), 7.53 (m, 1H), 3.38 (t, 2H, J=7.3 Hz), 2.60 (t, 2H), 1.61 (m, 2H), 1.47—1.33 (m, 10H); 13C NMR (CD3OD) 8 167.8, 152.7, 149.2, 137.1, 132.4, 125.3, 42.8, 41.3, 34.1, 30.7, 30.6, 28.2, 28.2, 22.2.
N—[8—(Quinolin—4—ylamino)octyl]nicotinamide N—(8—aminooctyl)nicotinamide (5.66 g, 22.7 mmol) was taken up in 100 mL of 1—pentanol, and then 50 mL of le material was d by lation. The mixture was cooled below boiling, and tripropylamine (9.50 mL, 49.8 mmol) and 4—chloroquinoline (4.08 g, 25.0 mmol) were added. Heating at re?ux was resumed. After 22 hr, volatile material was removed by evaporation. The mixture was partitioned between DCM (175, 2x100 mL) and a combination of 25 mL of 1N NaOH and 25 mL of 5% N32CO3. The combined organic phases were dried over , filtered, and concentrated to give a dark syrup. Two crystallizations from MeOH/HZO and drying in vacuo over P205 gave 2.31 g of tan solid. Rf0.56 (15% MeOH/DCM + 2% TEA); mp 1395-1410 0C; 1H NMR (DMSO-dg) 5 8.97 (m, 1H), 8.66 (m, 1H), 8.61 (t, 1H, J=5.5 Hz), 8.35 (d, 1H, J=5.1 Hz), 8.19 (d, 1H, J=8.8 Hz), 8.14 (ddd, 1H, J=1.4, 2.2, 7.7 Hz), 7.74 (dd, 1H, J=1.1, 8.5 Hz), 7.57 (m, 1H), 7.46 (m, 1H), 7.38 (ddd, 1H, J=1.4, 7.0, 8.4 Hz), 7.16 (t, 1H, J=5 Hz), 6.40 (d, 1H, J=5.5 Hz), 3.27-3.22 (m, 4H), 1.65 (m, 2H), 1.44 (m, 2H), 1.30 (m, 8H); 13C NMR (DMSO-d6) 5 164.6, 151.6, 150.4, 150.2, 148.3, 148.0, 134.8, 130.1, 128.7, 123.7, 123.4, 121.7, 118.8, 98.0, 42.4, 39.2, 29.0, 28.8, 28.7, 27.8, 26.6, 26.4.
Example 83: N—[8—(Quinolin—4—ylamino)octyl]isonicotinamide / WH\I“ N—(8-Aminooctyl)isonicotinamide A mixture of 1,8-diaminooctane (7.66 g, 53 mmol) and methyl isonicotinate (910 mg, 6.64 mmol) was heated at 130 0C for 60 hr. The cooled mixture was partitioned between DCM and 5% N32C03, and the organic phase was dried over ous NazSO4 and concentrated. FC (15% MeOH/DCM + 2% TEA) gave 539 mg of oily solid. Rf0.15 (15% CM + 2% TEA); 1H NMR (20% CD3OD/CDC13) 5 8.59 and 7.66 (m, 4H, AA’BB’), 3.33 (m, 2H), 3.10 (m, 1H, NH), 278 (m, 2H), 1.85 (s, 2H, N?z), 1.57—1.24 (m, 12H).
N—[8—(Quinolin—4—ylamino)octyl]isonicotinamide A mixture of N—(8— ctyl)isonicotinamide (539 mg, 2.16 mmol), 4—chloroquinoline (536 mg, 3.29 mmol), DIEA (2 mL, 12 mmol) and 0.5 mL of DMF was heated at 140 0C in a sealed tube for 89 hr.
Then, the volatile components were evaporated, and the residue was purified by EC (8% MeOH/DCM) to give 113 mg of product. Rf 0.13 (10% MeOH/DCM); 1H NMR (20% CD30D/CDC13) 5 8.58 and 7.62 (m, 4H, AA’BB’), 8.35 (d, 1H, J=5.4 Hz), 7.83 (dd, 1H, 120.7, 2014/013992 8.4 Hz), 7.71 (m, 1H), 7.55 (ddd, 1H, J=1.3, 7.0, 8.2 Hz), 7.35 (ddd, 1H, J=1.2, 6.9, 8.4 HZ), 6.34 (d, 1H, J=5.5 Hz), 3.37—3.21 (m, 4H), 1.70—1.22 (m, 12H).
Example 84: N—(Pyridin—4—ylmethyl)quinolin—4—amine HN /| /|\N N—(Pyridin—4—ylmethyl)quinolin—4—amine was prepared following the method for idin—2— ylmethyl)quinolin—4—amine. Rf 0.29 (5% MeOH/DCM + 2% TEA);1H NMR (CDCl3) 5 8.51—8.47 (m, 2H), 8.39 (d, 1H, J=5.4 Hz), 8.03-8.00 (m, 1H), 7.95 (dd, 1H, J=1.0, 8.4 Hz), 7.59 (ddd, 1, J=1.2, 6.9, 8.4 Hz), 7.40 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.28-7.22 (m, 2H), 6.61 (br s, 1H), 6.19 (d, 1H, J=5.4 Hz), 4.56 (br s, 2H).
Example 85: N—(Pyridinylmethyl)quinolinamine HN /| /|\N N—(Pyridinylmethyl)quinolinamine was prepared following the method for N—(pyridin ylmethyl)quinolin-4—amine. Rf 0.36 (5% MeOH/DCM + 2% TEA);1H NMR (CDC13) 8 8.56 (d, 1H, J=2.0 Hz), 8.45 (dd, 1H, J=1.7, 5.0 Hz), 8.41 (d, 1H, J=5.2 Hz), 7.98 (d, 1H, J=8.4 Hz), 7.91 (dd, 1H, J=1.0, 8.4 Hz), 7.61 (ddd, 1H, J=1.7, 2.0, 7.9 Hz), 7.54 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 7.33 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.17 (dd, 1H, 125.0, 7.9 Hz), 6.61 (br s, 1H), 6.29 (d, 1H, J=5.5 Hz), 4.50 (m, 2H, AB).
Example 86: N—(Pyridin—2—ylmethyl)quinolin—4—amine HN /| A mixture of 4—chloroquinoline (228 mg, 1.40 mmol), 2—(aminomethyl)pyridine (144 mg, 1.33 mmol), and DIEA (0.50 mL) was heated at 130 0C in a sealed tube for 48 hr. Then, the mixture was cooled, partitioned between EA and 5% Na2C03 and brine, dried over NaZSO4, and concentrated. FC (3% MeOH/DCM + 2% TEA) gave product—containing fractions, which were concentrated. The residue was taken up in DCM and washed with 5% N32CO3, dried over NaZSO4, and trated to give the product. Rf0.54 (5% MeOH/DCM + 2% TEA); 1H NMR (CDC13) 5 .54 (m, 1H), 8.46 (d, 1H, J=5.4 Hz), 7.99-7.91 (m, 2H), .52 (m, 2H), 7.37 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.26-7.23 (m, 1H), .13 (m, 1H), 7.03 (br s, 1H), 6.32 (d, 1H, J=5.4 Hz), 4.52 (m, 2H, AB).
Example 87: N—Hexquuinolin—4—amine @j/N A mixture of 4-chloroquinoline (248 mg, 1.52 mmol) and 1-hexylamine (2 mL, 15 mmol) was heated in a sealed tube at 100 °C for 2 days, 120-130 0C for 2 days, and 150 0C for 1 day. The mixture was cooled and partitioned between EA and 5% Na2C03 and brine, and the organic phase was dried over Na2804 and concentrated in vacuo. SPE, washing with 25% EA/Hex and eluting with 12% MeOH/DCM, followed by repurification by preparative TLC (10% MeOH/DCM), gave the product as an oil. Rf 0.16 (5% MeOH/DCM); 1H NMR (CDC13) 8 8.48 (d, 1H, J=5.4 Hz), 7.97 (dd, 1H, J=1.0, 8.4 Hz), 7.8? (d, 1H, J=8.4 Hz), 7.60 (ddd, 1H, 121.5, 6.9, 8.4 Hz), 7.40 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.40 (d, 1H, J=5.7 Hz), 5.66 (br s, 1H, NH), 3.32 (m, 2H), 1.75 (m, 2H), 1.46—1.26 (m, 6H), 0.89 (m, 3H).
Example 88: N—(Decyl)quinolin—4—amine :jkT/ A mixture of 1—aminodecane (4.36 g, 27.8 mmol), tripropylamine (8.00 mL, 42.0 mmol), and 4— chloroquinoline (4.55 g, 27.9 mmol) in 25 mL of l—pentanol was heated at re?ux for 3 days. 2014/013992 Then, the volatile components were evaporated. The e was take up in DCM (150 mL) and washed with 5% N32CO3 (100 mL). The aqueous phase was extracted with DCM (100 mL), and the combined organic phases were dried over , filtered, and concentrated to give a dark . SPE, eluting with 1% and then 5% MeOH/DCM + 2% TEA, gave product fractions that were concentrated, ioned between DCM (150, 100 mL) and 5% N32CO3 (100 mL), dried over NagSO4, filtered, and concentrated. Recrystallization from EA/Hex gave 4.14 g colorless solid. Rf0.30 (5% MeOH/DCM + 2% TEA); mp 79.0-80.0 0C; 1H NMR (CDCl3) 5 8.56 (d, 1H, J=5.5 Hz), 7.97 (dd, 1H, J=1.1, 8.4 Hz), 7.72 (m, 1H), 7.62 (ddd, 1H, J=l.4, 7.0, 8.4 Hz), 7.41 (m, 1H), 6.43 (d, 1H, J=5.5 Hz), 4.97 (br s, 1H, NH), 3.31 (m, 2H), 1.76 (m, 2H), 1.46 (m, 2H), 1.39—1.27 (m, 12H), 0.88 (m, 3H); 13C NMR (CDC13) 5 152.2, 149.9, 149.6, 129.2, 128.2, 125.0, 122.7, 121.0, 102.4, 62.0, 51.8, 32.6, 28.0, 25.7, 22.4, 14.0.
Example 89: N—(Dodecyl)quinolin—4-amine A mixture of 4-chloroquinoline (3.25 g, 19.9 mmol), l-dodecylamine (3.80 g, 20.5 mmol), and tripropylamine (5.90 mL, 30.9 mmol) in 30 mL of l-pentanol was heated at re?ux for 16.5 hr.
Then, the volatile components were evaporated in vacuo. The residue was partitioned between DCM (150, 100 mL) and a mixture of 1N NaOH and 5% Na2C03 (20 mL each). The organic phases were dried over NaZSO4 and concentrated. Crystallization from ice—cold 10% EA/Hex, washing the collected solid with ice—cold 20% EtzO/Hex, gave 4.95 g colorless solid (mp 81.5- 82.0 0C). LC/MS (230 nm) indicated the presence of 5-10% impurity. SPE (1% TEA/EA) ted an impurity with predominantly aryl hydrogens by NMR. The product was tallized from ice—cold 10% EA/Hex to give 4.70 g colorless solid. Rf 0.12 (10% MeOH/DCM); mp 80.5—81.5 0C; 1H NMR(CDC13)5 8.56 (d, 1H, J=5.1 Hz), 7.97 (dd, 1H, J=1.1, 8.4 Hz), 7.72 (m, 1H), 7.62 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 7.42 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 6.42 (d, 1H, J=5.5 Hz), 4.98 (br s, 1H, NH), 3.31 (m, 2H), 1.76 (p, 2H, J=7.3 Hz), 1.47 (m, 2H), 1.38—1.26 (m, 16H), 0.88 (t, 3H, J=6.8 Hz);13C NMR (CDC13) 5 151.3, 149.8, 148.7, 130.3, 2014/013992 129.1, 124.7, 119.3, 118.9, 99.0, 43.5, 32.1, 29.8, 29.8, 29.8, 29.8, 29.6, 29.5, 29.2, 27.4, 22.9, 14.3.
Example 90: N1,NS—Di(quinolin—4—yl)octane—1,8—diamine HN \ CE? I” A mixture of 1,8—octanediamine and excess 4—chloroquinoline and DIEA in NMP was heated at 160 0C in a sealed tube for 3 days. The mixture was cooled and purified by SPE, washing with 1% MeOH/DCM and then eluting with 7.5% MeOH/DCM + 2% TEA to give the product as a solid. Rf0.05 (EA + 2% TEA); 1H NMR (20% CD3OD/CDC13) 5 8.32 (d, 2H, J=5.7 Hz), 7.85— 7.80 (m, 4), 7.58 (ddd, 2H, J=1.2, 6.9, 8.2 Hz), 7.38 (ddd, 2H, J=1.2, 6.9, 8.4 Hz), 6.37 (d, 2H, J=5.7 Hz), 3.38-3.25 (m, 4H), 1.73-1.24 (m, 12H).
Example 91: N-[8-(Hexyloxy)octyl]quinolinamine 8—(Hexyloxy)octanoic acid imately 6.0 mL of Jones reagent was added to a mixture of 8—(hexyloxy)octan—1—ol (2.1 g, 9.1 mmol) and 50 mL of DCM cooled by an ice bath, after which the green color of the mixture did not persist. Then, the mixture was washed with H20 and 0.1M HCl, and the organic phase was dried over MgSO4, d with 5 mL of MeOH, filtered through a pad of silica gel, washing the pad with 5% MeOH/DCM, and concentrated. EC (5% MeOH/DCM) gave 1.6 g of product. Rf 0.3 (5% MeOH/DCM); 1H NMR (CDClg) 8 3.4 (t, 4H), 2.3 (m, 2H), 1.7—1.4 (m, 6H), 1.4—1.2 (m, 12H), 0.9 (m, 3H). 8—(Hexyloxy)—N—(quinolin—6—yl)octanamide A mixture of 6—aminoquinoline (0.5 g, 3.5 mmol), 8—(hexyloxy)octanoic acid (847 mg, 3.47 mmol), l—hydroxybenzotriazole (469 mg, 3.47 mmol), 4—dimethylaminopyridine (42 mg, 0.3 mmol), and EDC (663 mg, 3.47 mmol) in 20 mL of DCM was reacted until the starting material was consumed, as ed by TLC. Then, the volatile ents were evaporated, and the residue was ioned between EA and H20, 5% N32CO3, H20, and brine, and the organic phases were dried over NaZSO4 and concentrated. FC (50% EA/Hex) gave 225 mg of the t. Rf 0.4 (50% EA/Hex); 1H NMR (CDC13) 5 8.8 (m, 1H), 8.4 (m, 1H), 8.15 (m, 1H), 8.05 (m, 1H), 7.9 (br s, 1H, NH), 7.6 (m, 1H), 7.4 (m, 1H), 3.4 (t, 4H), 2.4 (t, 2H), 1.7 (m, 2H), 1.6-1.4 (m, 4H), 1.4—1.2 (m, 12H), 0.85 (m, 3H).
N—[8—(Hexyloxy)octyl]quinolin—6—amine A mixture of 8—(hexyloxy)—N—(quinolin—6— yl)octanamide (171 mg, 0.46 mmol) and 20 mL of THF was cooled by an ice bath before 70 mg of lithium aluminum hydride was added. The mixture was allowed to warm slowly to room temperature overnight. Then, the mixture was recooled, and 0.7 mL of H20, 0.7 mL of 15% NaOH, and 2.1 mL of H20 were added cautiously. The mixture was filtered through a pad of Celite, washing with 5% MeOH/DCM, and the filtrate was concentrated. The residue was partitioned between EA and 5% Na2C03 and brine, and the organic phase was dried over Na2$O4 and concentrated. FC (50% EA/Hex) gave 100 mg of the product. Rf 0.3 (50% EA/Hex); 1H NMR(CDC13) 5 8.6 (m, 1H), 7.95-7.85 (m, 2H), 7.3 (m, 1H), 7.1 (m, 1H), 7.7 (m, 1H), 3.4 (t, 4H), 3.2 (t, 2H), 2 (m, 20H), 0.85 (t, 3H).
Example 92: N-[8—(Hexyloxy)octy1]quinolin—3—amine \ N\/\/\/\/\O/\/\/\ N—[8—(Hexyloxy)octyl]quinolin—3—amine (66 mg) was prepared following the method for N—[8- (hexyloxy)octyl]quinolin—6—amine starting with 3—aminoquinoline (728 mg). 8—(Hexyloxy)—N—(quinolin—3—yl)octanamide: 1H NMR (CDClg) 5 9.05 (br s, 1H), 8.95 (br, s, 1H), 8.5 (br s, 1H, NH), 8.1 (d, 1H), 7.8 (d, 1H), 5 (m, 2H), 3.4 (m, 4H), 2.5 (t, 2H), 1.8 (m, 2H), 1.7—1.2 (m, 16H), 0.85 (t, 3H). 206—181 N—[8—(Hexyloxy)octyl]quinolin—3—amine 1H NMR ) 5 8.6 (d, 1H), 8.0 (d, 1H), 7.6 (d, 1H), 7.5-7.3 (m, 2H), 7.0 (m, 1H), 4.3 (br s, 1H, NH), 3.5-3.3 (m, 4H), 3.2 (m, 2H), 1.8—1.2 (m, 20H), 0.9 (m, 3H).
Example 93: N—[8—(Hexyloxy)octyl]quinolin—8—amine /\/O\/\/\/ \ N—[8—(Hexyloxy)octyl]quinolin—8—amine (58 mg) was prepared following the method for N—[8— (hexyloxy)octyl]quinolin—6—amine ng with 8—aminoquinoline (472 mg). 8—(Hexyloxy)—N—(quinolin—8—yl)octanamide: Rf 0.7 (10% EA/Hex); 1H NMR (CDC13) 5 9.8 (br s, 1H, NH), 8.85—8.75 (m, 2H), 8.2 (m, 1H), 7.6—7.4 (m, 3H), 3.4 (m, 4H), 2.6 (t, 2H), 1.8 (m, 2H), 1.7-1.2 (m, 16H), 0.9 (m, 3H).
Hexyloxy)octyl]quinolinamine: Rf 0.6 (50% EA/Hex); 1H NMR (CDClg) 8 8.7 (d, 1H), 8.1 (br s, 1H), 7.5-7.3 (m, 2H), 7.0 (d, 1H), 6.7 (d, 1H), 3.5-3.3 (m, 4H), 3.3 (m, 2H), 1.8 (m, 2H), 1.7-1.2 (m, 18H), 0.9 (m, 3H).
Example 94: N—[8—(Hexyloxy)octy1]—2—(trifluoromethyl)quinolin—4—amine /\/\/\/\/ \/\/\/O N CF3 A mixture of 8—(hexyloxy)octan—1—amine (350 mg, 1.53 mmol), 4—chloro—2— trifluoromethquuinoline (420 mg, 1.81 mmol) and TEA (0.32 mL, 1.84 mmol) in 1 mL of NMP was heated at 150 0C for 16 hr. The mixture was cooled and partitioned between EA and 5% NaZCO3. The organic phases were washed with brine, dried over NaZSO4, and concentrated.
Purification by preparative TLC gave the product. Rf 0.38 (20% EA/Hex); 1H NMR (CDC13) 5 8.01 (m, 1H), 7.75 (d, 1H, J=8.4 Hz), 7.62 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.42 (ddd, 1H, J=1.2, 7.0, 8.4 HZ), 6.65 (s, 1H), 5.45 (m, 1H, NH), 3.38—3.34 (m, 4H), 3.27 (m, 2H), 1.76—1.18 (m, 20H), 0.85 (m, 3H).
Example 95: 7—Chloro—N—decquuinolin—4—amine HN/\/\/\/\/\ CI N/ 7—Chloro—N—decquuinolin—4—amine (8.10 g) was prepared following the method for 7—chloro—N— dodecquuinolin—4—amine, starting with 5.18 g of l—decylamine and 6.53 g of 4,7— dichloroquinoline. Mp 1025-1030 0C x); 1H NMR (CDC13) 5 88.5 (d, 1H, J=5.5 Hz), 7.9 (d, 1H, J=1.9 Hz), 7.6 (d, 1H, J=8.8 Hz), 7.3 (m, 1H), 6.4 (d, 1H, J=5.5 Hz), 5.1 (br m, 1H, NH), 3.3 (m, 2H), 1.7 (m, 2H), 1.5-1.3 (m, 14H), 0.8 (m, 3H); 13C NMR(CDC13) 5 152.2, 149.9, 149.4, 134.9, 129.0, 125.4, 121.1, 117.3, 99.2, 43.5, 32.1, 29.7, 29.7, 29.6, 29.5, 29.1, 27.3, 22.9, 14.3.
Example 96: 7-Chloro-N—dodecquuinolinamine CI N A mixture of l-dodecylamine (4.57 g, 24.7 mmol), tripropylamine (9.4 mL, 49 mmol), 4,7— roquinoline (4.89 g, 24.7 mmol) and 50 mL of l-pentanol were heated at re?ux for 22 hr.
Then, the volatile components were ated. The residue was partitioned between EA and 5% N32C03 and brine, and the organic phase was dried over NaZSO4 and concentrated. SPE (50% EA/Hex) gave the product as a yellow solid. The t was taken up in DCM, washed with 5% N32C03, dried over NaZSO4, and concentrated. The product was crystallized from ice—cold 20% EA/Hex to give 7.50 g colorless solid. Rf 0.30 (50% EA/Hex); mp 95.0—97.0 0C; 1H NMR (CDC13)5 8.5 (d, 1H, J=5.1 Hz), 7.9 (d, 1H, J=1.9 Hz), 7.6 (d, 1H, J=8.8 Hz), 7.3 (m, 1H), 6.39 (d, 1H, J=5.5 Hz), 5.0 (br m, 1H, NH), 3.3 (m, 2H), 1.8 (m, 2H), 1.5-1.2 (m, 20H, 0.9 (m, 3H); WO 20995 2014/013992 13C NMR(CDCl3)5152.3, 149.9, 149.4, 135.0, 129.1, 125.4, 121.0, 117.3, 99.3, 43.5, 32.1, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 29.1, 27.3, 22.9, 14.3.
Example 97: N—(Decyl)quinazolin—4—amine HN/V\/\/\/\ A mixture of 4—chloroquinazoline (6.90 g, 42.1 mmol), l—decylamine (10.8 mL, 54.3 mmol), and TEA (8.90 mL, 62.7 mmol) in 50 mL of IPA was heated at re?ux for 6 hr, then d to stand overnight. Then, the volatile components were evaporated, and the residue was taken up in DCM and washed with a mixture of 20 mL of 1N NaOH and 20 mL of 5% Na2C03. The organic phase was dried over ous NaZSO4 and filtered through a pad of silica gel, washing with 5% MeOH/DCM. The filtrate was concentrated to give a solid. The solid was washed with 25 mL and 10 mL portions of 20% EtZO/Hex, then dried in vacuo to give 11.22 g of colorless solid. Rf 0.41 (10% MeOH/DCM); mp 72.5-73.0 0C; 1H NMR (CDCl3) 5 8.66 (s, 1H), 7.82 (dd, 1H, J=1.1, 8.8 Hz), 7.73-7.69 (m, 2H), 7.44 (m, 1H), 5.83 (br s, 1H, NH), 3.65 (m, 2H), 1.72 (m, 2H), 1.46-1.25 (m, 14H), 0.86 (t, 3H, J=7.0 Hz); 13C NMR(CDC13) 8 159.7, 155.7, 149.6, 132.7, 128.8, 126.1, 120.6, 115.2, 41.6, 32.1, 29.8, 29.7, 29.6, 29.5, 27.6, 22.9, 14.3.
Example 98: cquuinazolin—4—amine /\/\/\/\/\/\ 1—Dodecylamine (4.20 g, 22.7 mmol) was taken up in 45 mL of IPA, and 10 mL was removed by distillation. Then, the mixture was cooled slightly, and TEA (6.5 mL, 46 mmol) and 4— chloroquinazoline (3.72 g, 22.7 mmol) were added. The mixture was heated at reflux for 7 hr.
Then, most of the volatile components were removed by distillation. The residue was partitioned between DCM (150, 100 mL) and a mixture of 1N NaOH and 5% N32CO3 (20 mL each). The organic phases were dried over NaZSO4 and concentrated. SPE (30, 50, and 60% EA/Hex step gradient) gave product—containing fractions that were concentrated, taken up in DCM, washed with 5% N32CO3, dried over NaZSO4, and concentrated to a syrup. Crystallization from ice—cold % EA/Hex gave 6.05 g colorless solid. Rf 0.20 (50% EA/Hex); mp 74.0—75.0 0C; 1H NMR (CDC13) 5 866 (s, 1H), 7.82 (m, 1H), 7.74-7.69 (m, 2H), 7.45 (m, 1H), 5.76 (br s, 1H, NH), 3.65 (m, 2H), 1.72 (m, 2H), 1.46-1.25 (m, 18H), 0.87 (m, 3H); 13C NMR (CDC13) 5 159.6, 155.7, 149.6, 132.7, 128.9, 126.1, 120.6, 115.1, 41.6, 32.1, 29.8, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 27.3, 22.9, 14.3.
Example 99: N—Decyl—7—?uoroquinazolin—4—amine /W\/\/\ F N A mixture of 1—decylamine (1.2 mL, 6.0 mmol), 4—chloro—7—?uoroquinazoline (1.1 g, 6.0 mmol), and TEA (1.3 mL, 9.3 mmol) in 10 mL of IPA was heated at re?ux for 6 hr. Then, the volatile components were evaporated, and the residue was partitioned between DCM (400, 300 mL) and % N32C03 (400 mL). The organic phases were dried over anhydrous NaZSO4, filtered through a pad of silica gel, g with 10% MeOH/DCM, and concentrated. The t was crystallized from EA/Hex. e 100: N—Dodecy1—7—f1uoroquinazolinamine /\/\/\/\/\/\ F N cyl-7—?uoroquinazolin—4—amine was made from 1—dodecylamine (1.2 mL, 5.2 mmol), 4- chloro—7—?uoroquinazoline (1.0 g, 5.5 mmol), and TEA (1.2 mL, 8.6 mmol) in 10 mL of IPA following the method for the preparation of N—decyl-7—?uoroquinazolin—4—amine. e 101: 7—Chloro—N—decquuinazolin—4—amine HN/\/\/\/\/\ 130”A CI N 7—Chloro— N—decquuinazolin—4—amine was made from 1—decylamine (1.5 mL, 7.0 mmol), 4,7— dichloroquinazoline (1.4 g, 7.0 mmol), and TEA (2.0 mL, 14 mmol) in 15 mL of IPA following the method for the preparation of N—decyl—7—?uoroquinazolin—4—amine.
Example 102: 7—Chloro—N—dodecquuinazolin—4—amine /\/\/\/\/\/\ D?”A Cl N 7-Chloro— cquuinazolin—4—amine was made from 1—dodecylamine (1.3 g, 7.0 mmol), 4,7— dichloroquinazoline (1.4 g, 7.0 mmol), and TEA (2.0 mL, 14 mmol) in 15 mL of IPA following the method for the preparation of N-decyl?uoroquinazolinamine.
Example 103: N-(6-Butoxyhexyl)quinazolinamine /\/\/\/ 6—Butoxyhexan-1—amine (7.20 g, 41.1 mmol) was taken up in 200 mL, and 50 mL was removed by distillation. The mixture was cooled ly, and TEA (17.4 mL, 124 mmol) and 4— chloroquinazoline (11.11 g, 67.7 mmol) were added. The e was heated at reflux for 38 hr, then allowed to stand at room temperature for 3 days. The volatile components were evaporated.
The residue was partitioned n DCM (150, 2x50 mL) and a mixture of 40 mL 1N NaOH and 40 mL of 5% Na2C03. The organic phases were dried over anhydrous NaZSO4 and evaporated onto silica gel. SPE, washing with 30% EA/Hex and eluting with 60% EA/Hex, gave a yellow syrup that crystallized from 10% EA/Hex at —20 0C to give 4.64 g of colorless solid. Rf 0.25 (50% EA/Hex); mp 40—46 0C; 1H NMR (CDClg) 5 8.64 (s, 1H), 7.84 (d, 1H, J=8.4 Hz), 7.78-7.70 (m, 2H), 7.46 (ddd, 1H, J=1.4, 7.3, 8.4 Hz), 6.12 (br s, 1H, NH), 3.66 (m, 2H), 3.41- 3.37 (m, 4H), 1.74 (m, 2H), 1.62-1.30 (m, 10H), 0.90 (t, 3H, J=7.3 C NMR (CDC13) 5 159.8, 155.2, 148.6, 133.0, 128.1, 126.3, 120.9, 115.0, 70.9, 70.9, 41.6, 32.0, 29.8, 29.4, 27.1, 26.2, 19.6, 14.1. e 104: N—[8—(Hexyloxy)octyl]quinazolin—4—amine HN/\/\/\/\/O\/\/\/ 8—(Hexyloxy)octan—l—ol tanediol (201.4 g, 1.38 mol) was taken up in 1.3 L of IPA, and 250 mL of volatile material was removed by distillation. The mixture was allowed to cool below boiling, and sodium metal (6.9 g, 0.30 mol) was added in portions while maintaining a blanket of argon. After the addition was completed, the mixture was boiled for one hour, and then it was d to stir at room temperature overnight. l-Bromohexane (32.2 mL, 0.23 mol) was added in a slow stream. After 25 hr, the mixture was warmed gently. Precipitate began to form. After 2 days of warming, the mixture was heated to distill 400 mL of volatile material.
Then, heating was halted, and 16 g of NH4Cl in 48 mL of H20 was added. After 1 hr, the distillation was resumed and 450 mL of distillate was collected. Heating was halted, and 214 g of silica gel was added to the hot e. The warm mixture was d well and cooled. The excess diol was removed by SPE using 30% EA/Hex, which afforded 25.9 g of light yellow oil containing the desired product. Rf 0.19 (20% EA/Hex); 1H NMR (CDCl3) 5 3.63-3.58 (m, 2H), 3.37 (t, 4H, J=6.7 Hz), 1.66 (br s, 1H, OH), 1.57—1.50 (m, 6H), 1.30—1.28 (m, 14H), 0.87 (t, 3H, J26.6 Hz). 1,8—Octanediol was recovered by eluting with 5% MeOH/DCM, evaporation of solvent, and crystallization of three crops from , which afforded 182.4 g of colorless solid. 8—(Hexyloxy)octyl methanesulfonate 8—(Hexyloxy)octan—1—ol was taken up in 250 mL of DCM and cooled using an ice bath. TEA (21.0 mL, 150 mmol) and methanesulfonyl chloride (10.5 mL, 134 mmol) were added in turn. After 1.25 hr, 20 g of ice chips were added. Most of the volatile material was evaporated. The residue was partitioned between 1:1 EA/Hex (3x300 mL) and H20, saturated NaHCOg, H2O, 1M HCl, H20, and brine (100 mL each). The combined organic phases were dried over Na2SO4, filtered through a pad of silica gel, and trated. Rf 0.28 (20% ); 1H NMR (CDCl3) 8 4.21 (t, 2H, J=6.6 Hz), 3.38 (t, 2H, J=6.4 Hz), 3.37 (t, 2H, J=6.7 Hz), 2.98 (s, 3H), 1.72 (m, 2H), 1.61—1.46 (m, 4H), 1.40-1.24 (m, 14H), 0.87 (t, 3H, J=6.8 Hz).
N—[8—(Hexyloxy)octyl]phthalimide Toluene (100 mL) was mixed with the crude 8— (hexyloxy)octyl methanesulfonate and then was evaporated. The residue was taken up in 120 mL of DMF and 60 mL of NMP. Potassium phthalimide (25.0 g, 135 mmol) was added. After mixing for 21.5 hr, 50 mL of H20 was added, and the volatile material was evaporated. The residue was partitioned between EA (3x300 mL) and H20 (150 mL), saturated NaHC03 (150 mL), and brine (2x150 mL). The ed organic phases were dried over Na2SO4, filtered through a pad of silica gel, and concentrated. Rf 0.50 (10% EA/Hex); 1H NMR (CDClg) 8 7.81 and 7.68 (m, 4H, AA’BB’), 3.65 (t, 2H, J=7.3 Hz), 3.36 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.7 Hz), .48 (m, 6H), 1.29-1.22 (m, 14H), 0.86 (t, 3H, J=6.8 Hz). 8-(Hexyloxy)octanamine IPA (100 mL) was mixed with the crude N—[8- (hexyloxy)octy1]phthalimide and then was evaporated. The residue was taken up in 450 mL of EtOH, hydrazine drate (6.60 mL, 136 mmol) was added, and the mixture was heated at re?ux overnight. The mixture was concentrated by lation of 300 mL of volatile material.
Heating was halted, 150 mL of 1M HCl was added to the hot mixture, and the mixture was allowed to cool. The itate was removed by ?ltration, and it was washed with 1:1 EtOH/H2O (2x100 mL). The filtrate was concentrated to 100 mL, and the pH was adjusted to >10 using NaOH pellets. The mixture was extracted with DCM (3x250 mL), and the combined c phases were dried over Na2SO4, filtered, and concentrated to give 27.6 g of cloudy liquid. 1H NMR (CDC13) 5 3.36 (t, 4H, J=6.7 Hz), 2.66 (t, 2H, J=6.9 Hz), 1.52 (m, 2H), 1.44— 1.28 (m, 18H), 0.86 (m, 3H).
N—[8—(Hexyloxy)octyl]quinazolin—4—amine Crude 8—(hexyloxy)octan—l—amine was taken up in 400 mL of IPA, and 250 mL of volatile material was removed by distillation. The mixture was cooled, and TEA (16.8 mL, 120 mmol) and 4—chloroquinazoline (9.8 g, 60 mmol) were added.
The mixture was heated at re?ux for 4 hr. TLC of an aliquot indicated a substantial ty of ninhydrin (+) material remained. TEA (11.2 mL, 80 mmol) and 4—chloroquinazoline (6.5 g, 38 mmol) were added. After 5 hr additional heating the mixture was allowed to cool and d 12 hr. Then, the volatile components were evaporated, and the e was partitioned between DCM (300, 2x150 mL) and 1N NaOH and 5% N32C03 (100 mL each). The combined organic phases were dried over NaZSO4, filtered, and concentrated. SPE, eluting with 20%, 30%, and 50% EA/Hex, gave product fractions that were combined and concentrated. The residue was taken up in 300 mL of EA, filtered, and concentrated. The resulting yellow solid was recrystallized twice from 10% EA/Hex to give 30.3 g of pale yellow solid. Rf 0.11 (40% EA/Hex); mp 67.0—67.5 °C; 1H NMR(CDC13)8 8.66 (s, 1H), 7.83 (d, 1H, J=7.8 Hz), 7.75—7.70 (m, 2H), 7.46 (m, 1H), 5.81 (br s, 1H, NH), 3.65 (dt, 2H, J=5.5, 7.4 Hz), 3.38 (t, 4H), 1.73 (m, 2H), 1.59-1.52 (m, 4H), 1.46-1.24 (m, 14H), 0.87 (t, 3H, J=6.9 Hz); 13C C13)8 159.7, 155.6, 149.4, 132.8, 128.7, 126.2, 120.6, 115.1, 71.2, 71.1, 41.7, 41.5, 31.9, 30.0, 29.6, 29.6, 29.5, 27.2, 26.4, 26.1, 22.8, 14.3.
Example 105: N-[8—(4—Methoxyphenoxy)octyl]quinazolin—4—amine HN/\/\/\/\/O\©\\ N OCH3 ethoxyphenoxy)octan—l—amine (4.03 g, 16.1 mm) was taken up in 125 mL of IPA, and 50 mL of volatile components were removed by distillation. The mixture was cooled slightly, and TEA (4.50 mL, 32.1 mmol) and roquinazoline (2.92 g, 17.7 mmol) were added. Heating at re?ux was d. After 24 hr, the mixture was allowed to cool, and 15 mL of 1N NaOH were added. The volatile components were evaporated. The residue was diluted with DCM, washed with 5% N32CO3, dried over anhydrous NaZSO4, and concentrated onto silica gel. SPE, washing with 50% EA/Hex and eluting with 40% EA/Hex + 2% TEA, gave product—containing fractions, which were concentrated, taken up in DCM, washed with 5% N32CO3, dried over anhydrous NaZSO4, and concentrated to give a yellow solid. Recrystallization form EA/Hex gave 3.93 g of white solid. Rf0.41 (50% EA/Hex + 2% TEA); mp 97.0—98.0 0C; 1H NMR (CDC13) 5 8.66 (s, 1H), 7.81 (dd, 1H, J=0.7, 8.4 Hz), 7.51 (m, 1H), 7.69 (ddd, 1H, J=l.5, 7.0, 8.5 Hz), 7.41 (ddd, 1H,J=1.5, 7.0, 8.4 Hz), 6.83—6.78 (m, 4H, AA’BB’), 6.09 (m, 1H, NH), 3.87 (t, 2H, J=6.6 Hz), 3.74 (s, 3H), 3.67 (m, 2H), 1.76-1.66 (m, 4H), 1.46—1.33 (m, 8H); 13C NMR ) 5 159.7, 155.6, 153.8, 153.4, 149.5, 132.6, 128.6, 126.0, 120.8, 115.6, 115.2, 114.8, 68.7, 55.9, 41.5, 29.5, 29.4, 29.4, 27.1, 26.1.
Example 106: N— { 2—[2— (Hexyloxy)phenoxy]ethyl}quinazolin—4—amine HN/\/0 N/ 2-[2-(Hexyloxy)phenoxy]ethanamine (15.32 g, 64.6 mmol) was taken up in 350 mL of IPA, and 50 mL was removed by distillation. The mixture was cooled slightly, and TEA (18.0 mL, 128 mmol) and 4-chloroquinazoline (11.0 g, 67.1 mmol) were added. The e was heated at re?ux for 16 hr. Then, the volatile components were ated and the residue was partitioned between DCM and 5% N32CO3 (500 mL of each). The organic phase was dried over N32804 and concentrated. The solid was recrystallized from EA/Hex to give 16.0 g of solid. 1H NMR (CDC13) 5 8.6 (s, 1H), 7.9—7.7 (m, 3H), 7.4 (m, 1H), 8 (m, 4H), 6.6 (br s, 1H, NH), 4.3 (m, 2H), 4.1—4.0 (m, 4H), 1.8 (m, 2H), 1.4 (m, 2H), 1.3—1.2 (m, 4H), 0.8 (m, 3H).
Example 107: N—{ 3—[2—(Hexyloxy)phenoxy]propyl}quinazolin—4—amine HNMO/g \ WV 2—(Hexyloxy)phenol A mixture of catechol (47.5 g, 432 mmol), l—bromohexane (71.2 g, 432 mmol), and K2C03 (71.5 g, 518 mmol) in 120 mL of NMP and 240 mL of DMF was heated at 60 0C for 24 hr. Then, the volatile components were evaporated, and the slurry was partitioned between EA (600, 2x250 mL) and H20, 5% NaZCO3 (2x), H20, 0.1M HCl, and brine (150 mL each). The organic phases were dried over NaZSO4 and evaporated onto silica gel. SPE (10% EA/Hex) gave 75.5 g of a colorless liquid that contained a 25:1 mole ratio of 2— oxy)phenol and l,2—bis(hexyloxy)benzene, as ated from the NMR spectrum. The reaction was repeated using catechol (71.68 g, 652 mmol), l—bromohexane (91.0 mL, 651 mmol), and K2CO3 (108 g, 783 mmol) in 240 mL of DMF at room temperature. The reaction gave 96.3 g pale yellow liquid that contained a 1:1 mole ratio of 2—(hexyloxy)phenol and 1,2— bis(hexyloxy)benzene.
N—{3—[2—(Hexyloxy)phenoxy]propyl}phthalimide A 1:1 mixture of 2—(hexyloxy)phenol and 1,2-bis(hexyloxy)benzene (47.2 g, 100 mmol of phenol), K2C03 (18.7 g, 136 mmol), and N-(3- bromopropyl)phthalimide (26.8 g, 100 mmol) in 100 mL of DMF was heated at 55 0C for 24 hr.
Then, the mixture was , and most of the le components were evaporated. The residue was partitioned between EA (3x250 mL) and H20 (3x200 mL), 0.05M HCl (2x150 mL), and brine (150 mL). The combined organic phases were dried over Na2804 and concentrated. SPE, washing with 5% EA/Hex to elute residual starting materials and then eluting the product with % EA/Hex, gave 29.8 g of white solid. Rf 0.41 (20% EA/Hex). 3—[2—(Hexyloxy)phenoxy]propan—1—amine A e of N—{3—[2— (hexyloxy)phenoxy]propyl}phthalimide (29.8 g, 78.2 mmol) and ine monohydrate (4.80 mL, 101 mmol) in 300 mL of EtOH was heated at re?ux for 16 hr. Then, heating was stopped, and 50 mL of 2M HCl was added. The slurry was mixed for 2 hr, then filtered through a pad of Celite, washing with 100 mL of 10% aqueous EtOH. The filtrate was adjusted to pH 10 using NaOH pellets and concentrated. SPE, washing with 3% MeOH/DCM and eluting with 8% MeOH/DCM + 2% TEA, gave 15.5 g of yellow oil.
WO 20995 3—[2—(Hexyloxy)phenoxy]propan—l—amine (15.5 g, 61.8 mmol) was taken up in 250 mL of IPA, and 50 mL was removed by distillation. The mixture was cooled slightly, and TEA (10.5 mL, 74.8 mmol) and 4—chloroquinazoline (l 1.1 g, 67.6 mmol) were added. The mixture was heated at re?ux for 16 hr. Then, most of the volatile components were evaporated, and the residue was partitioned between EA (300, 2x250 mL) and 5% N212CO3 and brine (150 mL each). The c phases were dried over anhydrous NaZSO4 and concentrated to a dark liquid. Trituration with two portions of ice—cold 50% EtzO/Hex gave 14.9 g of light tan solid. Rf 0.20 (50% EA/Hex + 2% TEA) 0.28 (5% MeOH/DCM + 2% TEA); mp 67.0—67.5 0C; 1H NMR (CDC13) 8 8.65 (s, 1H), 7.85—7.81 (m, 2H), 7.70 (ddd, 1H, J=1.5, 7.0, 8.4 Hz), 7.38 (ddd, lH, J=1.1, 6.9, 8.0 Hz), 7.11 (br s, 1H, NH), .89 (m, 4H), 4.24 (m, 2H), 4.04 (m, 2H), 3.93 (m, 2H), 2.24 (m, 2H), 1.71 (m, 2H), 1.37 (m, 2H), 1.23-1.17 (m, 4H), 0.81 (m, 3H); 13C NMR(CDC13)5159.7, 155.5, 149.5, 149.2, 148.6, 132.6, 128.3, 126.0, 122.5, 121.6, 121.3, 115.5, 115.3, 113.8, 70.5, 69.2, 40.9, 31.6, 29.2, 28.5, 25.8, 22.7, 14.1.
Example 108: N- { 4-[2-(Hexyloxy)phenoxy]butyl }quinazolinamine won\ N 4—[2—(Hexyloxy)phenoxy]butan—1—amine (13.82 g, 52.2 mmol) was taken up in 300 mL of IPA, and 50 mL was removed by distillation. Then, the mixture was cooled slightly, and TEA (15 mL, 107 mmol) and 4—chloroquinazoline (8.6 g, 52 mmol) were added. The mixture was heated at reflux for16 hr. Then, the volatile components were evaporated and the residue was partitioned between DCM and 5% N32CO3 (500 mL of each). The organic phase was dried over Na2$O4 and trated. The solid was recrystallized from EA/Hex to give 8.3 g of colorless solid. 2014/013992 Example 109: N—[8—(Quinazolin—4—ylamino)octyl]nicotinamide H | /\/\/\/\/N \ N N—(8—Aminooctyl)nicotinamide (2.60 g, 10.4 mmol) was taken up in 65 mL of IPA, and 30 mL of volatile components were removed by distillation. The mixture was cooled, and TEA (2.90 mL, .7 mmol) and 4—chloroquinazoline (1.88 g, 11.5 mmol) were added. The mixture was heated at re?ux for 6 hr. Then, the volatile components were evaporated, and the residue was partitioned between DCM and a mixture of 20 mL of 1N NaOH and 20 mL of 5% Na2C03. The dark aqueous phase was extracted with 40 mL of 1—butanol. The combined organic phases were concentrated. The residue was taken up in 10% MeOH/DCM + 2% TEA and filtered through a pad of silica gel. The filtrate was concentrated to give a dark solid. The solid was recrystallized from 10% aqueous MeOH, which removed some of the color. tallization from EtOH gave two crops of light tan solid with comparable 1H NMR spectra; the crops were combined to give 2.08 g with mp 173-176 °C and 67% purity by LC (230 nm). FC (10% to 12% CM step gradient) and recrystallization from IPA/H20 gave 1.52 g of pale yellow solid, 89% purity by LC (230 nm). Trituration with ice-cold Eth and then 30% EA/Hex at room temperature gave a solid with mp 1725-1760 °C and 90% purity by LC (230 nm). 1H NMR (40 oC, DMSO—dé) 8 8.96 (d, 1H, J=1.5 Hz), 8.66 (d, 1H, J=3.3 Hz), 8.56 (br s, 1H), 8.42 (s, 1H), 8.21—8.13 (m, 3H), 7.72 (m, 1H), 7.63 (m, 1H), 7.48—7.44 (m, 2H), 3.51 (m, 2H), 3.23 (m, 2H), 1.62 (m, 2H), 1.51 (m, 2H), 2 (m, 8H); 13C NMR (DMSO—d6) 8 164.6, 159.3, 155.1, 151.6, 149.0, 148.3, 134.8, 132.3, 130.1, 127.4, 125.4, 123.4, 122.6, 114.9, 40.4, 39.2, 29.0, 28.8, 28.7, 28.5, 26.5, 26.4.
Example 1 10: Hexyloxy)benzyl]quinazolin—4—amine CELEUOVWN/ xyloxy)phenyl]methanamine (18.5 g 89.3 mmol) was taken up in 300 mL of IPA, and 100 mL of volatile material was removed by lation. The mixture was cooled, and TEA (25.3 mL, 180 mmol) and 4—chloroquinazoline (16.1 g, 98.3 mmol) were added. The mixture was heated at re?ux for 5 hr, and then stirred at room temperature overnight. Then, the volatile ents were evaporated, and the residue was taken up in DCM (200 mL) and washed with 1N NaOH (100 mL). The aqueous phase was extracted with DCM (100 mL). The combined organic phases were dried over NaZSO4, filtered, and concentrated to give a red—brown solid.
SPE, eluting with 20%, 30%, and 50% EA/Hex, gave product fractions that were combined and concentrated to yield a brown solid. Recrystallization from EA/Hex gave 21.8 g of the product as a colorless solid. Rf0.2l (50% EA/Hex); mp 1060—1070 0C; 1H NMR (CDC13) 5 8.69 (s, 1H), 7.84 (d, 1H), 7.74-7.71 (m, 2H), 7.44 (m, 1H), 7.25 (m, 1H), 6.96-6.93 (m, 2H), 6.83 (dd, 1H, J=2.2, 8.5 Hz), 6.18 (br s, 1H), 4.83 (m, 2H, AB), 3.92 (t, 2H, J=6.6 Hz), 1.75 (m, 2H), 1.42 (m, 2H), 1.33—1.28 (m, 4H), 0.89 (m, 3H); 13C NMR (CDC13) 5 159.8, 159.5, 155.8, 149.6, 139.7, 132.9, 130.1, 128.8, 126.3, 120.8, 120.2, 115.0, 114.5, 113.8, 68.2, 45.5, 31.8, 29.4, 25.9, 22.8, 14.2. e 1 1 1: N-[3-(Decyloxy)benzyl]quinazolinamine HNUOWWV (3—(Decyloxy)phenyl)methanol A mixture of 3-hydroxybenzyl alcohol (36.2 g, 292 mmol), 1—bromodecane (55.5 mL, 269 mmol), and K2CO3 (44.3 g, 321 mmol) in 60 mL of NMP and 120 mL of DMF was mixed at 60 0C for 2 days with the aid of a mechanical r. Then, the volatile components were removed in vacuo. The resulting slurry was partitioned between 50% EA/Hex (300, 2x250 mL) and H20 (400 mL), 0.2N NaOH (150 mL), H20 (150 mL), 2M HCl (150 mL), H20 (150 mL), and brine (150 mL). The organic phases were dried over anhydrous NaZSO4, filtered through a pad of silica gel, and concentrated to 67.8 g of amber oil. The oil solidified exothermically. NMR indicated the presence of residual odecane and EA. 1H NMR (CDC13)5 7.2 (m, 1H), 6.9 (m, 2H), 6.8 (m, 1H), 3.9 (br s, 2H, AB), 3.9 (t, 2H, J=6.6 HZ), 2.6 (br s, 1H, OH), 1.8 (m, 2H), 1.5 (m, 2H), 1.4—1.2 (m, 12H), 0.9 (m, 3H); 13C NMR ) 5 159.5, 142.7, 129.6, 119.0, 113.8, 113.0, 68.1, 65.2, 32.0, 29.8, 29.7, 29.6, 29.5, 29.4, 26.2, 22.8, 14.3. 1—(Chloromethyl)—3—(decyloxy)benzene A mixture of [3—(decyloxy)phenyl]methanol (58.4 g, 221 mmol) and 150 mL of toluene was added dropwise to a mixture of thionyl de (19.4 mL, 266 mmol) and 50 mL of toluene. During the addition, gas evolution was observed. After 16 hr, the mixture was heated at re?ux. After 1 hr, 150 mL of volatile al was removed by distillation. Then, the remaining volatiles were evaporated in vacuo.
N—[3—(Decyloxy)benzyl]phthalimide The residue was taken up in 120 mL of DMF and 60 mL of NMP, potassium phthalimide (49.2 g, 266 mmol) was added, and the mixture was heated at 60 0C for 24 hr. Then, the mixture was cooled and partitioned between 50% EA/Hex and H20 (2x), 0.1M HCl, and brine. The organic phases were dried over Na2804, filtered through a pad of silica gel, and concentrated to 90.4 g of amber oil. 1H NMR (CDCl3) 5 7.8 and 7.7 (m, 4H, ), 7.2 (m, 1H), 7.0 (m, 2H), 6.8 (m, 1H), 4.8 (s, 2H), 3.9 (t, 2H, J=6.6 Hz), 1.7 (m, 2H), 1.4 (m, 2H), 2 (m, 12H), 0.9 (m, 3H); 13C NMR(CDC13) 5 168.2, 159.6, 137.9, 134.2, 132.3, 129.9, 123.6, 120.8, 114.8, 114.1, 68.2, 41.8, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 26.2, 22.9, 14.3. [3—(Decyloxy)phenyl]methanamine IPA (50 mL) was mixed with the residue and then evaporated to remove residual EA. The residue was taken up in 400 mL of EtOH, ine monohydrate (14.5 mL, 299 mmol) was added, and the mixture was heated at re?ux. After 6 hr, the mixture was cooled, and 150 mL of 2M HCl was added. The solid precipitate was broken up to form a slurry, which was filtered and washed with 20% aqueous IPA. The filtrate was adjusted to pH 10 by adding NaOH pellets. Then, the e was concentrated. The resulting liquid was partitioned between DCM and 5% N212C03, and the organic phase was dried over anhydrous Na2804 and concentrated.
N—[3-(Decyloxy)benzyl]quinazolin—4—amine Crude [3—(decyloxy)phenyl]methanamine was taken up in 400 mL of IPA, and 100 mL of volatile components were removed by distillation. The WO 20995 mixture was allowed to cool slightly. TEA (39 mL, 278 mmol) and 4—chloroquinazoline 22.4 g, 136 mmol) were added. The mixture was heated at re?ux for 20 hr. Then, the mixture was allowed to cool, and the volatile components were evaporated. The mixture was partitioned between DCM (350, 2x100 mL) and 2N NaOH (150 mL). The organic phases were dried over anhydrous NaZSO4, 150 mL of MeOH were added, and the mixture was ed through a pad of silica gel. The filtrate was concentrated to give a pink solid. The solid was tallized from EA/Hex to give a lightly colored solid. The solid was recrystallized from IPA to give 43.4 g of colorless solid. Rf0.47 (10% MeOH/DCM); mp 93.0—95.5 0C; 1H NMR (CDCI3) 5 8.71 (s, 1H), 7.86 (d, 1H, J=8.4 Hz), 7.76-7.68 (m, 2H), 7.46 (m, 1H), 7.27 (m, 1H), 6.98-6.94 (m, 2H), 6.84 (m, 1H), 5.95 (br s, 1H, NH), 4.84 (m, 2H, AB), 3.94 (t, 2H, J=6.6 Hz), 1.77 (m, 2H), 1.43 (m, 2H), 1.29—1.26 (m, 12H), 0.87 (m, 3H); 13C NMR(CDC13) 5 159.8, 159.4, 155.6, 149.8, 139.8, 132.9, 130.1, 128.9, 126.3, 120.7, 120.2, 115.0, 114.6, 113.8, 68.3, 45.6, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 26.3, 22.9, 14.3.
Example 1 12: N-(3-Phenoxybenzyl)quinazolinamine HN/\©/O\©\ N | N/) noxyphenyl)methanamine (1.55 g, 7.79 mmol) was taken up in 60 mL of IPA, and 15 mL of volatile material was removed by distillation. The mixture was cooled, and TEA (1.50 mL, .7 mmol) and 4—chloroquinazoline (1.20 g, 7.32 mmol) in 15 mL of IPA were added. The mixture was heated at re?ux for 5.5 hr, and then stirred at room temperature overnight. Then, the volatile components were evaporated, and the residue was partitioned between DCM (3x70 mL) and 5% N32CO3 (40 mL). The combined organic phases were dried over NaZSO4, filtered, and concentrated. SPE, eluting with 25% and then 55% EA/Hex, gave product ons that were combined and trated to yield an orange solid. Recrystallization from EA/Hex gave a pink solid, and then from MeOH gave 1.29 g of a light pink solid. Rf 0.19 (50% EA/Hex); mp 146.5— 148.0 0C; 1H NMR (CDC13) 5 8.66 (s, 1H), 7.83 (d, 1H, J=8.5 Hz), 7.77 (d, 1H, J=8.1 Hz), 7.71 (m, 1H), 7.42 (m, 1H), 7.30 (m, 3H), 7.10 (m, 2H), 7.04 (br s, 1H), 6.99 (m, 2H), 6.90 (m, 1H), 6.44 (m, 1H, NH), 4.84 (m, 2H, AB); 13C NMR (CDC13) 8 159.5, 157.9, 157.0, 155.5, 149.6, 140.4, 132.9, 130.3, 130.0, 128.7, 126.3, 123.7, 122.6, 120.9, 119.2, 118.3, 117.9, 115.1, 45.1.
Example 1 13: N—[4—(Decyloxy)benzyl]quinazolin—4—amine d)!HN/\©\O/\/\/\/\/\N 4-(Decyloxy)benzonitrile A e of oxybenzonitrile ( 4.32 g, 36.3 mmol), l— bromodecane (6.80 mL, 32.9 mmol), and K2C03 (6.61 g, 47.8 mmol) in 20 mL of DMF was reacted for 2 days. The solvent was evaporated in vacuo. The residue was partitioned between 50% EA/Hex (3X150 mL) and 5% Na2C03 (3x80 mL), H20 (40 mL), 0.1M HCl (40 mL), and brine (80 mL). The organic phases were dried over anhydrous NaZSO4 and concentrated to give 8.30 g of colorless oil that solidified upon standing. 1H NMR (CDC13) 8 7.54 and 6.90 (m, 4H, AA’BB’), 3.97 (t, 2H, J=6.6 Hz), 1.78 (m, 2H), 1.42 (m, 2H), 1.34-1.25 (m, 12H), 0.86 (m, 3H); 13’C NMR(CDC13) 8 162.6, 134.0, 119.4, 115.3, 103.7, 68.5, 32.0, 29.6, 29.4, 29.4, 29.1, 26.0, 22.8, 14.2. [4-(Decyloxy)phenyl]methanamine (7.61 g) was prepared as a colorless solid by the method for [4—(hexyloxy)phenyl]methanamine by treating 4—(decyloxy)benzonitile with 2 g of LAH. 1H NMR (CDC13) 8 7.2 (m, 2H), 6.8 (m, 2H), 3.90 (t, 2H, J=6.6 Hz), 3.76 (s, 2H), 1.75 (m, 2H), 1.55 (m, 2H), 1.43 (m, 2H), 1.4—1.2 (m, 10H), 0.87 (m, 3H); 13C NMR (CDC13) 8 158.1, 135.4, 128.3, 114.5, 68.0, 46.0, 32.0, 29.6, 29.6, 29.5, 29.4, 29.4, 28.1, 26.1, 22.7, 14.2.
N—[4—(Decyloxy)benzyl]quinazolin—4—amine (3.77 g) was prepared from[4— (decyloxy)phenyl]methanamine (3.04 g, 11.6 mmol), 4—chloroquinazoline (2.60 g, 15.8 mmol), TEA (3.40 mL, 24.2 mmol), and IPA (50 mL) using the method for N—(3— phenoxybenzyl)quinazolin—4—amine. The product was recrystallized from 30% EA/Hex. Rf0.24 (5% CM); mp 1030—1045 0C; 1H NMR(CDC13) 8 8.71 (s, 1H), 7.85 (dd, 1H, 120.7, 8.4 Hz), 7.74 (dd, 1H, J=l.5, 6.9 Hz), 7.69 (m, 1H), 7.44 (ddd, 1H, J=l.l, 7.0, 8.1 Hz), 7.31 (m, 2H), 6.88 (m, 2H), 5.90 (br s, 1H, NH), 4.78 (m, 2H, AB), 3.95 (t, 2H, J=6.6 Hz), 1.77 (m, 2H), 1.45 (m, 2H), 1.4—1.2 (m, 12H), 0.88 (m, 3H); 13C NMR(CDC13)5159.6, 159.1, 155.7, 149.7, 132.8, 130.0, 129.7, 128.9, 126.2, 120.8, 115.0, 68.3, 45.2, 32.1, 29.8, 29.8, 29.6, 29.5, 29.4, 26.2, 22.9, 14.3.
Example 114: N—[4—(Hexyloxy)benzyl]quinazolin—4—amine Cb?m N—[—4(Hexyloxy)benzyl] quinazolin—4—amine (31.9 g) was prepared from [4— (hexyloxy)phenyl]methanamine (32 g), 4-chloroquinazoline (19 g), TEA (32.5 mL), and IPA (250 mL) following the method for the preparation of N—(3—phenoxybenzyl)quinazolin-4—amine.
Mp 1090—1110 0C (from IPA); 1H NMR (CDC13) 5 8.68 (s, 1H), 7.82 (m, 1H), 7.71 (m, 2H), 7.41 (m, 1H), 7.29 (m, 2H, J=2.9, 4.8, 9.5 Hz, ), 6.87 (m, 2H, J=2.9, 5.1, 9.5 Hz, AA’BB’), 6.11 (br s, 1H, NH), 4.77 (m, 2H, AB), 3.93 (t, 2H, J=6.6 Hz), 1.76 (m, 2H), 1.5 (m, 2H), 1.4—1.3 (m, 4H), 0.89 (m, 3H); 13C C13) 5 159.4, 150.0, 155.6, 149.6, 132.8, 130.0, 129.6, 128.7, 126.2, 120.8, 115.0, 115.0, 68.3, 45.1, 31.8, 29.4, 25.9, 22.8, 14.2.
Example 115: 1-[2—(Ethoxymethy1)—1H—imidazo[4,5-c]quinolin—1—y1]—2—methy1propan—2—ol 23fN 3—Nitroquinolin—4—ol 70% Aqueous nitric acid (6.1 mL) was added dropwise to a mixture of 4- yquinoline (10 g, 69 mmol) and 100 mL of acetic acid heated at re?ux. After 15 min, the mixture was allowed to cool to room temperature. Dilution with EtOH resulted in the formation of a precipitate, which was filtered and washed sequentially with EtOH, H20, and EtOH. Drying of the filtrate in vacuo gave 4.62 g of a light yellow powder. 1H NMR (DMSO—d6) 8 9.2 (s, 1H), 8.3 (d, 1H), 7.9-7.7 (m, 2H), 7.5 (m, 1H). 4—Chloro—3—nitroquinoline orus oxychloride (2.5 mL, 27 mmol) was added dropwise to a mixture of 3—nitroquinolin—4—ol (4.6 g, 24 mmol) and 100 mL of DMF. The mixture was heated at 100 0C for 15 min, and then poured onto stirred ice. The slurry was neutralized with solid NaHCOg, and the precipitate was filtered and washed with saturated NaHC03 and H20. The filtrate was taken up in DCM, dried over anhydrous NaZSO4, and concentrated to give 2.3 g of solid. yl—l—(3—nitroquinolin—4—yl)propan—2—ol A mixture of 4—chloro—3—nitroquinoline (2.3 g, 11 mmol), 1—amino—2—methylpropan—2—ol (1.0 g, 11 mmol), TEA (9.3 mL), and 100 mL of DCM was heated at re?ux until the starting material was consumed. The mixture was allowed to cool, washed with saturated NaHC03 and H20, dried over anhydrous , and concentrated to give 1.01 g of product. 1H NMR (DMSO-d6) 8 9.9 (br s, 1H, NH), 9.2 (s, 1H), 8.5 (d, 1H), 7.9— 7.8 (m, 2H), 7.6 (m, 1H), 5.1 (s, 1H, OH), 3.8 (m, 2H, ABX), 1.2 (s, 6H). 1-(3-Aminoquinolinylamino)methylpropanol 2-Methyl(3-nitroquinolin yl)propanol (1.01 g, mmol), 10% Pd-C (200 mg), and 20 mL of toluene were stirred under an atmosphere of hydrogen until the starting material was consumed. The en was replaced by argon, and the mixture was filtered through a pad of Celite and concentrated by ation to give 586 mg of product. 1H NMR (CD3OD) 8 8.3 (s, 1H), 8.1 (m, 1H), 7.8 (m, 1H), 7.5—7.4 (m, 2H), 7.2—7.0 (m, 2H, ABX), 1.2 (s, 6H). 1—[2—(Ethoxymethyl)—1H—imidazo[4,5—c]quinolin—1—yl]-2—methylpropan—2—ol A mixture of 1—(3—aminoquinolin—4—ylamino)—2—methylpropan—2—ol (586 mg, 2.54 mmol) and 0.4 mL of ethoxyacetic acid was heated at 130 °C for 3 hr. The cooled e was poured into 5 mL of H20 and made basic with 6N NaOH. The resulting solid was collected by filtration, washed with H20, and dried in vacuo to give 655 mg of product. 1H NMR (CDC13) 5 9.1 (s, 1H), 8.3 (m, 1H), 8.1 (m, 1H), 7.7-7.5 (m, 2H), 4.9 (br s, 2H), 4.8 (br s, 2H), 3.6 (q, 2H), 1.3 (s, 6H), 1.2 (t, 3H).
Example 1 16: l—(4—Amino— l—isobutyl— 1H—imidazo[4,5—c] quinolin—2—yl)pentyl acetate >—CH.
CdN\/ N NH2 N—Isobutyl—3—nitroquinolin—4—amine 4—Chloro—3—nitroquinoline was prepared from 3— nitroquinolin—4—ol (5.5 g, 28.8 mmol). Isobutylamine (3.2 mL, 32 mmol) was added slowly to a e of the 4—chloro—3—nitroquinoline, TBA (24 mL, 170 mmol), and 40 mL of DCM. The mixture was heated at re?ux for 30 min. Then, the volatile components were evaporated, and the residue was taken up in aqueous acid and filtered. The filtrate was adjusted to pH 8-9 by adding concentrated NH4OH, and the resulting solid was filtered and washed with H20. Drying in vacuo gave 6.49 g of product. 1H NMR(CDC13) 5 9.8 (br s, 1H, NH), 9.3 (s, 1H), 8.3 (m, 1H), 8.0 (m, 1H), 7.8 (m, 1H), 7.4 (m, 1H), 3.8 (m, 2H), 2.1 (m, 1H), 1.1 (d, 6H).
N4-Isobutquuinoline-3,4-diamine A mixture of N-isobutylnitroquinolinamine (19.0 g, 77.6 mmol) and 10% Pd-C (700 mg) in 200 mL of EA was reacted under an here of hydrogen at 42 psi until the starting material was consumed. Then, the hydrogen was replaced by argon, and the mixture was filtered through a pad of Celite. The filtrate was concentrated to give 15.2 g of product. 1H NMR (CDC13) 5 8.4 (s, 1H), 7.9 (m, 1H), 7.8 (m, 1H), 4 (m, 2H), 3.9- 3.6 (br m, 3H, NH), 3.0 (d, 2H), 1.9 (m, 1H), 1.0 (d, 6H). 1—Isobutyl—lH—imidazo[4,5—c]quinoline A mixture of butquuinoline—3,4—diamine (2.33 g, 10.8 mmol) and 17 mL of formic acid was heated at 100 0C for 3 hr. The volatile components were evaporated in vacuo. The residue was diluted with H20, made basic using trated NH4OH, and extracted with DCM. The organic solvent was replaced with EtZO, treated with activated charcoal, ed through a pad of Celite, and concentrated. NMR indicated the presence of starting material. The crude was mixed with triethyl orthoformate, heated at 100 0C for 3 hr, and processed as before to give 1.4 g of t. 1H NMR (CDClg) 5 9.3 (s, 1H), 8.3 (m, 1H), 8.1 (m, 1H), 7.9 (s, 1H), 7.7—7.5 (m, 2H), 4.3 (d, 2H), 2.3 (m, 1H), 1.0 (d, 6H). 1—(1—Isobutyl—lH—imidazo[4,5—c]quinolin—2—yl)pentan—l—ol n—Butyllithium (1.5M in hexanes, 3.6 mL) was added to a mixture of l—isobutyl—1H—imidazo[4,5—c]quinoline (1.4 g, 4.9 mmol) and 25 mL of THE cooled by a dry ice/IPA bath. After 15 min, valeraldehyde (0.80 mL, 7.5 mmol) was added. The mixture was allowed to warm to room temperature. After 3 hr, H20 and EtZO were added, and the organic phase was separated, dried over anhydrous MgSO4, and concentrated. EC, eluting with EA, gave 990 mg of the product. 1H NMR (CDC13) 5 9.2 (s, 1H), 8.1 (m, 1H), 7.9 (m, 1H), 7.7—7.5 (m, 2H), 4.95 (m, 1H), 4.5 (m, 1H), 4.3 (m, 1H), 2.3 (m, 2H), 1.6-1.3 (m, 4H), 1.1 (d, 3H), 1.0—0.8 (m, 6H). 1-(1—Isobutyl—1H—imidazo[4,5—c]quinolinyl)pentyl acetate Acetic anhydride (0.400 mL, 4.24 mmol) and TEA (0.510 mL, 3.64 mmol) were added sequentially to a mixture of 1-(1- yl-1H—imidazo[4,5-c]quinolinyl)pentan-l-ol (818 mg, 2.75 mmol) and 20 mL of DCM.
After 16 hr, the mixture was diluted with 1 volume of DCM and washed with H20 and saturated NaHCOg. The organic phase was dried over anhydrous MgSO4 and concentrated to give 1.00 g of product. 1H NMR(CDC13) 8 9.3 (s, 1H), 8.25 (m, 1H), 8.1 (m, 1H), 7.75-7.55 (m, 2H), 6.1 (m, 1H), 4.5 (m, 2H, ABX), 2.3 (m, 2H), 2.1 (s, 3H), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 1.0—0.8 (m, 6H). 2—(1—Acetoxypentyl)—1—isobutyl—1H—imidazo[4,5—c]quinoline 5—oxide A mixture of l—(l— isobutyl—lH—imidazo[4,5—c]quinolin—2—yl)penty1 e (980 mg, 2.91 mmol) and 32% peracetic acid (0.22 mL, 3.2 mmol) in 20 mL of EA was heated at re?ux for 1 hr and stirred at room temperature overnight. The volatile components were evaporated in vacuo, and the e was ioned between DCM and saturated NaHC03 and H20. The c phase was dried over anhydrous NaZSO4 and concentrated to give a solid. The solid was slurried with cold acetone, filtered, and dried to give 750 mg of product. 1H NMR ) 5 9.3 (s, 1H), 9.0 (m, 1H), 8.5 (br s, 2H, N?z), 8.15 (m, 1H), 7.85-7.75 (m, 2H), 6.0 (dd, 1H), 4.5 (m, 2H, ABX), 2.3 (m, 2H), 2.1 (s, 3H), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 0.95 (d, 3H), 0.9 (m, 3H). 1—(4—Amino—1—isobutyl—1H—imidazo[4,5—c]quinolin—2—yl)pentyl acetate A mixture of 4— toluenesulfonyl chloride (447 mg, 2.34 mmol) and 15 mL of DCM was added slowly to a mixture of 2—(1—acetoxypentyl)—1—isobutyl—1H—imidazo[4,5—c]quinoline 5—oxide (750 mg, 2.13 mmol) and 8 mL of concentrated NH4OH cooled by an ice bath. The mixture was allowed to warm to room temperature overnight. The e was diluted with DCM and washed with saturated NaHCOg, and the c phase was dried over anhydrous NaZSO4 and concentrated to give 650 mg of colorless solid. 1H NMR (CDC13) 5 7.9 (d, 1H), 7.7 (d, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 6.1 (dd, 1H), 5.5 (br s, 2H, N?z), 4.4 (m, 2H, ABX), 2.3 (m, 2H), 2.15 (m, 1H), 2.1 (s, 3), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 1.0-0.8 (m, 6H).
Example 117: 1—Isobutyl—2—pentadecyl-1H-imidazo[4,5—c]quinolin—4—ol V\N,\(\/WVW\/ N OH 2-Chloro-N-isobutylnitroquinolinamine A e of isobutylamine (10.0 mL, 101 mmol) and TEA (15.6 mL, 111 mmol) in 10 mL of 1:1 DMF/DCM was added slowly to 2,4- dichloro—3—nitroquinoline (26.94 g, 111 mmol) in 100 mL of 4:1 DMF/DCM cooled with an ice bath. The mixture was allowed to warm to room temperature overnight. Then, the le components were evaporated, and the residue was partitioned between EA and saturated NaHC03 and brine, dried over NaZSO4, and trated. FC (15% EA/Hex) gave the product as an orange solid. Recrystallization from EA/Hex gave 3 crops of the t (17.97 g) as a light orange solid. 2—Chloro—N4—isobutquuinoline—3,4—diamine A mixture of 2—chloro—N—isobutyl—3—nitroquinolin-4— amine (996 mg, 3.57 mmol) and 35 mg of 5% Pt—C in 15 mL of MeOH was stirred under 2 atmospheres of hydrogen for 90 min. Then, the mixture was blanketed with argon, filtered through a pad of Celite and concentrated to dryness.
WO 20995 4—Chloro—l—isobutyl—2—pentadecyl— 1H—imidazo[4,5—c]quinoline A mixture of the crude 2— chloro—N4—isobutquuinoline—3,4—diamine and palmitic acid (3.66 g, 14.3 mmol) was heated at 180 0C for 4 hr. Then, the mixture was partially cooled and, while mixing, diluted with 400 mL of EA and 10 mL of 1M NaOH and 40 mL of 5% N32C03. The warm mixture was cooled with an ice bath, and a solid (presumably sodium palmitate) formed. The liquid was decanted from the solid, the layers were separated, and the aqueous layer was extracted with EA (2x150 mL). The organic phases were washed with 5% N32C03 (3x50 mL) and brine, dried over NaZSO4, and concentrated. FC (4% MeOH/DCM) gave fractions that ned the product, observed by TLC.
The fractions were concentrated, and two crops of the product (1.14 g) were crystallized from DCM/Hex. Rf 0.27 (5% MeOH/DCM); 1H NMR (CDC13) 5 7.8 (m, 2H), 7.4 (m, 1H), 7.3 (m, 1H), 4.2 (d, 2H, ABX), 2.9 (m, 2H), 2.3 (m, 1H), 1.9 (m, 2H), 1.5-1.2 (m, 24H), 1.0 (d, 6H). 0.85 (t, 3H). utylpentadecyl-1H-imidazo[4,5-c]quinolinol A e of 4-chloroisobutyl pentadecyl-1H—imidazo[4,5-c]quinoline (165 mg, 0.35 mmol) in 5 mL of 50% concentrated NH4OH/MeOH was heated at 160 0C for 72 hr. Then, the mixture was cooled and evaporated to a solid. The solid was washed with saturated NaHC03 and H20 and dried in vacuo to give 160 mg light gray solid. Rf0.29 (10% CM); 1H NMR (CDCl3) 5 12.1 (br s, 1H, OH), 7.8 (m, 2H), 7.4 (m, 1H), 7.3 (m, 1H), 4.2 (d, 2H, ABX), 2.9 (m, 2H), 2.3 (m, 1H), 1.9 (m, 2H), 1.5- 1.2 (m, 24H), 1.0 (d, 6H), 0.85 (t, 3H). e 1 18: 1—Octyl— lH—imidazo[4,5—c]quinoline N’\\ :jkfx/ N 2,4—Dihydroxy—3—nitroquinoline Concentrated nitric acid (12.4 mL) was added to a mechanically—stirred mixture of 2,4—dihydroxyquinoline (20.2 g, 125 mmol) in 160 mL of acetic acid at re?ux. After 20 min, heating was stopped. After a further 15 min, 3 volumes of ice chips were added, and the mixture was stirred 30 min. The precipitate was filtered and washed with four times with 1 volume of ice—cold H20. After drying in vacuo, 23.0 g of orange solid was obtained. 2,4—Dichloro—3—nitroquinolineA mixture of 2,4—dihydroxy—3—nitroquinoline (5.08 g, 24.7 mmol) and phenylphosphonic dichloride (13.9 mL, 98.4 mmol) was heated at 140 0C for 3 hr. After the mixture had cooled at, it was added to 18.5 g of NaHC03 in 150 mL ice—cold H20. The pH was at least 6. The solid was filtered and washed twice with H20. After drying in vacuo, 5.09 g of a tan solid was obtained. 2—Chloro—3—nitro—N—octquuinolin—4—amine A mixture of 2,4—dichloro—3—nitroquinoline (1.0 g, 4.1 mmol), lamine (0.75 mL), TEA (3.5 mL), and 20 mL of DCM were heated at re?ux for 1 hr. Then, the volatile material was evaporated, the residue was taken up in H20, and the pH was adjusted to 8—9 with concentrated HCl and concentrated NH4OH. The precipitate was collected and washed with H2O. After drying in vacuo, 1.65 g of a solid was obtained.
N4-Octquuinoline-3,4-diamine (515 mg) was obtained by treating 2-chloronitro-N- octquuinolinamine (1.33 g) with the conditions used to prepare N—[8- oxy)octyl]pyrimidinamine. 1H NMR (CDClg) 5 8.5 (s, 1H), 8.05 (d, 1H), 7.9 (d, 1H), 7.5 (m, 1H), 7.35 (m, 1H), 4.1 (br s, 2H, N?2), 3.5 (m, 2H), 1.75 (m, 2H), 1.6—1.1 (m, 10H), 0.85 (m, 3H). 1—0ctyl—lH—imidazo[4,5—c]quinoline (400 mg) was obtained by ng N4—octquuinoline—3,4- diamine (515 mg) with the conditions used to prepare 1—[8—(hexyloxy)octyl]—1H—imidazo[4,5— c]pyridine. 1H NMR(CDC13) 5 9.35 (s, 1H), 8.6 (m, 1H), 8.2 (d, 1H), 8.0 (s, 1H), 7.75 (m, 2H), 4.6 (t, 2H), 2.0 (m, 2H), 1.5-1.1 (m, 10H), 0.9 (m, 3H). e 1 19: l —Hexadecyl— 1H—imidazo[4,5—c]quinoline N’\\ 2—Chloro—3—nitro—N—octquuinolin—4—amine A mixture of 2,4—dichloro—3—nitroquinoline (1.0 g, 4.1 mmol), 1—octylamine (0.75 mL), TEA (3.5 mL), and 20 mL of DCM were heated at re?ux for 1 hr. Then, the volatile material was evaporated, the residue was taken up in H20, and the pH was adjusted to 8—9 with concentrated HCl and concentrated NH4OH. The precipitate was collected and washed with H20. After drying in vacuo, 1.65 g of a solid was obtained.
N4—Octquuinoline—3,4—diamine (515 mg) was obtained by treating 2—chloro—3—nitro—N— octquuinolin—4—amine (1.33 g) with the conditions used to e N—[8— (hexyloxy)octyl]pyrimidin—4—amine. 1H NMR (CDCl3) 5 8.5 (s, 1H), 8.05 (d, 1H), 7.9 (d, 1H), 7.5 (m, 1H), 7.35 (m, 1H), 4.1 (br s, 2H, NH;), 3.5 (m, 2H), 1.75 (m, 2H), 1.6-1.1 (m, 10H), 0.85 (m, 3H). l—1H—imidazo[4,5—c]quinoline (400 mg) was obtained by treating N4—octquuinoline—3,4— diamine (515 mg) with the conditions used to prepare 1-[8-(hexyloxy)octyl]—1H—imidazo[4,5- c]pyridine. 1H NMR (CDC13) 8 9.35 (s, 1H), 8.6 (m, 1H), 8.2 (d, 1H), 8.0 (s, 1H), 7.75 (m, 2H), 4.6 (t, 2H), 2.0 (m, 2H), 1.5-1.1 (m, 10H), 0.9 (m, 3H).
Example 120: 1-Hexadecyl-1H—imidazo[4,5-c]quinolinamine N’\\ CCKN\ N NH2 1—Hexadecyl-1H—imidazo[4,5—c]quinolin—4—amine was made following the method for the ation of utyl—2—pentadecyl—1H—imidazo[4,5—c]quinolin—4—ol, using 2,4—dichloro—3— uinoline (1.00 g), 1—hexadecylamine (1.00 g), 8 mL of triethyl orthoforrnate at re?ux for imidazole ring formation, and a solution of 1 mL of anhydrous NH3 in 8 mL of anhydrous IPA in the final reaction. Final purification used FC (5% MeOH/DCM, Rf0. 17). 1H NMR (CDClg) 5 7.9 (m, 1H), 7.8 (m, 1H), 7.75 (s, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 5.6 (br s, 1H, NH), 4.5 (t, 2H), 2.0 (m, 2H), 1.5-1.2 (m, 26H), 0.85 (t, 3H).
Example 121: l—[2— (Dodecyloxy)ethyl]— lH—imidazo[4,5—c]quinoline W0\/\N’\\ ©ij/ 2—(Dodecyloxy)ethanol 60% Dispersion of sodium hydride in mineral oil (8.3 g, 208 mmol) was washed in Hex (2x). Then, a e of ethylene glycol (17.4 mL, 312 mmol) in 250 mL of DMF and 25 mL of DCM was added slowly while g with an ice bath. After 1 hr, 1— iodododecane (104 mmol) was added. The mixture was allowed to warm to room temberature.
After 24 hr, the volatile components were ated, and the residue was partitioned between EA and 100 mL of 1M HCl, then 0.1M HCl and 5% Na28203, then 0.1M HCl, then brine, and the organic phases were dried over MgSO4 and concentrated. SPE, g with 5% EA/Hex and eluting with 40% EA/Hex, gave 10.15 g of product. Rf 0.48 (40% EA/Hex); 1H NMR (CDC13) 53.7 (m, 2H), 3.55—3.40 (m, 4H), 2.1 (br s, 1H, OH), 1.6 (m, 2H), 1.4-1.2 (m, 18H), 0.85 (t, 3H). 2-(Dodecyloxy)ethyl methanesulfonate as a crude material was prepared from 2- (dodecyloxy)ethanol (10.15 g, 44.1 mmol), methanesulfonyl chloride (4.3 mL, 53 mmol), and triethylamine (7.5 mL, 53 mmol) in 200 mL of THF, and carried on. Rf 0.56 (40% EA/Hex). 1—(2—Iodoethoxy)dodecane (14.9 g) was prepared from 2-(dodecyloxy)ethy1 methanesulfonate and 12.9 g of sodium iodide by the Finkelstein reaction. Rf 0.94 (40% EA/Hex) 0.46 (5% );1H NMR (CDClg) 5 3.7 (t, 2H), 3.45 (t, 2H), 3.25 (t, 2H), 1.6 (m, 2H), 1.4—1.2 (m, 18H), 0.85 (t, 3H). 1—(2—Azidoethoxy)dodecane as a crude was prepared from 1—(2—iodoethoxy)dodecane (14.9 g, 43.8 mmol) and sodium azide (2.85g, 43.8 mmol) in 33 mL of DMF. Rf 0.28 (5% ); 1H NMR(CDC13) 5 3.6 (t, 2H), 3.45 (t, 2H), 3.35 (t, 2H), 1.6 (m, 2H), 1.4—1.2 (m, 18H), 0.85 (t, 3H). 2—(Dodecyloxy)ethanamine was prepared by the catalytic hydrogenation of the crude 1—(2— azidoethoxy)dodecane using 1.5 g of 5% Pd—C in 150 mL of MeOH. SPE, washing with 50% EA/Hex and eluting with 15% MeOH/DCM + 2% TEA, gave 8.0 g of t. 1—[2—(Dodecyloxy)ethyl]—lH—imidazo[4,5—c]quinoline (103 mg) was prepared by the method for the preparation of l—hexadecyl—lH—imidazo[4,5—c]quinolin—4—amine ng with 2— (dodecyloxy)ethanamine (2.73 g, 11.9 mmol) and 2,4—dichloro—3—nitroquinoline (2.94 g, 12.1 mmol), using reduction of both nitro and aryl chloride by zinc/HCl, and formation of the ole ring using 7 mL of triethyl orthoformate at re?ux. Final cation was by EC (5% MeOH/DCM, Rf0.10). 1H NMR (CDC13) 8 9.3 (s, 1H), 8.2 (d, 1H), 8.1 (d, 1H), 7.95 (s, 1H), 7.7-7.5 (m, 2H), 4.7 (m, 2H), 3.85 (m, 2H), 3.3 (m, 2H), 1.4 (m, 2H), 1.3-1.1 (m, 18H), 0.8 (m, 3H).
Example 122: 1-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H—imidazo[4,5-c]quinolinamine \/\/\/\/\/\/O\/\ N’\\ N4—[2—(Dodecyloxy)ethyl]—N2,N2—dimethyl—3—nitroquinoline-2,4—diamine Astoichiometric excess of 2-(dodecyloxy)ethanamine and 2,4—dichloronitroquinoline (486 mg, 2.0 mmol) and DIEA (0.38 mL, 2.18 mmol) in 10 m1 of DMF and 10 mL of DCM was mixed at room temperature for 2 days. No on was observed by TLC. The DCM was evaporated and replaced by toluene, and the mixture was heated at re?ux for 6 hr. Then, the reaction was cooled, partitioned between EA and saturated NaHC03 and brine, and the organic phase was dried over Na2804 and concentrated. FC (10% to 20% EA/Hex step gradient) gave 306 mg of N4—[2— (Dodecyloxy)ethyl]—N2,N2—dimethyl—3—nitroquinoline—2,4—diamine as orange oil, as well as 376 mg of N2,N4—bis[2—(dodecyloxy)ethyl]—3—nitroquinoline—2,4—diamine as orange oil. 1H NMR (CDClg) 57.9 (m, 2H), 7.6—7.55 (m, 2H), 7.1 (m, 1H), 3.8 (m, 2H), 3.5—3.4 (m, 4H), 3.0 (s, 6H), 1.6 (m, 2H), 1.4—1.2 (m, 18H), 0.85 (t, 3H). l—[2—(Dodecyloxy)ethyl]—N,N—dimethyl— lH—imidazo[4,5—c]quinolin—4—amine The nitro group of N4—[2—(dodecyloxy)ethyl]—N2,N2—dimethyl—3—nitroquinoline—2,4—diamine (306 mg, 0.70 mmol) was reduced using zinc/HCl, and the ortho diamine was reacted with triethyl orthoformate at re?ux to give 197 mg of the product after FC (5%MeOH/DCM). Rf 0.15 (5% CM); 1H NMR(CDC13) 8 7.9 (m, 2H), 7.8 (s, 1H), 7.45 (m, 1H), 7.2 (m, 1H), 4.6 (t, 2H), 3.85 (t, 2H), 3.6 (s, 6H), 3.3 (t, 2H), 1.5 (m, 2H), 1.3—1.1 (m, 18H), 0.85 (t, 3H).
Example 123: l—[6—(Octyloxy)hexyl]-1H—imidazo[4,5—c]quinoline \/\/\/\/O\/\/\/\ (:07N,\\NN/ 6-(Octyloxy)hexan—1—ol Sodium hydride (6.38 g, 266 mmol) was added cautiously to a mixture of 1,6—hexanediol (47.2 g, 400 mmol) and 120 mL of DMF cooled by an ice bath. After min, a mixture of octane (31.9 g, 133 mmol) in 120 mL of DCM was added. The mixture was allowed to warm to room temperature overnight. Then, the volatile components were evaporated, and the residue was ioned between EA and 0.1M HCl, 5% Nagsgog, H20, and brine. The organic phases were dried over anhydrous MgSO4 and concentrated. SPE, washing with 2% EA/Hex and eluting with 40% EA/Hex, gave 13.0 g of colorless oil. Rf0.40 (50% ); 1H NMR (CDC13) 8 3.59 (t, 2H, J=6.7 Hz), 3.36 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.7 Hz), 2.02 (br s, 1H, CH), 1.56—1.47 (m, 6H), 1.40-1.20 (m, 14H), 0.84 (m, 3H). 2—Chloro—3-nitro—N—[6—(octyloxy)hexyl]quinolin—4—amine TEA (8.40 mL, 59.9 mmol) was added to a mixture of 6—(octyloxy)hexan—1—ol (7.60 g, 33.0 mmol) and methanesulfonyl chloride (4.56 mL, 58.3 mmol) in 190 mL of DME cooled by an ice bath. The mixture was allowed to warm to room temperature. After 4 hr, 5 mL of H20 were added and the volatile components were evaporated. The residue was partitioned n EA (3x150 mL) and H20, saturated NaHCOg, H20, 1M HCl, H20, and brine (100 mL each). The organic phases were dried over MgSO4 and concentrated to a colorless oil. The oil was taken up in 250 mL of acetone, sodium iodide (9.9 g, 66 mmol) was added, and the mixture was heated at re?ux for 2 hr. The volatile components were ated, and the e was partitioned between EA and H20, 5% WO 20995 NaZSZOg, H20, and brine. The c phases were dried over MgSO4 and concentrated. SPE (5% EA/Hex) gave a purple oil. The oil was taken up in 25 mL of DMF and 10 mL of toluene, potassium phthalimide (5.55 g, 30 mmol) was added, and the mixture was heated at re?ux for 4 hr. Then, the mixture was cooled and partitioned between EA and 0.1M HCl, 5% Na28203, H20, and brine. The organic phases were dried over MgSO4 and concentrated. SPE, washing with 5% EA/Hex and eluting with 7.5% EA/Hex, gave 10.05 g colorless oil. The oil was taken up in 500 mL of 5% IPA/EtOH, hydrazine monohydrate (2.0 mL, 41 mmol) was added, and the mixture was heated at reflux for 4 hr. The mixture was cooled and concentrated. The residue was partitioned between DCM and 5% N32CO3. The organic phase was dried over anhydrous NaZSO4 and concentrated. SPE, washing with 50% EA/Hex and eluting with 15% MeOH/DCM + 2% TEA, gave 1.91 g of colorless oil. The oil was taken up in a mixture of 9 mL of DMA and 9 mL of toluene, and 2,4—dichloro—3—nitroquinoline (2.16 g, 8.87 mmol) and DIEA (1.45 mL, 8.32 mmol) were added. The mixture was reacted at room temperature for 88 hr and at re?ux for 2 days. The mixture was cooled, the volatile ents were evaporated, and the residue was partitioned between EA and 5% Na2C03 and brine. The organic phases were dried over Na2S04 and concentrated. SPE (20% EA/Hex) gave product-containing fractions with impurities. FC (20% EA/Hex) gave 2.06 g of yellow oil that solidified upon standing. The solid was tallized from EA/Hex to give 1.70 g of yellow solid. Rf 0.22 (20% EA/Hex); 1H NMR (CDC13) 8 7.84 (d, 1H, J=7.9 Hz), 7.76 (dd, 1H, J=1.2, 8.4 Hz), 7.63 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.42 (ddd, 1H, J=1.3, 7.0, 8.4 Hz), 5.98 (t, 1H, J=4.7 Hz, NH), 3.38—3.29 (m, 6H), 1.66 (m, 2H), 1.56—1.42 (m, 4H), 1.36—1.34 (m, 4H), 1.2—1.1 (m, 10H), 0.8 (m, 3H).
Octyloxy)hexyl]—lH—imidazo[4,5—c]quinoline Four mL of a 1:3 mixture of concentrated HCl and MeOH was added slowly to a mixture of 2—chloro—3—nitro—N—[6— oxy)hexyl]quinolin—4—amine (357 mg, 0.82 mmol), zinc dust (320 mg), and 20 mL of DCM cooled by an ice bath. The mixture was allowed to warm to room temperature. After 16 hr, the volatile components were evaporated, the residue was diluted with 75 mL of DCM, and the pH was adjusted to >8 using 5% Na2C03. The organic phase was separated, dried over anhydrous NaZSO4, and concentrated. Triethyl ormate (5 mL) was added to the crude product, and the mixture was heated at 130 0C for 6 hr. Then, the mixture was cooled and concentrated. The WO 20995 residue was partitioned between DCM and 5% N32CO3. The organic phase was dried over NaZSO4 and concentrated. FC (3% and 5% MeOH/DCM step gradient) gave 101 mg of brown oil. Rf0.2l (5% MeOH/DCM); 1H NMR (CDC13) 5 9.31 (s, 1H), 8.26 (m, 1H), 8.12 (m, 1H), 7.92 (s, 1H), 7.70-7.58 (m, 2H), 4.54 (t, 2H, J=7.2 Hz), 3.34 (t, 2H, J=6.2 Hz), 3.33 (t, 2H, J=6.7 Hz), 2.00 (m, 2H), 1.56-1.39 (m, 6H), 1.3—1.1 (m, 12H), 0.83 (m, 3H).
Example 124: l—(8—Ethoxyoctyl)— 1H—imidazo[4,5—c]quinoline \/O\/\/\/\/\ N,\\ CGN\ 1-(8—Ethoxyoctyl)—1H—imidazo[4,5—c]quinoline was made by the method used for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, substituting 8—ethoxyoctan—1—amine for 1-octylamine. 8— Ethoxyoctan— l—amine was made by the method used for the preparation of 8—(hexyloxy)octan—1— amine, using iodoethane and 1,8-octanediol as starting materials.
Example 125: ethoxyoctyl)-1H—imidazo[4,5-c]quinoline N’\\ 1—(8—Methoxyoctyl)—1H—imidazo[4,5—c]quinoline was made by the method used for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, substituting oxyoctan—1—amine for 1- octylamine.
Example 126: l—(8—Butoxyoctyl)— 1H—imidazo[4,5—c]quinoline WO\/\/\/\/\ N’\\N N 1—(8—Butoxyoctyl)— lH—imidazo[4,5—c]quinoline was made by the method used for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, tuting 8—butoxyoctan—l—amine for l—octylamine. 8— Butoxyoctan—l—amine was made by the method used for the preparation of lO—(hexyloxy)decan— l—amine, using l—bromobutane and l,8—octanediol as starting als. e 127: l—[9—(Hexyloxy)nonyl]—1H—imidazo[4,5—c]quinoline /\/\/\O/\/\/\/\/\N’\\ m“N/ 9—(Benzyloxy)nonan—l—ol, as 8.79 g of colorless oil, was made by the method used for the preparation of 8—(benzyloxy)octan—1—ol, using 27.1 g of 1,9—nonanediol, 7.85 mL of benzyl chloride in 20 mL of DME, 1.80 g of sodium hydride, 60% dispersion in mineral oil, and 300 mL of DMF. Rf0.12 (20% EA/Hex); 1H NMR (CDC13) 5 7.37-7.22 (m, 5H), 4.49 (s, 2H), 3.61 (t, 2H, J=6.6 Hz), 3.45 (t, 2H, J=6.7 Hz), 1.65-1.49 (m, 4H), 1.36-1.21 (m, 10H). {[9-(Hexyloxy)nonyloxy]methyl}benzene Sodium hydride (920 mg, 38.3 mmol) was added to a mixture of 9-(benzyloxy)nonanol (8.79 g, 35.2 mmol) and 200 mL of DME. After 1 hr, 1- iodohexane (10.6 g, 50 mmol) was added. After 40 hr, analysis by TLC indicated little conversion. Another portion of sodium hydride was added. After 8 hr, another portion of sodium hydride and l-bromohexane (7.0 mL, 50 mmol) were added. The mixture was stirred 48 hr, then allowed to stand for several weeks. Then, 6 mL of concentrated NH4OH were added usly.
After 16 hr, the volatile components were evaporated. The residue was partitioned between EA (3x250 mL) and H20 (100 mL), 5% Na28203 (100 mL), H20 (100 mL), 0.1M HCl (2x100 mL), and brine (100 mL). The c phases were dried over anhydrous NaZSO4 and concentrated.
SPE (5% EA/Hex) gave 8.47 g of colorless oil. Rf0.75 (20% EA/Hex); 1H NMR (CDClg) 8 7.34— 7.23 (m, 5H), 4.49 (s, 2H), 3.48—3.36 (m, 6H), 1.68—1.51 (m, 6H), 1.5—1.2 (m, 16H), 0.88 (t, 3H, J+6.8 Hz). 1—(Hexyloxy)—9—iodononane A e of {[9—(hexyloxy)nonyloxy]methyl}benzene (8.47 g, 25.4 mmol), trimethylsilane ( 20 mL, 158 mmol), and sodium iodide (23.7 g, 158 mmol) in 150 mL of DCM was heated at re?ux for 60 hr, then mixed at room temperature for 48 hr.
Then, the le components were evaporated. The residue was partitioned between EA (3x250 mL) and saturated NaHC03 (100 mL), 5% Na2S203 (100 mL), H20 (100 mL), and brine (100 mL). The organic phases were dried over anhydrous MgSO4 and concentrated. Analysis by TLC ted the presence of 9—(hexyloxy)nonan—1—ol with low Rf. The mixture was taken up in 25 mL of toluene and then concentrated. The purple oil was taken up in another 25 mL of toluene, 5 mL of phosphorus oxychloride was added, and the mixture was heated at re?ux until the suspected alcohol was consumed, as observed by TLC analysis. The mixture was cooled with an ice bath, and saturated NaHC03 was added slowly, accompanied by gas evolution. The mixture was extracted with EA (3x250 mL), and the organic phases were washed with H20, 0.1M HCl, and brine (100 mL each), dried over MgSO4, and concentrated. SPE (2% EA/Hex), discarding early fractions that ned benzyl halides, gave 3.76 g of product as amber oil. Rf 0.53 (5% EA/Hex); 1H NMR(CDC13) 8 3.37 (t, 4H, J=6.7 Hz), 3.16 (m, 2H), 1.80 (m, 2H), 1.57—1.49 (m, 4H), 1.4—1.2 (m, 16H), 0.87 (m, 3H).
N—[9-(Hexyloxy)nonyl]phthalimide A e of 1-(hexyloxy)iodononane (3.80 g, 14.4 mmol), and ium phthalimide (2.70 g, 14.6 mmol) in 8 mL of DMF was heated at 100 0C for 5 hr. The mixture was cooled and partitioned between EA (3x250 mL) and 5% Na2C03, H20, % Na2S203, H20, 0.1M HCl, and brine (100 mL each). The organic phases were dried over anhydrous MgSO4 and concentrated. SPE, washing with 5% EA/Hex and eluting with 7.5% EA/Hex, gave 3.30 g of product as a solid. Rf 0.26 (10% EA/Hex); 1H NMR (CDC13) 8 7.80 and 7.67 (m, 4H, AA’BB’), 3.64 (m, 2H), 3.35 (t, 2H, J=6.7 Hz), 3.34 (t, 2H, J=6.7 Hz), 1.77—1.47 (m, 6H), 1.28-1.22 (m, 16H), 0.86 (m, 3H). 9—(Hexyloxy)nonan—1—amine A mixture of N—[9—(hexyloxy)nonyl]phthalimide (3.05 g, 8.18 mmol) and hydrazine monohydrate (0.58 mL, 12 mmol) in 50 mL of 5% OH was heated at re?ux for 4 hr. The mixture was cooled and concentrated. The residue was partitioned between DCM and 5% . The c phase was dried over ous NaZSO4 and concentrated.
SPE, washing with 50% EA/Hex and eluting with 15% MeOH/DCM + 2% TEA, gave 1.08 g of a mixture of 9—(hexyloxy)nonan—l—amine and phthalhydrazide. Rf 0. ll (15% MeOH/DCM + 2% TEA); 1H NMR (CDCl3) 5 4.6 (br s, 2H, N?z), 3.4—3.3 (m, 4H), 2.7 (t, 2H), 1.7-1.1 (m, 22H), 0.8 (m, 3H). 2—Chloro—N—[9—(hexyloxy)nonyl]—3—nitroquinolin—4—amine The mixture of 9—(hexyloxy)nonan—l— amine and phthalhydrazide was reacted with 2,4—dichloro—3—nitroquinoline (1.11 g, 4.56 mmol) and TEA (0.63 mL, 4.49 mmol) in 9 mL of DMF and 16 mL of toluene heated at re?ux. After 24 hr, the mixture was cooled, partitioned between EA and H20, 5% N32CO3, and brine, dried over anhydrous NaZSO4, and concentrated. FC, g with 15% and then 20% EA/Hex, gave 1.35 g of yellow product as an oil that solidified upon standing. Recrystallization from cold EA/Hex gave 650 mg of yellow solid. Rf0.18 (20% EA/Hex); 1H NMR (CDClg) 5 7.87 (d, 1H, J=8.6 Hz), 7.78 (dd, 1H, J=l.3, 9.5 Hz), 7.67.65 (m, 1H), 7.45 (m, 1H), 5.99 (t, 1H, J=4.7 Hz, NH), 3.39—3.31 (m, 6H), 1.66 (m, 2H), .45 (m, 4H), 1 (m, 16H), 0.82 (m, 3H). 1-[9—(Hexyloxy)nonyl]—1H—imidazo[4,5-c]quinoline Six mL of a 1:3 mixture of concentrated HCl and MeOH was added slowly to a mixture of 2—chloro—N—[9—(hexyloxy)nonyl]—3-nitroquinolin—4— amine (674 mg, 1.50 mmol), zinc dust (585 mg), and 25 mL of DCM cooled by an ice bath. The mixture was allowed to warm to room temperature. After 1 hr, the volatile components were evaporated, the residue was diluted with 75 mL of DCM, and the pH was adjusted to >8 using % N32C03. The organic phase was separated, dried over anhydrous NaZSO4, and concentrated.
Rf 0.41 (15% MeOH/DCM) Triethyl ormate (4 mL) was added to the crude t, and the mixture was heated at 130 0C for 6 hr. Then, the mixture was cooled and concentrated. FC (3% and 5% MeOH/DCM step gradient) gave 273 mg of brown oil. Rf 0.27 (5% MeOH/DCM); 1H NMR ) 5 9.22 (s, 1H), 8.16 (m, 1H),7.98 (m, 1H), 7.60—7.47 (m, 2H), 4.38 (t, 2H, J=7.1 Hz), 3.27 (t, 2H, J=6.7 Hz), 3.26 (t, 2H, J=6.7 Hz), 1.86 (m, 2H), 1.45—1.41 (m, 4H), 1.4- 1.1 (m, 16H), 0.78 (m, 3H).
Example 128: l—(lO—Butoxydecyl)—1H—imidazo[4,5—c]quinoline O\/\/\/\/\/\ N 1—(10—Butoxydecyl)—1H—imidazo[4,5—c]quinoline was made by the method used for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, substituting 10—butoxydecan—1—amine for 1— octylamine. 10—Butoxydecan—1—amine was made by the method used for the preparation of 10— (hexyloxy)decan—1—amine, using 1—bromobutane and 1,10—decanediol as starting materials. Rf 0.23 (5% MeOH/DCM); 1H NMR(CDC13) 5 9.32 (s, 1H), 8.27 (m, 1H), 8.12 (m, 1H), 7.93 (s, 1H), 7.66 (m, 2H), 4.54 (t, 2H, J=7.2 Hz), 3.36 (t, 2H, J=6.5 Hz), 3.35 (t, 2H, J=6.5 HZ), 1.99 (m, 2H), 1.57—1.13 (m, 18H), 0.88 (t, 3H, J=7.3 Hz).
Example 129: 4—Amino—1—[8—(hexyloxy)octyl]pyridinium salts N: X A mixture of 8-(hexyloxy)octyl methanesulfonate (0.5 g, 1.62 mmol) and opyridine (450 mg) in 20 mL of THF was heated at re?ux for 18 hr. The e was concentrated and purified by PC (5% MeOH/DCM) to give 396 mg of an oily solid. Recrystallization from MeOH gave a solid. Mp 108-110 0C; 1H NMR(CDC13) 8 8.4 (br s, 1.4H), 7.8 (d, 2H), 7.2 (d, 2H), 4.1 (m, 2H), 3.35 (m, 4H), 2.4 (br s, 4.5H), 1.8 (m, 2H), 1.6 (m, 4H), 2 (m, 14H), 0.8 (m, 3H).
Example 130: 4—(8—Methoxyocty1amino)— 1 —methylpyridinium iodide N\/\/\/\/\ I. |\ OCH3 H3C’ A mixture of N—(8—methoxyoctyl)pyridin—4—amine (176 mg, 0.74 mmol) and iodomethane (0.5 mL, 8 mmol) in 4 mL of acetone was heated at 80 0C in a sealed tube for 1.5 hr, then allowed to stand at room temperature for 2 days, during which a precipitate formed. The volatile components were evaporated from the precipitated product. 1H NMR (CDCl3) 5 8.47 (m, 1H), 7.99 (m, 2H), 7.57 (m, 1H), 6.59 (m, 1H), 4.04 (s, 3H), 3.35-3.21 (m, 4H), 3.29 (s, 3H), 1.71 (m, 2H), 1.54—1.28 (m, 10H).
Example 131: l—[8—(Hexyloxy)octyl] — 1H—imidazo[4,5—c]pyridine \/\/\/O\/\/\/\/\ N’\\ N—[8—(Hexyloxy)octyl]—3—nitropyridin—4—amine A mixture of 3—nitropyridin—4—ol (510 mg, 3.64 mol) in 1 mL of phenylphosphonic dichloride was heated at 170—140 0C for 3 hr. Then, the mixture was cooled and partitioned between EA and saturated . The organic phase was washed with brine, dried over NaZSO4, filtered h a pad of silica gel, and concentrated to give crude 4—chloro—3—nitropyridine. 8—(Hexyloxy)octan—1—amine was taken up in 10 mL of pyridine, and 5 mL of volatile material was evaporated from the mixture. The e was cooled with an ice bath, TEA (0.44 mL, 3.14 mol) was added, and then a mixture of the chloropyridine prepared above and 10 mL of DCM was added. The mixture was allowed to warm to room ature overnight. Then, the reaction was concentrated by evaporation, and the residue was partitioned between EA and saturated NaHCOg. The organic phases were washed with brine, dried over NaZSO4, and concentrated. cation by EC (50% ) gave 405 mg of N—[8-(hexyloxy)octyl]nitropyridinamine as a yellow oil. Rf 0.28 (50% EA/Hex); 1H NMR(CDC13) 5 9.16 (s, 1H), 8.24 d, 1H, J=6.2 Hz), 8.12 (br s, 1H), 6.66 (d, 1H, J=6.2 Hz), 3.38-3.25 (m, 6H), 1.70 (m, 2H), 1.52-1.47 (m, 4H), 1.39-1.18 (m, 14H), 0.84 (t, 3H, J=6.7 Hz).
N4—[8—(Hexyloxy)octyl]pyridine—3,4—diamine A mixture of N—[8—(hexyloxy)octyl]—3— nitropyridinamine (405 mg, 1.15 mol) and 45 mg of 10% Pd/C in 30 mL of MeOH was d under an atmosphere of hydrogen for 5 hr. Then, the catalyst was removed by filtration through Celite, and the filtrate was concentrated. Purification by SPE, washing with 10% MeOH/DCM and then eluting with 15% MeOH/DCM + 2% TEA, gave 216 mg of N4—[8— (hexyloxy)octyl]pyridine—3,4—diamine. Rf 0.05 (15% CM, ninhydrin (+)); 1H NMR (CDC13)5 7.86 (d, 1H, J=5.4 Hz), 7.79 (s, 1H), 6.38 (d, 1H, J=5.4 Hz), 4.53 (br s, 1H), 3.62 (br s, 2H), 3.34 (t, 4H, J=6.7 Hz), 3.08 (m, 2H), 1.62—1.46 (m, 6H), 1.27—1.24 (m, 14H), 0.83 (t, 3H, J=6.8 Hz). 1—[8—(Hexyloxy)octyl]—1H—imidazo[4,5—c]pyridine A e of N4—[8— (hexyloxy)octyl]pyridine—3,4—diamine (216 mg, 0.67 mol) in 2 mL of triethyl orthoformate was heated at re?ux for 6 hr. Then, volatile material was removed by evaporation, and the residue was partitioned between EA and saturated NaHCO3. The organic phases were washed with brine, dried over NaZSO4, and concentrated. Purification by EC (7% MeOH/DCM) gave 217 mg of 1— [8—(hexyloxy)octyl]—1H—imidazo[4,5—c]pyridine as an amber oil. Rf 0.11 (5% MeOH/DCM); 1H NMR (CDC13) 5 9.02 (s, 1H), 8.34 (d, 1H, J=5.7 Hz), 7.86 (s, 1H), 7.25 (m, 1H), 4.08 (t, 2H, J=7.0 Hz), 3.30-3.25 (m, 4H), 1.78 (m, 2H), 1.45—1.43 (m, 4H), 1.22-1.19 (m, 14H), 0.78 (t, 3H, J=6.7 Hz).
Example 132: l—Hexadecyl—1H—imidazo[4,5—c]pyridine [$1\ N—Hexadecylnitropyridinamine 1-Hexadecylamine was taken up in 10 mL of pyridine, and 6 mL of volatile components were removed by distillation. The mixture was cooled, and a mixture of 4-chloronitropyridine in 10 mL of DCM and 10 mL of DMF was added. Then, TEA (0.46 mL, 3.28 mmol) was added and the e was heated at gentle re?ux. After 16 hr, the cooled mixture was taken up in EA and washed with saturated NaHCOg, H20, and brine. The c phase was dried over anhydrous Na2$O4 and concentrated. SPE, washing with 10% EA/Hex and eluting with 20% EA/Hex, gave 626 mg of solid. Rf 0.34 (50% EA/Hex); 1H NMR (CDC13) 5 9.19 (s, 1H), 8.26 (d, 1H, J=6.1 Hz), 8.15 (br s, 1H, NH), 6.68 (d, 1H, J=6.2 Hz), 3.30 (m, 2H), 1.72 (m, 2H), .17 (m, 26H), 0.86 (m, 3H). 1—Hexadecyl—1H—imidazo[4,5—c]pyridine A mixture of decyl—3—nitropyridin—4—amine (626 mg, 1.79 mmol) and 65 mg of 10% Pd—C in 25 mL of 1:1 EA/MeOH was stirred under a blanket of en for 40 hr. The hydrogen atmosphere was replaced by argon, and the mixture was filtered through a pad of Celite and trated. SPE, washing with 10% MeOH/DCM and eluting with 10% MeOH/DCM + 2% TEA, gave 540 mg of colorless solid. The solid was taken up in 8 mL of triethyl orthoformate and heated at re?ux for 4 hr. Then, the volatile components were evaporated. The residue was taken up in a fresh 8—mL portion of yl orthoformate and heated at re?ux for 6 hr. The volatile components were ated. PC of the residue (5% MeOH/DCM) gave 375 mg of tan solid. Rf 0.10 (5% MeOH/DCM); 1H NMR (CDC13) 5 9.06 (s, 1H), 8.39 (d, 1H, J=5.7 Hz), 7.92 (s, 1H), 7.31 (dd, 1H, J=l.0, 5.7 Hz), 4.12 (m, 2H), 1.82 (m, 2H), 1.26—1.18 (m, 26H), 0.81 (t, 3H, J=6.6 Hz). e 133: l—( l 0—Butoxydecyl)— 1H—imidazo[4,5—c]pyridine O\/\/\/\/\/\ 1-(10—Butoxydecyl)—1H—imidazo[4,5—c]pyridine (231 mg) as an amber oil was prepared following the method for 1—[8—(hexyloxy)octyl]—1H—imidazo[4,5—c]pyridine, using 492 mg of 4— hydroxy—3—nitropyridine and 535 mg of 10-butoxydecan—1—amine.
N—(10-Butoxydecyl)nitropyridinamine: Rf0.30 (50% EA/Hex); 1H NMR (CDClg) 8 9.18 (s, 1H), 8.25 (d, 1H, J=6.0 Hz), 8.14 (br s, 1H, NH), 6.68 (d, 1H, J=6.2 Hz), 3.39-3.26 (m, 6H), 1.71 (m, 2H), 1.57-1.47 (m, 4H), 1.40-1.27 (m, 14H), 0.88 (t, 3H, J=7.2 Hz).
N4—(10—Butoxydecyl)pyridine—3,4—diamine: Rf 0.08 (15% MeOH/DCM); 1H NMR (CDC13) 5 7.89 (d, 1H, J=6.4 Hz), 7.83 (s, 1H), 6.41 (d, 1H, J=6.4 Hz), 4.41 (br s, 1H, NH), 3.58 (br s, 2H, N?z), 3.39-3.33 (m, 4H), 3.11—3.10 (br m, 2H), 1.66-1.47 (m, 6H), 1.40—1.26 (m, 14H), 0.88 (t, 3H, J=7.2 Hz).
Butoxydecyl)—1H—imidazo[4,5—c]pyridine: RfO. 15 (5% MeOH/DCM); 1H NMR (CDClg) 5 9.06 (s, 1H), 8.38 (d, 1H, J=5.7 Hz), 7.88 (d, 1H), 7.28 (d, 1H, J=5.4 Hz), 4.12 (m, 2H), 3.35— 3.29 (m, 4H), 1.82 (m, 2H), 1.53—1.43 (m, 4H), 1.36-1.20 (m, 14H), 0.84 (m, 3H).
Example 134: N—(8—Methoxyoctyl)pyridin—4—amine \ N\/\/\/\/\ I OCH3 A mixture of 4—chloropyridine hydrochloride (1.50 g, 10.0 mmol), 8—methoxyoctan—1—amine (894 mg, 5.62 mmol), TEA (1.80 mL, 10.4 mmol), and 4 mL of IPA was heated at 0 0C in a sealed tube for 48 hr. Then, the mixture was cooled and the volatile components were evaporated. The residue was partitioned n DCM and 5% N32CO3, and the organic phase was dried over NaZSO4 and concentrated. FC (1% TEA + 0%, 2%, 3% MeOH/DCM step gradient) gave 176 mg of solid. Rf 0.13 (10% MeOH/DCM); 1H NMR (CDCl3) 5 8.6 (m, 1H), 7.8 (m, 2H), 6.9 (m, 2H), 3.3 (m, 5H), 3.2 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.4-1.2 (m, 8H).
Example 135: N—[8—(Hexyloxy)octyl]pyridin—3—amine (j/NWOWl/ 8-(Hexyloxy)octanal (1.12 g, 4.91 mmol), prepared by the Swem oxidation of 8- (hexyloxy)octanol, was mixed with 3-aminopyridine (500 mg, 5.32 mmol) in 5 mL of acetontrile and 0.4 mL of 1M HCl. Then, 0.37 mL of 1M sodium cyanoborohydride in THF was added. After 20 hr, the e was ioned between EA and 5% Na2C03 and brine, and the organic phase was dried over Na2$O4 and concentrated. FC (70% EA/Hex) gave 160 mg of the product. 1H NMR (CDC13) 5 8.0 (m, 1H), 7.9 (m, 1H), 7.1 (m, 1H), 6.9 (m, 1H), 3.4 (t, 4H), 3.1 (t, 2H), 1.7-1.5 (m, 6H), 1.5—1.2 (m, 14H), 0.85 (m, 3H).
Example 136: N—[8—(Hexyloxy)octyl]pyridin-2—amine \ N\/\/\/\/\O/\/\/\ A e of 2—aminopyridine (458 mg, 4.8 mmol) and 8—(hexyloxy)octyl methanesulfonate (0.5 g, 1.6 mmol) in 20 mL of THF was heated at re?ux for 3 hr. Then, the reaction was cooled and worked up following the procedure for N—[8—(hexyloxy)octyl]pyridin—3—amine to give 100 mg of product. 1H NMR(CDC13) 5 8.0 (m, 1H), 7.4 (m, 1H), 6.55 (m, 1H), 6.35 (m, 1H), 4.6 (br s, 1H, NH), 3.4 (t, 4H), 3.2 (m, 2H), 5 (m, 6H), 1.5—1.2 (m, 14H), 0.85 (m, 3H).
Example 137: Hexyloxy)octyl]pyrimidin—4—amine HN/\/\/\/\/O\/\/\/ 0”| N/) 6—Chloro—N—[8—(Hexyloxy)octyl]pyrimidin—4—amine 8—(Hexyloxy)octan—1—amine (636 mg, 2.78 mmol) was taken up in 15 mL of pyridine, and then 10 mL of le material was removed by distillation. The mixture was cooled to room temperature, and 15 mL of DCM, 4,6- dichloropyrimidine (621 mg, 4.17 mmol), and TEA (0.47 mL, 3.35 mmol) were added sequentially. After being stirred overnight, TLC indicated the presence of the amine starting material, so a second quantity of 4,6-dichloropyrimidine was added and the mixture was heated at re?ux for 3 hr. Then, the mixture was cooled, the volatile al was evaporated, and the residue was partitioned between EA and 5% N32CO3. The organic phases were washed with brine, dried over Na2804, filtered through a pad of silica gel, and concentrated. Purification by PC (30% EA/Hex) gave 767 mg of 6-chloro-N-[8-(hexyloxy)octyl]pyrimidinamine as a tan solid. Rf0.18 (20% EA/Hex); 1H C13)8 8.30 (s, 1H), 6.30 (d, 1H, J=1.0 Hz), 5.36 (br s, 1H, NH), 3.37 (t, 4H, J=6.9 Hz), 3.24 (m, 2H, AB), 1.6-1.5 (m, 6H), 1.3—1.2(m, 14H), 0.8? (m, 3H).
N—[8—(Hexyloxy)octyl]pyrimidin—4—amine A mixture of 6—chloro—N—[8—(hexyloxy)octyl] pyrimidin—4-amine (767 mg, 2.25 mmol) in 30 mL of DCM and 6.8 mL of 2M HCl/IPA was cooled using an ice bath. Then, 876 mg of zinc dust was added. After 45 min, the e was allowed to warm to room temperature. After being stirred overnight, the mixture was partitioned between DCM and 5% Na2C03. The organic phase was dried over NaZSO4 and concentrated.
Purification by PC H/DCM) gave 229 mg of N—[8—(hexyloxy)octyl]pyrimidin—4—amine as a colorless solid. Rf0.2l (5% MeOH/DCM); 1H NMR (CDCl3) 5 8.46 (s, 1H), 8.08 (d, 1H, J=5.7 Hz), 6.25 (dd, 1H, J=1.2, 5.9 Hz), 5.59 (br s, 1H), 3.33 (t, 4H, J=6.7 Hz), 3.21 (m, 2H, AB), 1.58—1.45 (m, 6H), .17 (m, 14H), 0.83 (m, 3H).
Example 138: N—[8—Hexyloxy)octyl)pyrimidin—2—amine N m A mixture of 2—chloropyrimidine (272 mg, 2.39 mmol), 8—(hexyloxy)octan—l—amine (548 mg, 2.39 mmol), and TEA (0.34 mL, 2.42 mmol) in 10 mL of DMF was heated at 80—90 0C for 2 hr.
Then, the mixture was partitioned between EA and 5% N32C03 (2x) and brine, and the organic phase was dried over NaZSO4 and concentrated. FC (50% EA/Hex) gave 227 mg of product as a yellow solid. 1H NMR (CDClg) 8 8.2 (d, 2H), 6.4 (d, 2H), 5.6 (br s, 1H, NH), 3.3 (m, 4H), 1.6— 1.4 (m, 6H), 1.4—1.2 (m, 14H), 0.8 (m, 3H).
Example 139: 1-[8-(Hexyloxy)octyl]phenyl-1H—imidazole WWN‘ /\/\/\ 4-Phenylimidazole (1.0 g, 6.9 mmol) was added to a mixture of sodium tert-butoxide (7.9 mmol) in 20 mL of DMF cooled by an ice bath. After 30 min, 8-(hexyloxy)octyl methanesulfonate (2.14 g, 6.95 mmol) was added, and the mixture was allowed to come to room ature. After 6 hr, volatile components were evaporated. The residue was taken up in EA and washed with saturated NaHC03, 0.1M HCl, and H20. The organic phase was dried over anhydrous Na2S04 and trated. FC (70% EA/Hex) gave 2.5 g of 1-[8—(hexyloxy)octyl]—4—phenyl—1H— ole.1H NMR (CDClg) 5 7.8 (m, 2H), 7.6 (s, 1H), 7.4 (m, 2H), 7.2 (m, 2H), 3.9 (t, 2H), 3.4 (m, 4H), 1.8 (m, 2H), 1.6—1.5 (m, 4H), 1.4—1.2 (m, 14H), 0.9 (m, 3H).
Example 140: N—[8—(Hexyloxy)octyl]isoquinolin— 1 —amine HN/\/\/\/\/O\/\/\/ l—Chloroisoquinoline (390 mg, 2.38 mmol), 8—(hexyloxy)octan—l—amine (360 mg, 1.57 mmol), and triethylamine (0.22 mL, 1.57 mmol) in 2 mL of DMA was heated at 80 0C for 24 hr. Then the mixture was cooled and partitioned between EA and 5% N32CO3 and brine, and the c phase was dried over NaZSO4 and concentrated. EC (20% EA/Hex) gave 87 mg of the product.
Rf0.25 (20% EA/Hex); 1H NMR (CDC13) 8 7.97 (d, l, J=6.0 Hz), .73 (m, l), 7.67—7.64 (m, 1), 7.59-7.53 (m, l), 7.47-7.41 (m, 1), 6.89 (d, 1, J=5.9 Hz), 5.25 (br s, l), 3.62—3.55 (m, 2), 3.38 (t, 4, J=6.7 Hz), 1.77—1.67 (m, 2), 1.58—1.24 (m, 18), 0.89—0.84 (m, 4).
Example 141: N—[8—(Hexyloxy)octyl]isoquinolin—5—amine /\/\/\/\/O\/\/\/ N—[8—(Hexyloxy)octyl]isoquinolin—S-amine (123 mg) was prepared following the method for N— [8-(hexyloxy)octyl]quinolinamine starting with 8-(hexyloxy)octanoic acid (300 mg, 123 mmol) and 5-aminoisoquinoline (174 mg, 1.21 mmol). 1H NMR (CDClg) 8 9.14 (d, 1, J=0.7 Hz), 8.44 (d, 1, J=6.1 Hz), 7.57-7.54 (m, 1), 7.45 (t, 1, J=7.9 Hz), 7.30-7.25 (m, 1), 6.74 (dd, 1, J=0.7, 7.7 Hz), 4.35 (br s, 1), 3.41-3.35 (m, 4), 3.27-3.22 (m, 2), 1.80-1.70 (m, 2), 1.57-1.21 (m, 18), 0.89-0.84 (m, 3). e 142: N—[8—(Hexyloxy)octyl]quinoxalin-2—amine (I TN N\/\/\/\/\WO/ N—[8—(Hexyloxy)octyl]quinoxalin—2—amine (238 mg) was ed following the method for N- [8—(hexyloxy)octyl]isoquinolin—l—amine starting with 8—(hexyloxy)octan—l—amine (380 mg, 1.66 mmol) and 2—chloroquinoxaline (413 mg, 2.50 mmol), but the reaction proceeded at room temperature over 4 days. Rf0.20 (20% ); 1H NMR (CDC13) 5 8.14 (s, l), 7.80 (dd, 1, J=1.2, 8.1 Hz), 7.64 (m, l), 7.50 (m, l), 7.29 (m, l), 5.24 (br t, l), 3.46 (m, 2), 3.37—3.32 (m, 4), 1.66—1.47 (m, 6), 1.31—1.25 (m, 14), 0.84 (m, 3).
Example 143: l—[8—(Hexyloxy)octyl]—1H—benzimidazole QN/VWVOWV,4 8—(Hexyloxy)octyl methanesulfonate (9.4 g, 31 mmol) was added to a mixture of benzimidazole (4.0 g, 31 mmol) and sodium tert—butoxide (31 mmol) in 100 mL of DMF. After 6 hr, the volatile components were evaporated, and the residue was partitioned between EA and ted NaHCOg, 0.1M HCl, and H20, and the c phases were dried over NaZSO4 and concentrated.
FC (70% EA/Hex) gave 7.4 g of the t. 1H NMR (CDC13) 5 7.9 (s, 1H), 7.8 (m, 1H), 7.4 (m, 1H), 7.2 (m, 2H), 4.1 (t, 2H), 3.3 (m, 4H), 1.9 (m, 2H), 1.7-1.5 (m, 4H), 1.4-1.2 (m, 14H), 0.9 (m, 3H).
Example 144: N—[8—(Hexyloxy)octyl]pyrazin—2—amine NWN\/\/\/\/\O/\/\/\ N—[8-(Hexyloxy)octyl]pyrazinamine (102 mg) was prepared following the method for N—[8- (hexyloxy)octyl]isoquinolinamine starting with 8-(hexyloxy)octanamine (583 mg, 2.54 mmol) and 2-chloropyrazine (0.25 mL, 2.81 mmol) and heating at 70 °C for 5 days. Rf0.26 (40% EA/Hex); 1H NMR (CDC13) 8 7.9 (m, 1H), 7.8 (m, 1H), 7.7 (m, 1H), 4.8 (br s, 1H, NH), 3.4—3.2 (m, 6H), 1.6—1.4 (m, 6H), 1.4—1.2 (m, 14H), 0.8 (m, 3H). e 145: 1—[8—(Hexyloxy)octyl]—1H—indole Q]/\/\/\/\/O\/\/\/ 1— [8—(Hexyloxy)octyl]—]—l—Hindole (1.0 g) was prepared following the method for 1— [8— (hexyloxy)octyl]—lH—benzimidazole starting with indole (836 mg, 7.1 mmol), 8—(hexyloxy)octyl methanesulfonate (1.1 g, 3.6 mmol), and 7.1 mmol of sodium tert—butoxide. 1H NMR (CDC13) 5 7.6 (d, 1H), 7.3 (d, 1H), 7.2 (m, 1H), 7.1 (m, 2H), 6.5 (d, 1H), 4.1 (t, 2H), 3.4 (m, 4H), 1.8 (m, 2H), 1.7—1.5 (m, 4H), 1.4-1.2 (m, 14H), 0.9 (m, 3H). e 146: 3—[8—(Hexyloxy)octyl]—3H—imidazo[4,5—b]pyridine \ / N/\/\/\/\/O\/\/\/ 3—[8—(Hexyloxy)octyl]—3H—imidazo[4,5—b]pyridine was ed following the method for l—[8— (hexyloxy)octyl]—lH—imidazo[4,5—c]pyridine starting from 2—chloro—3—nitropyridine (479 mg, 3.0 mmol) and 8—(hexyloxy)octan—l—amine (0.69 g, 3.0 mmol). Since 2—chloro—3—nitropyridine was commercially available, the first step in the l—[8—(hexyloxy)octyl]—lH—imidazo[4,5—c]pyridine preparation (chlorination using phenylphosphonic dichloride) was not med. Rf 0.31 (5% MeOH/DCCM); 1H C13) 8 8.21 (dd, 1, J=1.5, 4.7 Hz), 7.89 (s, 1), 7.87 (m, 1), 7.02 (dd, 1, J=4.7, 7.9 Hz), 4.09 (m, 2), 3.21-3.15 (m, 4), 1.74 (m, 2), 1.36-1.32 (m, 4), 1.14—1.10 (m, 14), 0.69 (m, 3).
Example 147: 1-Dodecyl-1H—imidazo[4,5-c]quinoline N’\\ 1—Dodecyl—1H—imidazo[4,5—c]quinoline (510 mg) was prepared following the method for the preparation of l-octyl—1H—imidazo[4,5—c]quinoline, starting with 2,4—dichloro—3—nitroquinoline (1.0 g, 4.1 mmol) and 1—dodecy1amine (1.0 g, 4.5 mmol). 1H NMR (CDC13) 5 8.5 (s, 1H), 8.15 (d, 1H), 8.05 (d, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 3.7 (t, 2H), 1.8 (m, 2H), 1.5—1.1 (m, 18H), 0.8 (m, 3H).
Example 148: l—[3—(Decyloxy)propyl]— lH—imidazo[4,5—c]quinoline WO/\/\ N’\\ yloxy)propan—1—amine (7.17 g of a solid) was ed following the method for the preparation of 8—butoxyoctan—1—amine, starting from 1,3—propanediol (26.3 mL, 363 mmol) and 1—iododecane (121 mmol) mixed in 240 mL of 1:1 DCM/DMF. 1—[3—(Decyloxy)propyl]—1H—imidazo[4,5—c]quinoline (127 mg) was prepared following the method for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, starting with 2,4—dichloro—3— nitroquinoline (1.94 g, 7.99 mmol) and 3—(decyloxy)propan—1—amine (1.72 g, 7.99 mmol). 1H NMR(CDC13) 5 8.9.3 (s, 1H), 8.3 (m, 2H), 7.95 (s, 1H), 7.7-7.5 (m 2H), 4.7 (t, 2H), 3.5—3.3 (m, 4H), 2.2 (m, 2H), 1.6 (m, 2H), 2 (m, 14H), 0.8 (t, 3H).
Example 149: Decyloxy)butyl]-1H—imidazo[4,5—c]quinoline 4-(Decyloxy)butanamine (2.42 g, 7.28 mmol) was prepared by lithium aluminum hydride reduction of 4-(decyloxy)butyronitrile, which was prepared in poor yield from the sodium alkoxide of l-decanol and 4-bromobutyronitrile.
Decyloxy)butyl]—1H—imidazo[4,5—c]quinoline (78 mg) was prepared following the method for the preparation of 1—octyl—1H—imidazo[4,5—c]quinoline, starting with 2,4—dichloro—3— nitroquinoline (1.77 g, 7.28 mmol) and 4—(decyloxy)butan—1—amine (2.42 g, 7.28 mmol). 1H NMR(CDC13) 5 9.3 (s, 1H), 8.25 (m, 1H), 8.15 (m, 1H), 7.95 (s, 1H), 7.7—7.5 (m, 2H), 4.6 (t, 2H), 3.5—3.3 (m, 4H), 2.1 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.4—1.1 (m, 14H), 0.8 (t, 3H).
Example 150: 1—[8—(Hexyloxy)octyl]—1H—imidazo[4,5—c]quinoline \/\/\/O\/\/\/\/\ N’\\ 2014/013992 1—[8—(Hexyloxy)octy1]—1H—imidazo[4,5—c]quinoline was made by the method used for the preparation of 1—octy1—1H—imidazo[4,5—c]quinoline, substituting 8—(hexyloxy)octan—1—amine for 1—octylamine.
Example 151: 1—{ 5 — [3—(Hexyloxy)propoxy]pentyl } — 1H—imidazo[4,5—c]quinoline /\/\/\OMOW N’\\ on?“/ N 1—{5—[3—(Hexyloxy)propoxy]penty1}—1H—imidazo[4,5—c]quinoline (2.75 g of brown oil) was made by the method used for the preparation of 1—octy1—1H—imidazo[4,5—c]quinoline, starting with 2,4— dichloro—3—nitroquinoline (5.35 g, 22 mmol) and 5—[3—(hexyloxy)propoxy]pentanamine (4.90 g, 20 mmol).1H NMR (CDC13) 5 9.3 (s, 1H), 8.25 (m, 1H), 8.1 (m, 1H), 7.9 (s, 1H), 7.7—7.5 (m, 2H), 4.5 (t, 2H), 3.5—3.3 (m, 8H), 2.0 (m, 2H), 1.8 (m, 2H), 1.7—1.4 (m, 6H), 1.4—1.2 (m, 6H), 0.8 (m, 3H).
Example 152: 1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H—imidazo[4,5-c]quinoline O ,\\ 1—{3—[3—(Hexyloxy)phenoxy]propyl}—1H—imidazo[4,5-c]quinoline (1.33 g of brown oil) was made by the method used for the preparation of 1—octy1—1H—imidazo[4,5—c]quinoline, starting with 2,4—dichloro—3—nitroquinoline (4.33 g, 17.8 mmol) and 3—[2—(hexyloxy)phenoxy]propan—1- amine (4.37 g, 17.8 mmol).1H C13)8 9.3 (s, 1H), 8.3—8.1 (m, 2H), 7.9 (s, 1H), 7.7—7.5 (m, 2H), 7.1 (m, 1H), 6.6-6.4 (m, 3H), 4.7 (t, 2H), 3.95-3.80 (m, 4H), 2.4 (m, 2H), 1.7 (m, 2H), 1.5—1.2 (m, 6H), 0.8 (m, 3H).
ICAL ACTIVITY EXAMPLES ANTI—INFLAMMATORY EXAMPLES EXAMPLE A: Selective killing of tivated in?ammatory hages by Compound AC.
Summary: THP—l is a human AML cell line that can be d into a macrophage—like cell by treatment with 0.2 uM vitamin—D3 (vit—D3) for 3—5 days. In the absence of an atory activator (LPS; bacterial endotoxin), AC exerted little effect on cell viability in THP—1 cells over a 6 hour period. Similarly, LPS in the absence of AC induced only a low level of cell death. In contrast, when both components, LPS and AC were added to vit—D3 activated THP-1 cells, massive cytotoxicity was observed within 6 hours. These observations te that stimulated macrophages participating in an in?ammatory reaction may be specifically targeted for deactivation with AC.
Experiment Overview: 1. Vit-D3 activated THP-1 cells were transferred to the wells of a 24-well dish 2. Compound AC, LPS from E.coli 0111:B4 or both components were added 3. After 6 hours at 37C the wells viable cell counts were performed by FACS Experimental procedures Cell culture: THP—1 cells (ATCC) treated with 0.2 uM vitamin—D3 (EMD Biosciences) for 4 days prior to day 0 were transferred to the wells of 24—well dishes (1x106 cells in lml cRPMI [RPMI (ATCC) + % AFBS (ATCC)]. LPS from E.coli 01 l 1:B4 (Sigma—Aldrich) and compound AC were added to appropriate wells and the plates placed in a 37C incubator. After 6 hours the wells were sed for Annexin V apoptosis assay. 2014/013992 FACS cell count and viability assay: After 6 hours, 500 pl of the cell suspension from each well was transferred to 3ml FACS tubes and 50 ul CountBright beads (Invitrogen) were added to each tube. Samples were vortexed, 2 ul propidium iodide (150 MM) (Sigma—Aldrich) added then acquired on the FACSCalibur.
Results: As shown in Table l, in the e of a second pro—inflammatory signal (LPS), AC exerted little effect on cell viability in THP—1 cells over a 6 hour period. Similarly, LPS in the absence of AC induced only a low level of cell death. In marked contrast, when both LPS and AC were added to vit—D3 activated THP—1 cells, e cytotoxicity was observed within 6 hours.
Cytotoxicity increased in a AC dose—dependent manner.
Table 1: Dose—dependent acute cell death in AC—treated THP—1 cells primed with LPS (Viable cell t change from 0 hours) Compound AC No LPS Plus LPS concentration (100ng/ml) 0 (0.1% DMSO) 0.5 ”M AC 1.0 uM AC 2.0 uM AC -10.63 —77.43 As shown in Table 2, in the absence of a second signal (LPS), AC, in a concentration range of 0.1 to 2 pM, exerted little effect on cell viability in THP—1 cells over a 6 hour period. Similarly, LPS in the absence of AC induced a low level of cell death that increased in a dose dependent manner. In st, when both components, LPS and AC, were added to vit—D3 activated THP— 1 cells, e cytotoxicity was observed within 6 hours. Cytotoxicity appeared to have reached maximal level with the lowest dose of LPS used (1 ng/ml).
Table 2: Titration of LPS in the THP—l acute/5—hour AC + LPS—induced cell death model (Viable cell t change from 0 hours) LPS THP—l viable cell % from 0 hours concentration 5 hours treatment Conclusion: AC selectively reduces viability of pro—in?ammatory LPS-activated macrophages, with relative g of nonstimulated macrophages. A very low dose of LPS (1 ng/ml) ed suf?cient activation of macrophages to make them susceptible to AC.
EXAMPLE B: Relative potency of Compound AC and chloroquine for inactivation of in?ammatory macrophages Background: THP—l is a human AML cell line that can be induced into a macrophage—like cell with vitamin—D3 (vit—D3) then activated into an in?ammatory state by stimulation with LPS (bacterial xin). In the macrophage, LPS binding to toll—like receptor 4 (TLR—4) leads to WO 20995 NF-KB activation and ion of in?ammatory cytokines which can lead to tissue damage in in?ammatory diseases.
Compounds of the invention inactivate in?ammatory macrophages by accumulating in acidic vacuoles and disrupting their ure and function, inhibiting release of vesicular in?ammatory mediators and inducing cytosolic changes that r macrophage death or dysfunction, including inhibition of autophagy; autophagy is important for differentiation of monocytes into macrophages. The aim of this study was to compare relative potency of a compound of the invention, AC, with chloroquine. Both AC and chloroquine are 4—aminoquinoline derivatives, and chloroquine is known to be useful for treatment of several al in?ammatory diseases.
In this experiment, cell viability was monitored and uptake and accumulation of acridine orange, a lysosomotropic ?uorescent dye, was used to assess lysosomal acidification and ity. JC—l dye was used to measure s of test compounds on mitochondrial membrane potential (MMP); reduction of MMP is a feature of apoptotic cell death.
Experimental procedures: 1. Vit-D3 activated THP-1 cells (0.5x106 cells in 2 ml) were transferred to the wells of a 24- well dish Compound AC was added at a concentration of 0.5 uM, 1.0 uM or 5.0 uM Chloroquine was added at a concentration of 25.0 uM, 50.0 uM or 100.0 uM LPS from E.coli 0111:B4 (1 ng/ml final tration) was added to some wells 99>.WN After 5 hours viable cell count, ne Orange (A.O.) uptake and JC—1 mitochondrial loading were determined by ?uorescence—activated cell sorting (FACS) Cell line information: THP—l: ATCC TIB—202 Organism: Human, male, one—year infant Organ: eral blood Disease: Acute Monocytic Leukemia (AML) Cell type: Monocyte Growth properties: Suspension in RPMI plus 10% FBS Test Compounds: Compound Conc. Supplier Batch info.
Alfa Aesar 43998 E26X026 AC N/A 073 1 12DZ Chloroquine diphosphate SIGMA C6628 JR (C-Q-) Bafilomycin A1 (Baf A1) SIGMA B1793 040912JR Crude—LPS E.c0110111:B4 SIGMA L4391 111611JR Acridine Orange (A.O.) Invitrogen A3568 092311JR JC-1 Invitrogen T3168 JR CCCP Invitrogen 818978 M34152 Sterile water HyClone AXF3933 SH30529.03 5 Sterile DPBS N/A e AW]2125 SH30529.03 3 Cell e: THP—1 cells (p39) treated with 0.1 uM Vit—D3 (100 uM) in DMSO] for 3 days were counted, spun down, ended in serum—free RPMI (Lonza 12—115F) and transferred to the wells of two 24—well dishes (0.5X106 cells in 2ml). Compound AC was added (in triplicate) at 0.1 uM, 0.5 uM and 1.0 uM, Chloroquine diphosphate was added (in triplicate) at 10.0 uM, 50.0 uM and 100.0 uM. Crude—LPS from E.coli 0111:B4 was added to some wells (1ng/ml final conc) and the plates placed in a 37C incubator. lul of Baf A1 (50 nM final conc) was added to one well (no LPS) at T=4 hours to serve as a compensation control for Acridine Orange loading. After 5 hours, 500ul aliquots of cells were transferred to FACS tubes and Viable cell counts, A.O. loading and JC—1 accumulation determined by FACS.
Acridine Orange (A.O.) uptake and viability cell count assay — 5 hour time point: s were ed, 2 ul of 50 ug/ml A.O. stock solution was added (200 ng/ml final) and the tubes incubated at 37C for 15 minutes. The tubes were washed twice in DPBS, ended in 500p] DPBS and acquired on the FACSCalibur. Acridine Orange exhibits strong ?uorescence in both FL—l (green — RNA binding) and FL—3 (far red — acidic lysosomes).
Results: As shown in Table 3 below, in the absence of LPS, low doses of AC had low direct cytotoxic effects that increased in a concentration ent manner at the acute/ (5 —hour) time point.
Chloroquine followed a similar trend though this required 100—fold more drug versus AC; 100uM quine was approximately equivalent to luM AC.
In the presence of a low dose of LPS (1 ng/ml), cytotoxicity was increased with addition of 0.1uM (lOOnM) AC. Addition of 10 uM, 50 uM or 100 uM Chloroquine had a smaller effect on LPS-induced cell death than did 1 uM AC, indicating approximately 100x higher potency of AC than chloroquine for inactivating LPS-stimulated as well as basal THP-1 cells.
Both AC and chloroquine reduced acridine orange ?uorescence in THP-1 cells primed with Vitamin D3 and activated with 0.1 ng/ml LPS (Table 4), ting deacidification or disruption of lysosomal integrity. AC was approximately 50x more potent than chloroquine for ng acridine orange ?uorescence.
AC treatment led to a dose—dependent reduction in mitochondrial depolarization, resulting in a decrease mitochondrial accumulation of red JC—l dimers.
LPS alone (1 ng/ml) had no effect on mitochondrial integrity but potentiated AC—induced mitochondrial depolarization. In contrast Chloroquine had little or no direct effect on mitochondrial integrity at concentrations up to 100uM in the absence or presence of LPS.
Table 3: Effect of AC and chloroquine on cell Viability after 5 hours +/—LPS in Vit—D3 activated THP—1 cells THP—l Viable cell count/well Test compound percent change from 0 hrs concentration lng/ml LPS Mean i SE Mean 1 SE DMSO (Vehicle) 0.00 i 2.37 —10.20 i 6.47 0.1 uM AC —l7.46i2.84 -32.77 i 1.98 0.5 “M AC J_r 2.27 -40.99 i 5.01 —31.20 i 2.71 -49.63 i 0.96 .0 M C.Q. -7.34 i 0.53 -17.38 i 4.44 50.0 M C.Q. -17.11 i 2.70 -30.13 i 1.23 100.0 M C.Q. —31.44 i 1.37 -43.98 i 1.73 REMAINDER OF PAGE INTENTIONALLY BLANK Table 4: Effect of AC and chloroquine on acridine orange cence after 5 hours +/—LPS in Vit—D3 activated THP—l cells A.O. FL—3 ?uorescence (MFI) Treatment percent change from DMSO no No LPS lng/ml LPS Mean i SE Mean 1 SE 0.00 i 3.89 —2l.06 i 0.45 0.1uM AC —27.64 i 9.68 -54.72 i 2.74 0.5uM AC -54.59 i 4.05 -68.24 i 2.39 1.0uM AC -69.52 i 2.05 -81.11 i 2.65 .0uM C.Q. —49.37 i 6.16 -64.76 i 3.01 50.0uM C.Q. -63.45 i 2.36 -72.28 i 0.78 100.0uM C.Q. -91.25 i 0.60 -88.28 i 1.60 REMAINDER OF PAGE INTENTIONALLY BLANK Table 5: Effect of AC and chloroquine on JC—l accumulation in mitochondria after 5 hours +/— LPS in Vit—D3 activated THP—1 cells JC—l Red cells (functional mitochondria) percent change from Treatment DMSO (no LPS) No LPS 1 ng/ml LPS Mean i SE Mean 1 SE 0.00 i 1.59 -0.33 i 0.69 .91 -1.66i0.96 —4.39 i 1.40 -7.19 i 1.52 1.0 uM AC -10.40 i 2.08 -16.41i 2.60 .0 uM C.Q. 2.58 i 0.81 4.39 i 0.81 50.0 uM C.Q. -0.70 i 1.24 2.21 i 0.63 100.0 uM C.Q. -1.40 i 0.67 1.07 i 0.39 Conclusion: AC displays selectivity for inactivating LPS—activated macrophages versus unstimulated cells.
AC also attenuated acridine orange accumulation in lysosomes, ting that it caused lysosomal tion. AC was approximately 100 fold more potent than quine for inactivating macrophages, and about 50 times more potent than chloroquine for disrupting lysosomal integrity as measured by acridine orange accumulation.
E C: Screen of compounds of the invention for anti—in?ammatory activity in vitro Background: THP—l is a human acute myeloid leukemia (AML) cell line that can be induced into a macrophage—like cell with Vitamin—D3 (vit—D3). In the macrophage, LPS (lipopolysaccharide; endotoxin) stimulation of toll—like receptor 4 ) leads to NF-KB activation and secretion of atory cytokines but also the priming of programmed death pathways through RIP and Caspase 8. The e of this complex regulatory network is dependent on highly specific kinases, enzymes that e ATP. Disruption of either cytosolic pH or ATP availability/energy level uncouples this control network and the can macrophage shift away from production of in?ammatory cytokines towards a mmed death event, which has the net effect of limiting in?ammatory damage.
Compounds of the invention have been shown to inactivate macrophages rapidly (within 5 to 6 hours) when the macrophages have been put into a ?ammatory state activated with LPS.
More than 200 compounds of the invention were screened for anti—in?ammatory activity in the THP—l system to assess their relative potency and activity in vitro.
Summary: Addition of LPS to compound-treated macrophages resulted in acute/5-hour cell death; this activity sed in a concentration dependent manner. Treatment with test nds alone exhibited only a low level of acute cytotoxicity.
The majority of compounds tested displayed signi?cant y to inactivate pro—in?ammatory THP—1 cells in accord with the proposed mechanism of action involving lysosome disruption, which is not dependent upon binding to a specific protein target. Of the compounds tested, seven demonstrated higher activity than the active benchmark compound AC: CJ, AM, AG, CX, AF, BM and AH.
At the lowest tration tested (0.1 uM), all seven tested compounds were more active than AC in causing death of cells treated with LPS. At concentrations of 0.5 uM and above all compounds, including AC, reached a maximum activity threshold.
Results: Addition of LPS to test compound—treated macrophages resulted in massive 5—hour cell death; this activity sed in a concentration dependent manner (Table 6). Treatment with compounds alone without pro—in?ammatory activation of the macrophages with LPS exhibited only a low level of acute cytotoxicity.
At the lowest concentration tested (0.1 uM), seven compounds were more active than AC in conditioning the cells for LPS—induced cell death. At concentrations of 0.5 uM and above, all eight compounds, including AC, reached a maximum activity threshold.
Compound CX was the most effective cytotoxic nd at the acute/5—hour time point, ed by a te activity group including CJ, AF, 30006 and BM. AG and AM exerted the lowest effect on cytoplasmic conditioning, albeit still greater than that shown by AC.
Table 6: Compound screen: Reduction in viable THP-l cell count (percent change) from 0 hours after treatment with test compounds for 5 hours Comound (0.1uM) Comound (1.0 uM) Compound Plus LPS Plus LPS Mean i SE Mean 1 SE Mean i SE Mean 1 SE Vehicle -7.42 i 3.07 0.00 i 4.71 -7.42 i 3.07 0.00 i 4.71 AC —15.14i2.06 —7.48 i 5.82 -44.25 i 2.53 —9.60 i 1.96 C] -30.15 i441 -5.53 i 3.89 -41.62 i 1.80 —6.99 i 1.55 -19.80 i196 -5.57 i 2.67 -44.05 i 1.38 —8.47 i 3.31 —21.28 i 1.52 —6.24 i 0.69 -38.58 i 0.73 —4.02 i 2.83 —38.09 i 0.41 —8.00 i 1.41 —49.57 i 2.44 —9.20 i 3.09 —27.32 i 4.69 —8.99 i 2.00 -44.82 i 2.46 -6.02 i 2.31 —25.80 i 3.26 —3.96 i 0.82 —39.17 i 2.18 —4.18 i 2.46 AH —26.55 i 0.95 —9.66 i 1.34 —35.51 i 3.90 —7.87 i 0.98 2014/013992 EXAMPLE D: Anti—in?ammatory activity of compounds of the invention Compounds of the invention have been shown to directly inhibit NF-KB, damage ellular acidic lysosomes leading to proton leakage and acidification of the cytoplasm and also damage mitochondria reducing the cellular energy level. Together these actions result in direct cell death in some vulnerable cell types, over a period of about 48 hours. Additionally in the macrophage, cytoplasmic acidification and energy depletion by compounds of the invention prime the cell for inactivation when exposed to low concentrations of LPS, leading to an acute (5—hour) cell death event through a combination of Caspase—driven apoptosis and RIP—driven necrosis.
Compounds of the invention were tested at 0.1 uM versus AC in the LPS—triggered THP—l cell death assay. Both acute/S—hour and chronic/48—hour phases of cell death were assessed.
Compounds were ed in s with DMSO as the negative control and AC as the high activity control. Compounds were tested at the low concentration of 0.1 uM with a View toward identifying agents more potent than the benchmark agent AC; at higher concentrations, e.g. 1 uM, most compounds of the ion are active in inducing cell death in this assay, which makes entiation from AC less clear than at a 10 fold lower drug concentration.
Results/Summary: Seven of the compounds not only demonstrated equivalent activity to AC at the acute/S—hour time point (cell conditioning) but were also more active than AC at the chronic/48—hour time point (retention): CJ, AM, AG, CX, AF, BM and AH.
A further 15 tested compounds demonstrated equivalent activity to AC at both the 5—hour and 48—hour time : CI, CL, AL, AR, AN, AD, BH, CV, AJ, BD, BU, BK, EW, AK and AB.
The remaining 187 compounds exhibited lower anti—in?ammatory activity than AC at the tested concentraction of 0.1 uM. However, this screen was conducted at a suboptimal concentration to detect the most potent nds in the y; low activity at a concentration of 0.1 mM in the t of this assay is still consistent with significant and potent anti—in?ammatory activity when compared to chloroquine or other antimalarials.
Summary Table 7: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1uM test compound) Cell death time point Compound Acute/S—hour Chronic/48—hour Mean SE Mean SE DMSO —l9.09 6.46 52.22 6.74 AC 3.83 4.12 27.70 CH —23.58 1.41- 53.55 7.24 ON 1 WU] 28.46 1.27 CJ —39.08 . 6 15.44 4.55 CK 4. 7 CL 086 .34 1.43 50.12 1.11 cw 43.71 2.34 DA 2597 2.71 43.55 6.40 DB 2573 0.25 20.47 3.28 BA —20.15 1.07 41.79 6.41 CY -29.18 1.70 47.86 2.06 CZ 53.70 1.63 CP —21.87 1.68 49.81 4.04 .49 BG —26.46 3.81 38.39 10.97 Summary Table 8: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1uM test compound) Cell death time point Compound 5—hour Chronic/48—hour Mean SE SE .05 7.90 4.64 2.63 0.81 3.73 17.34 8.29 4.16 9.59 3.39 7.17 4.54 7.16 7.09 3.87 3.12 1.13 2.15 2.81 AE —37.73 3.86 4.11 2.24 AB —20.14 0.71 56.56 5.96 REMAlNDER OF PAGE INTENTIONALLY BLANK Summary Table 9: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound Acute/S—hour c/48—hour Mean SE SE 0.40 35.66 3.27 1.94 14.24 1.47 2.17 19.14 4.63 1.18 39.53 5.09 2.45 33.86 1.63 2.14 31.64 4.04 2.07 31.07 8.11 4.07 18.03 3.64 2.14 27.30 8.06 3.87 34.36 2.98 1.56 41.84 3.25 2.45 28.60 12.70 2.80 2.74 1.15 24.32 3.49 4.94 2.24 0.73 47.40 8.60 REMAINDER OF PAGE INTENTIONALLY BLANK Summary Table 10: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound 5—hour Chronic/48—hour Mean SE SE 0.95 28.09 5.15 0.31 11.13 3.65 0.91 25.19 0.81 2.78 42.36 6.73 2.99 37.38 8.16 4.26 44.34 4.25 3.02 25.65 6.11 3.09 39.26 1.86 1.57 22.32 6.35 3.09 34.67 10.04 3.36 36.46 8.92 7.00 5.64 6.72 4.28 2.44 2.50 0.16 2.29 1.42 5.20 3.02 16.12 2.95 3.16 2.36 2.48 15.96 2.96 2.26 38.76 3.70 1.73 18.20 4.10 REMAlNDER OF PAGE INTENTIONALLY BLANK Summary Table 11: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound Acute/5—hour Chronic/48—hour Mean SE SE 0.94 1.11 2.33 —23.17 2.92 2.85 —5 .72 1.19 4.75 -6.80 3.16 2.07 0.65 3.12 1.94 6.40 11.50 0.36 -l7.21 4.61 BS —17.29 1.13 -6.51 2.77 y Table 12: Compound screen: Viable cell percent change after 5 and 48 hours in the THP-l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound Acute/S-hour Chronic/48-hour SE Mean SE 13 2.21 —24.59 1.48 FD —34.27 2.34 —3.68 4.14 FB —43.02 2.59 —10.18 3.14 FC —34.17 7.15 —20.85 1.63 FH —29.93 1.60 -5.12 4.01 FF —25.50 0.78 -4.74 0.92 FE —28.83 3.01 —11.23 1.97 FY —35.57 2.74 -1.84 3.24 BP —26.04 1.33 -3.39 7.15 FG —24.92 3.17 1.15 3.75 FZ —23.87 1.56 —5.31 3.01 y Table 13: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound Acute/5—hour Chronic/48—hour AC —36.91 0.49 3.97 GA —22.33 1.00 4.55 FI -23.79 2.33 1.85 GB —25.77 0.93 4.19 CE —30.76 3.40 2.96 F] -31.23 2.21 2.43 GC -27.62 3.64 7.07 1.80 3-66 1.51 2.47 2.59 4-50 0-86 3-30 3-48 3.41 —31.34 0.29 2.28 -22.83 2.09 2.40 REMAINDER OF PAGE INTENTIONALLY BLANK Summary Table 14: Compound screen: Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound 5—hour Chronic/48—hour Mean SE DMSO 9.11 9.96 AC —16.35 2.21 1.57 —3.09 6.02 1.15 —0.47 2.36 1.22 —1.83 3.18 1.21 3.59 3.14 1.79 -2.75 1.97 1.69 10.62 5.40 1.04 -1.09 0.38 1.96 1.27 3.15 2.66 -3.62 2.06 3.71 3.86 1.52 2.48 6.64 2.20 1.27 2.34 2.71 2.64 REMAINDER OF PAGE INTENTIONALLY BLANK y Table 15: Compound : Viable cell percent change after 5 and 48 hours in the THP—l cell death assay (10 ng/ml LPS 0.1 uM test compound) Cell death time point Compound Acute/5—hour Chronic/48— hour Mean SE SE DMSO 40.68 6.03 AC —41.20 2.33 16.40 3.98 DG —25.02 0.28 37.90 7.88 —27.53 1.35 50.89 5.57 —26.78 1.89 24.71 1.45 42.14 2.90 36.08 4.32 .10 6.23 —29.46 3.65 32.85 4.45 —29.40 1.20 39.64 5.24 .72 2.28 —32.45 1.49 30.34 2.30 28.35 4.70 38.59 1.87 EXAMPLE E: Anti-in?ammatory properties of Compound AC in a model of skin in?ammation Objective: To evaluate the n?ammatory properties of compounds of the invention in a 12- O—tetradecanoylphorbol—13—acetate (TPA) induced c skin in?ammation mouse model.
Topically applied phorbol esters such as TPA induce skin in?ammation involving edema, macrophage and T cell infiltration and epidermal hyperplasia (Alford et al., 1992), and this system has been used as an animal model for dermatitis, mimicking aspects of human in?ammatory skin disorders. TPA is also known as a tumor promoter, so that agents which inhibit hyperproliferative or angiogenic actions of TPA may inhibit tumor promotion. s Drug formulations: Compound AC was dissolved in isopropyl ate:propylene glycol (1:1) + 0.9% DMSO at the indicated concentrations. TPA was dissolved in acetone:water (99:1).
Dexamethasone (0.06%) was dissolved in normal saline.
Mice: HSD—ICR(CD—1R) female mice at 8—10 weeks of age were used in this experiment.
Experimental Design: Mice were placed into six groups of 10 mice each. 20 ML of 0.01% TPA was administered to each ear on days 0, 2, 4, 7, 9, ll, 13, 15, 18, 20, and 22. 20 ML of AC at various concentrations or 20 ML of thasone solution was applied to the ears daily beginning on day 7, after in?ammatory changes in ear thickness were established. Ear thickness was measured with calipers every three days.
Results Compound AC treatment prevented in?ammatory thickening of mouse ears treated with TPA. ogy indicated that both TPA—induced edema and epidermal hyperplasia were reduced by AC, as was angiogenesis. The potency of AC was able to that of dexamethasone, with signi?cant activity ed at the lowest dose of 12.5 micrograms of AC per ear per day.
Table 16. Ear thickness of vehicle and compound-treated mice: day 22 Treatment Ear thickness (mm) Vehicle 0.646 1 0.1161 Dexamethasone, 0.05 mg/ear 0.301 + 0 0722 AC, 0.0125 mg/ear 0.362 i 0.0394 AC, 0.025 mg/ear 0.390 i 0 0319 AC, 0.05 mg/ear 0.391 i 0.0334 AC, 0.075 mg/ear 0.395 i 0.0438 Reference Alford JG, Stanley PL, Todderud G, sch KM. (1992) Temporal infiltration of leukocyte subsets into mouse skin d with phorbol ester. Agents Actions. 37(3—4):260—7 EXAMPLE F: Anti—in?ammatory effects of compounds of the invention on psoriasiform dermatitis in mice WO 20995 Topical imiquimod (IMQ), a toll—like receptor t, has been established as a model of In?ammatory skin diseases including psoriasis and atopic dermatitis. Dermal in?ammatory changes and gene expression in mice treated with l imiquimod mimic human sis and dermatitis (van der Fits et al., 2009; Swindell et al., 2011). The effect of a set of compounds of the invention were tested in a mouse model of imiquimod—induced dermatitis, with topical tacrolimus and dexamethasone as comparators for assessing safety and efficacy relative to standard agents used to treat dermatitis in humans.
Compounds to be tested for anti—in?ammatory activity were individually dissolved in ethanol at a concentration of 0.6% and then mixed with 9 volumes of petrolatum (melted on a heated water bath at 50 degrees C), yielding ointments containing 0.06% active drug. Dexamethasone nt was prepared similarly, though at a final concentration of 0.03%, e 0.06% dexamethasone applied topically in preliminary experiments had caused significant weight loss due to systemic absorption. Commercial 0.1% tacrolimus ointment (ProTopicTM; Novartis) was also used as an active comparator. Petrolatum containing 10% ethanol was used as a control ent.
Female Balb/C mice (8 weeks old) were randomized and divided into groups of 5 animals each.
Polyethylene collars were affixed to the mice to prevent them from easily scratching their ears. % mod was applied to both ears of each mouse (20 iters per ear) daily for 5 days, and then every other day for the full duration of the study. In?ammatory changes, including a doubling of ear thickness were apparent by day 5. On day 7 after initiation of imiquimod, treatment with topical agents was started. Both ears of each mouse were treated with test ointments, with one compound per mouse.
Ear thickness and PASI assessments (Psoriasis Area and ty Index, a standard psoriasis scoring system) were recorded twice per week throughout the study. The PASI score comprises the sum of evaluations of swelling, erythema and g on scales from 0 to 4; the maximum PASI score is 12, and the minimum, in unaffected skin, is 0).
Results Imiquimod treatment resulted in significant in?ammatory changes, including an increase in ear thickness and a change in PASI scores; control ears reached the maximum possible value in the PASI g system, with severe thickening, erythema and scaling. Compounds of the invention, d topically in an nt base, reduced imiquimod—induced in?ammatory damage to mouse ears, as assessed by caliper measurements of thickness and PASI scoring of appearance. The ator drugs tacrolimus and dexamethasone also reduced ear thickness and PASI scores. Notably, AF was superior to the commercial clinical form of topical 0.1% tacrolimus (Protopic nt) in reducing ear thickness and PASI score. The anti—in?ammatory activity of dexamethasone was accompanied by significant loss of body weight, indicating systemic toxicity due to dexamethasone absorption. Neither compounds of the invention nor tacrolimus affected body weight. In addition to inducing in?ammation of the ears imiquimod transfer from the ears to the scalps of mice resulted in loss of hair and psoriasiform dermatitis on the head, from n the ears, forward to the nose. In dexamethasone—treated mice, this area remained hairless after treatment at the end of the experiment; in contrast, hair growth was ined in this area during daily ent with AF, indicating that AF inhibited ogic in?ammation without also impairing tissue normal tissue maintenance. A known side effect of treatment with dexamethasone and other topical corticosteroids is thinning and weakening of the treated areas; the lack of hair th may re?ect the clinical problem of skin atrophy known as a side effect of topical dexamethasone. AF was equally effective at 0.06% and 0.6% concentrations in the ointment base, indicating a wide therapeutic window. All of the tested compounds of the invention reduced IMQ—induced changes in ear thickness, thus demonstrating their anti—in?ammatory ty in vivo.
REMAINDER OF PAGE INTENTIONALLY BLANK Table 17: Ear thickness in mice with imiquimod—induced dermatitis ent Mean i SEM Untreated (no IMQ) 0220 i 0.004 Control 1.355 i 0.004 AF 0.06% 0.355 i 0.005 * AF 0.6% 0.390 i 0.008 * 0.577+0.019* 0.613 i 0.010 * 0.589+0.018* *=1ess than control ear thickness, p<.05 REMAINDER OF PAGE INTENTIONALLY BLANK Table 18: PASI Scores in mice with imiquimod-induced psoriasiform dermatitis Treatment Mean ± SEM Untreated (no IMQ) 0.000 ± 0.000 Control 12.000 ± 0.000 AF 0.06% 3.575 ± 0.158 * AF 0.6% 4.875 ± 0.155 * AC 7.150 ± 0.221 * BM 9.250 ± 0.183 * EF 7.275 ± 0.199 * DD 7.450 ± 0.322* DU 7.975 ± 0.621 * DE 7.250 ± 0.183 * AE 11.550 ± 0.281 Dexamethasone 4.525 ± 0.375 * Tacrolimus 0.1% 6.075 ± 0.0990 * *=less than control PASI score, p<.05 DER OF PAGE INTENTIONALLY BLANK Table 19: Body weights of mice with imiquimod-induced psoriasiform dermatitis Treatment Body Weight (mean ± SEM) Initial (g) Final (g) D BW (g) Control 21.2 ± 0.8 21.9 ± 0.7 + 0.7 AF 0.06% 20.5 ± 0.8 20.9 ± 0.6 + 0.4 AF 0.6% 20.8 ± 0.6 20.4 ± 0.6 - 0.4 AC 21.1 ± 0.7 21.3 ± 0.6 + 0.2 BM 20.8 ± 0.7 20.9 ± 0.6 + 0.1 EF 21.5 ± 0.6 21.3 ± 0.2 - 0.2 DD 20.9 ± 0.8 20.7 ± 0.6 - 0.2 DU 20.4 ± 0.7 20.9 ± 0.5 + 0.5 DE 20.6 ± 0.5 20.5 ± 0.5 - 0.1 AE 20.9 ± 0.5 21.3 ± 0.4 + 0.4 Dexamethasone 20.5 ± 0.6 18.1 ± 0.5 * -2.4 * Tacrolimus 0.1% 20.9 ± 0.7 20.4 ± 0.6 -0.5 * Less than initial body weight, P<.02 References ll WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, Wang XJ, Sano S, Prens EP, DiGiovanni J, Pittelkow MR, Ward NL, Gudjonsson JE. (2011) Genome-wide sion profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One. 6(4):e18266 van der Fits L, s S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182(9):5836-45 EXAMPLE G: Effects of compounds of the invention in a mouse model of multiple sclerosis Multiple sclerosis (MS) is an autoimmune disease mediated ing destruction by the immune system of myelin sheaths surrounding neuron axons in the brain. An established animal model for this e is Experimental Autoiimune Encephalitis (EAE), induced by immunization of mice with proteins or peptides that induce an immune se to myelin—specific proteins.
In this experiment, EAE was induced by immunization of mice with a peptide from proteolipid protein (PLP), a known antigenic target in MS. Several compounds of the invention were administered orally to assess their effect on the course of EAE, with quantitative evaluation of disease symptoms as an endpoint. Linomide, a small molecule immunomodulator with known activity in EAE models was used as a comparator drug.
Materials and Methods 41 mice received subcutaneous injections of 90 ug PLP139-151 in 200 uL of PBS on Day 0.
The PLP was ed in incomplete Freund’s adjuvant (IFA) by mixing 10 mL IFA with 40 mg M. tuberculosis H37Ra (final concentration 4 mg/ml M. ulosis). The resulting mixture is complete Freund’s adjuvant (CFA).
For injection, an emulsion of PLPl39—15 l and CPA was prepared by mixing 1 mL of stock solution with 1 mL of CFA while vortexing for 15 minutes to form an emulsion.
Mice received vehicle or a test compound (60 g; suspended in 1% aqueous ypropylmethylcellulose) by oral gavage, three times per week for 2 weeks followed by once daily ent for 4 onal weeks, beginning on Day 14. Vials with vehicle and with compounds were coded by letters (A—E) in order to obtain blind readings of disease severity.
Group 1 (n=7) Vehicle Group 2 (n=6): AZ Group 3 (n=7): CZ Group 4 (n=7): CP Group 5 (n=7): CQ Group 6 (n=7) Linomide Mice were monitored every other day for the pment of clinical symptoms according to the grading system below.
Grading System for Clinical Assessment of EAE Score Clinical Signs 0 Normal mouse, no overt signs of disease 1 Lim tail21 and hind limb weaknessb, but not both 2 Lim tail21 and hind limb weakness' 3 Partial hind limb aral sisC 4 e hind limb inaral sis' Moribund state; death by EAE; sacrifice for humane reasons “Limp tail: complete ?accidity of the tail, and absence of curling at the tip of the tail when mouse is picked up. bHind limb ss: observed as a waddling gait, the objective sign being that, in walking, mouse’s hind limbs fall through the wire cage tops. al hind limb paralysis: mouse can no longer use hind limbs to maintain rump posture or walk but can still move one or both limbs to some . dComplete hind limb paralysis: total loss of movement in hind limbs; mouse drags itself only on its forelimbs. Mice at this stage are given food on the cage ?oor, long sipper tubes, and daily subcutaneous saline injections to prevent death by ation.
Results: Mice in all groups were displaying comparable mild EAE disease symptoms by day 14 after PLP ion, at which time oral treatment with the test agents was initiated. At the termination of the study, on Day 46, Vehicle—treated mice displayed more severe disease symptom scores than did the treatment groups. Compounds of the invention displayed protective activity comparable to the positive control compound linomide.
Table 20 Treatment EAE Score on Day 14 EAE Score on Day 46 (Before Treatment) Vehicle 0.71 i 0.18 3.57 i 0.48 Linomide 0.93 i 0.19 2.29 i 0.48 AZ 0.83 i 0.41 2.50 i 0.29 CZ 1.00 i 0.00 2.29 i 0.20 CP 0.86 i 0.14 1.86 i 0.34 ANTIFUNGAL AND ANTIPARASITIC EXAMPLES EXAMPLE H2Anti—Candida Activity of Compounds of the Invention Reagents Manufacturer/Catalog # Lot # Candida albicans strain 3153 ATCC 28367 61794 YPD Broth KD Medical YLF-3260 032111-03 Sabouraud Dextrose Agar KD Medical #YPL-1050 C21-03 Sterile PBS, pH7.4 Quality Biological Inc; #114131 DMSO Sigma; cat#D2650 Experiment overview: A single colony of Candida Albicans was grown in 50 ml YPD broth overnight (19 hr). The cells were washed with PBS and 4 CFU/ml of C. AZbicans (144 ul/well) in YPD medium were plated in 96 well . Test compounds were then added to each well with concentration ranged from 5 to 40 MM as final concentrations. The plates were ted at 30°C ght (24 hrs) and OD at 600nm was read at the end of incubation as an index of yeast cell y.
Results: Most of the compounds tested showed inhibition of Candida growth.. Based on inhibition curves, IC50 (50% inhibition of fungal growth) and MIC (99% of inhibition of fungal growth) values of compounds were calculated using XLfit and listed in the following table. The compounds with higher antifungal activity have the lower numerical values.
Table 21: 50% Inhibition (ICSO) and m Inhibition Concentration (MIC) Value I050 (uM) MIC (uM) AL BR * The MIC cannot be calculated for these compounds due to insufficient data points.
Procedure: : Preparation of Candida albicans Cells 1. One day prior to the inoculum preparation, pick a single colony of a albicans strain 3153 (lot# 61794) from the Sabouraud Dextrose Agar plate using the inoculum loop and inoculate into a 250 mL ?ask containing 50ml of YPD growth medium Incubate at 30 0C with shaking at 150rpm for at least 18 hours with ed lid to allow air in and facilitate growth.
Examine an aliquot of the culture under a microscope for Candida cell morphology and lack of bacterial contamination; >95% of Candida cells should be blastoconidia.
Transfer 25ml the overnight culture into a 50—ml plastic able centrifuge tube, and centrifuge at 1000Xg for 20min. d the supernatant and wash the pellet with 4ml of PBS at three times. Vortex and centrifuge, 1000xg for 10min.
After the third wash, se the pellet with 2ml PBS and vortex.
Make three 1:10 serial dilutions in sterile PBS (10*, 102, 103) from the 2 ml cell suspension using 15ml culture tubes. The ?nal volume in each tube is 5 m1.
Count the number of cells in cell suspension from the 10'3 dilution tube on the hemocytometer.
To calculate cell concentration per ml: Average number of cells in one large square x dilution factor x 104 104 2 conversion factor to convert 10'4ml to 1 ml The cell number in 50—fold dilution of 10‘3 was: 14x104 CFU/ml 9. Make a 1:4 dilution in YPD medium from the 50—fold dilution of 10'3 cell suspension for testing compounds.
The final C. albicans cell tration for the test: 3.5X104CFU/1’1’ll . Plated l44ul/well of the above dilution of cell on 96—well plates.
Part—II: C. ns Growth Inhibition Testing with Compounds 1. From 10 mM DMSO stock solutions, make serial dilutions of compounds to 0.13, 0.25, 0.40, 0.55, 0.75 and l.0mM ons 2. Add 6ul each of diluted compound ons per well in duplicates. The final concentrations were 0, 5, 10, 16, 22, 30 and 40 micromolar. 3. Incubated all plates at 30C for overnight (~24 hours). 4. Read ance at OD600 for each plate. 6. Calculate the % inhibition of each compound against the DMSO treated cell.
EXAMPLE 1: Evaluation of ty of Compounds against Saccharomyces cerevisiae Reagents Manufacturer/Catalog # Lot # Baker’s yeast Red Star YPD Broth KD Medical YLF-3260 032111—03 Sabouraud Dextrose Agar KD Medical #YPL-1050 C21—03 Sterile PBS, pH7.4 Quality Biological Inc; #1 14—058—131 DMSO Sigma; cat#D2650 Experiment overview: An overnight culture of S. seae was dilution in YPD broth to concentration of 40,000/ml 40 and 150ul/well was plated in 96 well plates. Compounds were then added to each well with concentration ranged from 4 to 50 MM as final concentration. The plates were inoculated at 30°C overnight with shaking at 220 rpm and absorbance at 600 nm was read after 18 hour incubation. 2014/013992 Results: Among all the effect compounds against S. cerevisiae, compounds AL, BG, and AW were the most effective ones. Compound AI generated lower IC50 from XLfit calculation, even though it could not reach near 100% kill at high concentration like other compounds did. Chloroquine (C.Q.) did not show any inhibition of yeast growth up to 50uM. ing listed IC50 (50% inhibition of fungal ) and MIC (99% of inhibition of fungal growth) values of compounds (calculated using XLfit) based on inhibition curves.
Table 22: Anti—S. cerevisiae — 50% Inhibition (IC50) and Maximum Inhibition Concentration (MIC) Value Com pou nd inactive co mp0 und AL BA AM BT AG AC AN CA AZ CB BE Chloroquine *The MIC cannot be calculated for these compounds due to insufficient data points.
Procedure: Part—I: Preparation of Yeast Cells 1. One days prior to the inoculum preparation, pick a single colony of S. cereViseae from the Sabouraud Dextrose Agar plate using the inoculum loop and inoculate into a 50 mL tube containing 10ml of YPD growth medium Incubate at 30 0C with shaking at 220rpm for 24 hours with loosen lid to allow air in and facilitates growth.
Examine an aliquot of the culture under a microscope for yeast cell morphology and lack of bacterial contamination.
Dilute the overnight culture with YPD medium at 1:30 dilution (70ul to 2.1ml) and count the number of cells as 4,230,000/ml.
Mix 620 pl of 1:30 dilution and 64.4 ml YPD to make final concentration of 40,000/ml cells 6. Plated 144 ul/well in four l plates.
Part—II: Yeast Growth tion Testing 1. From 10 mM DMSO stock solutions, make serial dilutions of compounds to 0.1, 0.2, 0.3, 0.63 and 1.25 mM solutions Add 6 ul each of diluted compound solutions per well in duplicates. The final concentrations were 0, 4, 8, 12, 25 and 50 micromolar.
Incubated all plates at 30C for overnight (~18 hours) with 220 rpm shaking.
Read absorbance at OD600 for each plate on Spectra Max Plus plate . ate the % inhibition of each compound against the DMSO treated cell and plotted.
EXAMPLE J: Anti—Trichophyton Activity of Compounds of the Invention Tricophyton rubrum is one of the primary fungi responsible for persistent, treatment—resistant l infections.
Reagents Manufacturer/Catalog # Lot # Trichophyton rubrum ACTT, MYA—4438 59404737 PDB (potato dextrose broth) VWR 61000— 102 0000130316 PDA (potato dextrose agar) VWR 90008—416 1 Sterile PBS, pH7.4 Quality Biological Inc; #1 14—058—131 DMSO Sigma; cat#D2650 ell plate VWR 29442— 120 04709006 (Costar 3422, 24well with 8pm) Experiment overview: Trichophyton grown on two agar plates were collected by scraping into 10 ml saline and filtered h 8 um filters. The filtered solution was diluted (1:75) and plated in 96 well plates and treated with selected compounds of the invention.
Results: This ment included some active compounds from previous experiment and added several untested compounds. Culture treated by compounds AW, AX, AT, AE or AH showed no visible fungal grow with even the lowest concentration (6uM) tested, representing their est inhibitory effect against trichophyton growth. Most of rest compounds also inhibited fungal growth with higher concentration (12—18 uM). AO, AP, AF, BL, AQ and B0 showed only partial or no inhibition on fungal grow with highest concentration (40uM) . Following table listed the maximum inhibition concentration (MIC) based on scoring by eye.
Table 23 Compound MIC, Compound MIC, HM Compound MIC, MM AL 12 AO >40 AX 6 AM 12 AP ~40 AT 6 AG 18 AC 18 BO >40 AN 18 AF >40 BP 12 AZ 18 BL >40 AK 18 BE 12 AC) >40 BM 18 BF 18 AU 12 AE 6 BG 12 AS 25 AH 6 B] 18 AV 25 AB 18 BI 18 AW 6 C12-Im 18 Procedure: Part—I: Preparation of Trichophyton rubrum Cells Scrape frozen Trichophyton culture from ATCC vial and suspended in 100 pl PDB, and then plate on a PDA plate. Incubate plate at 30 C for 4 days.
The plate was covered almost full. Scrap colonies from two plates in 10ml saline and filter through 8pm filter in a 24 well transwell plate (used 2 wells). Take OD of collected solution at 52 0nm and 600 nm: A 520 nm = 0.13; A 600 nm = 0.092 1x without on A 520 nm 2 0.061; A 600 nm 2 0.037 1:25 dilution Make 90ml of 1:75 dilution in PDB broth from the filtered cell sion by mixing 1.2 ml of cell solution with 88.8ml PDB and t 144 ul/well in 5 X 96 well plates.
Part—II: Trichoph?on Growth Inhibition Testing with Compounds 1. From 10 mM DMSO stock solutions, make serial dilutions of compounds to 0.15, 0.3, 0.45, 0.63 and 1 mM solutions 2. Add 6 111 each of diluted compound solutions per well in triplicates. The final trations were 0, 6, 12, 18, 25 and 40 micromolar. 3. Wrap the plates with parafilms and incubate all plates at 30°C for 6 days.
Take picture of the plates on KODAK imager with 17 captures of 1.5 sec/capture for total of 25.5 second exposure.
EXAMPLE K:Anti—Cryptococcus Activity of Compounds of the Invention Reagents Manufacturer/Catalog # Lot # coccus neoformans Stain ID 52 ATCC 24067 4282211 YM Broth TEKNOVA #Y073l Y073105J 1101 Sabouraud Dextrose Agar KD Medical #YPL— 1050 C21—03 e PBS, pH7.4 Quality Biological Inc; #114—058—131 DMSO Sigma; cat#D2650 Experiment ew: Cryptococcus mans (serotype D) were plated in 96 well plates with 144 til/well of 8 x10e5 CFU/ml in YM growth medium. Diluted compounds were then added to each well with concentration ranged from 4 to 60 uM as final concentration in ates. The plates were inoculated at 37°C for total of 48 hours. Two readings of OD at 600nm were measured after 30 and 48 hour treatments.
Results: Most compounds tested in this assay inhibited the growth of coccus, with compounds AL, AG, AW, AX, AA, AE, AH, AK, BM, and EN as the most ive ones. It is noteworthy that compounds AA and AC were quite active against Cryptococcus, comparing with their relative weak ties against Candida and S. cereviseae. Overall it seems that Cryptococcus is more susceptible to compounds of the invention than the other fungi tested. Chloroquine had very weak activity against Cryptococcus, with a maximum growth inhibition of 40% at a concentration of 100 micromolar, so that its IC50 is greater than this concentration. IC50 (concentration for 50% of inhibition) and MIC (concentration for maximum—99% of inhibition) were calculated using XLfit based on OD of 48 hour reading are listed in the following table.
Table 24 I050 I050 ure: Part-I: Preparation of fungal Cells 1. Pick a single colony of Cryptococcus from the YM agar plate using the inoculum loop and inoculate into a 125 ml ?ask containing 25 ml of YM growth medium. 2. Incubate at 37 °C with shaking at 220 rpm for 24 hours with loosen lid to allow air in and facilitates . 3. Examine an aliquot of the culture under a microscope for yeast cell morphology and lack of bacterial contamination. 4. Dilute the overnight culture with YM medium at 1:100 dilution and count the number of cells as 1X106cfu/ml. 5. Make a final concentration of cells suspension at 8X105 cfu /ml in YM medium. 6. Plate 144 ul/well of 8X105 cfu /ml cell suspension on 96—well plates.
Part—II: Cryptococcus Growth tion Testing with Compounds 1. From 10mM DMSO stock solutions, make serial dilutions of compounds to 0.1, 0.2, 0.3, 0.5, 1.0 and 1.5 mM solution 2. Add 6ul each of diluted nd solutions per well in duplicates. The final concentrations were 0, 4, 8, 12, 20, 40 and 60 micromolar. 3. Incubated all plates at 37°C overnight (30 hours) with 150 rpm shaking. 4. Read absorbance at OD600 for each plate. 5. Leave plates in 37°C incubator for another day and read absorbance at OD600 again at 48 hours to ensure the inhibitory effect of the compounds. 6. Calculated the % inhibition and IC50 of each compound against untreated cells.
EXAMPLE L: Anti-Cryptococcus (serotype A) Activity of Compounds of the Invention Reagents Manufacturer/Catalog # Lot # Cryptococcus neaformans serotype A ATCC MYA-1017 58178990 YPD Broth KD Medical 60 090712-04 aud Dextrose Agar KD Medical #YPL—1050 C21—03 Sterile PBS, pH7.4 y Biological Inc; #1 14—058—131 DMSO Sigma; cat#D2650 Experiment overview: Cryptococcus neoformans (serotype A) were plated in 96 well plates with 144 til/well of 5 X10e5 CFU/ml in YPD growth medium. Diluted compounds were then added to each well with concentration ranged from 0.05 to 10 uM as final concentration in duplicates. The plates were ated at 30°C. Two readings of OD at 600nm were measured after 18hr and 48 hour treatments.
Results: Most compounds tested in this assay ted the growth of Cryptococcus (serotype A), with AX, AK, BM, AE and AH as the most effective ones. Cl2—imidazol had relative weak activity against Cryptococcus serotype A at low concentration. Data plotted was based on 26 hour reading because 18 hour reading was too low. IC50 (concentration for 50% of inhibition) and MIC (concentration for maximum — 99% of inhibition) were calculated using XLfit based on OD of 26 hour reading are listed in the ing table.
Table 25: 50% Inhibition (IC50) and m Inhibition Concentration (MIC) Value |C50, uM MIC, uM It is worthy of note that C. neoformans (serotype A) is the most sensitive fungus to the compounds compared to the other tested species, including C. Albicans, S. siae, Trichophyton , and Cryptococcus serotype D Procedure: Part—I: Preparation of fungal cells 1. Pick a single colony of Cryptococcus from the Sabouraud Dextrose agar plate using the inoculum loop and inoculate into a l25ml ?ask containing 25ml of YPD growth medium 2. Incubate at 30 0C with shaking at 220 rpm for 24 hours with loosen lid to allow air in and facilitates growth. 3. Examine an aliquot of the culture under a microscope for yeast cell morphology and lack of bacterial contamination. 4. Dilute the overnight culture with YPD medium at 1:100 dilution and count the number of cells as 8X106cfu/ml.
. Make a final concentration of cells suspension at 5x105 cfu /ml in YPD medium after the stock e had been stored at 4°C for 3 days. 6. Plate 144 ul/well of 5X105 cfu /ml cell suspension on 96—well plates.
Part—II: Cryptococcus Growth Inhibition Testing with Compounds 1. From 10mM DMSO stock ons, make serial dilutions of compounds to 0.0013, 0.0025, , 0.025, 0.05, 0.125 and 0.25 mM solution 2. Add 6ul each of diluted compound solutions per well in duplicates. The final trations were 0, 0.05, 0.1, 0.5, 1.0, 2.0, 5.0 and 10 micromolar. 3. Incubated all plates at 30°C overnight with 175rpm shaking. 4. Read absorbance at OD600 after 18 and 26 hours for each plate.
. Calculated the %inhibition and 1C50 of each compound against the ted cell.
EXAMPLE M: Effects of compounds of the Invention on THP—l—derived macrophage antifungal activity; pment of a phagocytosed Cryptococcus neoformans antifungal screen Background: In the preceding examples compounds have been shown to possess direct anti— fungal activity t coccus neoformans at concentrations less than 5 uM. The compounds, being weak bases, are lysosomotropic, concentrating in the acidic lysosomal compartment of macrophages. Some pathogenic fungi, such as Cryptococcus neoformans, reside in acidic lysosomes of macrophages in an effort to avoid the host immune system (Srikanta et al., 2011. 2014/013992 Another lysosomotropic drug, chloroquine, which has some direct anti—fungal activity at the much higher tration of lOOuM in C. mans, has been shown to enhance anti—fungal activity of macrophages against C. neoformans when tested at only 10 uM. This effect was shown to be due to the drug concentrating in lysosomes housing the yeast (Harrison et a1., 2000) The potential therefore exists for compounds of the invention to behave in a manner similar to chloroquine for attacking Cryptococcus or other organisms residing in macrophages, but at much lower concentrations.
Results/Summary: The compounds tested (AM, BM, AH and AC) all showed clear dose dependent inhibition of fungal growth after phagocytosis and lysis. AH showed the highest potency with near 100% inhibition of the fungal growth at 2uM.
The IC50 values after macrophage phagocytosis were comparable to the IC50 values for direct inhibition of fungal growth, in the absence of macrophages reported in an earlier study.
The compounds were capable of killing C. neoformans (serotype A) even when the fungus was d within live macrophages.
References: 1: A sensitive high—throughput assay for evaluating host-pathogen interactions in Cryptococcus neofomans infection Srikanta, D et a1 (2011) PLoS ONE 6(7): 622773 2: Conditional ity of the diprotic weak bases Chloroquine and Quinacrine against Cryptococcus neoformans Harrison, T. S et al (2000) J Infect Disease 182: p283—289 Results: Two concentrations of hages (1X105 and 2x105/well) and a high concentration of C. neoformans (4X106/well) (MOI values of 40 and 20 respectively) were tested in this experiment.
WO 20995 All of the compounds tested showed clear dose ent inhibition of fungal growth after phagocytosis and lysis. Phagocytosis by macrophages did not protect the fungus cells from antifungal activity of compounds of the invention.
The IC50 values after macrophage phagocytosis were comparable to the IC50 values for direct inhibition of fungal growth, in the absence of macrophages.
Table 26: IC50 for inhibition of fungal growth by compounds directly or after macrophage ytosis Compound IC50 value (uM) No macrophages 1x10 macrophages 2X10 macrophages 1.57 1. 13 0.85 0.69 1.31 0.39 0.25 AC 1.15 1.29 1.35 Experimental procedures: Experiment ew for assay development plate #4: THP-1 cells were adjusted to 5x105/ml or ml in cRPMI + PMA 200 pl was transferred to a ?at-bottomed 96-well dish (1x105 and well) (48hrs at 37C) Media was removed and fresh cRPMI + PMA added (further 24hrs at 37C) C. neoformans cells in DPBS were opsonized with human serum (60mins at 30C) The opsonized yeast was washed (DPBS) and resuspended at 1X107/m1 or 2X107/m1 in cRPMI. 100ul added to macrophage plate (1x106 and 2x106/well) (4hrs at 37C) washed X4 with DPBS 100p] of cRPMI was added to each well (18hrs at 37C) Compound AC was added to some wells.
Media was removed, no wash, 25ul 0.05% Triton X—100 added to lyse cells (3 mins RT rocking) 125p] YPD broth was added and the plate incubated (24hrs at 30C then 24hrs at 37C) C. neoformans growth was determined on a Spectrophotometer (600nm) after 24 and 48 hours Cell line information: THP—l: ATCC TIB—202 Organism: Human, male, one—year old infant Organ: Peripheral blood e: Acute Monocytic Leukemia (AML) Cell type: Monocyte Growth properties: Suspension in RPMI plus 10% FBS THP— l—derived macrophage entiation protocol (PMA): THP—1 cells (p15) grown in cRPMI [RPMI (Lonza 12—115F) plus 10% AFBS (Lonza DE14— 701F)] were counted on a hemacytometer. Cells were spun at 1,800 rpm, RT for 5 mins, supernatant aspirated, pellet bed then adjusted to 5.0X105/1’1’ll and 1.0X106/1'1'll in cRPMI supplemented with 0.2ug/ml phorbol 12—myristate 13—acetate (PMA) (1 mg/ml in DMSO Sigma P8139). 200ul aliquots of each cell concentration were transferred to 42 wells (half a plate) of a ?at-bottomed 96—well dish (1X105 and 2X105/we11) and placed in a 37C incubator for 48 hours, media was then d and 200 pl of fresh cRPMI + PMA added. The plate was incubated for an additional 24 hours at 37 C then processed for yeast uptake.
Yeast strain information: C?gtococcus neotormans: ATCC MYA-1017 Designation: CDC21 Isolation: Derived from strain H99 from patient with Hodgkin’s disease, New York Antigenic properties: pe-A Growth properties: Suspension in YEPD broth 25C Opsonization of Cryptococcus neoformans cells (human serum only): In parallel to hage preparation, C. neoformans cells were grown from a single colony in 20ml YPD broth at 30C ght. Absorbance of 1:10 dilution of the overnight (ON) culture gave 0.89 OD at 600nm. Estimated tration of this stock was 4X108 cells/ml (2x108 cells/ml gave an OD 600nm of 0.426 in an r study Cryptococcus macrophage development plate 3 12). The cells were washed with DPBS once and resuspended in 2ml DPBS. 230 pl of this stock (~60x107 cells) was brought up to 500 pl with DPBS in an Eppendorf tube. For Opsonization, 500 pl of human serum (SIGMA S7023) was added and the tube incubated at 30 C for 60 mins with orbital shaking. The opsonized fungal cells were washed three times with 800ul DPBS (1,100g for 2 min) and resuspended in 800p] DPBS. A 1:200 dilution of cells was counted (4.25X106/ml), equivalent to 8.5X108/l’1’11 for the 1X stock. 470 pl of the 1X stock was brought up tolOml with cRPMI for a final concentration of 4x107/ml.
Macrophage mediated anti—fungal activity assay: Media was aspirated from the prepared macrophage plate and 100ul of the opsonized fungal cell suspension added to the wells. Media without yeast was added to triplicate wells for each macrophage concentration to provide background readings. Three empty wells (no macrophages) were seeded with fungus to serve as the wash control. The plates were then ted at 37 C for 4 hours then washed 4 times with DPBS (plates were shakes brie?y after addition of DPBS to se wash efficiency). 144 pl of cRPMI was added to each well and 6ul of 12.5 uM, 25 uM and 50 uM stocks of compounds AM, BM, AH, and AC added in triplicate for final concentrations of 0.5 uM, luM or 2 uM. The plate was incubated at 37 C, 5% CO2 for 18 hours.
Media was removed, 25ul of 0.05% Triton X—100 (SIGMA T—9284) in DPBS was added to each well and the plate rocked at RT for 3 min, to lyse the cells. 125 pl YPD broth (KD Medical YLF—3260) was then added to each well and the plate placed in a 30C incubator. C. neoformans cell growth was determined by measuring absorbance at 600nm on a Spectrophotometer ra Max Plus using program x Pro) after 30 hours.
EXAMPLE N: Antifungal Activity as Determined by Minimum tory and Fungicidal Concentrations OBJECTIVE The objective of this study was to determine the antifungal activity of eight experimental compounds against a representative panel of fungal isolates, including Candida ns, C. glabrata, Cryptococcus neoformans, Trichophyton rubrum, Aspergillus fumigatus, and us spp. Antifungal activity was measured by minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC).
MATERIALS Isolates Three recent clinical strains of each species, taken from the culture collection at the Center for Medical Mycology, Case Western University, were tested.
Antifungal Agents Compounds in powder form were dissolved in DMSO. Serial dilutions of each compound were then prepared in RPMI—l640 in a range of 0125—64 ug/ml.
MIC testing was performed according to the CLSI M27—A3 and M38—A2 rds for the susceptibility testing of yeasts and filamentous fungi, respectively (1, 2). Test isolates were subcultured from frozen slants onto potato dextrose agar plates (Trichophyton rubmm was subcultured onto oatmeal plates for conidia production) and checked for purity. Inocula were then prepared in RPMI—1640 (YNB for Cryptococcus) to a concentration of 0.5 — 2.5 x 103 colony—forming units (CFU)/ml or 0.4 - 5 x 104 conidia/ml for yeast and filamentous fungi, respectively. MIC endpoints were read at 50% and 100% inhibition, as compared to the growth control, at both 24 and 48 hrs (C. neoformans were incubated for 72 hrs and T. rubmm strains were incubated for 96 hrs).
MFC determinations were performed according to the modifications previously described by Canton et al. and Ghannoum and Isham. (3, 4) Specifically, the total contents of each clear well from the MIC assay were tured onto potato dextrose agar. To avoid antifungal carryover, the aliquots were allowed to soak into the agar and then were streaked for isolation once dry, thus ng the cells from the drug source. Fungicidal activity was defined as a 2 99.9% reduction in the number of colony forming units (CFU)/ml from the ng inoculum count, with compounds being determined as cidal if the MFC fell within 4 dilutions of the MIC.
The data shows that all eight compounds demonstrated antifungal activity against the strains tested, although MIC and MFC results were strain specific. As can be seen in Table 27, compound AC showed the lowest MIC values t the C. albicans strains at both the 50% and 100% inhibition at 24 hrs (<0. 12—025 and <0. 12—1 ug/ml, respectively) and 48 hrs (<0.l2—l and 0.5—2 ug/ml, respectively). Importantly, compound AC was cidal against 2 of the 3 C. albicans strains tested. nd AG demonstrated similar MIC and MFC values against the C. albicans strains.
Table 28 shows that compounds AG and AC were also the most active against the C. ta strains tested. After 24 hrs, the MIC at 50% for compound AG was 0.25—l ug/ml and 0.5—2 at 100%. After 48 hrs, the corresponding compound AG values were both 0.5—2 ug/ml. After 24 hrs, the MIC at 50% for compound AC was 0.5—1 ug/ml and l—2 at 100%. After 48 hrs, the corresponding compound AC values were 1—2 (50%) and 2—4 ug/ml (100%). Both compounds AG and AC were cidal against all of the C. glabrata strains .
As can be seen in Table 29, compounds AX and AH demonstrated the st antifungal activity against the Cryptococcus neoformans strains tested. Compound AX had MIC values of 0.12—2 and 0.5-4 ug/ml at 50% and 100% inhibition, respectively, while compound AH had corresponding values of 0004-2 and 025-2 ug/ml. Both compounds were cidal against all 3 neoformans isolates.
Table 30 shows the MIC and MFC values of the eight compounds t the Aspergillus fumigatus strains. Compounds AE, AH, and AC showed equivalent inhibitory activity, with compound AE demonstrating MIC values of <0.12—0.5 and <0.12—1 ug/ml at 50% and 100% inhibition, respectively, after 24 hrs. After 48 hrs, the corresponding values for compound AE were 0.5—2 and 1—4 ug/ml. Compound AH demonstrated MIC values of <0. 12 and 0.25—0.5 ug/ml at 50% and 100% inhibition, respectively, after 24 hrs. After 48 hrs, the corresponding values for compound AH were 025—1 and 0.25—4 ug/ml. For compound AC, the MIC values at 24 hrs were <0. 12 and 0.25—0.5 ug/ml for 50% and 100% tion, respectively, while the corresponding values at 48 hrs were 0.5 —l and l ug/ml. r, only nds AL, AM, and AG were cidal against one of the A. fumigatus strains (MRL 28397).
In Table 31, it can be seen that compounds AE, AH, and AC were the most active against the Rhizopus strains. At 24 hrs, compound AE showed MIC values of <0. 12 and l—2 ug/ml for 50% and 100% inhibition, respectively, with corresponding 48 hr values of l—2 and l—4 ug/ml.
Compound AH showed MIC values of 025—05 and 2 ug/ml for 50% and 100% inhibition, tively, at 24 hrs and 2 ug/ml for both endpoint readings at 48 hrs. At 24 hrs, compound AC showed MIC values of <0.l2—0.25 and 0.5 ug/ml for 50% and 100% inhibition, respectively, with corresponding 48 hr values of 0.5 and 0.5—1 ug/ml. Generally, no cidal activity was demonstrated against the Rhizopus strains tested.
Finally, Table 32 shows the MIC and MFC values of the eight compound against T. rubrum. At the 50% inhibition endpoint, compounds AG, AX, AE, AH, and AC showed lent activity (<0. 12—4 ug/ml overall). At the 100% inhibition endpoint, compounds AG, AH, and AC were equivalent (0.25—4 ug/ml overall), with compounds AX and AE g slightly higher (0.25—16 ug/ml). Within the definition of cidality (MFC within 4 dilutions of the MIC) all compounds were considered cidal against the T. rubrum strains, though the MFC were high in some strains (8-16 ug/ml).
Overall, nds AE, AH, and AC appeared to demonstrate the greatest inhibitory activity t the most fungal strains tested.
References for Example N 1. CLSI. Reference Methodfor Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard — Second n. CLSI document M27—A2 (ISBN 1—56238—469—4).
CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087—1898 USA, 2002. 2. CLSI. Reference Methodfor Broth Dilution ngal Susceptibility Testing of Filamentous Fungi; Approved Standard— Second Edition. CLSI document M38—A2 [ISBN 89]. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087— 1898 USA, 2008. 3. Canton E, Peman J, Viudes A, Quindos G, Gobemado M, Espinel—Ingroff A. 2003.
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida s.
Diagn Microbiol Infect Dis. 45:203—6. 4. Ghannoum MA, Isham N. 2007. nazole and Caspofungin Cidality Against Non— Albicans Candida Species. Infectious Diseases in Clinical Practice. l5(4):250—253. .93? m?wbm 2:833 §§§0 Hm?www momma 0n:2 was.
. USE mm 50 3:833 exoOm $00: USE .
. EEQEM exoOm $00: EEEQKS: exoOm $00: .0 0:2 0:2 800 owns: .0 0:2 0:2 0:2 :0 owns: 0:2 0:2 W0 2014/120995 PCT/USZOl4/013992 0< ”NH .ov v-90 v-90 E< Wmmd ?aw v-NH.ov onNd .93? Nam SEE: as :0 % >>< 2:33 Q 5:35 @335:sz :Sb?wo?th Hm?www 3&me momma momma“ % 0n:2 A< A< 0n:2 i was. vm N was 0:2 0:2 .om 9592800 llllllll!n????mgg R$00: 6:50.800 gags: exoOm $00: .mm Quow $00: 2an Ax 0:2 0n:2 owns: 0:2 0:2 0:2 2an 235 .0:2 0:2 0n:2 ANTICANCER EXAMPLES EXAMPLE 0: Compounds of the invention inhibit eic breast cancer growth in mice Cancer models in mice generally either involve syngeneic murine tumors in immunocompetent mice or xenografts of human tumors in immunocompromised mice. An important aspect of using murine tumors in mice is that the tumor and host have much closer c similarity than do human xenografts in mice and therefore can be a very rigorous test of selectivity of agents for inhibiting proliferation of cancer cells versus normal tissues. 4T1 is breast cancer cell line commonly used as a syngeneic cancer model. Test compounds were chosen based upon their ability to selectively to kill 4T1 mouse mammary breast cancer cells relative to a normal mouse mammary cell line in vitro.
Female Balb/C mice were randomized into treatment groups anle3 4T1 cells were ed into into the mammary fat pad of each mouse in 0.1mL PBS on 4/28/10 (day 0). Mice received test compounds by oral gavage in 1% hydroxypropylmethylcellulose from day 2 until day 30. Tumor growth was ed by caliper measurements twice per week and tumor weight after necropsy, and body weight was also monitored.
Treatment groups were: TJQMPP’N?‘ Vehicle (1% hydroxypropylmethylcellulose; HPMC) CI (lZOumol/kg/day) BA (lZOumol/kg/day) CP (lZOumol/kg/day) CQ (lZOumol/kg/day) AA (lZOumol/kg/day) AC (lZOumol/kg/day) Table 33: Results Treatment Final Tumor l Body Final Body A BW % Volume (mm3) Weight (g) Weight Vehicle 906 i 316 22.2 i1.1 21.8 :r 0.7 CI 702 i 244 21.8 i 0.8 20.6 i 0.6 -5.5 % BA 641 i 159 25.5 i 1.5 24.8 i 2.0 —2.7 % 352i114 24.1:r0.9 24.1J_r1.3 CQ 140 i 60 24.9 i 0.6 24.4 i' 0.9 —2.0 % AA 563 i 175 21.4 i1.0 20.3 i' 1.3 —5.1 % AC 723i 185 21.5i 1.0 1971- 1.1 -8.4% Compounds of the invention reduced tumor growth versus vehicle—treated mice after daily oral administration at a dose of 120 uM/kg/day for 33 days, with acceptable toxicity (less than 10% body weight loss). CQ was the most active of the compounds tested in this experiment in the 4T1 breast cancer model. Compounds were chosen for in vivo g based upon their ability to selectively to kill 4T1 mouse mammary breast cancer cells relative to a normal mouse mammary cell line in vitro, indicating a correspondence between in vitro cancer cell line cytotoxicity in vivo ncer activity of compounds of the invention.
EXAMPLE P: Effects of Compound AC in mice g xenografts of human hormone- independent prostate cancer Experimental ure Standard models for prostate cancer use subcutaneous xenografts of human prostate cancer cell line. Local measurable tumors are produced at the site of injection of the cells, and they asize to critical tissues such as the bones, lungs and liver. Mortality in this model is due to ases impairing tissue function. Compounds of the invention were assessed for inhibition of tumor growth and reduction or delay of mortality in the PC—3 prostate cancer model, which mimics an advanced, androgen—independent stage of prostate cancer. female nude mice (female Hsdzathymic nude—Foxnlnu) received PC—3 cells (5X106 per mouse in 0.1mL PBS) by subcutaneous ion into the right hind ?ank. After 8 days tumors were palpable and mice were divided into two groups with approximately equal mean tumor sizes.
Mice received AC or vehicle (saline) via intraperitoneal (i.p.) injection once daily until day 79. 1. Vehicle (0.9 % saline): Mean pretreatment tumor volume 55.7 mm3; body weight 26.6 i 0.9 g) 2. Compound AC: 120 umol/kg/day. Mean pretreatment tumor volume 59.6 mm}; body weight 26.8 i 0.5 g) Tumors were ed with rs twice per week, and body weights and mortality were also monitored.
Results All 5 vehicle-treated mice died by day 35 (Individual days of death 20, 24, 24, 26, and 35). One mouse in the AC-treated group died on day 65 and the remaining 4 ed until the study was terminated on day 79.
In the longest-surviving vehicle—treated mouse, the tumor volume was 3007% larger at time of death on day 35 than at initiation of treatment; all other e—treated animals died of metastatic disease with smaller primary tumor sizes. Among mice treated with AC, tumors had enlarged to an average of 949 % of initial size at day 77; two of the mice surviving to the end of the study had no detectable tumors at that time and were deemed complete regressions, and one regressed more than 50% from the initial tumor size. AC—treated mice had a mean body weight of 28.9 i 1.3 g at end of study; a weight gain rather than a weight loss from the initial group body weight of 26.8 i 0.5 g indicates that the treatment was well tolerated. Daily injections of AC therefore ly improved survival and decreased tumor size, including producing complete and partial regressions, in mice bearing hormone—independent prostate cancers.
EXAMPLE Q: Effects of compounds of the invention in a mouse model of liver ases of human colorectal cancer A major cause of morbidity and mortality in patients with colorectal cancer is metastasis of the tumor into the liver; colorectal cancer can often be successfully resected from the y site, but metastases to the liver are much less accessible to surgical treatment. A mouse model of colorectal cancer metastasis to the liver has been established, using HCT—l l6 colon adenocarcinoma cells ed into the spleen of athymic (nude) mice. The HCT—l 16 cancer cells spontaneously spread from the spleen into the liver via the circulation, and they form tumors in the liver (Ishizu, K., , N., Yamazaki, K., Tsuruo, T., Sadahiro, S., Makuuchi, H., and Yamori, T. Development and Characterization of a Model of Liver asis Using Human Colon Cancer HCT—116. Biol. Pharm. Bull. 2007, 30(9): 1779-1783).
Compounds CQ and AA were tested for antitumor activity in the HCT—l 16 model of metastatic colorectal cancer.
Methods: Mice (female Hsdzathymic nude-Foxnlnu) were anesthetized with xylazine/ketamine intraperitoneal injection, followed by incision approximately 10mm on the left subcostal region (area disinfected with ethanol) to expose the peritoneum. The peritoneum was opened for about 8mm near the spleen, and 2.5X106 cells in 50 uL PBS were ed into the spleen using a 30G . The spleen was repositioned, and the surgical area was closed using sutures and clips.
N Treatment Dose (umol/kg) Dose Volume (per mouse) Vehicle N/A 0.4mL CQ 240 0.4mL AA 240 0.4mL 2014/013992 The day after receiving cells, mice were randomized into groups of five based upon body weight to provide groups with approximately equivalent mean body weight. Mice received a single, daily oral dose of test e or vehicle (1% hydroxypropylmethylcellulose) beginning 48 hours ing cell injection into the spleen.
At study termination 28 days after HCT—l 16 cell injection, body weights were recorded, and spleens and livers were removed, weighed and ?xed in 10% formalin. Livers were sectioned and stained; the relative areas of normal and tumor tissue were quantified in histology sections with quantitative planimetry software.
Results: Tumors in the Vehicle control group occupied 14% of the liver as assessed by tative planimetry in histology sections. Both compounds CQ and AC markedly reduced the area of liver invaded by metastatic cancer cells. The Vehicle group had a 12% higher liver weight/body weight ratio than the groups treated with either CQ or AC, corroborating the histology planimetry measurements indicating that tumors increased the total liver mass in the Vehicle group. Body weights were not icantly different between groups of mice treated with vehicle-treated versus test compounds, ting that the compounds of the invention were well tolerated at a dose of 240 umol/kg/day for 28 days.
Table 34 Tumor Area Tumor Area Liver Weight Final Body Weight Treatment % of Total Liver % of Vehicle % of Body Weight Grams Group e 14 i 5.6 % 100 % 6.1 i 0.3 % 27.4 i 0.9 CQ 0.02 i 0.01% * 0.15% * 5.3 i 0.1% 26.2 i 0.9 NS AA 0.2 i 0.26 % * 1.5% * 5.3 i 0.2 % 28.2 i 1.5 NS = less than Vehicle group, P< .02 EXAMPLE R: Effects of compounds of the ion, sorafenib, and combinations in a mouse model of human hepatocellular carcinoma Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers ide, generally developing as a uence of chronic infection with hepatitis B or C viruses. The tyrosine kinase inhibitor sorafenib is a multikinase inhibitor used for treatment of advanced HCC, and has both direct antitumor and antiangiogenic properties. Compounds of the invention act via a different mechanism of action than does sorafenib or other kinase inhibitors; therefore it is possible that compounds of the invention, in addition to displaying single agent activity, may also e the efficacy of sorafenib or other standard treatments in HCC and other cancers.
The Hep3B hepatocellular carcinoma cell line is human in origin, contains genetic traces of hepatitis B virus, and can be injected into the livers of athymic immunocompromised mice as a model of primary HCC. Oral sorafenib is active in this model and was used as both a positive control treatment and as a partner for combination therapy with a selection of compounds of the invention. The test compounds were all administered orally.
The test compounds of the invention were ded in 1% hydroxypropylmethylcellulose (HPMC) using a sonicator equipped with a microtip to ze particle size and maximize uniformity of the suspension. Sorafenib was dissolved in a 1:1 mixture of Cremophor EL and ethanol by heating to 60°C for 1 minute and then sonicating for 10 minutes to fully suspend.
Female nude mice (Hsdzathymic nude—Foxnln") weighing approximately 25 g were anesthetized with ketamine/xylazine, laid on their backs, and a l—cm erse on made through the skin and peritoneum of the left upper abdomen. The mediant lobe of the liver was exposed by applying gentle pressure on the abdomen. 1.5—2x106 Hep3B cells in a ZOML volume of eleMEM serum free (lzl) were slowly ted by subserosal injection into the liver using a 27—gauge needle on a Hamilton syringe. The liver was allowed to slip back into place, and the peritoneum was closed with sutures and wound clips.
Mice were divided into 8 groups of mice each following injection of cells; the vehicle/vehicle group comprised 12 mice and the other groups comprised 8 or 9. Mice began receiving oral testdrug treatments 48hr post cell injection.
Table 35 Daily Dose Group No. of Treatment No. Animals 1% HPMC vehicle; cremophor 1 12 N/A veh1cle Sorafenib; 30mg/kg/day 1% HPMC vehicle 180um01/kg/day cremophor vehicle 180umol/kg/day;20mg/kg/day 360umol/kg/day cremophor vehicle 360Mmol/kg/day; 20mg/kg/day 7 8 360pmol/kg/day cremophor vehicle 8 9 AB + sorafenib 360umol/kg/day; 20mg/kg/day The test nds, sorafenib, and vehicles were administered by oral gavage. Sorafenib or its cremophor—containing vehicle were given in the morning and compounds of the invention or their HPMC e was administered in the afternoon each day; all animals ed two gavage treatments of drugs or appropriate vehicles daily. In the group with sorafenib as the only active test agent, the daily dose was 30 mg/kg; when ed with compounds of the invention, the sorafenib dose was reduced to 20 mg/kg because the tolerability of the combination was n, and also because possible improved anticancer activity of compounds of the invention combined with a lower dose of sorafenib over a higher dose of sorafenib alone would more clearly demonstrate advantageous activity of compounds of the invention.
Mice were sacrificed at day 35 after 2 of the initial 12 vehicle—treated mice had died from tumor progression; livers were removed and photographed, and tumors were dissected out for measurement and weighing.
Results All vehicle—treated mice developed tumors, with a mean weight of about 2 grams at the time of sacri?ce. Sorafenib (30 mg/kg/day) as a single agent reduced the tumor size by more than 50%. nds AC and AB alone also reduced tumor size by more than 50%; AK alone produced a cally but not statistically significant ion in tumor size versus vehicle. on of sorafenib (20 mg/kg/day) to compounds of the ion resulted in better inhibition of tumor growth than was achieved with sorafenib alone at 30 mg/kg/day. The combinations of DD or AB with sorafenib produced more complete regressions (no viable tumor detected at necropsy) than single-agent treatments. All treatments including combinations were well-tolerated as indicated by maintenance of body weight throughout the entire duration of the study.
Table 36. Effects of compounds of the invention alone and in combination with sorafenib on growth of cellular carcinoma in nude mice Tumor Weight Complete Body Weight (g) Mean i Treatment (g) Regression SEM Mean i SEM Initial Final e 2.03 i 0.37 26.0 i 0.4 26.4 i 0.5 Sorafenib 0.81 i' 0.20 * 25.9 i' 0.7 24.9 i 0.4 AC 0.49 i- 0.17 * 25.4 i- 0.5 25.6 i 0.7 AC + Sorafenib 0.17 i 0.07 *+ 24.9 i 0.5 25.2 i 0.9 AK 1.56 i 0.39 25.9 i 0.7 24.9 i 0.9 AK+ Sorafenib 0.48 + 0.22 * 25.1 i 0.7 25.1i 1.3 _E0.88 + 033 * 2 26.2 i- 0.7 26.0 :r 0.9 _n0.38 6 25-3 i 0-7 :r 0.18 * 25.7 i- 0.8 = less than Vehicle group, P<.02 + = less than Sorafenib group, p<.02 EXAMPLE S: In vitro screen for anticancer activity against 4T1 murine breast cancer and PC-3 human prostate cancer Compounds of the invention were screened for ability to kill or inhibit proliferation of cancer cell lines in vitro, as a complement to in vivo studies on subsets of compounds demonstrating anticancer efficacy in vivo, at doses that were well tolerated after either oral or intraperitoneal administration.
Anticancer activity against 4T1 murine breast cancer cells cancer cells was assessed in vitro by seeding 1x104 cells/well in ?at bottom culture plates, then treating with ed 1 uM or 5 uM trations of nds for 18hr after plating. Then 10 ML of Wstl dye reagent, a tetrazolium dye indicator for cell death, was added/well and incubated approximately 2hr before being assayed on the Biotek EL800 Universal microplate reader (450nm, nce 630nm).
Activity against PC3 human prostate cancer cells in vitro was assessed by a similar method.
PC—3 prostate cancer cells were plated at 2x104 cells/well in 96 well ?at bottom tissue culture plates, and ted for approximately 20 hours with vehicle or test compounds at trations of 0.4, 0.5 or 2.5 MM as ted for specific compounds in the right—hand column of Table 37. A 1/10th volume of Wstl dye was added/well and incubated for two hours in the cell culture incubator. Samples were analyzed in triplicate on an EL800 Universal Microplate Reader at 450nm, reference wavelength 630nm.
Numerical values in the Table 37 represent percent of cancer cell survival relative to vehicle treated cells at the indicated trations, with values under 100 indicating anticancer cytotoxic activity at the drugs concentrations tested.
Table 37 _——— BH 19.3 98.5 0.4ttM WO 20995 0.5 M 0.4MM 0.4MM 0.4MM 0.4MM 0.4 M 0.4MM 0.4MM 0.4 M E____0.4MM 2.5 M ————2.5 M ————WM ————Wm I3____ ———m-WM 0.4 M I3____0.4m ———— ———— ———— ———— 0.4 M 0.4 M ————Wm ————Wm ———— 0.4 M —_—— —_—— 2.5 M —_—— E____ 2.5 M “mm25W m-_——25W E__——2.5 M 1.5 M 0.4 M ————WM ————WM ———— "rm-— ———— ———— ———— ———— ———— ————BZ ———— ———— ———— ——m_— ———— ———— EL 108 39.4 41.8 2.5},LM 2014/013992 ———— —_—— 14.1 0MM —_—— —_—— —_—— ——_—MM —_m-— ——_—2.MM 2.MM 0.4 M 18 0MM —_—— 2.MM ————OMM ———— ———— Iz_———OMM ———m_2.5 M ———— ———E-s M 2.5 M IB-_-_o.MM 0.5 M ————2.MM ———-2.5 M m———2.MM 38.1 24.5 0.5MM 0.5 M 2.5“ 2.5m GD 24.3 2.5uM EXAMPLE T: Effects of compounds of the invention of ance of human te cancer cells to cytotoxic chemotherapy agents in vitro Cancer therapy is ed by inherent or acquired resistance of tumor to single cytotoxic anticancer agents. One mechanism of cancer cell resistance to chemotherapy agents such as anthracylines, platinum compounds, vinca alkaloids, taxanes, and some tyrosine kinase inhibitors, is to ter anticancer agents in lysosomes or related acidic vacuoles. Compounds of the invention were tested in vitro for their ability to increase sensitivity to several other classes of anticancer agents to which PC—3 prostate cancer cells are relatively resitant in vitro and in vivo.
PC-3 prostate cancer cells were plated at 2x104 cells/well in 96 well ?at bottom tissue culture plates, and incubated imately 20 hours. Cells were treated with an anticipated suboptimal concentration of test compounds for cell killing as a single agent for imately 30 minutes.
Chemotherapeutic agents (doxorubicin, oxaliplatin, paclitaxel or vincristine at concentrations suboptimal for PC—3 cell killing) were added and PC-3 cells were incubated for an onal 72 hours before being assayed using Wstl reagent. A 1/ 10th volume of Wstl dye was added/well and incubated for two hours in the cell culture incubator. Samples were analyzed in triplicate on an EL800 Universal Microplate Reader at 450nm, reference wavelength 630 nm.
In Table 38, numerical values in the column headed “No Chemo” represent percent cell survival after exposure to the compounds of the invention at concentrations indicated to the left of that column. In the columns headed by the names of the four chemotherapeutic agents, values lower than the corresponding “No Chemo” values indicate better anticancer activity of the ic combination of the cytotoxic agent in combination with a compound of the invention than was obtained with either class of compound alone. At the trations ted, the minimal activity of the chemotherapy agents alone during 72 hours of exposure was normalized to 100% for y in discerning synergistic or additive effects of compounds of the invention. The results indicate that, at the concentrations tested, a broad range of compounds of the invention increase sensitivity of cancer cells to one or more of the tested cytotoxic herapy agents doxorubicin, oxaliplatin, paclitaxel or vincristine.
Table 38: Cytotoxicity of suboptimal concentrations of compounds of the invention alone and combined With cytotoxic herapy agents Compound [HM] No Doxorubicin Oxaliplatin Paclitaxel Vincristine Chemo 3.50M 100uM 50uM 100nM Vehicle (100) (100) (100) (100) (100) 84-6 67-4 CJ 04uM 53.7 18. 9 19.7 51.7 16.9 642 138.2 503 27.7 51-8 28.1 54-8 26 50-1 69.5 21- 8 17-1 51-6 32-8 AR 0.4uM 57 22.4 24.1 54.1 24.2 54.7 23. 9 23.1 46.1 46.7 45.9 21.7 22.2 48.2 38.1 98.5 35.7 30.6 61 71.6 73.8 36.2 30.6 21.4 36.1 95.4 33.6 26.9 54.1 71.2 98.5 31.9 26.6 55.9 69.4 99.1 44.1 41.2 64 74.9 92.8 40.9 37.2 57.1 74.1 99.1 40.1 36.2 59.2 71.1 95.7 82.8 91.3 100.8 19.1 23.9 56.8 64.1 50.2 50.8 110.9 76.6 84.3 71.7 81.7 24.7 56 62.3 40.3 29.6 WO 20995 145-7 148-7 CY 0.40M 40.5 76.6 84.3 71.7 81.7 74-5 48-2 CQ 2.50M 95.8 86.5 93.8 34.8 47.1 69-7 82-8 CT 2.50M 34.5 63.2 71.9 46.3 46.3 CM 5 M 74-8 81-3 BB 2.50M 16.3 20.4 24.7 25 17.2 -8 20-1 BD 0.40M 29.3 66.1 61.3 28.4 33.3 DY 5M 23-3 18-3 DZ 0.40M 84.8 85.6 86.7 71.8 89 EA 0.461735 84.5 BE 04 45-3 47.1 24-3 23.4 EG 049M 95-3 88.5 EB 2-5 143-3 982 136-8 91-6 93-1 91-1 164-8 164-9 DN 2.50M 31.7 64.1 78 64.7 72.3 68-6 74 DF 0.40M 101.9 88.7 96.5 89.4 95.4 45.6 79.2 91.1 105.4 92.1 59.2 79.9 89.9 93.4 90.1 31.5 59.9 68.7 49.2 35.5 82.6 38.6 31 22.2 43 61.5 32.8 30 14 34.1 70 86.4 97 97.1 98.6 19.1 35 32.4 25.2 22.6 24 48.1 57.2 31 26.7 31.6 76.7 61.9 23.3 32.2 BK 0.40M 29.2 32.1 27.3 20.6 28.3 WO 20995 120 141-4 111-2 BY 2.50M 96.6 98.4 101.1 99.9 94.1 86-1 70-8 FT 2.50M 41.1 74.4 94.2 85.2 78.3 128-5 1046 AS 2.50M 31.1 51.1 555 36.8 30.8 344 37-2 AW 0.40M 382 59.5 51.3 33.6 90-1 78-7 AT 040M 34.6 65.4 768 57.4 32.9 928 69-7 FB 250M 97.7 89.1 955 93.2 98.6 ___E-—1318 114.9 FF 51M 1361 1101 FE 511M 113-7 373 91 80.1 95-1 93 47-2 41 F2 5 M 1148 38-5 GA 1.5M 41. 3 82.2 91.8 109.2 84.2 762 38-8 CD 2.50M 16.6 19.5 201 23.2 17.1 2.5M 21.4 48.5 251 26.9 21.4 0.50M 38.6 75.1 97.3 82.2 0.50M 35.5 47.4 62 18 39 19.8 59.5 63.2 30.3 26.4 126.4 68.8 83.5 70.3 75.3 2.50M 24.3 39.5 26.? 27 23.5

Claims (34)

What is claimed is:
1. A compound represented by Formula IB1 or a pharmaceutically acceptable salt thereof wherein n is 1; Q is absent; R1 is hydrogen or halo; and R7 is phenyl substituted by alkoxy having from 6 to 10 carbon atoms or phenoxy.
2. The nd or salt of claim 1, wherein the nd is selected from the group consisting of: N-[3-(Hexyloxy)benzyl]quinazolinamine, N-[3-(Decyloxy)benzyl]quinazolinamine, N-[4-(Decyloxy)benzyl]quinazolinamine, N-[4-(Hexyloxy)benzyl]quinazolinamine.
3. The compound or salt of claim 1, wherein the compound is N-(3- Phenoxybenzyl)quinazolinamine.
4. Use of the compound or pharmaceutically acceptable salt of any one of claims 1 to 3 in the manufacture of a medicament for treating or preventing a condition in a mammalian subject; the ion being ed from the group consisting of an inflammatory disease, a fungal infection, a unicellular parasitic infection, and a neoplastic disease.
5. A pharmaceutical composition adapted for use in ng or preventing a condition in a mammalian subject; the condition being selected from the group consisting of an inflammatory disease, a fungal infection, a unicellular parasitic infection, and a stic disease, the pharmaceutical ition comprising the compound or pharmaceutically acceptable salt of any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
6. The use according to claim 4 or pharmaceutical composition according to claim 5, wherein the mammalian subject is a human subject.
7. The use according to claim 4 or pharmaceutical composition according to claim 5, wherein the condition is an matory disease.
8. The use according to claim 4 or pharmaceutical composition according to claim 5, wherein the condition is a fungal infection.
9. The use or pharmaceutical composition of claim 8, wherein the fungus is selected from the group consisting of Candida, Saccharomyces, Trichophyton, Cryptococcus, Aspergillus, and
10. The use or pharmaceutical composition of claim 9, wherein the Candida is Candida albicans or Candida glabrata.
11. The use or ceutical composition of claim 9, n the Saccharomyces is Saccharomyces cerevisiae.
12. The use or pharmaceutical composition of claim 9, wherein the Trichophyton is Trichophyton rubrum.
13. The use or pharmaceutical composition of claim 9, wherein the Cryptococcus is Cryptococcus mans.
14. The, use or pharmaceutical composition of claim 13, wherein the Cryptococcus neoformans is Cryptococcus neoformans pe D or Cryptococcus neoformans serotype A.
15. The use or pharmaceutical composition of claim 9, wherein the Aspergillus is Aspergillus fumigatus.
16. The use ing to claim 4 or pharmaceutical ition according to claim 5, wherein the condition is infection with a unicellular parasitic microorganism.
17. The use or ceutical composition of claim 16, wherein the parasitic infection is infection with a parasitic microorganism that resides within acidic vacuoles in cells of the subject.
18. The use or pharmaceutical composition of claim 16, wherein the parasitic microorganism is ed from the group consisting of mycobacteria, gram positive bacteria, amoebae, and gram negative bacteria.
19. The use or pharmaceutical composition of claim 16, wherein the parasitic microorganism is selected from the group consisting of tuberculosis, listeria, leishmania, a trypanosome, Coxiella burnetii, and a Plasmodium.
20. The use according to claim 4 or ceutical composition ing to claim 5, wherein the condition is a neoplastic disease.
21. The use or pharmaceutical composition of claim 20, wherein the neoplastic disease is a hematologic cancer.
22. The use or pharmaceutical composition of claim 20, wherein the neoplastic disease is a solid tumor.
23. The use ing to claim 4 or pharmaceutical composition according to claim 5, wherein the compound or composition is adapted for topical administration to the subject.
24. The use according to claim 4 or pharmaceutical composition according to claim 5, wherein the compound or composition is adapted for systemic administration to the t.
25. The use or pharmaceutical composition of claim 24, wherein the compound or composition is adapted for oral, rectal, parenteral or nasal administration.
26. A method of inhibiting a fungus ex vivo, sing ting a surface or the fungus with the compound or pharmaceutically acceptable salt of any one of claims 1 to 3.
27. The method of claim 26, n the fungus is ed from the group consisting of Candida, Saccharomyces, Trichophyton, Cryptococcus, illus, and Rhizopus.
28. The method of claim 27, wherein the Candida is Candida albicans or Candida glabrata.
29. The method of claim 27, wherein the romyces is Saccharomyces cerevisiae.
30. The method of claim 27, wherein the Trichophyton is Trichophyton rubrum.
31. The method of claim 27, wherein the Cryptococcus is Cryptococcus neoformans.
32. The method of claim 31, wherein the Cryptococcus neoformans is Cryptococcus neoformans serotype D or Cryptococcus neoformans serotype A.
33. The method of claim 27, wherein the Aspergillus is Aspergillus fumigatus.
34. The compound of any one of claims 1 to 3, substantially as described herein with reference to any one of the Examples or
NZ749999A 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity NZ749999B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759512P 2013-02-01 2013-02-01
US61/759,512 2013-02-01
NZ709885A NZ709885A (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity

Publications (2)

Publication Number Publication Date
NZ749999A NZ749999A (en) 2020-09-25
NZ749999B2 true NZ749999B2 (en) 2021-01-06

Family

ID=

Similar Documents

Publication Publication Date Title
US10934284B2 (en) Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
US9957226B2 (en) Antimicrobial compounds
AU2020200510B2 (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
NZ749999B2 (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US11274106B2 (en) Topoisomerase inhibitors with antibacterial and anticancer activity
US20230416244A1 (en) Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
KR102070361B1 (en) Deuterated cftr potentiators
CA2983499A1 (en) Crystalline salts of morphine sulfate
WO2023069613A1 (en) Arylimidamides for use in treatment of cancers
Ralph Synthesis and anti-leishmanial activity of novel 2, 3-disubstituted-4 (3H)-quinazolinone derivatives
Šůs Synthesis of precursors of 4-quinolones against Trypanosoma brucei for 18F-radiolabelling